{
  "questions": [
    {
      "id": "63f03006f36125a426000018",
      "type": "summary",
      "body": "What were the results of the DESTINY-Breast04 Trial?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35665782",
          "text": "CONCLUSIONS\nIn this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.",
          "offsetInBeginSection": 2191,
          "offsetInEndSection": 2414,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36386213",
          "text": "DESTINY-Breast04 (NCT03734029) has demonstrated the antitumor activity of trastuzumab deruxtecan (T-DXd).",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 277,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31022475",
          "text": "After evaluating the results of these 6 studies, none of the SNPs was significantly associated with ONJ.",
          "offsetInBeginSection": 732,
          "offsetInEndSection": 836,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35666611",
          "text": "Findings from the phase III DESTINY-Breast04 trial indicate that the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is effective for patients with inoperable/metastatic HER2-low breast cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33023880",
          "text": "using a validated scoring criterion.\n\n\nRESULTS\nOne hundred and seven studies met the inclusion criteria. The median quality score across studies was 1",
          "offsetInBeginSection": 1053,
          "offsetInEndSection": 1203,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31039047",
          "text": "In total, 45 samples were positive with breath testing and the number of positives with established forensic methods was 46.",
          "offsetInBeginSection": 1411,
          "offsetInEndSection": 1535,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33023880",
          "text": "and temperature selected in over 50% of the studies. Malaria incidence (47%) and prevalence (35%) were the most commonly mapped outcomes, with Bayesia",
          "offsetInBeginSection": 1333,
          "offsetInEndSection": 1483,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31039047",
          "text": "In 54 of these cases (81%) the results regarding a positive or negative drug test result agreed and in 13 they disagreed.",
          "offsetInBeginSection": 884,
          "offsetInEndSection": 1005,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2748781",
          "text": "Yet like him, physicians must realize that the small successes they can achieve while contending against destiny are what count.",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 262,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17690310",
          "text": "We report here the 30-day mortality and 6- and 12-month functional outcomes from the DESTINY trial.",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 276,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9422017",
          "text": "RESULTS\nThe proportion of women who were allowed a trial of labour ranged from 37% to 97% across reports.",
          "offsetInBeginSection": 505,
          "offsetInEndSection": 610,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35665782",
          "text": "The key secondary end points were progression-free survival among all patients and overall survival in the hormone receptor-positive cohort and among all patients.",
          "offsetInBeginSection": 845,
          "offsetInEndSection": 1008,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9422017",
        "http://www.ncbi.nlm.nih.gov/pubmed/2748781",
        "http://www.ncbi.nlm.nih.gov/pubmed/35666611",
        "http://www.ncbi.nlm.nih.gov/pubmed/36386213",
        "http://www.ncbi.nlm.nih.gov/pubmed/17690310",
        "http://www.ncbi.nlm.nih.gov/pubmed/31022475",
        "http://www.ncbi.nlm.nih.gov/pubmed/31039047",
        "http://www.ncbi.nlm.nih.gov/pubmed/35665782",
        "http://www.ncbi.nlm.nih.gov/pubmed/33023880"
      ]
    },
    {
      "id": "641ad941690f196b5100003d",
      "type": "yesno",
      "body": "Are LOQ and LOD the same?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8013092",
          "text": "of the corresponding statistical LODs. The empirical LODs and LOQs are identical for these GC-MS assays. The observations made here about the LOD/LOQ ",
          "offsetInBeginSection": 988,
          "offsetInEndSection": 1138,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20166602",
          "text": "The results indicated that the estimated LODs and LOQs were not equivalent and could vary by a factor of 5 to 6 for the different methods.",
          "offsetInBeginSection": 488,
          "offsetInEndSection": 626,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16353984",
          "text": "The practical LOD and LOQ were 0.1% and 0.5%, respectively, and comparable to the calculated LOD and LOQ.",
          "offsetInBeginSection": 1159,
          "offsetInEndSection": 1264,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21603916",
          "text": "Real-time PCR (qPCR) is the principal technique for the quantification of pathogen biomass in host tissue, yet no generic methods exist for the determination of the limit of quantification (LOQ) and the limit of detection (LOD) in qPCR.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29110333",
          "text": "precision, accuracy, and robustness. The LOD and LOQ obtained were 0.8 and 2.7\u00a0\u03bcg/mL, respectively. In addition, the method offers higher sensitivity ",
          "offsetInBeginSection": 518,
          "offsetInEndSection": 668,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28911409",
          "text": "Our conclusion is that the visual evaluation method provided much more realistic LOD and LOQ values.",
          "offsetInBeginSection": 1081,
          "offsetInEndSection": 1181,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34155649",
          "text": "The LOD and LOQ were in the ranges of 0.16-0.39 and 0.52-1.28\u00a0mg/kg, respectively.",
          "offsetInBeginSection": 593,
          "offsetInEndSection": 675,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15936163",
          "text": "nt (r) of 0.9999, calculated by least square method. The LOD and LOQ were 0.08 and 0.26 microg/mL, respectively. Based on the preliminary spectrophoto",
          "offsetInBeginSection": 632,
          "offsetInEndSection": 782,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11878590",
          "text": "The limits of detection (LOD) and quantitation (LOQ) were 0.6 and 2.1 microg/L, respectively.",
          "offsetInBeginSection": 500,
          "offsetInEndSection": 593,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34155649",
          "text": "The LOD and LOQ were in the ranges of 0.16-0.39 and 0.52-1.28\u00a0mg/kg, respectively.",
          "offsetInBeginSection": 593,
          "offsetInEndSection": 675,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33799266",
          "text": "Results indicated that the dynamic ranges of three fur-bearing animals were all from 1% to 90%; the limit of detection (LOD) and limit of quantification (LOQ) for three fur-bearing animals were same, with LOD 0.1% (w/w) and LOQ 1% (w/w).",
          "offsetInBeginSection": 591,
          "offsetInEndSection": 828,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27291863",
          "text": "LOD and LOQ for the R-(-)-ibuprofen were LOD=1.60\u00d710-11mol and LOQ=4.85\u00d710-11mol, respectively.",
          "offsetInBeginSection": 902,
          "offsetInEndSection": 997,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36367473",
          "text": "Overall, LOD/LOQ methods or statistical analysis comparing means are recommended for future use in microplastic studies.",
          "offsetInBeginSection": 1249,
          "offsetInEndSection": 1369,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18178357",
          "text": "The LOD and LOQ values were found to be 0.3 and 1.0 microg/ml, respectively.",
          "offsetInBeginSection": 560,
          "offsetInEndSection": 636,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21313803",
          "text": "The LOD and LOQ of nine compounds were in the range of 0.09-10 and 0.3-25 microg/mL, respectively.",
          "offsetInBeginSection": 363,
          "offsetInEndSection": 461,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21662779",
          "text": "For ESI-MS detection, LOD and LOQ are in the ranges 10-25 and 20-50 \u03bcg/L, respectively.",
          "offsetInBeginSection": 588,
          "offsetInEndSection": 675,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19588457",
          "text": "lol enantiomers, respectively. LOD and LOQ values were found to be the lowest limits reported before. The calibration curves were linear in the concen",
          "offsetInBeginSection": 596,
          "offsetInEndSection": 746,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32308686",
          "text": "omparable with a selected HPLC reference method. Both methods displayed same precision and credibility. Reaction stoichiometry between tryptophan and ",
          "offsetInBeginSection": 623,
          "offsetInEndSection": 773,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31108780",
          "text": "Besides, LOD and LOQ of glycidyl ester were 0.024 and 0.06\u202fmg/kg respectively.",
          "offsetInBeginSection": 656,
          "offsetInEndSection": 734,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1783594",
          "text": "LOD and LOQ are equivalent to 3 and 10 times, respectively, the background signal contributed by a sample matrix blank.",
          "offsetInBeginSection": 687,
          "offsetInEndSection": 806,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35295076",
          "text": "Given their superimposable outcomes, the LODneg and LODpos-LOQneg categories were combined.",
          "offsetInBeginSection": 975,
          "offsetInEndSection": 1066,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31680080",
          "text": "Same method with same mobile phase was applied on rat plasma and there was no interference.",
          "offsetInBeginSection": 1474,
          "offsetInEndSection": 1565,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27886648",
          "text": "Limit of detection (LOD) and limit of quantification (LOQ) of the method were found to be 2.3 and 7.8\u03bcgL-1, respectively.",
          "offsetInBeginSection": 270,
          "offsetInEndSection": 391,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14647939",
          "text": "Immunoanalytical methods at a very low limit of detection (LOD) and a low limit of quantification (LOQ) are becoming more and more important for environmental analysis and especially for monitoring drinking water quality.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22165002",
          "text": "The LOD and LOQ of five pregnane compounds were found to be in the range of 1-5 and 3-15 microg/mL, respectively, by HPLC using photodiode array detection.",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1783594",
          "text": "LOD and LOQ are equivalent to 3 and 10 times, respectively, the background signal contributed by a sample matrix blank.",
          "offsetInBeginSection": 687,
          "offsetInEndSection": 806,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29566782",
          "text": "A comparison of LOD and LOQ values calculated by various methods and LLOQ shows a considerable difference.",
          "offsetInBeginSection": 667,
          "offsetInEndSection": 773,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27154653",
          "text": "nce the sensitivity for bilirubin determination with LOD and LOQ of 0.5nM and 1.5nM, respectively. In parallel, an isocratic HPLC-DAD method was devel",
          "offsetInBeginSection": 701,
          "offsetInEndSection": 851,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14960708",
          "text": "No significant matrix effects of the genomic background DNA on the estimation of LOD and LOQ were found.",
          "offsetInBeginSection": 1296,
          "offsetInEndSection": 1400,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29105560",
          "text": "The limit of detection (LOD) and limit of quantification (LOQ)of MEL were 0.006 and 0.019\u00a0mg kg-1, respectively.",
          "offsetInBeginSection": 334,
          "offsetInEndSection": 446,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007500",
          "text": "-20.00 mg/mL with a correlation coefficient of 0.9998. The LOD and LOQ were 0.22 and 0.50 mg/mL, respectively. Also, the HPLC method to determine DHA ",
          "offsetInBeginSection": 667,
          "offsetInEndSection": 817,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15936163",
          "text": "1N) present a correlation coefficient (r) of 0.9999. The LOD and LOQ were 0.14 and 0.46 microg/mL, respectively. Statistical analysis by t- and F-test",
          "offsetInBeginSection": 1020,
          "offsetInEndSection": 1170,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21662779",
          "text": "For ESI-MS detection, LOD and LOQ are in the ranges 10-25 and 20-50 \u03bcg/L, respectively.",
          "offsetInBeginSection": 588,
          "offsetInEndSection": 675,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007500",
          "text": "mL with a correlation coefficient of 0.9998. The LOD and LOQ were 0.22 and 0.50 mg/mL, respectively. Also, the HPLC method to determine DHA was compar",
          "offsetInBeginSection": 677,
          "offsetInEndSection": 827,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30086968",
          "text": "The same for lipophilic toxins, with better LODs and LOQs than the EU official method.",
          "offsetInBeginSection": 411,
          "offsetInEndSection": 497,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20220523",
          "text": "Various thresholds exist including limit of detection (LOD), limit of quantification (LOQ), and limit of blank (LOB).",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 280,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27291863",
          "text": "LOD and LOQ for the R-(-)-ibuprofen were LOD=1.60\u00d710-11mol and LOQ=4.85\u00d710-11mol, respectively.",
          "offsetInBeginSection": 902,
          "offsetInEndSection": 997,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18298073",
          "text": "f qualitative PCR assay; the absolute LOD and LOQ were low to 10 and 20 copies of canola genomic DNA in quantitative PCR assay, respectively. Furtherm",
          "offsetInBeginSection": 691,
          "offsetInEndSection": 841,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36367473",
          "text": "This study identified 6 commonly implemented strategies: a) No correction; b) Subtraction; c) Mean Subtraction; d) Spectral Similarity; e) Limits of detection/ limits of quantification (LOD/LOQ) or f) Statistical analysis, of which many variations are possible.",
          "offsetInBeginSection": 334,
          "offsetInEndSection": 595,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25907667",
          "text": "Moreover, LOD and LOQ decrease with decrease of data acquisition frequency (DAF).",
          "offsetInBeginSection": 641,
          "offsetInEndSection": 722,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31355390",
          "text": "A methodology is proposed, based on Raman spectroscopy coupled with multivariate analysis, to determine the Limit of Detection (LOD) and Limit of Quantification (LOQ) for therapeutic drug monitoring in human serum, using the examples of Busulfan, a cell cycle non-specific alkylating antineoplastic agent, and, Methotrexate, a chemotherapeutic agent and immune system suppressant.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 380,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16353984",
          "text": "ntiomorph and to assess the error, instrument reproducibility and limits of detection (LOD) and quantification (LOQ) of the method. Physical mixtures ",
          "offsetInBeginSection": 181,
          "offsetInEndSection": 331,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25907667",
          "text": "Moreover, LOD and LOQ decrease with decrease of data acquisition frequency (DAF).",
          "offsetInBeginSection": 641,
          "offsetInEndSection": 722,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20299027",
          "text": "LOD and LOQ after OASIS HLB clean-up varied from 0.9 microg/kg to 3.5 microg/kg and from 3.1 microg/kg to 11.7 microg/kg, respectively.",
          "offsetInBeginSection": 1627,
          "offsetInEndSection": 1762,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19167854",
          "text": "atan sulfate, an impurity in heparin sulfate, were determined to be 0.1% and 0.8%, respectively. This manuscript is not a policy document and is not i",
          "offsetInBeginSection": 592,
          "offsetInEndSection": 742,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24401401",
          "text": "The paper is devoted to the evaluation of limit of detection (LOD) and limit of quantification (LOQ) values in concentration domain by using 4 different approaches; namely 3\u03c3 and 10\u03c3 approaches, ULA2 approach, PBA approach and MDL approach.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10958968",
          "text": "tive ions was reinforced by incorporating piperidine post column. Limits of detection (LOD) and limits of quantitation (LOQ) were experimentally deter",
          "offsetInBeginSection": 500,
          "offsetInEndSection": 650,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18996077",
          "text": "Results showed no significant discrepancy between LOD/LOQ obtained by the different techniques. Validation experiments corroborated the calculated LOQ. The results indicate that any single technique can provide meaningful values",
          "offsetInBeginSection": 579,
          "offsetInEndSection": 807,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31108780",
        "http://www.ncbi.nlm.nih.gov/pubmed/20220523",
        "http://www.ncbi.nlm.nih.gov/pubmed/14960708",
        "http://www.ncbi.nlm.nih.gov/pubmed/35295076",
        "http://www.ncbi.nlm.nih.gov/pubmed/11878590",
        "http://www.ncbi.nlm.nih.gov/pubmed/21313803",
        "http://www.ncbi.nlm.nih.gov/pubmed/28911409",
        "http://www.ncbi.nlm.nih.gov/pubmed/36367473",
        "http://www.ncbi.nlm.nih.gov/pubmed/29110333",
        "http://www.ncbi.nlm.nih.gov/pubmed/8013092",
        "http://www.ncbi.nlm.nih.gov/pubmed/27291863",
        "http://www.ncbi.nlm.nih.gov/pubmed/21662779",
        "http://www.ncbi.nlm.nih.gov/pubmed/29105560",
        "http://www.ncbi.nlm.nih.gov/pubmed/34155649",
        "http://www.ncbi.nlm.nih.gov/pubmed/16353984",
        "http://www.ncbi.nlm.nih.gov/pubmed/21603916",
        "http://www.ncbi.nlm.nih.gov/pubmed/33799266",
        "http://www.ncbi.nlm.nih.gov/pubmed/18996077",
        "http://www.ncbi.nlm.nih.gov/pubmed/31355390",
        "http://www.ncbi.nlm.nih.gov/pubmed/10958968",
        "http://www.ncbi.nlm.nih.gov/pubmed/25907667",
        "http://www.ncbi.nlm.nih.gov/pubmed/19007500",
        "http://www.ncbi.nlm.nih.gov/pubmed/29566782",
        "http://www.ncbi.nlm.nih.gov/pubmed/22165002",
        "http://www.ncbi.nlm.nih.gov/pubmed/20166602",
        "http://www.ncbi.nlm.nih.gov/pubmed/14647939",
        "http://www.ncbi.nlm.nih.gov/pubmed/19588457",
        "http://www.ncbi.nlm.nih.gov/pubmed/18298073",
        "http://www.ncbi.nlm.nih.gov/pubmed/19167854",
        "http://www.ncbi.nlm.nih.gov/pubmed/18178357",
        "http://www.ncbi.nlm.nih.gov/pubmed/31680080",
        "http://www.ncbi.nlm.nih.gov/pubmed/20299027",
        "http://www.ncbi.nlm.nih.gov/pubmed/24401401",
        "http://www.ncbi.nlm.nih.gov/pubmed/32308686",
        "http://www.ncbi.nlm.nih.gov/pubmed/27886648",
        "http://www.ncbi.nlm.nih.gov/pubmed/15936163",
        "http://www.ncbi.nlm.nih.gov/pubmed/30086968",
        "http://www.ncbi.nlm.nih.gov/pubmed/27154653",
        "http://www.ncbi.nlm.nih.gov/pubmed/1783594"
      ]
    },
    {
      "id": "642a029d57b1c7a315000011",
      "type": "summary",
      "body": "Histone acetyltransferases (HATs) transfer acetyl groups from acetyl CoA to lysine residues on histones. What is the purpose of this transfer?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32157780",
          "text": "ansfer acetyl groups onto histones and thereby regulate both gene expression and chromosomal structures. Previous work has shown that the activation o",
          "offsetInBeginSection": 63,
          "offsetInEndSection": 213,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32695779",
          "text": "The eukaryotic histone acetylation cycle is composed of three classes of proteins, histone acetyltransferases (HATs) that add acetyl groups to lysine amino acids, bromodomain (BRD) containing proteins that are one of the most characterized of several protein domains that recognize acetyl-lysine (Kac) and effect downstream function, and histone deacetylases (HDACs) that catalyze the reverse reaction.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 402,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11112280",
          "text": "residues in the N-terminal tails of nucleosomal histones to promote transcriptional activation. Recent structural and enzymatic work on the GCN5/PCAF ",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12391296",
          "text": "ther transcription factors, such as the p53 tumor suppressor, to promote gene activation. HAT enzymes fall into subfamilies with divergence in sequenc",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12368900",
          "text": " A (CoA) to acetylate specific Lys residues within histones to regulate gene expression. The structure of an ESA1-CoA complex reveals structural simil",
          "offsetInBeginSection": 108,
          "offsetInEndSection": 258,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29261229",
          "text": "e family that regulates these processes by catalyzing the transfer of an acetyl moiety onto target proteins. Perturbations of cellular acetylation pro",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 311,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12624111",
          "text": ") are a group of enzymes that play a significant role in the regulation of gene expression. These enzymes covalently modify the N-terminal lysine resi",
          "offsetInBeginSection": 32,
          "offsetInEndSection": 182,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10790315",
          "text": "Histone acetyltransferases (HATs) catalyze the acetyl-group transfer from acetyl-CoA to the epsilon-amino group of specific lysine residues within core histone proteins.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21057107",
          "text": "tisubunit complexes in which accessory proteins regulate substrate specificity and catalytic efficiency. Rtt109 is a particularly interesting example ",
          "offsetInBeginSection": 54,
          "offsetInEndSection": 204,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31818759",
          "text": "enzyme A (Ac-CoA) to lysine residues of substrate peptide, thus generating CoA molecule. Later, CoA, which acts as an initiator, can embrace its aptam",
          "offsetInBeginSection": 371,
          "offsetInEndSection": 521,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30725455",
          "text": "The Michaelis constant (Km) of most histone acetyltransferases (HATs), which specifically target histone proteins, falls within the range of cellular acetyl-CoA concentrations.",
          "offsetInBeginSection": 522,
          "offsetInEndSection": 698,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17223684",
          "text": "Together, the results suggest that MYST family HATs utilize a direct-attack mechanism within an Esa1 x acetyl-CoA x histone ternary complex.",
          "offsetInBeginSection": 1617,
          "offsetInEndSection": 1757,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19056256",
          "text": "The ability of HATs to form distinct multi-subunit complexes provides a means to regulate HAT activity by altering substrate specificity, targeting to specific loci, enhancing acetyltransferase activity, restricting access of non-target proteins, and coordinating the multiple enzyme activities of the complex.",
          "offsetInBeginSection": 458,
          "offsetInEndSection": 768,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10485713",
          "text": "ithin the aminoterminal tails of core histones to facilitate access to DNA by transcriptional activators. Here we report the high-resolution crystal s",
          "offsetInBeginSection": 367,
          "offsetInEndSection": 517,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31606077",
          "text": "Histone acetyltransferases catalyze the addition of these chemical modifications to histone lysine residues.",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19577000",
          "text": "Different subtypes of histone acetyl transferases (HATs) catalyze the acetylation of histones on specific lysine residues.",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 271,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28240169",
          "text": "Histone acetyltransferases (HATs) are epigenetic drivers that catalyze the acetyl transfer from acetyl-CoA to lysines of both histone and non-histone substrates and thereby induce transcription either by chromatin remodeling or direct transcription factor activation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 267,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21981917",
          "text": "Histone acetyltransferases (HATs) are an essential regulatory component in chromatin biology.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32764680",
          "text": "to lysine residues of histones and play a central role in transcriptional regulation in diverse biological processes. Dysregulation of HAT activity ca",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25707943",
          "text": "cleosomal histone tails provides a crucial mechanism for epigenetic control of gene expression. Acetyl groups are coupled to lysine residues by histon",
          "offsetInBeginSection": 40,
          "offsetInEndSection": 190,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21908798",
          "text": "Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from an acetyl-coenzyme A donor molecule to specific lysine residues within proteins.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10579936",
          "text": "he core histone proteins is strongly correlated to the regulation of gene transcription in vivo. To directly study the effects of histone acetylation ",
          "offsetInBeginSection": 67,
          "offsetInEndSection": 217,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27231488",
          "text": "Histone acetyltransferases (HATs) are epigenetic enzymes that install acetyl groups onto lysine residues of cellular proteins such as histones, transcription factors, nuclear receptors, and enzymes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10373413",
          "text": "Within chromatin, reversible acetylation of core histones is critical for transcriptional activation of eukaryotic target genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15313419",
          "text": "The group of enzymes, histone acetyltransferases (HATs), involved in this crucial step of gene regulation, covalently modifies the N-terminal lysine residues of histones by the addition of an acetyl group from acetyl coenzyme A. Dysfunction of these enzymes is often associated with several diseases, ranging from neurodegenerative disorders to cancer.",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 435,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26065557",
          "text": "Histone acetyltransferases (HATs) mediate the transfer of an acetyl group from the cofactor, acetyl-CoA, to the side chain amino group of specific lysines in diverse protein substrates, most notably nuclear histones.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28496053",
          "text": "cation that plays a fundamental role in regulating eukaryotic gene expression and chromatin structure/function. Key enzymes for removing acetyl groups",
          "offsetInBeginSection": 60,
          "offsetInEndSection": 210,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17464243",
          "text": "onal modification of histones is an important process in the regulation of gene expression. Aberrant expression and recruitment and disrupted activiti",
          "offsetInBeginSection": 260,
          "offsetInEndSection": 410,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15955204",
          "text": "Histone acetylation regulates gene transcription. Histone acetylation is a reversible process: histone acetyltransferases (HAT) transfer the acetyl mo",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8514763",
          "text": "in vitro transfer of acetyl groups from [1-14C]acetyl-CoA to non-acetylated pea histone H4. Up to three acetyl groups can be introduced into the histone. The resulting mono-, di-, and triacetylated H4 isoforms were separated and sequenced to determine the acetylated sites. Only sites 5, 12, and 16 were used by histone acetyltransferase B, but no clear preference among them was observed. The absence of modification of other potentially acetylatable sites is another indication that acetylation of the different lysine residues in the N-terminal H4 tail serves as a specific signal in different nuclear processes",
          "offsetInBeginSection": 240,
          "offsetInEndSection": 854,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7308193",
          "text": "Polyamines have been shown to increase the rate of transfer of acetyl groups from acetyl-CoA to endogenous histones in chromatin and nuclei from 50-h-old Artemia nauplii, with little changes in the rate of deacetylation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17325692",
          "text": "Histone deacetylases (HDACs) and histone acetyl transferases (HATs) are two counteracting enzyme families whose enzymatic activity controls the acetylation state of protein lysine residues, notably those contained in the N-terminal extensions of the core histones.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27231488",
          "text": "vity of inhibitors in in vitro studies and their potential use as therapeutic agents. To bridge this gap, new potent HAT inhibitors with improved prop",
          "offsetInBeginSection": 629,
          "offsetInEndSection": 779,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10373413",
          "text": "Our results suggest that the HAT reaction involves the formation of a ternary complex (histones, acetyl-CoA, and enzyme) where the epsilon-amino group of histone lysine residues directly attacks the bound acetyl-CoA.",
          "offsetInBeginSection": 840,
          "offsetInEndSection": 1056,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27631103",
          "text": "Histone acetyltransferases (HATs) and histone deacetylases (HDACs) catalyze the addition and removal of acetyl groups on lysine residues, a post-translational modification important for the DDR.",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 341,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27231488",
          "text": "A characteristic feature of HATs is that they are bi-substrate enzymes that catalyze reactions between two substrates: the cofactor acetyl coenzyme A (Ac-CoA) and a lysine-containing substrate.",
          "offsetInBeginSection": 1362,
          "offsetInEndSection": 1555,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30725455",
          "text": "ch, when present on chromatin-bound histones, facilitates the accessibility of DNA for gene transcription. The central metabolite, acetyl-CoA, is a su",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35042977",
          "text": "Histone acetylation has also recently been shown to mediate cellular memory.",
          "offsetInBeginSection": 872,
          "offsetInEndSection": 948,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16085424",
          "text": "Both methods are highly applicable in determining steady-state reaction rates, and obtaining the kinetic constants Vmax, Km, and V/K from substrate saturation curves.",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 817,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27761814",
          "text": "HAT activity results in the addition of acetyl groups on the lysine residues of histone tails leading to decondensation of the chromatin, and increased gene transcription in general, whereas HDACs remove these acetyl groups, thus leading to an overall suppression of gene transcription.",
          "offsetInBeginSection": 168,
          "offsetInEndSection": 454,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26198144",
          "text": "Two types of enzymes - histone acetyltransferases (HATs) and histone deacetylases (HDACs) establish and maintain specific patterns of histone acetylation in balance, thereby contributing to both transcriptional activation and repression of specific sets of genes.",
          "offsetInBeginSection": 264,
          "offsetInEndSection": 527,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21933453",
          "text": "Acetylation of lysine residues is a post-translational modification with broad relevance to cellular signalling and disease biology.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17223684",
          "text": "Gcn5-like HATs utilize an ordered sequential mechanism involving direct nucleophilic attack of the N-epsilon-lysine on the enzyme-bound acetyl-CoA.",
          "offsetInBeginSection": 113,
          "offsetInEndSection": 260,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21879443",
          "text": "etyl-CoA to the \u03b5-amino group of a lysine residue. This is posttranslational and reversible, with its level dynamically maintained by lysine acetyltra",
          "offsetInBeginSection": 70,
          "offsetInEndSection": 220,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32764680",
          "text": "Mechanistically, our data propose that acetylated histones provide a platform for the recruitment of MLL-fusion-associated adaptor proteins such as BRD4 and AF4 to gene promoters.",
          "offsetInBeginSection": 840,
          "offsetInEndSection": 1019,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17694092",
          "text": "The post-translational modification of histones plays an important role in chromatin regulation, a process that insures the fidelity of gene expression and other DNA transactions.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11437232",
          "text": "Histone acetyltransferases (HATs) transfer the acetyl moiety of acetyl-coenzyme A to the epsilon-amino group; this reaction is reverted by histone deacetylases (HDACs).",
          "offsetInBeginSection": 325,
          "offsetInEndSection": 493,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17694092",
          "text": "man diseases such as cancer and metabolic disorders, thus making them important drug targets. Significant mechanistic insights into the function of HA",
          "offsetInBeginSection": 594,
          "offsetInEndSection": 744,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21879443",
        "http://www.ncbi.nlm.nih.gov/pubmed/17223684",
        "http://www.ncbi.nlm.nih.gov/pubmed/15313419",
        "http://www.ncbi.nlm.nih.gov/pubmed/12624111",
        "http://www.ncbi.nlm.nih.gov/pubmed/32695779",
        "http://www.ncbi.nlm.nih.gov/pubmed/15955204",
        "http://www.ncbi.nlm.nih.gov/pubmed/16085424",
        "http://www.ncbi.nlm.nih.gov/pubmed/10485713",
        "http://www.ncbi.nlm.nih.gov/pubmed/32764680",
        "http://www.ncbi.nlm.nih.gov/pubmed/21908798",
        "http://www.ncbi.nlm.nih.gov/pubmed/12391296",
        "http://www.ncbi.nlm.nih.gov/pubmed/28496053",
        "http://www.ncbi.nlm.nih.gov/pubmed/27631103",
        "http://www.ncbi.nlm.nih.gov/pubmed/21933453",
        "http://www.ncbi.nlm.nih.gov/pubmed/8514763",
        "http://www.ncbi.nlm.nih.gov/pubmed/11437232",
        "http://www.ncbi.nlm.nih.gov/pubmed/32157780",
        "http://www.ncbi.nlm.nih.gov/pubmed/31818759",
        "http://www.ncbi.nlm.nih.gov/pubmed/19577000",
        "http://www.ncbi.nlm.nih.gov/pubmed/12368900",
        "http://www.ncbi.nlm.nih.gov/pubmed/27231488",
        "http://www.ncbi.nlm.nih.gov/pubmed/31606077",
        "http://www.ncbi.nlm.nih.gov/pubmed/25707943",
        "http://www.ncbi.nlm.nih.gov/pubmed/28240169",
        "http://www.ncbi.nlm.nih.gov/pubmed/10579936",
        "http://www.ncbi.nlm.nih.gov/pubmed/26065557",
        "http://www.ncbi.nlm.nih.gov/pubmed/21981917",
        "http://www.ncbi.nlm.nih.gov/pubmed/35042977",
        "http://www.ncbi.nlm.nih.gov/pubmed/26198144",
        "http://www.ncbi.nlm.nih.gov/pubmed/21057107",
        "http://www.ncbi.nlm.nih.gov/pubmed/17325692",
        "http://www.ncbi.nlm.nih.gov/pubmed/19056256",
        "http://www.ncbi.nlm.nih.gov/pubmed/29261229",
        "http://www.ncbi.nlm.nih.gov/pubmed/10373413",
        "http://www.ncbi.nlm.nih.gov/pubmed/11112280",
        "http://www.ncbi.nlm.nih.gov/pubmed/30725455",
        "http://www.ncbi.nlm.nih.gov/pubmed/17464243",
        "http://www.ncbi.nlm.nih.gov/pubmed/17694092",
        "http://www.ncbi.nlm.nih.gov/pubmed/27761814",
        "http://www.ncbi.nlm.nih.gov/pubmed/7308193",
        "http://www.ncbi.nlm.nih.gov/pubmed/10790315"
      ]
    },
    {
      "id": "6432fc0457b1c7a31500001f",
      "type": "factoid",
      "body": "Which gene is most frequently mutated in hereditary angioedema ?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34065094",
          "text": "he hands, feet, limbs, face, intestinal tract, or airway. Mutations in SERPING1, the gene that encodes C1-INH (C1 esterase inhibitor), are responsible",
          "offsetInBeginSection": 185,
          "offsetInEndSection": 335,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36203343",
          "text": "), 8/79 (9%), and 3/79 (4%) of the patients respectively, revealing that SPTB is the most frequently mutated HS gene in Eastern China. Most SPTB and A",
          "offsetInBeginSection": 539,
          "offsetInEndSection": 689,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27470642",
          "text": "Angioedema can be caused by C1-inhibitor deficiency (C1-INH-hereditary angioedema and C1-INH-acquired angioedema), mutations in coagulation factor XII (FXII-hereditary angioedema), and treatment with angiotensin-converting enzyme inhibitors (ACEI-acquired angioedema).",
          "offsetInBeginSection": 695,
          "offsetInEndSection": 963,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30044938",
          "text": "BACKGROUND\nHereditary angioedema is a life-threatening illness caused by mutations in the gene encoding C1 inhibitor (also called C1 esterase inhibitor) that lead to overactivation of the kallikrein-bradykinin cascade.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33780405",
          "text": "used by either a C1 esterase inhibitor deficiency (type 1) or mutation (type 2). This leads to overproduction of bradykinin resulting in vasodilation,",
          "offsetInBeginSection": 80,
          "offsetInEndSection": 230,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36417927",
          "text": "The fundamental cause of hereditary angioedema in almost all patients is a mutation in the SERPING1 gene leading to a deficiency in C1-inhibitor.",
          "offsetInBeginSection": 424,
          "offsetInEndSection": 569,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33593719",
          "text": "childhood or adolescence. Most of these patients have mutations in the SERPING1 gene, causing either low C1 inhibitor production (hereditary angioedem",
          "offsetInBeginSection": 353,
          "offsetInEndSection": 503,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30146609",
          "text": "Genetic testing revealed a heterozygous nonsense mutation of the SERPING1 gene, and a diagnosis of hereditary angioedema was made.",
          "offsetInBeginSection": 520,
          "offsetInEndSection": 650,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760113",
          "text": "utosomal-dominant and life-threatening disorder caused by mutations in SERPING1 gene. It is characterized by attacks of angioedema involving the skin ",
          "offsetInBeginSection": 76,
          "offsetInEndSection": 226,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27116602",
          "text": "d function of bradykinin. Alterations detected in at least one more gene (F12) are nowadays considered responsible for 25\u00a0% of cases of hereditary ang",
          "offsetInBeginSection": 539,
          "offsetInEndSection": 689,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19477491",
          "text": "BACKGROUND\nHereditary angioedema caused by mutations in the factor XII gene is a recently described disease entity that occurs mainly in women.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282866",
          "text": "HAE results from mutations in the SERPING1 gene that lead to a loss of functional C1 inhibitor.",
          "offsetInBeginSection": 1180,
          "offsetInEndSection": 1275,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27271546",
          "text": "therapeutic characteristics of patients with HAE linked to a mutation of FXII gene. Fifty-seven patients were identified from 24 different families. I",
          "offsetInBeginSection": 569,
          "offsetInEndSection": 719,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14572812",
          "text": "tion, and genetically by a heterogeneous group of mutations in the C1 inhibitor gene that have an autosomal dominant mode of transmission. Androgens a",
          "offsetInBeginSection": 160,
          "offsetInEndSection": 310,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27826968",
          "text": "ct in the C1 esterase inhibitor (C1-INH) consequent to mutation in the SERPING1 gene, which encodes C1-INH. This disease manifests as recurrent, non-p",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282866",
          "text": "HAE results from mutations in the SERPING1 gene that lead to a loss of functional C1 inhibitor.",
          "offsetInBeginSection": 1180,
          "offsetInEndSection": 1275,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20955596",
          "text": "The disease results from mutations in the C1 esterase inhibitor gene that cause C1 esterase inhibitor deficiency.",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 408,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30530986",
          "text": "Hereditary angioedema (HAE) is a rare genetic disorder primarily caused by mutations in the SERPING1 gene encoding the C1 inhibitor (C1INH) that leads to plasma deficiency, resulting in recurrent attacks of severe swelling.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31574187",
          "text": "Over the last years, information grew fast, and mutations in different genes, in addition to C1-inhibitor, were found to be causative.",
          "offsetInBeginSection": 168,
          "offsetInEndSection": 302,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8792821",
          "text": "The polymerase chain reaction and nucleotide sequence analysis have been used to characterize a point mutation in the seventh exon of one allele of the C1-inhibitor gene in a family with type I hereditary angioedema.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20667118",
          "text": "Recently, in some families mutations in the coagulation factor XII (Hageman factor) gene were detected in the affected persons.",
          "offsetInBeginSection": 528,
          "offsetInEndSection": 655,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22882460",
          "text": " role in the classical pathway of the complement system. Mutations in C1INH gene cause quantitative or qualitative deficiencies in C1INH, which can le",
          "offsetInBeginSection": 39,
          "offsetInEndSection": 189,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19656474",
          "text": "In some families, mutations in the coagulation factor XII (Hageman factor) gene were detected in the affected persons.",
          "offsetInBeginSection": 522,
          "offsetInEndSection": 640,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34838707",
          "text": "Both type I and II HAE-C1INH result from inherited or spontaneous mutations in the SERPING1 gene, which encodes for C1INH.",
          "offsetInBeginSection": 399,
          "offsetInEndSection": 521,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28601681",
          "text": "e genetic\u00a0disease usually caused by mutation in the C1 inhibitor or the coagulation Factor XII gene. However, in a series of patients with HAE, no cau",
          "offsetInBeginSection": 47,
          "offsetInEndSection": 197,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21623829",
          "text": "ive subjects were interviewed and investigated for mutation at the C1 inhibitor gene. Subjects reporting a history of recurrent episodes of angioedema",
          "offsetInBeginSection": 591,
          "offsetInEndSection": 741,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21623829",
          "text": "ading to elevated levels of bradykinin. More than 200 mutations in C1 inhibitor gene have been reported. The aim of this study was to analyze clinical",
          "offsetInBeginSection": 188,
          "offsetInEndSection": 338,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33271064",
          "text": "In the most frequent phenotype, there is a quantitative and/or functional deficiency in the C1esterase inhibitor protein, which regulates the activation of the complement, contact and fibrinolysis systems with greater formation of bradykinin, the main mediator of angioedema.",
          "offsetInBeginSection": 379,
          "offsetInEndSection": 654,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24176211",
          "text": "In some families mutations in the coagulation factor XII (Hageman factor) gene were detected.",
          "offsetInBeginSection": 524,
          "offsetInEndSection": 617,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22195758",
          "text": "Abdominal pain, angioedema, bradykinin, C1 inhibitor, hereditary,  inherited, swelling.",
          "offsetInBeginSection": 525,
          "offsetInEndSection": 612,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16634360",
          "text": "It is caused by heterozygous defects in the C1 inhibitor gene located on chromosome 11q, and it has an autosomal dominant inheritance pattern.",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 340,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25538858",
          "text": "More than 200 point mutations in the C1 inhibitor gene have been found to be associated with HAE.",
          "offsetInBeginSection": 154,
          "offsetInEndSection": 251,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166502",
          "text": "1-INH protein concentrations and functions. A mutation (c.1247T>A) in C1-INH gene was detected. They were diagnosed as having hereditary angioedema wi",
          "offsetInBeginSection": 717,
          "offsetInEndSection": 867,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17085286",
          "text": "Recently, in some families mutations in the coagulation factor XII (Hageman factor) gene were detected in the affected women.",
          "offsetInBeginSection": 424,
          "offsetInEndSection": 549,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8586465",
          "text": "d protein 4.1. Recent mutation analyses have revealed that the NF2 tumor suppressor gene is frequently mutated not only in vestibular schwannomas and ",
          "offsetInBeginSection": 1248,
          "offsetInEndSection": 1398,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166502",
          "text": "METHODS\nThe medical history, clinical features and C1-INH gene mutation of a Turkish family were investigated and outcomes of long-term treatments were described.",
          "offsetInBeginSection": 275,
          "offsetInEndSection": 437,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27271546",
          "text": "HAE with normal C1-INH is associated in 20% of cases with mutations in the gene for factor XII (FXII) or FXII-HAE.",
          "offsetInBeginSection": 153,
          "offsetInEndSection": 267,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19477491",
          "text": "and tranexamic acid (1 woman). No difference between mutation p.Thr309Arg and p.Thr309Lys was found.\n\n\nCONCLUSIONS\nFacial swelling is a cardinal sympt",
          "offsetInBeginSection": 1427,
          "offsetInEndSection": 1577,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366422",
          "text": "re autosomal dominant disorder caused by reduced activity of the C1 esterase inhibitor. Clinically, angioedema most often involves the upper extremiti",
          "offsetInBeginSection": 35,
          "offsetInEndSection": 185,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27826968",
          "text": "mally low C1-INH activity (less than 25%; normal range: 70%-130%). The SERPING1 gene mutation was confirmed in this patient. She was treated with prop",
          "offsetInBeginSection": 1064,
          "offsetInEndSection": 1214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33593719",
          "text": "y angioedema symptoms owing to mutations in FXII, PLG, ANGPT1, KNG1, and MYOF genes. Patients who exhibit none of these genetic mutations despite havi",
          "offsetInBeginSection": 826,
          "offsetInEndSection": 976,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28601681",
          "text": "ers and showed reduced binding capability to its receptor.\n\n\nCONCLUSION\nANGPT1 impairment is associated with angioedema, and ANGPT1 variants can be th",
          "offsetInBeginSection": 1680,
          "offsetInEndSection": 1830,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33442779",
          "text": "These include genetic mutations in factor 12 gene, plasminogen gene, angiopoietin gene, kininogen 1, and myoferlin genes.",
          "offsetInBeginSection": 519,
          "offsetInEndSection": 640,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24484972",
          "text": "In HAE with normal C1INH, mutations in the F12 gene have been identified in a subset of individuals, but the genetic defect remains unknown in most patients.",
          "offsetInBeginSection": 760,
          "offsetInEndSection": 917,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28601681",
          "text": "ltiplex family with U-HAE and performed whole-exome sequencing. The angiopoietin-1 gene (ANGPT1) was investigated in all patients with familial or spo",
          "offsetInBeginSection": 757,
          "offsetInEndSection": 907,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22014012",
          "text": "Hereditary angioedema is most frequently caused by a deficiency of C1-inhibitor.",
          "offsetInBeginSection": 317,
          "offsetInEndSection": 397,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33593719",
          "text": "ibitor-induced acquired angioedema, and hereditary angioedema with normal C1 inhibitor makes the diagnosis more challenging. Future efforts should foc",
          "offsetInBeginSection": 2691,
          "offsetInEndSection": 2841,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15675329",
          "text": "Acquired C1 inhibitor deficiency is most frequently associated with B-cell lymphoproliferative disease.",
          "offsetInBeginSection": 318,
          "offsetInEndSection": 421,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24484972",
          "text": "tions in the SERPING1 gene that result in decreased plasma levels of functional C1INH. In HAE with normal C1INH, mutations in the F12 gene have been i",
          "offsetInBeginSection": 673,
          "offsetInEndSection": 823,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21251443",
          "text": "isorder resulting from an inherited deficiency or dysfunction of the C1 inhibitor. It is characterized by recurrent, circumscribed, and self-limiting ",
          "offsetInBeginSection": 41,
          "offsetInEndSection": 191,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8586465",
        "http://www.ncbi.nlm.nih.gov/pubmed/28601681",
        "http://www.ncbi.nlm.nih.gov/pubmed/15675329",
        "http://www.ncbi.nlm.nih.gov/pubmed/20667118",
        "http://www.ncbi.nlm.nih.gov/pubmed/19656474",
        "http://www.ncbi.nlm.nih.gov/pubmed/21251443",
        "http://www.ncbi.nlm.nih.gov/pubmed/27271546",
        "http://www.ncbi.nlm.nih.gov/pubmed/24176211",
        "http://www.ncbi.nlm.nih.gov/pubmed/27470642",
        "http://www.ncbi.nlm.nih.gov/pubmed/31574187",
        "http://www.ncbi.nlm.nih.gov/pubmed/33780405",
        "http://www.ncbi.nlm.nih.gov/pubmed/27366422",
        "http://www.ncbi.nlm.nih.gov/pubmed/25538858",
        "http://www.ncbi.nlm.nih.gov/pubmed/36203343",
        "http://www.ncbi.nlm.nih.gov/pubmed/34838707",
        "http://www.ncbi.nlm.nih.gov/pubmed/34065094",
        "http://www.ncbi.nlm.nih.gov/pubmed/21623829",
        "http://www.ncbi.nlm.nih.gov/pubmed/27826968",
        "http://www.ncbi.nlm.nih.gov/pubmed/29166502",
        "http://www.ncbi.nlm.nih.gov/pubmed/20955596",
        "http://www.ncbi.nlm.nih.gov/pubmed/8792821",
        "http://www.ncbi.nlm.nih.gov/pubmed/33271064",
        "http://www.ncbi.nlm.nih.gov/pubmed/30146609",
        "http://www.ncbi.nlm.nih.gov/pubmed/19477491",
        "http://www.ncbi.nlm.nih.gov/pubmed/24484972",
        "http://www.ncbi.nlm.nih.gov/pubmed/22014012",
        "http://www.ncbi.nlm.nih.gov/pubmed/17085286",
        "http://www.ncbi.nlm.nih.gov/pubmed/36417927",
        "http://www.ncbi.nlm.nih.gov/pubmed/22195758",
        "http://www.ncbi.nlm.nih.gov/pubmed/16634360",
        "http://www.ncbi.nlm.nih.gov/pubmed/14572812",
        "http://www.ncbi.nlm.nih.gov/pubmed/24760113",
        "http://www.ncbi.nlm.nih.gov/pubmed/27116602",
        "http://www.ncbi.nlm.nih.gov/pubmed/33593719",
        "http://www.ncbi.nlm.nih.gov/pubmed/33442779",
        "http://www.ncbi.nlm.nih.gov/pubmed/22882460",
        "http://www.ncbi.nlm.nih.gov/pubmed/30044938",
        "http://www.ncbi.nlm.nih.gov/pubmed/23282866",
        "http://www.ncbi.nlm.nih.gov/pubmed/30530986"
      ]
    },
    {
      "id": "64178edb690f196b51000025",
      "type": "summary",
      "body": "What is casimersen's mechanism of action?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
          "text": "In the present study, we posit that normative change is a plausible mechanism and provide a test of this in an eating disorder prevention group program.",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 278,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826604",
          "text": "ivation consistent with left free wall accessory pathway. With induction of tachycardia, beats with LBBB morphology have shorter cycle length than tho",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 305,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283",
          "text": "The role of the mirror mechanism in cognition remains an intriguing and hotly debated topic in cognitive neuroscience.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20735416",
          "text": "mechanism of action of general anaesthetics (GAs) involving membranes and protein receptors. I provide the reasons why the GABA type A receptor, the N",
          "offsetInBeginSection": 227,
          "offsetInEndSection": 377,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
          "text": "However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged.",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19719780",
          "text": "d the position to date and suggested a new mechanistic contender, receptor rebinding. Despite this, they still do not come to any clear conclusion. Mu",
          "offsetInBeginSection": 185,
          "offsetInEndSection": 335,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "nal heterogeneity in the specific vasoconstrictor involved. Oxygen-induced vasoconstriction may serve as a protective mechanism to reduce the oxidativ",
          "offsetInBeginSection": 1422,
          "offsetInEndSection": 1572,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10029375",
          "text": "These drugs can induce cell cycle arrest and apoptosis in colon cancer cell lines through a mechanism that is fundamentally different from the apoptosis caused by cancer chemotherapeutic agents.",
          "offsetInBeginSection": 1011,
          "offsetInEndSection": 1205,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19719780",
        "http://www.ncbi.nlm.nih.gov/pubmed/20735416",
        "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
        "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
        "http://www.ncbi.nlm.nih.gov/pubmed/10029375",
        "http://www.ncbi.nlm.nih.gov/pubmed/34826604",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
        "http://www.ncbi.nlm.nih.gov/pubmed/23089283"
      ]
    },
    {
      "id": "6402bf2b201352f04a000007",
      "type": "summary",
      "body": "What is the mechanism of action of tiragolumab?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576957",
          "text": " (16\u00b72% [6\u00b77-25\u00b77]) in the placebo plus atezolizumab group had an objective response (p=0\u00b7031). Median progression-free survival was 5\u00b74 months (95% C",
          "offsetInBeginSection": 2161,
          "offsetInEndSection": 2311,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32576590",
          "text": "tion with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically signifi",
          "offsetInBeginSection": 52,
          "offsetInEndSection": 202,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576957",
          "text": "INTERPRETATION\nTiragolumab plus atezolizumab showed a clinically meaningful improvement in objective response rate and progression-free survival compared with placebo plus atezolizumab in patients with chemotherapy-naive, PD-L1-positive, recurrent or metastatic NSCLC.",
          "offsetInBeginSection": 2991,
          "offsetInEndSection": 3259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576957",
          "text": "BACKGROUND\nTargeted inhibition of the PD-L1-PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune checkpoint agents, such as tiragolumab.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26292636",
          "text": "Tramadol is an analgesic that is used worldwide for pain, but its mechanisms of action have not been fully elucidated.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35292828",
          "text": "Together these data suggest that the association of atezolizumab and tiragolumab could restore function of CD4 and CD8 TILs in MSS-CRC and could be tested in a clinical trial in colorectal cancer patients with MSS status.",
          "offsetInBeginSection": 1406,
          "offsetInEndSection": 1627,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35292828",
          "text": "Together these data suggest that the association of atezolizumab and tiragolumab could restore function of CD4 and CD8 TILs in MSS-CRC and could be tested in a clinical trial in colorectal cancer patients with MSS status.",
          "offsetInBeginSection": 1406,
          "offsetInEndSection": 1627,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35292828",
          "text": "Our aim was to evaluate ex vivo the capacity of the combination of atezolizumab (anti-PD-L1) and tiragolumab (anti-TIGIT) to reactivate the immune response of tumor infiltrating lymphocytes (TILs) in MSS-CRC.",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 398,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35652612",
          "text": "Genentech's TIGIT-targeted antibody tiragolumab missed its endpoints in two late-stage lung cancer trials, raising doubts about one of the most widely studied next-generation checkpoint targets in immuno-oncology.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283",
          "text": "The role of the mirror mechanism in cognition remains an intriguing and hotly debated topic in cognitive neuroscience.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19719780",
          "text": "The mechanism of the long duration of action of salmeterol at beta(2)-adrenoceptors has long been a matter of debate, and is still unresolved.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8957109",
          "text": "The major effects of anti-TNFalpha therapy are in downregulating cytokine activity, and in reducing leucocyte trafficking to the joints.",
          "offsetInBeginSection": 543,
          "offsetInEndSection": 679,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19719780",
        "http://www.ncbi.nlm.nih.gov/pubmed/35576957",
        "http://www.ncbi.nlm.nih.gov/pubmed/32576590",
        "http://www.ncbi.nlm.nih.gov/pubmed/35652612",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
        "http://www.ncbi.nlm.nih.gov/pubmed/26292636",
        "http://www.ncbi.nlm.nih.gov/pubmed/23089283",
        "http://www.ncbi.nlm.nih.gov/pubmed/8957109",
        "http://www.ncbi.nlm.nih.gov/pubmed/35292828"
      ]
    },
    {
      "id": "641d8fd6690f196b51000041",
      "type": "list",
      "body": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34421896",
          "text": "Conclusions\nOur study highlighted the importance of mitophagy in MS and suggested the potential application of PINK1 and PARKIN as biomarkers to predict disease activity.",
          "offsetInBeginSection": 1039,
          "offsetInEndSection": 1209,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35887254",
          "text": "This review aims to provide an update on recent studies regarding issues related to NMOSD, including the pathophysiology of the disease, the potential use of serum and cerebrospinal fluid cytokines as disease biomarkers, the clinical utilization of ocular coherence tomography, and the comparison of different animal models of NMOSD.",
          "offsetInBeginSection": 549,
          "offsetInEndSection": 882,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31471502",
          "text": "th a sensitivity of 73.0% and a specificity of 75.8%.\n\n\nCONCLUSIONS\nsGFAP and sNfL are likely to be good biomarkers of disease activity and disability",
          "offsetInBeginSection": 1327,
          "offsetInEndSection": 1477,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25468778",
          "text": "The serum levels of IL-21, IL-6, IL-17, TNF-\u03b1 and IL-10 were analyzed by ELISA assays.",
          "offsetInBeginSection": 465,
          "offsetInEndSection": 551,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33019871",
          "text": "This article summarized the research progress in serum and cerebrospinal fluid biomarkers of astrocytes, neurons, myelin sheath, and other damage after the onset of NMOSD.",
          "offsetInBeginSection": 619,
          "offsetInEndSection": 790,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27049569",
          "text": "toimmune diseases. To explore the roles of the IL-12 family members IL-27 and IL-35 in the pathogenesis of neuromyelitis optica spectrum disorders (NM",
          "offsetInBeginSection": 61,
          "offsetInEndSection": 211,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25027264",
          "text": "Since the discovery of aquaporin 4-IgG, a sensitive and highly specific biomarker of neuromyelitis optica (NMO), a wide range of syndromes have been recognized as being associated with this condition.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36378751",
          "text": "ing remission may be predictive of future disease activity. Serial serum GFAP measurements are emerging as a biomarker to monitor disease activity in ",
          "offsetInBeginSection": 1234,
          "offsetInEndSection": 1384,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29478727",
          "text": "Serum immunoglobulin G autoantibodies (NMO-IgG) are identified in the majority of NMOSD patients.",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32961928",
          "text": "We highlight short chain fatty acids, lipoproteins, amino acids, and lactate as candidate diagnostic biomarkers.",
          "offsetInBeginSection": 875,
          "offsetInEndSection": 987,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32184342",
          "text": "CONCLUSION\nThe pattern of serum biomarkers of disease activity and disability in MOGAD showed a distinct feature from those in NMOSD with AQP4-Ab, which implicates different pathogeneses between the 2 diseases.",
          "offsetInBeginSection": 1420,
          "offsetInEndSection": 1630,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27402111",
          "text": "ing with MRI, cerebrospinal fluid analysis along with determination of AQP4-IgG serum autoantibody status, and exclusion of other disorders. Two major",
          "offsetInBeginSection": 841,
          "offsetInEndSection": 991,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32547558",
          "text": "Exosomal microRNAs (miRNAs) are emerging biomarkers for demyelinating diseases.",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 226,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34259579",
          "text": "al coherence tomography angiography (OCT-A), measurement of glial fibrillary acidic protein (GFAP) serum levels, and assessment of visual acuity.\n\n\nRE",
          "offsetInBeginSection": 594,
          "offsetInEndSection": 744,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938660",
          "text": "As our understanding regarding the immune pathophysiology of NMOSD expands, emerging biomarkers, including serum neurofilament light chain and glial fibrillary acidic protein (GFAP), may facilitate earlier relapse detection and inform long-term treatment decisions.",
          "offsetInBeginSection": 1216,
          "offsetInEndSection": 1481,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26941483",
          "text": "Currently, new drugs targeting specific points of the Th17 pathways are already being tested in clinical trials and provide basis for the development of biomarkers to monitor disease activity.",
          "offsetInBeginSection": 702,
          "offsetInEndSection": 894,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25468778",
          "text": "The serum levels of IL-21, IL-6, IL-17, TNF-\u03b1 and IL-10 were analyzed by ELISA assays.",
          "offsetInBeginSection": 465,
          "offsetInEndSection": 551,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31471502",
          "text": "OBJECTIVE\nTo test the hypothesis that serum levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), which are an intermediate astrocyte and neuron filaments, respectively, are clinically useful biomarkers of disease activity and disability in neuromyelitis optica spectrum disorders (NMOSD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 321,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24964112",
          "text": "Serum autoantibodies against aquaporin-4 (AQP4) are detected in most cases of NMOSD.",
          "offsetInBeginSection": 193,
          "offsetInEndSection": 277,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31664710",
          "text": "Recently, diagnosis and understanding of these diseases has been markedly enhanced by the discovery that serum autoantibodies that target aquaporin-4 (AQP4) are strongly associated with the disease.",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 400,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31664710",
          "text": "recently been evaluated. The results of these studies, involving monoclonal antibodies (mAbs) inhibiting terminal complement protein cleavage interfer",
          "offsetInBeginSection": 808,
          "offsetInEndSection": 958,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28248700",
          "text": "PURPOSE OF REVIEW\nSerum IgG autoantibodies against the myelin oligodendrocyte glycoprotein (MOG) are present in atypical demyelinating disorders such as neuromyelitis optica spectrum disorders (NMOSD) or acute disseminated encephalomyelitis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35401423",
          "text": "These include antibody titers, cytokine profiles, complement factors, and markers of neuronal (e.g., neurofilament light chain) or astroglial (e.g., glial fibrillary acidic protein) damage.",
          "offsetInBeginSection": 1340,
          "offsetInEndSection": 1529,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31382910",
          "text": "d Expanded Disability Status Scale (EDSS) scores.\n\n\nCONCLUSIONS\nSerum IL-36\u03b2 and IL-36\u03b3 levels were related to disease activity in NMOSD patients and ",
          "offsetInBeginSection": 665,
          "offsetInEndSection": 815,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35401423",
          "text": "These include antibody titers, cytokine profiles, complement factors, and markers of neuronal (e.g., neurofilament light chain) or astroglial (e.g., glial fibrillary acidic protein) damage.",
          "offsetInBeginSection": 1340,
          "offsetInEndSection": 1529,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32559008",
          "text": "METHODS\nFor 236 suspected NMOSD patients referred for serum aquaporin-4 immunoglobulin G antibody (AQP4-IgG) testing between 2012 and 2014, the three sets of NMOSD criteria [1999, 2006 NMO criteria and 2015 International Panel for NMO Diagnosis (IPND) criteria] were applied and compared to the final diagnosis.",
          "offsetInBeginSection": 376,
          "offsetInEndSection": 687,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32679524",
          "text": "We analyzed the associations between CSF YKL-40 levels and the clinical variables of NMOSD.",
          "offsetInBeginSection": 506,
          "offsetInEndSection": 597,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33272591",
          "text": "The disease concept of Neuromyelitis Optica Spectrum Disorders(NMOSD) has undergone a significant change over the last two decades including the detection of Myelin Oligodendrocyte Glycoprotein(MOG) antibody in patients who are seronegative for aquaporin-4 antibody.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 266,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32184342",
          "text": " those in neuromyelitis optica spectrum disorder (NMOSD) with anti-aquaporin-4 antibodies (AQP4-Abs).\n\n\nMETHODS\nUsing ultrasensitive single-molecule a",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 352,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32679524",
          "text": "Our aim of this study was to investigate cerebrospinal fluid (CSF) and serum YKL-40 levels in patients with NMOSD and their association with disease severity.",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 391,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938660",
          "text": "PURPOSE OF REVIEW\nThis article reviews the cardinal clinical features, distinct immunopathology, current diagnostic criteria, relapse-related risk factors, emerging biomarkers, and evolving treatment strategies pertaining to neuromyelitis optica spectrum disorders (NMOSD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 273,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35873620",
          "text": "The commonly altered proteins in all NMOSD variants with respect to control were smaug homolog protein and serum amyloid A. Truncated breast and ovarian cancer susceptibility protein and cystic fibrosis transmembrane conductance regulator protein were specifically upregulated and can act as potential biomarkers for neuromyelitis optica with autoantibody negativity to Aquaporin - 4 (AQP-4) and myelin oligodendrocyte (MOG) immunoglobulins.",
          "offsetInBeginSection": 686,
          "offsetInEndSection": 1127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36378751",
          "text": "kers for prognosis or treatment response are still lacking. Glial fibrillary acidic protein (GFAP) is mainly expressed in astrocytes and can be detect",
          "offsetInBeginSection": 472,
          "offsetInEndSection": 622,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34168058",
          "text": "OBJECTIVE\nTo determine whether distinct aquaporin-4 (AQP4)-IgG lineages play a role in neuromyelitis optica spectrum disorder (NMOSD) pathogenesis, we profiled the AQP4-IgG polyclonal serum repertoire and identified, quantified, and functionally characterized distinct AQP4-IgG lineages circulating in 2 patients with NMOSD.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 324,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33728474",
          "text": "eria enable the early diagnosis of NMOSD in patients with and without AQP4-IgG. Typical clinical manifestations include involvement of the spinal cord",
          "offsetInBeginSection": 502,
          "offsetInEndSection": 652,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33728474",
          "text": "Neuromyelitis optica spectrum disorder (NMOSD), derived from NMO or Devic's disease, is considered as a\u00a0distinct disease since the discovery of a\u00a0novel and pathogenic serum autoantibody targeting aquaporin\u20114 (AQP4-IgG) and is distinguished from classical multiple sclerosis (MS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 279,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32357803",
          "text": "EXPERT OPINION\nBeside anti-AQP4-IgG, other emerging biomarkers for NMOSD have been proposed.",
          "offsetInBeginSection": 563,
          "offsetInEndSection": 655,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31425702",
          "text": "nd improved treatment of the disease. Subsequently, myelin oligodendrocyte glycoprotein (MOG) IgG was recognized to be a marker for MOG-IgG-associated",
          "offsetInBeginSection": 516,
          "offsetInEndSection": 666,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34959021",
          "text": "MeSH include: Neuromyelitis optic and Rituximab or Azathioprine or Mycophenolate Mofetil; entry terms include: NMO Spectrum Disorder, NMO Spectrum Disorders, Neuromyelitis Optica (NMO) Spectrum Disorder, Neuromyelitis Optica Spectrum Disorders, Devic Neuromyelitis Optica, Neuromyelitis Optica, Devic, Devic's Disease, Devic Syndrome, Devic's Neuromyelitis Optica, Neuromyelitis Optica (NMO) Spectrum Disorders, CD20 Antibody, Rituximab CD20 Antibody, Mabthera, IDEC-C2B8 Antibody, GP2013, Rituxan, Mycophenolate Mofetil, Mofetil, Mycophenolate, Mycophenolic Acid, Morpholinoethyl Ester, Cellcept, Mycophenolate Sodium, Myfortic, Mycophenolate Mofetil Hydrochloride, Mofetil Hydrochloride, Mycophenolate, RS 61443, RS-61443, RS61443, azathioprine sodium, azathioprine sulfate (note: literature retrieval operators \"AND\" \"OR\" \"NOT\" are used to link MeSH with Entry Terms.)",
          "offsetInBeginSection": 771,
          "offsetInEndSection": 1642,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30056360",
          "text": "Due to the involvement of the PNS as indicated by electrodiagnostic examination, we verified the expression of aquaporin-4-channels on the proximal dorsal spinal radix of rats by staining rat tissue with human NMOSD serum.",
          "offsetInBeginSection": 333,
          "offsetInEndSection": 555,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33814893",
          "text": "isease, and further investigation is required in this population. Reliable biomarkers to guide therapy decisions are urgently needed. There is a pleth",
          "offsetInBeginSection": 692,
          "offsetInEndSection": 842,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35332817",
          "text": "Given the severe morbidity in AQP4-Ab NMOSD, prognostic biomarkers for disease severity are required to guide optimal therapy for patients.",
          "offsetInBeginSection": 617,
          "offsetInEndSection": 756,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31178306",
          "text": "dy indicated elevated protein and pleocytosis. Because serum anti-aquaporin-4 IgG antibody was positive, the patient was diagnosed with neuromyelitis ",
          "offsetInBeginSection": 570,
          "offsetInEndSection": 720,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32184342",
          "text": " in the sera of consecutive patients with MOGAD (n = 16) and NMOSD with AQP4-Ab (n = 33). Serum biomarker levels were compared between patients in rel",
          "offsetInBeginSection": 457,
          "offsetInEndSection": 607,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34212756",
          "text": "Among patients who did not develop new attacks during the main period (n\u2009=\u200962), serum levels of NfL, GFAP, and GFAP/NfL were significantly decreased over time in patients with attacks (<2\u2009months) at enrollment (n\u2009=\u200914 (23%)), whereas serum NfL and GFAP levels gradually increased in the others (n\u2009=\u200948 (77%)).",
          "offsetInBeginSection": 779,
          "offsetInEndSection": 1088,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28248700",
          "text": "odies are associated with a more benign disease course than aquaporin-4antibodies. However, recent findings challenged this view. Data from the two la",
          "offsetInBeginSection": 448,
          "offsetInEndSection": 598,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35810527",
          "text": "Our findings suggest that IL-6 serum level could serve as a biomarker for disease activity in NMOSD.",
          "offsetInBeginSection": 533,
          "offsetInEndSection": 633,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32547558",
          "text": " Hsa-miR-122-3p and hsa-miR-200a-5p had positive correlations with disease severity in NMOSD patients. Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed that the MAPK, Wnt and Ras signaling pathways were enriched. Further biological function analysis demonstrated that these two miRNAs might be involved in the immunoregulation of NMOSD pathogenesis. Our results indicated that miRNAs",
          "offsetInBeginSection": 1099,
          "offsetInEndSection": 1499,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31471502",
          "text": "Association of sGFAP and sNfL levels with clinical parameters was determined.",
          "offsetInBeginSection": 670,
          "offsetInEndSection": 747,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26538842",
          "text": "Novel biomarkers other than aquoporin 4 Immunoglobulin G (anti AQP4-IgG) have been discovered which may have clinical relevance.",
          "offsetInBeginSection": 406,
          "offsetInEndSection": 534,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30056360",
        "http://www.ncbi.nlm.nih.gov/pubmed/34421896",
        "http://www.ncbi.nlm.nih.gov/pubmed/35887254",
        "http://www.ncbi.nlm.nih.gov/pubmed/32559008",
        "http://www.ncbi.nlm.nih.gov/pubmed/27402111",
        "http://www.ncbi.nlm.nih.gov/pubmed/35401423",
        "http://www.ncbi.nlm.nih.gov/pubmed/32357803",
        "http://www.ncbi.nlm.nih.gov/pubmed/25027264",
        "http://www.ncbi.nlm.nih.gov/pubmed/26538842",
        "http://www.ncbi.nlm.nih.gov/pubmed/34168058",
        "http://www.ncbi.nlm.nih.gov/pubmed/35810527",
        "http://www.ncbi.nlm.nih.gov/pubmed/34212756",
        "http://www.ncbi.nlm.nih.gov/pubmed/27049569",
        "http://www.ncbi.nlm.nih.gov/pubmed/29478727",
        "http://www.ncbi.nlm.nih.gov/pubmed/33814893",
        "http://www.ncbi.nlm.nih.gov/pubmed/34259579",
        "http://www.ncbi.nlm.nih.gov/pubmed/28248700",
        "http://www.ncbi.nlm.nih.gov/pubmed/36378751",
        "http://www.ncbi.nlm.nih.gov/pubmed/26941483",
        "http://www.ncbi.nlm.nih.gov/pubmed/31178306",
        "http://www.ncbi.nlm.nih.gov/pubmed/32547558",
        "http://www.ncbi.nlm.nih.gov/pubmed/25468778",
        "http://www.ncbi.nlm.nih.gov/pubmed/33728474",
        "http://www.ncbi.nlm.nih.gov/pubmed/24964112",
        "http://www.ncbi.nlm.nih.gov/pubmed/35938660",
        "http://www.ncbi.nlm.nih.gov/pubmed/33272591",
        "http://www.ncbi.nlm.nih.gov/pubmed/33019871",
        "http://www.ncbi.nlm.nih.gov/pubmed/31471502",
        "http://www.ncbi.nlm.nih.gov/pubmed/32961928",
        "http://www.ncbi.nlm.nih.gov/pubmed/32679524",
        "http://www.ncbi.nlm.nih.gov/pubmed/31425702",
        "http://www.ncbi.nlm.nih.gov/pubmed/35332817",
        "http://www.ncbi.nlm.nih.gov/pubmed/35873620",
        "http://www.ncbi.nlm.nih.gov/pubmed/31382910",
        "http://www.ncbi.nlm.nih.gov/pubmed/34959021",
        "http://www.ncbi.nlm.nih.gov/pubmed/31664710",
        "http://www.ncbi.nlm.nih.gov/pubmed/32184342"
      ]
    },
    {
      "id": "6429d5c557b1c7a315000006",
      "type": "list",
      "body": "What are the major thrombotic complications in patients with COVID-19?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36289613",
          "text": "n has been associated with thrombotic complications, especially venous thromboembolism. Although arterial thrombotic complications are rarely seen in ",
          "offsetInBeginSection": 17,
          "offsetInEndSection": 167,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33569525",
          "text": "ne-third of COVID-19 patients show major thrombotic events, mostly pulmonary emboli. The endothelial expression of angiotensin-converting enzyme-2 rec",
          "offsetInBeginSection": 794,
          "offsetInEndSection": 944,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36113402",
          "text": "BACKGROUND\nThromboembolic events are common complications of COVID-19. Clinical study results on safety and efficacy of anticoagulation in COVID-19 ar",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35967591",
          "text": "These include microvascular and macrovascular thrombotic complications such as arterial and venous thromboembolism, myocardial injury or inflammation resulting in infarction, heart failure, and arrhythmias.",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 300,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35643053",
          "text": "Several observational studies have described hemostatic derangements and thrombotic complications in patients with COVID-19.",
          "offsetInBeginSection": 170,
          "offsetInEndSection": 294,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32586214",
          "text": "causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg,",
          "offsetInBeginSection": 1057,
          "offsetInEndSection": 1207,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34512059",
          "text": "Various pathophysiological mechanisms for thrombotic events in COVID-19 have been proposed, these include virus-induced endothelial cell damage, inflammation, and excess production of pro-inflammatory cytokines.",
          "offsetInBeginSection": 605,
          "offsetInEndSection": 816,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34884354",
          "text": "INTRODUCTION\nThrombosis and bleeding are recognized complications of the novel coronavirus infection (COVID-19), with a higher incidence described particularly in the critically ill.\n\n\nMETHODS\nA retrospective review of COVID-19 patients admitted to our intensive care units (ICU) between 1 January 2020 and 31 December 2020 was performed.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 338,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32551814",
          "text": "V-2). Coagulation dysfunction is a hallmark in patients with COVID-19. Fulminant thrombotic complications emerge as critical issues in patients with s",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 309,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34271813",
          "text": "Most of these complications are associated with venous thromboembolism and pulmonary embolism; and arterial thrombosis is rare.",
          "offsetInBeginSection": 89,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33529513",
          "text": "Furthermore, COVID-19 can commonly be complicated with acute thrombotic events, including venous thromboembolism, acute stroke, acute myocardial infarction, clotting of hemodialysis and extracorporeal membrane oxygenation (ECMO) catheters, and acute limb ischemia.",
          "offsetInBeginSection": 541,
          "offsetInEndSection": 805,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34938638",
          "text": "Such complications may include the pulmonary, renal, and other organs vasculature.",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 227,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32948243",
          "text": "The aim of this study was to define the incidence of thrombotic and haemorrhagic complications in critically ill patients with COVID-19.",
          "offsetInBeginSection": 153,
          "offsetInEndSection": 289,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32474145",
          "text": "Most of the reports on a high incidence of thrombotic complications are in relation to deep vein thrombosis and pulmonary embolism, while the evidence about arterial thrombosis in patients with COVID-19 is limited.",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 343,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33560945",
          "text": "CONCLUSION\nThis case demonstrates the importance of considering thrombotic complications, such as CVT, even in well-appearing COVID-19 patients with no other risk factors for thromboembolic disease.",
          "offsetInBeginSection": 536,
          "offsetInEndSection": 734,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32948243",
          "text": "CONCLUSION\nCritically ill patients with COVID-19 experience high rates of venous and arterial thrombotic complications.",
          "offsetInBeginSection": 1813,
          "offsetInEndSection": 1932,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33629339",
          "text": " of COVID-19 with special reference to thrombotic complication ('Storm of Blood Clots') and related predictive markers. The levels of plasminogen/plas",
          "offsetInBeginSection": 812,
          "offsetInEndSection": 962,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33296828",
          "text": "Common thrombotic complications include pulmonary embolism, cerebral infarction, or venous thromboembolism; less commonly seen are acute myocardial injury, renal artery thrombosis, and mesenteric ischemia.",
          "offsetInBeginSection": 300,
          "offsetInEndSection": 505,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34198348",
          "text": "These patients have a high risk for venous and arterial thrombosis of large and small vessels.",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 276,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32291094",
          "text": "27% (95%CI 17-37%) and arterial thrombotic events in 3.7% (95%CI 0-8.2%). PE was the most frequent thrombotic complication (n\u00a0=\u00a025, 81%). Age (adjuste",
          "offsetInBeginSection": 933,
          "offsetInEndSection": 1083,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35663719",
          "text": "While literature exists detailing the unique thrombotic and respiratory complications that can present as a result of COVID-19 coagulopathies, this field is continuously evolving and warrants further research.",
          "offsetInBeginSection": 1346,
          "offsetInEndSection": 1555,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34873931",
          "text": "These complications are related to increased blood hypercoagulabity, which can cause both venous and arterial thrombosis.",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33414129",
          "text": "COVID-19 has serious thrombotic complications in critically ill patients; however, thrombus is not a typical presenting symptom.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34884354",
          "text": "CONCLUSIONS\nThis study describes a high incidence of thrombotic and bleeding complications among critically ill COVID-19 patients.",
          "offsetInBeginSection": 2429,
          "offsetInEndSection": 2559,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36054979",
          "text": "In addition to a severe clinical presentation, comorbidities and age significantly contribute to the development of thrombotic complications in this disease.",
          "offsetInBeginSection": 216,
          "offsetInEndSection": 373,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32586214",
          "text": " of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke. Importantly, thrombotic complications a",
          "offsetInBeginSection": 293,
          "offsetInEndSection": 443,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36430724",
          "text": "atients are prone to thrombotic complications that may increase morbidity and mortality. These complications are thought to be driven by endothelial a",
          "offsetInBeginSection": 35,
          "offsetInEndSection": 185,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32882350",
          "text": "However, we have encountered acute arterial and venous thrombotic events after COVID-19 infection.",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 227,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32944087",
          "text": "Besides pneumonia-induced respiratory failure, thrombotic cardiovascular complications are increasingly emerging as a major COVID-19 symptom.",
          "offsetInBeginSection": 294,
          "offsetInEndSection": 435,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32882350",
          "text": "ndemic of 21 patients who had experienced major thrombotic events from infection with COVID-19. The findings from our cohort have highlighted the need",
          "offsetInBeginSection": 2027,
          "offsetInEndSection": 2177,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34512059",
          "text": ", especially among critically ill patients, and are associated with poor prognosis. To date, many studies have concluded that COVID-19 increases the i",
          "offsetInBeginSection": 327,
          "offsetInEndSection": 477,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34066226",
          "text": "Although the leading cause of mortality in patients with COVID-19 is hypoxic respiratory failure due to viral pneumonia and acute respiratory distress syndrome, accumulating evidence has shown that the risk of thromboembolism is substantially high in patients with severe COVID-19 and that a thromboembolic event is another major complication contributing to the high morbidity and mortality in patients with COVID-19.",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 564,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33074732",
          "text": "sease, due to the high incidence in critically ill patients and poor clinical outcomes. COVID-19 predisposes patients to a hypercoagulable state, howe",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 244,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34900401",
          "text": "In addition to the respiratory sequelae and systemic infection that ensues, an alarming number of micro and macrovascular thrombotic complications have been observed.",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 307,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34104443",
          "text": "mended but, in addition to thrombotic complications, bleeding is a significant cause of morbidity in patients with COVID-19. Idiopathic iliopsoas hema",
          "offsetInBeginSection": 118,
          "offsetInEndSection": 268,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33657964",
          "text": "COVID-19 pneumonia has been associated with high rates of thrombo-embolic complications, mostly venous thromboembolism (VTE), which is thought to be a combination of conventional VTE and in situ immunothrombosis in the pulmonary vascular tree.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32835150",
          "text": "n in COVID-19 patients and literature review on the occurrence of arterial thrombosis in patients with COVID-19. Our findings demonstrate that physici",
          "offsetInBeginSection": 296,
          "offsetInEndSection": 446,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36044652",
          "text": "However, venous thromboembolism, arterial thrombosis, and other vascular complications may go unnoticed in critical care settings.",
          "offsetInBeginSection": 236,
          "offsetInEndSection": 366,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32551814",
          "text": "ay contribute to an overwhelming activation of coagulation. Hypercoagulability and systemic thrombotic complications necessitate anticoagulant and thr",
          "offsetInBeginSection": 1367,
          "offsetInEndSection": 1517,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34060217",
          "text": "The aim of our study was to determine the incidence of late thrombotic complications (deep vein thrombosis, pulmonary embolism, stroke, new-onset vascular access thrombosis) in maintenance hemodialysis patients after recovery from COVID-19.",
          "offsetInBeginSection": 215,
          "offsetInEndSection": 455,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32492712",
          "text": "hemostatic and thrombotic complications of 400 hospital-admitted COVID-19 patients (144 critically ill) primarily receiving standard-dose prophylactic anticoagulation. Coagulation and inflammatory parameters were compared between patients with and without coagulation-associated complications. Multivariable logistic models examined the utility of these markers in predicting coagulation-associated complications, critical illness, and death. The radiographically confirmed VTE rate was 4.8% (95% confidence interval [CI], 2.9-7.3), and the overall thrombotic complication rate was 9.5%",
          "offsetInBeginSection": 287,
          "offsetInEndSection": 873,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32291094",
          "text": "INTRODUCTION\nCOVID-19 may predispose to both venous and arterial thromboembolism due to excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36334396",
          "text": "CONCLUSIONS\nSCUBE1 may be one of the major determinants of thrombotic complications, which is an increased cause of mortality and morbidity in COVID-19 patients so inhibition of this peptide may be among the therapeutic targets in patients with COVID-19.",
          "offsetInBeginSection": 1458,
          "offsetInEndSection": 1712,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34110529",
          "text": "Patients with Coronavirus Disease-2019 (COVID-19) have haemostatic dysfunction and are at higher risk of thrombotic complications.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36044652",
          "text": "The goal is to develop an approach for analysis using real-world data evidence that can be generalized to characterize thrombotic complications and additional conditions in other clinical settings as well, such as pneumonia or acute respiratory distress syndrome\u00a0in COVID-19 patients or in the intensive care unit.",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 1026,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34066226",
          "text": "In this review, we summarize the current understanding of relationships between SARS-CoV-2 infection, endothelial dysfunction, and pulmonary and extrapulmonary complications in patients with COVID-19.",
          "offsetInBeginSection": 1250,
          "offsetInEndSection": 1450,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32829885",
          "text": "Thrombotic complications due to COVID-19 are likely to occur due to a pro-coagulant pattern encountered in some of these patients or to a progressive endothelial thrombo-inflammatory syndrome causing microvascular disease.",
          "offsetInBeginSection": 500,
          "offsetInEndSection": 722,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33821230",
          "text": " 25% (95% CI, 18-32) in COVID-19. For venous thrombotic (VTC) complications and arterial thrombotic complications alone, these numbers were, respectiv",
          "offsetInBeginSection": 1292,
          "offsetInEndSection": 1442,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36054979",
          "text": "RESULTS\nSymptomatic thrombotic events were observed in 7 out of 30 (23\u00a0%) COVID-19 patients with thrombophilia, and 12 out of 60 (20\u00a0%) without thrombophilia, P\u00a0=\u00a00.715.",
          "offsetInBeginSection": 1152,
          "offsetInEndSection": 1321,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34306276",
          "text": "We present three cases of intrabdominal thrombotic complications related to the state of hypercoagulability of COVID-19 and its tomographic features.",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 261,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36430724",
        "http://www.ncbi.nlm.nih.gov/pubmed/33560945",
        "http://www.ncbi.nlm.nih.gov/pubmed/34938638",
        "http://www.ncbi.nlm.nih.gov/pubmed/33629339",
        "http://www.ncbi.nlm.nih.gov/pubmed/35663719",
        "http://www.ncbi.nlm.nih.gov/pubmed/32948243",
        "http://www.ncbi.nlm.nih.gov/pubmed/34066226",
        "http://www.ncbi.nlm.nih.gov/pubmed/34900401",
        "http://www.ncbi.nlm.nih.gov/pubmed/34884354",
        "http://www.ncbi.nlm.nih.gov/pubmed/36054979",
        "http://www.ncbi.nlm.nih.gov/pubmed/34873931",
        "http://www.ncbi.nlm.nih.gov/pubmed/34104443",
        "http://www.ncbi.nlm.nih.gov/pubmed/33529513",
        "http://www.ncbi.nlm.nih.gov/pubmed/34060217",
        "http://www.ncbi.nlm.nih.gov/pubmed/35643053",
        "http://www.ncbi.nlm.nih.gov/pubmed/34110529",
        "http://www.ncbi.nlm.nih.gov/pubmed/34271813",
        "http://www.ncbi.nlm.nih.gov/pubmed/36334396",
        "http://www.ncbi.nlm.nih.gov/pubmed/32829885",
        "http://www.ncbi.nlm.nih.gov/pubmed/32492712",
        "http://www.ncbi.nlm.nih.gov/pubmed/33414129",
        "http://www.ncbi.nlm.nih.gov/pubmed/33821230",
        "http://www.ncbi.nlm.nih.gov/pubmed/34512059",
        "http://www.ncbi.nlm.nih.gov/pubmed/32835150",
        "http://www.ncbi.nlm.nih.gov/pubmed/36044652",
        "http://www.ncbi.nlm.nih.gov/pubmed/36113402",
        "http://www.ncbi.nlm.nih.gov/pubmed/33569525",
        "http://www.ncbi.nlm.nih.gov/pubmed/33074732",
        "http://www.ncbi.nlm.nih.gov/pubmed/32882350",
        "http://www.ncbi.nlm.nih.gov/pubmed/32474145",
        "http://www.ncbi.nlm.nih.gov/pubmed/35967591",
        "http://www.ncbi.nlm.nih.gov/pubmed/32551814",
        "http://www.ncbi.nlm.nih.gov/pubmed/36289613",
        "http://www.ncbi.nlm.nih.gov/pubmed/34306276",
        "http://www.ncbi.nlm.nih.gov/pubmed/34198348",
        "http://www.ncbi.nlm.nih.gov/pubmed/32291094",
        "http://www.ncbi.nlm.nih.gov/pubmed/33296828",
        "http://www.ncbi.nlm.nih.gov/pubmed/33657964",
        "http://www.ncbi.nlm.nih.gov/pubmed/32586214",
        "http://www.ncbi.nlm.nih.gov/pubmed/32944087"
      ]
    },
    {
      "id": "6433012b57b1c7a315000022",
      "type": "summary",
      "body": "What is Cinryze?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23776358",
          "text": "ted States: Berinert(\u00ae) for treating acute attacks and Cinryze(\u00ae) for prophylaxis in adolescent/adult patients. A recombinant C1-INH that is being con",
          "offsetInBeginSection": 745,
          "offsetInEndSection": 895,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20627701",
          "text": "Treatments approved by the Food and Drug Administration for routine prophylaxis include danazol given orally and the nanofiltered human C1 esterase inhibitor, CINRYZE, which is approved for intravenous administration.",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 327,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21942916",
          "text": "Intravenous nanofiltered human C1 inhibitor (C1-INH NF) concentrate (Cinryze\u00ae) is used as a direct replacement of deficient levels of plasma C1 inhibitor in patients with hereditary angioedema (HAE).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26756974",
          "text": "o long-term prophylaxis consisting in an individual dose of intravenous C1-INHc (Cinryze). None of the patients had been previously treated with ecall",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 932,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22282695",
          "text": "he United States was limited to androgen therapy. The human plasma-derived C1 esterase inhibitor (Cinryze\u2122), distributed by Lev Pharmaceuticals, was a",
          "offsetInBeginSection": 734,
          "offsetInEndSection": 884,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
          "text": "a blocking the production or function of bradykinin. Cinryze\u00ae is a nanofiltered C1-INH, approved in Europe for the acute treatment, preprocedure preve",
          "offsetInBeginSection": 406,
          "offsetInEndSection": 556,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24805006",
          "text": "STUDY DESIGN AND METHODS\nThe analysis included one transgenic (Ruconest) and three plasma-derived (Berinert, Cetor, Cinryze) C1-INH concentrates.",
          "offsetInBeginSection": 460,
          "offsetInEndSection": 605,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24805006",
          "text": "Additional bands in the plasma-derived products were \u03b11-antichymotrypsin, ceruloplasmin, Factor C3 (Cinryze/Cetor), and immunoglobulin heavy constant mu (Berinert).",
          "offsetInBeginSection": 1354,
          "offsetInEndSection": 1518,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26756974",
          "text": "ched to long-term prophylaxis consisting in an individual dose of intravenous C1-INHc (Cinryze). None of the patients had been previously treated with",
          "offsetInBeginSection": 776,
          "offsetInEndSection": 926,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
          "text": "Cinryze has FDA approval only for prophylaxis for children as young as 6 years old.",
          "offsetInBeginSection": 1021,
          "offsetInEndSection": 1104,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
          "text": "cute treatment and prophylaxis. Available agents include plasma-derived C1 esterase inhibitors (C1-INH) (Berinert, Haegarda, Cinryze), recombinant C1-",
          "offsetInBeginSection": 351,
          "offsetInEndSection": 501,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21895469",
          "text": "Cinryze is a pasteurized, nanofiltered plasma derived concentrate of C1-inhibitor (pdC1-INH) licensed for the prophylactic treatment of hereditary angioedema.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282867",
          "text": "One preparation, Cinryze, was approved by the U.S. Food & Drug Administration (FDA) for prophylaxis of HAE attacks in October 2008, and the second, Berinert, was approved by the FDA for treatment of acute attacks in October 2009.",
          "offsetInBeginSection": 796,
          "offsetInEndSection": 1025,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26106828",
          "text": "At the same time, a recombinant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent controlled trials to obtain marketing authorization.",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 875,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29279063",
          "text": "ts, and the mean age was 50.1 years. Cinryze and Berinert (both C1-esterase inhibitors) had the highest median scores (5.0) for patient confidence, fo",
          "offsetInBeginSection": 986,
          "offsetInEndSection": 1136,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282867",
          "text": "le-blind studies. One preparation, Cinryze, was approved by the U.S. Food & Drug Administration (FDA) for prophylaxis of HAE attacks in October 2008, ",
          "offsetInBeginSection": 778,
          "offsetInEndSection": 928,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33485376",
          "text": "She was treated with Cinryze\u00ae replacement therapy throughout the pregnancy 1000 IU i.v.",
          "offsetInBeginSection": 701,
          "offsetInEndSection": 788,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23776358",
          "text": " Berinert(\u00ae) for treating acute attacks and Cinryze(\u00ae) for prophylaxis in adolescent/adult patients. A recombinant C1-INH that is being considered for",
          "offsetInBeginSection": 756,
          "offsetInEndSection": 906,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24805006",
          "text": "ic (Ruconest) and three plasma-derived (Berinert, Cetor, Cinryze) C1-INH concentrates. C1-INH antigen concentration was determined by nephelometry, to",
          "offsetInBeginSection": 519,
          "offsetInEndSection": 669,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27660422",
          "text": "Three human plasma-derived C1-INH preparations are approved for HAE treatment in the US, the European Union, or both regions: Cinryze(\u00ae), Berinert(\u00ae), and Cetor(\u00ae); however, only Cinryze is approved for long-term prophylaxis.",
          "offsetInBeginSection": 570,
          "offsetInEndSection": 795,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29279063",
          "text": "For Cinryze, 64.3% selected it as the most effective and 57.1% tolerated it best.",
          "offsetInBeginSection": 1203,
          "offsetInEndSection": 1284,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31798210",
          "text": "Cryoneurolysis is the deliberate application of cold temperatures to nerves for therapeutic purposes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23776358",
        "http://www.ncbi.nlm.nih.gov/pubmed/31798210",
        "http://www.ncbi.nlm.nih.gov/pubmed/26756974",
        "http://www.ncbi.nlm.nih.gov/pubmed/21942916",
        "http://www.ncbi.nlm.nih.gov/pubmed/26106828",
        "http://www.ncbi.nlm.nih.gov/pubmed/33485376",
        "http://www.ncbi.nlm.nih.gov/pubmed/22282695",
        "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
        "http://www.ncbi.nlm.nih.gov/pubmed/29279063",
        "http://www.ncbi.nlm.nih.gov/pubmed/27660422",
        "http://www.ncbi.nlm.nih.gov/pubmed/23282867",
        "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
        "http://www.ncbi.nlm.nih.gov/pubmed/21895469",
        "http://www.ncbi.nlm.nih.gov/pubmed/24805006",
        "http://www.ncbi.nlm.nih.gov/pubmed/20627701"
      ]
    },
    {
      "id": "64179337690f196b51000034",
      "type": "yesno",
      "body": "Do machine learning-based methods outperform statistical methods for survival analysis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34862545",
          "text": " and within neurosciences, including neurosurgery. ML methods regularly outperform classical methods and have been successfully applied to, inter alia",
          "offsetInBeginSection": 568,
          "offsetInEndSection": 718,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12717015",
          "text": "It has been found that machine-learning methods outperform statistical methods and achieve an MCC of 0.11 when secondary structure information is used.",
          "offsetInBeginSection": 633,
          "offsetInEndSection": 784,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30584467",
          "text": "Both of the machine learning methods, the decision tree model and support vector machine, yielded the similar results.",
          "offsetInBeginSection": 994,
          "offsetInEndSection": 1112,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11185421",
          "text": "Despite their potential advantages over standard statistical methods, like their ability to model non-linear relationships and construct symbolic and interpretable models, their applications to survival analysis are at best rare, primarily because of the difficulty to appropriately handle censored data.",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 453,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36227551",
          "text": "Our results reveal that machine-learning-based models such as random survival forests, gradient boosted survival model, and survival support vector machine can outperform the traditional statistical methods, i.e., Cox proportional hazard model.",
          "offsetInBeginSection": 847,
          "offsetInEndSection": 1091,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30409119",
          "text": "on constraints (such as proportional hazard assumptions) and better predictive performance compared with statistical models. Upon comparing the concor",
          "offsetInBeginSection": 1858,
          "offsetInEndSection": 2008,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34910160",
          "text": "BACKGROUND\nMachine learning-based risk prediction models may outperform traditional statistical models in large datasets with many variables, by identifying both novel predictors and the complex interactions between them.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35316964",
          "text": "Machine learning models may outperform traditional statistical regression algorithms for predicting clinical outcomes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30825008",
          "text": "MLAs provided higher identification accuracy (30.8-100%) than distance- (15.1-97.4%) and tree-based methods (11.1-87.5%), with SMO performing the best among the machine learning classifiers.",
          "offsetInBeginSection": 1111,
          "offsetInEndSection": 1301,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36028137",
          "text": "CONCLUSION\nMachine learning algorithms such as the random forest were superior to conventional Cox regression and previously reported survival scores for predicting 1-month, 3-month, and 12-month survival following liver transplantation.",
          "offsetInBeginSection": 2443,
          "offsetInEndSection": 2680,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17904870",
          "text": "Results show that the machine learning methods outperform the template and probability-based methods.",
          "offsetInBeginSection": 642,
          "offsetInEndSection": 743,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20153956",
          "text": "g the identified various risk groups.\n\n\nRESULTS\nThe machine learning models performed very effectively in predicting the survival time: the support ve",
          "offsetInBeginSection": 1818,
          "offsetInEndSection": 1968,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36227551",
          "text": "ival model, and survival support vector machine can outperform the traditional statistical methods, i.e., Cox proportional hazard model. The highest C",
          "offsetInBeginSection": 955,
          "offsetInEndSection": 1105,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32628616",
          "text": "Comparison analysis showed that nonlinear models (K-nearest neighbor AUC 0.908, random forest AUC 0.938) outperform linear models (logistic regression AUC 0.865) on the same datasets, and machine-learning methods significantly surpassed traditional risk scales or fixed models (eg, Framingham cardiovascular disease risk models).",
          "offsetInBeginSection": 1600,
          "offsetInEndSection": 1929,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33313792",
          "text": "CONCLUSIONS\nThe machine learning model's predictions were more accurate than those of the treating physician or a traditional model.",
          "offsetInBeginSection": 1614,
          "offsetInEndSection": 1746,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35571512",
          "text": "Furthermore, RF, SVM, DT, AdaBoost, DT, and KNN outperform other machine learning algorithms in predicting the survival or death of COVID-19 patients.",
          "offsetInBeginSection": 986,
          "offsetInEndSection": 1136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20638252",
          "text": "RESULTS\nThe imputation methods based on machine learning algorithms outperformed imputation statistical methods in the prediction of patient outcome.",
          "offsetInBeginSection": 1204,
          "offsetInEndSection": 1353,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34161901",
          "text": "ed previously available hospitals. While machine learning algorithms outperform traditional econometric models in prediction, the gain they provide sh",
          "offsetInBeginSection": 337,
          "offsetInEndSection": 487,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20153956",
          "text": "CONCLUSIONS\nThis study demonstrated that the integrated machine learning method to select the predictor variables is more effective in developing the Cox survival models than the traditional methods commonly found in the literature.",
          "offsetInBeginSection": 2683,
          "offsetInEndSection": 2915,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29195449",
          "text": "Machine learning classifiers are shown to outperform conventional matched field processing for a deep water (600\u2009m depth) ocean acoustic-based ship range estimation problem in the Santa Barbara Channel Experiment when limited environmental information is known.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 261,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24573170",
          "text": "Most of the rule quality measures outperform Kaplan-Meier estimate and perform at least equally well as tree-based algorithms.",
          "offsetInBeginSection": 1137,
          "offsetInEndSection": 1263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290849",
          "text": "CONCLUSIONS\nThe preliminary results demonstrated that certain machine learning and radiomics analysis method could predict OS of non-small cell lung cancer accuracy.",
          "offsetInBeginSection": 1067,
          "offsetInEndSection": 1232,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20153956",
          "text": "CONCLUSIONS\nThis study demonstrated that the integrated machine learning method to select the predictor variables is more effective in developing the Cox survival models than the traditional methods commonly found in the literature.",
          "offsetInBeginSection": 2683,
          "offsetInEndSection": 2915,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27802931",
          "text": "We found that: (1) the machine learning-based methods outperform the direct-coupling-based methods for short-range contact prediction, while the latter are significantly better for long-range contact prediction.",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 862,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28358210",
          "text": "sed methods trained on the new training sets do not outperform the conventional scoring functions any more. On the contrary, the performance of conven",
          "offsetInBeginSection": 1022,
          "offsetInEndSection": 1172,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31896241",
          "text": "gh-dimensional genomic data. Furthermore, machine learning approaches have been adapted for survival analysis, to fit nonlinear and complex interactio",
          "offsetInBeginSection": 722,
          "offsetInEndSection": 872,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12603013",
          "text": "Furthermore, although machine learning and data mining methods are based on statistics, most such techniques do not address the biologist's requirement for sound mathematical confidence measures.",
          "offsetInBeginSection": 666,
          "offsetInEndSection": 861,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31070704",
          "text": "Simpler, traditional statistical methods such as ridge regression can outperform state-of-the-art machine learning methods in this setting.",
          "offsetInBeginSection": 1480,
          "offsetInEndSection": 1619,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32863727",
          "text": "universal kriging and the downscaler model, outperform all the other exposure assessment approaches regardless of season, urbanicity and PM2.5 concentration level.",
          "offsetInBeginSection": 1766,
          "offsetInEndSection": 1929,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36233640",
          "text": "The ensemble methods RF and XGB outperform other methods when data are less balanced, while SVM, LR, LASSO, and DFNN outperform other methods when data are more balanced.",
          "offsetInBeginSection": 2044,
          "offsetInEndSection": 2214,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12603013",
          "text": "m that allows a fair comparison of different models. The PNN clearly outperformed the other models. The results demonstrate the successful application",
          "offsetInBeginSection": 1625,
          "offsetInEndSection": 1775,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33215298",
          "text": "Overall, test results indicate that deep neural networks can be effective in learning the group morality of a population through observation, and outperform the Bayesian model in the cases of model mismatches.",
          "offsetInBeginSection": 603,
          "offsetInEndSection": 812,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36028137",
          "text": "RESULTS\nAmong the machine learning methods, the random forest yielded the highest area under the receiver operating characteristic curve (AUC-ROC) values (1-month\u00a0=\u00a00.80; 3-month\u00a0=\u00a00.85; and 12-month\u00a0=\u00a00.81) for predicting survival.",
          "offsetInBeginSection": 985,
          "offsetInEndSection": 1217,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32851450",
          "text": "For the machine learning-based prediction for unseen patients, both a model of the GMS of WLTB (0.73, CI: [0.60, 0.84]) and the Aerts radiomics prior model (0.76, CI: [0.65, 0.86]) applied on the WLTB showed a numerically higher predictive performance than TBS (0.68, CI: [0.54, 0.79]), radiomics (0.65, CI: [0.55, 0.78]), WLTB volume alone (0.53, CI: [0.40.",
          "offsetInBeginSection": 1133,
          "offsetInEndSection": 1491,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36028137",
          "text": "This study aimed to compare the performance of traditional statistical models with machine learning approaches for predicting survival following liver transplantation.",
          "offsetInBeginSection": 380,
          "offsetInEndSection": 547,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34883411",
          "text": "CONCLUSION\nThe RSF, a machine learning model, seems more sensitive and precise than the traditional Cox regression model in predicting suicidal behaviour.",
          "offsetInBeginSection": 1101,
          "offsetInEndSection": 1255,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30409119",
          "text": "When considering these spatially varying effects, machine learning models have fewer assumption constraints (such as proportional hazard assumptions) and better predictive performance compared with statistical models.",
          "offsetInBeginSection": 1765,
          "offsetInEndSection": 1982,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29584784",
          "text": "Moreover, we observed that their computational requirements are considerably greater than those of statistical methods.",
          "offsetInBeginSection": 661,
          "offsetInEndSection": 780,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30978508",
          "text": "METHODS AND RESULTS\nAuthors of \"Predictive Abilities of Machine Learning Techniques May Be Limited by Dataset Characteristics: Insights From the UNOS Database\" presented in the current issue of the Journal of Cardiac Failure that machine learning approaches do not provide significantly higher performance when compared to more traditional statistical approaches in predicting mortality following heart transplant.",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 667,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30632193",
          "text": "However, to the best of our knowledge, the plausibility of adapting the emerging extreme learning machine (ELM) algorithm for single-hidden-layer feedforward neural networks to survival analysis has not been explored.",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 470,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30825008",
          "text": "Machine-learning approaches (MLAs) for DNA barcoding outperform distance- and tree-based methods on identification accuracy and cost-effectiveness to arrive at species-level identification of wood.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31888507",
          "text": "We demonstrate superior performance relative to standard random forest methods for survival data.",
          "offsetInBeginSection": 1352,
          "offsetInEndSection": 1449,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27042700",
          "text": "Results suggest that LSVR is at a minimum competitive with favored machine learning methods and is able to outperform those methods in predicting ALS score one month in advance.",
          "offsetInBeginSection": 764,
          "offsetInEndSection": 941,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36233640",
          "text": "ions such as whether deep learning outperforms other machine learning methods when using non-image clinical data remain unanswered. Grid search has be",
          "offsetInBeginSection": 438,
          "offsetInEndSection": 588,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21368918",
          "text": "ts technique with log-rank score split criterion outperforms several other machine learning algorithms. Thus, pathway-based survival analysis using ma",
          "offsetInBeginSection": 1049,
          "offsetInEndSection": 1199,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32535186",
          "text": "RESULTS\nAmong the six state-of-the-art machine learning methods, the random forest had the best classification ability overall.",
          "offsetInBeginSection": 1085,
          "offsetInEndSection": 1212,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32851450",
          "text": "ver tumor burden (WLTB) in comparison to predictions based on the tumor burden score (TBS), WLTB volume alone, and a clinical model.\n\n\nMETHODS\nA total",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 408,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31896241",
          "text": "Furthermore, machine learning approaches have been adapted for survival analysis, to fit nonlinear and complex interaction effects between predictors, and achieve more accurate prediction of individual survival probability.",
          "offsetInBeginSection": 751,
          "offsetInEndSection": 974,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34845416",
          "text": "However, because they are just mathematical equations, they have flaws that limit the quality of their output.",
          "offsetInBeginSection": 971,
          "offsetInEndSection": 1081,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34910160",
          "text": "ith current knowledge about CVD risk factors. Deep learning outperformed Cox proportional hazards models on the basis of proportion of explained varia",
          "offsetInBeginSection": 1334,
          "offsetInEndSection": 1484,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34161901",
        "http://www.ncbi.nlm.nih.gov/pubmed/36227551",
        "http://www.ncbi.nlm.nih.gov/pubmed/24573170",
        "http://www.ncbi.nlm.nih.gov/pubmed/11185421",
        "http://www.ncbi.nlm.nih.gov/pubmed/20638252",
        "http://www.ncbi.nlm.nih.gov/pubmed/34910160",
        "http://www.ncbi.nlm.nih.gov/pubmed/36028137",
        "http://www.ncbi.nlm.nih.gov/pubmed/20153956",
        "http://www.ncbi.nlm.nih.gov/pubmed/31888507",
        "http://www.ncbi.nlm.nih.gov/pubmed/27042700",
        "http://www.ncbi.nlm.nih.gov/pubmed/35316964",
        "http://www.ncbi.nlm.nih.gov/pubmed/36233640",
        "http://www.ncbi.nlm.nih.gov/pubmed/30825008",
        "http://www.ncbi.nlm.nih.gov/pubmed/33313792",
        "http://www.ncbi.nlm.nih.gov/pubmed/12717015",
        "http://www.ncbi.nlm.nih.gov/pubmed/30632193",
        "http://www.ncbi.nlm.nih.gov/pubmed/28358210",
        "http://www.ncbi.nlm.nih.gov/pubmed/35571512",
        "http://www.ncbi.nlm.nih.gov/pubmed/30290849",
        "http://www.ncbi.nlm.nih.gov/pubmed/17904870",
        "http://www.ncbi.nlm.nih.gov/pubmed/30409119",
        "http://www.ncbi.nlm.nih.gov/pubmed/32535186",
        "http://www.ncbi.nlm.nih.gov/pubmed/34862545",
        "http://www.ncbi.nlm.nih.gov/pubmed/30978508",
        "http://www.ncbi.nlm.nih.gov/pubmed/32863727",
        "http://www.ncbi.nlm.nih.gov/pubmed/29195449",
        "http://www.ncbi.nlm.nih.gov/pubmed/27802931",
        "http://www.ncbi.nlm.nih.gov/pubmed/34883411",
        "http://www.ncbi.nlm.nih.gov/pubmed/32851450",
        "http://www.ncbi.nlm.nih.gov/pubmed/30584467",
        "http://www.ncbi.nlm.nih.gov/pubmed/32628616",
        "http://www.ncbi.nlm.nih.gov/pubmed/31896241",
        "http://www.ncbi.nlm.nih.gov/pubmed/12603013",
        "http://www.ncbi.nlm.nih.gov/pubmed/34845416",
        "http://www.ncbi.nlm.nih.gov/pubmed/31070704",
        "http://www.ncbi.nlm.nih.gov/pubmed/29584784",
        "http://www.ncbi.nlm.nih.gov/pubmed/21368918",
        "http://www.ncbi.nlm.nih.gov/pubmed/33215298"
      ]
    },
    {
      "id": "63f03c47f36125a42600001e",
      "type": "factoid",
      "body": "ZF2001 is used for which disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35034583",
          "text": "e (ZF2001) significantly increased neutralization titers to both WT and Omicron variant. Moreover, at day 14 post the third dose, neutralizing antibod",
          "offsetInBeginSection": 670,
          "offsetInEndSection": 820,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35596222",
          "text": "To investigate the protective efficacy and mechanism of ZF2001 (a protein subunit vaccine with conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia, the lethal challenge model of K18-hACE2 transgenic mice was used in this study.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34021265",
          "text": " CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-throughput single-cell V",
          "offsetInBeginSection": 292,
          "offsetInEndSection": 442,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36158819",
          "text": "iving the first dose of the ZF2001 RBD-subunit vaccine against coronavirus disease 2019 (COVID-19). Autopsy showed severe interstitial myocarditis, in",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 259,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34877393",
          "text": "es (NAbs) elicited by CoronaVac (inactivated vaccine) and ZF2001 (RBD-subunit vaccine) against B.1.617 and B.1.1.7 variants. Our results showed that, ",
          "offsetInBeginSection": 598,
          "offsetInEndSection": 748,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36426361",
          "text": "Background\nIn response to SARS-CoV-2 mutations and waning antibody levels after two-dose inactivated vaccines, we assessed whether a third dose of recombinant protein subunit vaccine (ZF2001) boosts immune responses.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35311493",
          "text": "ZF2001 has been approved for emergency use in China, Uzbekistan, Indonesia, and Columbia.",
          "offsetInBeginSection": 959,
          "offsetInEndSection": 1048,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35617368",
          "text": "eometric mean ratios of 2.0 (1.2 to 3.5) and 3.4 (1.8 to 6.4) compared to TIV. GMTs at 14 days after second boost of neutralizing antibodies increased",
          "offsetInBeginSection": 2528,
          "offsetInEndSection": 2678,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36426361",
          "text": "or the three groups (P=0.0005, P<0.0001, and P<0.0001).\n\n\nConclusion\nHeterologous boosting with ZF2001 was safe and immunogenic, and prime-boost inter",
          "offsetInBeginSection": 1350,
          "offsetInEndSection": 1500,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35634276",
          "text": "Conclusion\nSARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer patients.",
          "offsetInBeginSection": 1440,
          "offsetInEndSection": 1543,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35634276",
          "text": "ion, the IgG-positive rate (31.6%, 6/19) significantly decreased in thyroid cancer patients. The IgG-positive rate (81.0%, 64/79) was satisfactory wit",
          "offsetInBeginSection": 982,
          "offsetInEndSection": 1132,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35507481",
          "text": "The primary end point was the occurrence of symptomatic coronavirus disease 2019 (Covid-19), as confirmed on polymerase-chain-reaction assay, at least 7 days after receipt of the third dose.",
          "offsetInBeginSection": 777,
          "offsetInEndSection": 967,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34935594",
          "text": "In this study, we explored the immunogenicity of COVID-19 breakthrough patients, BBIBP-CorV homologous booster group and BBIBP-CorV/ZF2001 heterologous booster group against SARS-CoV-2 pseudotypes corresponding to the prototype, Beta, Delta, and the emergent Omicron variant.Notably, at 14 days post two-dose inactivated vaccines, pVNT titre increased to 67.4 GMTs against prototype, 8.85 against Beta and 35.07 against Delta, while neutralization activity against Omicron was below the lower limit of quantitation in 80% of the samples.",
          "offsetInBeginSection": 342,
          "offsetInEndSection": 879,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35311493",
          "text": "Two doses of ZF2001 protected Ad-hACE2-transduced mice against SARS-CoV-2 infection, as detected by reduced viral RNA and relieved lung injuries.",
          "offsetInBeginSection": 596,
          "offsetInEndSection": 741,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35507481",
          "text": "CONCLUSIONS\nIn a large cohort of adults, the ZF2001 vaccine was shown to be safe and effective against symptomatic and severe-to-critical Covid-19 for at least 6 months after full vaccination.",
          "offsetInBeginSection": 2295,
          "offsetInEndSection": 2487,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35634276",
        "http://www.ncbi.nlm.nih.gov/pubmed/34021265",
        "http://www.ncbi.nlm.nih.gov/pubmed/36158819",
        "http://www.ncbi.nlm.nih.gov/pubmed/34877393",
        "http://www.ncbi.nlm.nih.gov/pubmed/35617368",
        "http://www.ncbi.nlm.nih.gov/pubmed/35507481",
        "http://www.ncbi.nlm.nih.gov/pubmed/35596222",
        "http://www.ncbi.nlm.nih.gov/pubmed/34935594",
        "http://www.ncbi.nlm.nih.gov/pubmed/36426361",
        "http://www.ncbi.nlm.nih.gov/pubmed/35034583",
        "http://www.ncbi.nlm.nih.gov/pubmed/35311493"
      ]
    },
    {
      "id": "642c82c557b1c7a315000012",
      "type": "factoid",
      "body": "What mammal has the lowest known chromosome number?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186334",
          "text": "The species have 2n=36, a number considered as a pleisomorphic feature in Arecoideae since the modern species, according to floral morphology, have the lowest chromosome number (2n=28 and 2n=30).",
          "offsetInBeginSection": 1087,
          "offsetInEndSection": 1282,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24500949",
          "text": "kelihood-inferred changes in chromosome numbers among close relatives. Typhonium, the focal genus, includes species with 2n = 65 and 2n = 8, the lowes",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 636,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31879909",
          "text": "This system is based on hTERT-immortalized fibroblasts from a female Indian muntjac, a placental mammal with the lowest known chromosome number (n\u00a0=\u00a03).",
          "offsetInBeginSection": 1305,
          "offsetInEndSection": 1457,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25372387",
          "text": "ccur in nearby mountains (Hylomyscus and Beamys) were not recorded. Myosorex zinki, the only mammal endemic to Mt. Kilimanjaro, which previously was k",
          "offsetInBeginSection": 797,
          "offsetInEndSection": 947,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29706521",
          "text": "Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\u00a0= 6), to characterize and track individual chromosomes with distinct kinetochore size throughout mitosis.",
          "offsetInBeginSection": 615,
          "offsetInEndSection": 848,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22105874",
          "text": " patchy distribution, poor records and low abundances. It is also the phyllotine with the lowest known diploid chromosome number (2n = 18), however it",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 224,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25379715",
          "text": "The referred species presented the lowest chromosome number observed for the subfamily Myrmicinae and for the Hymenoptera found in the Neotropical region.",
          "offsetInBeginSection": 449,
          "offsetInEndSection": 603,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/5444269",
          "text": "The Indian muntjac (Muntiacus muntjak) has a diploid chromosome number of 7 in the male and 6 in the female, the lowest number yet described in a mammal.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32843950",
          "text": "o-2-phenylindole) staining. The karyotype analyses show that the male B. sinicus possesses the lowest chromosome number (2n = 15) ever observed in Mec",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 295,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4841572",
          "text": "The chocolate gourami, Sphaerichthys osphromonoides, has the lowest chromosome number reported for fishes, with 2n = 16 and n = 8.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9691174",
          "text": "osso, Central Brazil, represents the lowest chromosome number known for rodents. One female with nine chromosomes due to sex chromosome monosomy (2n =",
          "offsetInBeginSection": 140,
          "offsetInEndSection": 290,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30296783",
          "text": "e. In total, 2,758 spermatocytes and over 170,000 COs were examined. Suffolk rams exhibited the lowest mean number of COs (61.1 \u00b1 0.15) compared to Ic",
          "offsetInBeginSection": 533,
          "offsetInEndSection": 683,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17189914",
          "text": "Among marine mammals, a C-value has been estimated only for the bottlenose dolphin (Tursiops truncatus).",
          "offsetInBeginSection": 408,
          "offsetInEndSection": 512,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33089966",
          "text": "e X-chromosome scaffold, with a scaffold N50 of 115\u00a0Mb. Genome-wide heterozygosity is the lowest (0.01%) of any mammalian species analysed to date, bu",
          "offsetInBeginSection": 713,
          "offsetInEndSection": 863,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12971725",
          "text": "t chromosomes occupy fixed positions in the nuclei of mammal but not chicken sperm. We found that the positions of homologous chromosomes are conserve",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 198,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31879909",
          "text": "We believe that we can significantly broaden this scenario by establishing a unique placental mammal model system that combines the powerful genetic tools and low chromosome number of fission yeast and Drosophila melanogaster, with the exceptional cytological features of a rat kangaroo cell.",
          "offsetInBeginSection": 1012,
          "offsetInEndSection": 1304,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14608465",
          "text": "ty, with diploid numbers ranging from 2n=50 to 2n=16. We report on Callicebus lugens, which has the lowest diploid number (2n=16) yet found in the pri",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 321,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15954092",
          "text": "testis development and a means of activating the X chromosome. The duckbill platypus challenges these dogmas.(1,2) Gutzner et al.(1) find no recogniza",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 222,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24260698",
          "text": "The subterranean mole vole, Ellobius tancrei, with aspecific variability in autosomes (2n = 31-54) and unusual sex chromosomes (XX in males and females), represents an amazing model for studying the role of chromosome changes in speciation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15844355",
          "text": "The previously mapped gene Cntn3 was not found in this region, but instead located in the 74 Mb position of human chromosome 3p; (iii) the interspersed repeats of this region were more active than the average level of the whole human genome, especially (TA)n, the content of which was twice the genome average; (iv) this region had a conserved synteny extending from 104.1 Mb to 112.4 Mb on the mouse chromosome 6, which was 8% larger in size, not in accordance with the whole genome comparison, probably because the 3pter-p26 region was more likely to lose nucleotides and its mouse synteny had more active interspersed repeats.",
          "offsetInBeginSection": 585,
          "offsetInEndSection": 1214,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4528784",
          "text": "e in chromosome number has been about 20 times faster in mammals than in frogs. Whereas it takes only 3.5 million years, on the average, for a pair of",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 280,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29706521",
          "text": "Measurement of intra-kinetochore distances, serial-section electron microscopy, and RNAi against key kinetochore proteins confirmed a standard structural and functional organization of the Indian muntjac kinetochores and revealed that microtubule binding capacity scales with kinetochore size.",
          "offsetInBeginSection": 950,
          "offsetInEndSection": 1243,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31879909",
        "http://www.ncbi.nlm.nih.gov/pubmed/32843950",
        "http://www.ncbi.nlm.nih.gov/pubmed/22105874",
        "http://www.ncbi.nlm.nih.gov/pubmed/12971725",
        "http://www.ncbi.nlm.nih.gov/pubmed/27186334",
        "http://www.ncbi.nlm.nih.gov/pubmed/15844355",
        "http://www.ncbi.nlm.nih.gov/pubmed/25379715",
        "http://www.ncbi.nlm.nih.gov/pubmed/30296783",
        "http://www.ncbi.nlm.nih.gov/pubmed/29706521",
        "http://www.ncbi.nlm.nih.gov/pubmed/24260698",
        "http://www.ncbi.nlm.nih.gov/pubmed/33089966",
        "http://www.ncbi.nlm.nih.gov/pubmed/25372387",
        "http://www.ncbi.nlm.nih.gov/pubmed/17189914",
        "http://www.ncbi.nlm.nih.gov/pubmed/4841572",
        "http://www.ncbi.nlm.nih.gov/pubmed/14608465",
        "http://www.ncbi.nlm.nih.gov/pubmed/4528784",
        "http://www.ncbi.nlm.nih.gov/pubmed/15954092",
        "http://www.ncbi.nlm.nih.gov/pubmed/9691174",
        "http://www.ncbi.nlm.nih.gov/pubmed/24500949",
        "http://www.ncbi.nlm.nih.gov/pubmed/5444269"
      ]
    },
    {
      "id": "6429b41757b1c7a315000004",
      "type": "list",
      "body": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30582583",
          "text": "Chromatin is subject to an array of diverse posttranslational modifications (PTMs) that mostly occur in the amino termini of histone proteins (i.e., histone tail) and regulate the accessibility and functional state of the underlying DNA.",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 359,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22122749",
          "text": "n structure and function by modifying the biochemical properties of key amino acids. Histone methylation events, especially on arginine- and lysine-re",
          "offsetInBeginSection": 329,
          "offsetInEndSection": 479,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10825229",
          "text": "The most well studied posttranslational modification of histones is the acetylation of epsilon-amino groups on conserved lysine residues in the histones' amino-terminal tail domains.",
          "offsetInBeginSection": 214,
          "offsetInEndSection": 396,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27423860",
          "text": "Overall histone acetylation states are assessed from complete protease digestion to single amino acids, which is followed by MS analysis.",
          "offsetInBeginSection": 607,
          "offsetInEndSection": 744,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16987819",
          "text": "Biochemical assays on histone peptides show that essentially all epigenetic modifications on the 21 N-terminal amino acids of histone H3 cause a significant reduction in enzymatic activity.",
          "offsetInBeginSection": 294,
          "offsetInEndSection": 483,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11395403",
          "text": "Among the well-known covalent modifications of histones, the reversible acetylation of internal lysine residues in histone amino-terminal domains has long been positively linked to transcriptional activation.",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 363,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22122749",
        "http://www.ncbi.nlm.nih.gov/pubmed/30582583",
        "http://www.ncbi.nlm.nih.gov/pubmed/10825229",
        "http://www.ncbi.nlm.nih.gov/pubmed/16987819",
        "http://www.ncbi.nlm.nih.gov/pubmed/11395403",
        "http://www.ncbi.nlm.nih.gov/pubmed/27423860"
      ]
    },
    {
      "id": "643305b257b1c7a315000025",
      "type": "factoid",
      "body": "Which company produces Ruconest?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
          "text": "Available agents include plasma-derived C1 esterase inhibitors (C1-INH) (Berinert, Haegarda, Cinryze), recombinant C1-INH (Ruconest), bradykinin B2 receptor inhibitor (Icatibant), and kallikrein inhibitors (Ecallantide and lanadelumab).",
          "offsetInBeginSection": 383,
          "offsetInEndSection": 619,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26250409",
          "text": "This article will focus on the results of ten clinical studies demonstrating the efficacy and safety of Ruconest(\u00ae) (Pharming Group NV, Leiden, the Netherlands), which is now approved for use in Europe, Israel and the USA.",
          "offsetInBeginSection": 821,
          "offsetInEndSection": 1043,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26106828",
          "text": "At the same time, a recombinant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent controlled trials to obtain marketing authorization.",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 875,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25673959",
          "text": "Conestat alfa (Ruconest): first recombinant C1 esterase inhibitor for the treatment of acute attacks in patients with hereditary angioedema.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26106828",
          "text": "At the same time, a recombinant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent controlled trials to obtain marketing authorization.",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 875,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24278067",
          "text": "as follows: EUR 15,226 per QALY (Ruconest(\u00ae)) and EUR 27,786 per QALY (Berinert(\u00ae) P). The probability of cost-utility (ICUR < EUR 24,279 per QALY) as",
          "offsetInBeginSection": 1167,
          "offsetInEndSection": 1317,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34832963",
          "text": "a-derived Berinert\u00ae) or immune reaction (human recombinant C1INH from rabbit milk, Ruconest\u00ae). This study describes the physicochemical and biological",
          "offsetInBeginSection": 327,
          "offsetInEndSection": 477,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24278067",
        "http://www.ncbi.nlm.nih.gov/pubmed/25673959",
        "http://www.ncbi.nlm.nih.gov/pubmed/26106828",
        "http://www.ncbi.nlm.nih.gov/pubmed/34832963",
        "http://www.ncbi.nlm.nih.gov/pubmed/26250409",
        "http://www.ncbi.nlm.nih.gov/pubmed/31592791"
      ]
    },
    {
      "id": "641635fa690f196b5100001c",
      "type": "factoid",
      "body": "What is usually the age of diagnosis in Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25977513",
          "text": "Diagnosis usually occurs in childhood and is confirmed through genetic testing and/or muscle biopsy.",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 194,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802771",
          "text": "Duchenne Muscular Dystrophy (DMD) is the most frequent muscular dystrophy in childhood, with a worldwide incidence of one in 5000 live male births.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996334",
          "text": "The average age at diagnosis is 4.83 years but an early diagnosis is possible.",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 364,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16638505",
          "text": "ctioning of 25 Dutch males with Duchenne muscular dystrophy (mean age 10.1 years) were systematically assessed. This study relied on the use of a new ",
          "offsetInBeginSection": 237,
          "offsetInEndSection": 387,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
          "text": "The more severe Duchenne muscular dystrophy typically presents around ages 2 to 5 with gait disturbance, and historically has led to the loss of ambulation by age 12.",
          "offsetInBeginSection": 137,
          "offsetInEndSection": 303,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
          "text": " walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, medical, su",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 328,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
          "text": "RESULTS\nSurvey respondents included 52 people with Duchenne muscular dystrophy with a median age of 17 years (range: 14, 40) and 183 parents/guardians.",
          "offsetInBeginSection": 734,
          "offsetInEndSection": 885,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
          "text": "METHODS\nOnline surveys were sent to three groups: (a) people with a confirmed diagnosis of Duchenne muscular dystrophy (\u226514 years), (b) parents and guardians and (c) neuromuscular clinicians in the UK NorthStar Clinical Network.",
          "offsetInBeginSection": 417,
          "offsetInEndSection": 645,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24814059",
          "text": "METHODS\nWe performed a cross-sectional analysis of electrical impedance myography and quantitative ultrasound in 24 healthy boys and 24 with Duchenne muscular dystrophy, aged 2 to 14 years with trained research assistants performing all measurements.",
          "offsetInBeginSection": 391,
          "offsetInEndSection": 641,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7334343",
          "text": "A well examined muscular biopsy is usually conclusive without using an electron microscope, from the age of one year, if serous activity of CPK reaches twenty times the normal rate.",
          "offsetInBeginSection": 609,
          "offsetInEndSection": 790,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12026234",
          "text": "ion caused by Duchenne muscular dystrophy are usually detected during adolescence. However, decreased physical activity can allow better tolerance of ",
          "offsetInBeginSection": 33,
          "offsetInEndSection": 183,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10436681",
          "text": "n age of 3 years, but the accurate diagnosis was made at a mean age of 5.7 years. In only 15% of children, the disease was diagnosed in the first four",
          "offsetInBeginSection": 402,
          "offsetInEndSection": 552,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2347279",
          "text": "A needle muscle biopsy through a fetoscope for the antenatal diagnosis of Duchenne muscular dystrophy (DMD) was reported the mother was a carrier of 30 years old with a family history of Duchenne muscular dystrophy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2476078",
          "text": "A total of 33 young boys (mean age 3.4 years) with Duchenne muscular dystrophy and 21 normal controls (mean age 3.5 years) were assessed using the Griffiths's mental development scales and the Reynell language scales.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16322188",
          "text": "ood muscular dystrophies. The disease is typically diagnosed between 3 and 7 years of age and follows a predictable clinical course marked by progress",
          "offsetInBeginSection": 76,
          "offsetInEndSection": 226,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19027585",
          "text": "Although Duchenne muscular dystrophy can be genetically diagnosed in young patients, extensive electrocardiogram studies have not been reported.",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 239,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33662889",
          "text": "METHODS\nWe studied 11 boys with Duchenne muscular dystrophy aged 8.6 to 13.9 years and 11 healthy age- and sex-matched controls.",
          "offsetInBeginSection": 549,
          "offsetInEndSection": 677,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22204944",
          "text": "There were 77 Duchenne muscular dystrophy (median age at gastrostomy placement 26 years, range 13-47 years), 40 myotonic dystrophy (median age 54.5 years, range 13-70 years), 11 Fukuyama congenital muscular dystrophy (median age 22 years, range 13-29 years), 5 limb girdle muscular dystrophy (median age 62 years, range 43-78 years), and 5 facioscapulohumeral muscular dystrophy (median age 52 years, range 28-67 years) patients.",
          "offsetInBeginSection": 482,
          "offsetInEndSection": 911,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1667037",
          "text": "cases. In addition, CT scan showed a cortical atrophy after the age of 10 years. This finding suggests that a cerebral degenerative process is present",
          "offsetInBeginSection": 113,
          "offsetInEndSection": 263,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19394035",
          "text": "tine kinase was 4.7 years. Mean age at definitive diagnosis of DMD was 4.9 years.\n\n\nCONCLUSIONS\nThere is a delay of about 2.5 years between onset of D",
          "offsetInBeginSection": 850,
          "offsetInEndSection": 1000,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2739342",
          "text": "ease during the first three years of life, a maximum between the age of 3 and 4 and an asymptotic decline thereafter. Taking the blood samples under n",
          "offsetInBeginSection": 447,
          "offsetInEndSection": 597,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1920094",
          "text": "e end of the first decade, and usually results in death by the end of the second decade. In this study, the extensor digitorum longus and soleus muscl",
          "offsetInBeginSection": 203,
          "offsetInEndSection": 353,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10422002",
          "text": "Duchenne and Becker types of muscular dystrophy are usually differentiated according to age of onset and rate of progression criteria which are not sufficient.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19352159",
          "text": "RESULTS\nOnset and duration of neuromuscular blockade were significantly prolonged in adolescent Duchenne muscular dystrophy patients (onset time, 4.0 min; recovery index, 12.3 min; median), as compared with Duchenne muscular dystrophy children (onset time, 2.3 min; recovery index, 6.8 min), and also as compared with young controls (onset time, 2.0 min; recovery index, 4.4 min) and adolescent controls (onset time, 2.5 min; recovery index, 4.8 min).",
          "offsetInBeginSection": 812,
          "offsetInEndSection": 1263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802771",
          "text": "The association of Duchenne Muscular Dystrophy with seizures has been reported, and there is a higher prevalence of epilepsy in Duchenne Muscular Dystrophy patients (between 6.3% and 12.3%) than in the general pediatric population (0.5-1%).",
          "offsetInBeginSection": 443,
          "offsetInEndSection": 683,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9176541",
          "text": "METHODS\nThe thickness of the diaphragm was measured at the zone of apposition using B mode ultrasonography in 10 boys with Duchenne muscular dystrophy of mean (SD) age 10.3 (1.3) years and 12 normal controls of mean (SD) age 11.3 (2.0) years during relaxation (DiTrelax) and during maximum effort inspiratory manoeuvres (DiTPimax) at functional residual capacity.",
          "offsetInBeginSection": 140,
          "offsetInEndSection": 503,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32520799",
          "text": "Serum creatine kinase and transaminase concentrations were elevated in all ages, and those aged 3-4 yrs had the highest concentrations.",
          "offsetInBeginSection": 838,
          "offsetInEndSection": 973,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12206794",
          "text": "des three cohorts of three patients each. Patients must be at least 15 years of age. Diagnosis of Duchenne and Becker muscular dystrophy was confirmed",
          "offsetInBeginSection": 515,
          "offsetInEndSection": 665,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14713321",
          "text": "nal peptic ulcer has not been documented up to now.\n\n\nCASE PRESENTATION\nA 26-year-old male with Duchenne muscular dystrophy with a clinical and radiog",
          "offsetInBeginSection": 266,
          "offsetInEndSection": 416,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12026234",
          "text": "tening and norepinephrine plasma level (P = .66). The majority of younger adolescents with Duchenne muscular dystrophy and abnormal ventricular functi",
          "offsetInBeginSection": 940,
          "offsetInEndSection": 1090,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29581631",
          "text": "n a severe Duchenne muscular dystrophy phenotype.\n\n\nFINDINGS\nWe describe a 7-year-old boy with a rare pathogenic mutation in exon 29 c.3940C>T p.(Arg1",
          "offsetInBeginSection": 69,
          "offsetInEndSection": 219,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34064562",
          "text": "oval of the genetic treatment in Korea. This is the first report of an infantile presymptomatic Duchenne muscular dystrophy diagnosis using next-gener",
          "offsetInBeginSection": 1126,
          "offsetInEndSection": 1276,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21482750",
          "text": "Caregivers (21 mothers and 6 fathers; mean age, 40.04 years) of 27 Duchenne muscular dystrophy patients (mean age, 11.26 years) completed the validated Children Health Questionnaire-Parent Form 50 and the Family Strain Questionnaire.",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 519,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19449433",
          "text": "pertrophy of calf muscles, and muscle weakness, which became evident at 3 years of age. In addition, she had multiple congenital anomalies including a",
          "offsetInBeginSection": 760,
          "offsetInEndSection": 910,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33072986",
          "text": "Duchenne muscular dystrophy (DMD/Duchenne) is a progressive X-linked disease and is the most common pediatric-onset form of muscular dystrophy, affecting approximately 1:5000 live male births.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19352159",
          "text": "METHODS\nThe authors studied 11 children (6-9 yr) with moderate Duchenne muscular dystrophy, 11 adolescents (12-16 yr) with advanced Duchenne muscular dystrophy, and 2 age-matched control groups of 8 patients each (5-9 and 10-17 yr).",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 495,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29759004",
          "text": "Median age at definitive diagnosis was 4.25 years and 4.92 years for preterm and term males, respectively.",
          "offsetInBeginSection": 529,
          "offsetInEndSection": 635,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33662889",
          "text": "METHODS\nWe studied 11 boys with Duchenne muscular dystrophy aged 8.6 to 13.9 years and 11 healthy age- and sex-matched controls.",
          "offsetInBeginSection": 549,
          "offsetInEndSection": 677,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7618913",
          "text": "e diagnosis was suspected. Growth charts showed weight loss between 4 and 18 months of age. Length growth was affected while growth in head circumfere",
          "offsetInBeginSection": 193,
          "offsetInEndSection": 343,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26140505",
          "text": "s and usually succumb to cardiac or respiratory complications in their late 20s. This review provides an update on the current genetically based thera",
          "offsetInBeginSection": 1108,
          "offsetInEndSection": 1258,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22204944",
          "text": "There were 77 Duchenne muscular dystrophy (median age at gastrostomy placement 26 years, range 13-47 years), 40 myotonic dystrophy (median age 54.5 years, range 13-70 years), 11 Fukuyama congenital muscular dystrophy (median age 22 years, range 13-29 years), 5 limb girdle muscular dystrophy (median age 62 years, range 43-78 years), and 5 facioscapulohumeral muscular dystrophy (median age 52 years, range 28-67 years) patients.",
          "offsetInBeginSection": 482,
          "offsetInEndSection": 911,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7635950",
          "text": "hy patients, while transforming growth factor-beta 1 levels peaked at 2 and 6 yr of age. Transforming growth factor-beta 1 protein was also detected b",
          "offsetInBeginSection": 921,
          "offsetInEndSection": 1071,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954035",
          "text": "Therefore, it is essential to make a prenatal diagnosis and provide genetic counseling to reduce the birth of such boys.",
          "offsetInBeginSection": 179,
          "offsetInEndSection": 299,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32165079",
          "text": "This study describes sleep quantity and quality in both younger (4-9 years) and older (10-17 years) males with Duchenne muscular dystrophy (n\u00a0=\u00a019) and compares these characteristics with sleep characteristics of unaffected peers (n\u00a0=\u00a017).",
          "offsetInBeginSection": 427,
          "offsetInEndSection": 666,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28954035",
        "http://www.ncbi.nlm.nih.gov/pubmed/19449433",
        "http://www.ncbi.nlm.nih.gov/pubmed/25996334",
        "http://www.ncbi.nlm.nih.gov/pubmed/14713321",
        "http://www.ncbi.nlm.nih.gov/pubmed/19352159",
        "http://www.ncbi.nlm.nih.gov/pubmed/34064562",
        "http://www.ncbi.nlm.nih.gov/pubmed/28802771",
        "http://www.ncbi.nlm.nih.gov/pubmed/7334343",
        "http://www.ncbi.nlm.nih.gov/pubmed/12206794",
        "http://www.ncbi.nlm.nih.gov/pubmed/24814059",
        "http://www.ncbi.nlm.nih.gov/pubmed/10436681",
        "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
        "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
        "http://www.ncbi.nlm.nih.gov/pubmed/2347279",
        "http://www.ncbi.nlm.nih.gov/pubmed/1920094",
        "http://www.ncbi.nlm.nih.gov/pubmed/33072986",
        "http://www.ncbi.nlm.nih.gov/pubmed/22204944",
        "http://www.ncbi.nlm.nih.gov/pubmed/7618913",
        "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
        "http://www.ncbi.nlm.nih.gov/pubmed/19394035",
        "http://www.ncbi.nlm.nih.gov/pubmed/32520799",
        "http://www.ncbi.nlm.nih.gov/pubmed/16322188",
        "http://www.ncbi.nlm.nih.gov/pubmed/32165079",
        "http://www.ncbi.nlm.nih.gov/pubmed/2739342",
        "http://www.ncbi.nlm.nih.gov/pubmed/10422002",
        "http://www.ncbi.nlm.nih.gov/pubmed/21482750",
        "http://www.ncbi.nlm.nih.gov/pubmed/26140505",
        "http://www.ncbi.nlm.nih.gov/pubmed/25977513",
        "http://www.ncbi.nlm.nih.gov/pubmed/29759004",
        "http://www.ncbi.nlm.nih.gov/pubmed/2476078",
        "http://www.ncbi.nlm.nih.gov/pubmed/19027585",
        "http://www.ncbi.nlm.nih.gov/pubmed/33662889",
        "http://www.ncbi.nlm.nih.gov/pubmed/7635950",
        "http://www.ncbi.nlm.nih.gov/pubmed/29581631",
        "http://www.ncbi.nlm.nih.gov/pubmed/1667037",
        "http://www.ncbi.nlm.nih.gov/pubmed/12026234",
        "http://www.ncbi.nlm.nih.gov/pubmed/9176541",
        "http://www.ncbi.nlm.nih.gov/pubmed/16638505"
      ]
    },
    {
      "id": "6402c868201352f04a00000b",
      "type": "yesno",
      "body": "Was erythropoietin effective for optic neuritis in the TONE trial?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22465890",
          "text": "CONCLUSION\nErythropoietin may be effective, but should be used with caution.",
          "offsetInBeginSection": 1438,
          "offsetInEndSection": 1514,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926853",
          "text": "INTERPRETATION\nThese results give the first indications that erythropoietin might be neuroprotective in optic neuritis.",
          "offsetInBeginSection": 1767,
          "offsetInEndSection": 1886,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7821473",
          "text": "Few data are available concerning the effect of ivermectin on active optic neuritis.",
          "offsetInBeginSection": 518,
          "offsetInEndSection": 602,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9103884",
          "text": "ned pathology, therapy of this disease, and summarized our previous cases. Intravenous methylpredonisolone treatment is effective from our experience.",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 317,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35501141",
          "text": "icosteroids accelerated visual recovery in optic neuritis (ON) without improving outcome. This finding related largely to multiple sclerosis (MS), and",
          "offsetInBeginSection": 64,
          "offsetInEndSection": 214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30151023",
          "text": "ears and provided valuable data about clinical course, efficacy of steroid treatment, and risk of conversion to MS. Compared to the many studies in We",
          "offsetInBeginSection": 330,
          "offsetInEndSection": 480,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26932144",
          "text": "ys or placebo (0.9% saline) administered intravenously. With an estimated power of 80%, the calculated sample size is 100 patients. The trial started ",
          "offsetInBeginSection": 1547,
          "offsetInEndSection": 1697,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10340796",
          "text": "oup than in the control (P<.05).\n\n\nCONCLUSIONS\nPulse treatment does not appear effective for idiopathic optic neuritis even though visual function in ",
          "offsetInBeginSection": 1064,
          "offsetInEndSection": 1214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22465890",
          "text": "OBJECTIVE\nTo investigate the safety, tolerability, and short-term efficacy of treatment with erythropoietin in patients with optic neuritis as a first demyelination event.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926853",
          "text": "OBJECTIVE\nBased on findings in animal models of autoimmune optic nerve inflammation, we have assessed the safety and efficacy of erythropoietin in patients presenting with a first episode of optic neuritis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15601662",
          "text": "Functional and histo pathological data of retinal ganglion cells and optic nerves revealed that neuron and axon protection was most effective when erythropoietin treatment that was started at immunization was combined with high-dose methylprednisolone therapy given from days 1 to 3 of MOG-induced experimental autoimmune encephalomyelitis.",
          "offsetInBeginSection": 1147,
          "offsetInEndSection": 1487,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27706045",
          "text": "ute isolated optic neuritis did not influence further evolution of MRI lesions in the brain when comparing absolute numbers. However, early conversion",
          "offsetInBeginSection": 1161,
          "offsetInEndSection": 1311,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33735314",
          "text": "d degeneration of the optic nerve and retina. Currently available treatments are only partially effective and have a limited impact on the neuroinflam",
          "offsetInBeginSection": 154,
          "offsetInEndSection": 304,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7749521",
          "text": " acute attack of optic neuritis reduces the rate at which multiple sclerosis develops over a 2-year period of follow-up. The findings of the trial hav",
          "offsetInBeginSection": 261,
          "offsetInEndSection": 411,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7821473",
          "text": "Ivermectin does not appear to precipitate or exacerbate optic neuritis at a period of 7-14 days.",
          "offsetInBeginSection": 1527,
          "offsetInEndSection": 1623,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11033135",
          "text": "Systemic acyclovir and steroid are effective in the treatment of HZO optic neuritis.",
          "offsetInBeginSection": 785,
          "offsetInEndSection": 869,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052875",
          "text": "When compared with the baseline RNFL thickness of the affected eye, the neuroprotective effects of novel add-on treatments could not be demonstrated.",
          "offsetInBeginSection": 743,
          "offsetInEndSection": 892,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8719696",
          "text": "l follow up, this study showed that no single type of color defect was consistently associated with optic neuritis. Demyelinating optic neuritis does ",
          "offsetInBeginSection": 2572,
          "offsetInEndSection": 2722,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26367086",
          "text": "ng visual recovery in acute typical optic neuritis, but do not affect the final visual outcome. In optic neuritis patients, IVCS may delay progression",
          "offsetInBeginSection": 867,
          "offsetInEndSection": 1017,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31425702",
          "text": "Most multiple sclerosis disease-modifying agents are ineffective for AQP4-IgG-positive neuromyelitis optica spectrum disorder and MOG-IgG-associated disorder.",
          "offsetInBeginSection": 844,
          "offsetInEndSection": 1002,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10577521",
          "text": "II4e isopters on the Goldmann perimeter. Both test procedures were conducted according to the trial protocols, and quality control assessments and cli",
          "offsetInBeginSection": 837,
          "offsetInEndSection": 987,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8293145",
          "text": "The role of steroids in idiopathic optic neuritis has been clarified by the Optic Neuritis Treatment Trial.",
          "offsetInBeginSection": 453,
          "offsetInEndSection": 560,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26932144",
          "text": "T-G) in acute optic neuritis; however, the preparatory trial was not powered to show effects on visual function.\n\n\nMETHODS AND ANALYSIS\nTreatment of O",
          "offsetInBeginSection": 450,
          "offsetInEndSection": 600,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8614496",
          "text": "The Optic Neuritis Treatment Trial (ONTT) is a prospective study of corticosteroid treatment of acute optic neuritis (ON), with subsequent longitudinal follow-up to determine development of clinically definite multiple sclerosis (CDMS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22742888",
          "text": "study (VISION study) was designed to evaluate the efficacy of vision restoration therapy in optic neuritis patients. Eighty patients with a residual v",
          "offsetInBeginSection": 757,
          "offsetInEndSection": 907,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10320119",
          "text": "CONCLUSIONS\nIntravenous cyclophosphamide pulse therapy seems to be an effective treatment for optic neuritis refractory to corticosteroids, oral immunosuppressants, or both.",
          "offsetInBeginSection": 933,
          "offsetInEndSection": 1106,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30713249",
          "text": "However, there is no report investigating the histopathological efficacy of IVIg in optic neuritis models.",
          "offsetInBeginSection": 192,
          "offsetInEndSection": 298,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35533337",
          "text": "Chronic oral immunosuppression is preferred for the long term, but further research is necessary to establish the efficacy and cost-effectiveness of these practices.",
          "offsetInBeginSection": 1722,
          "offsetInEndSection": 1887,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34800417",
          "text": " clinical trials in patients with optic neuritis. We assessed the safety and efficacy of erythropoietin in patients with optic neuritis as a clinicall",
          "offsetInBeginSection": 128,
          "offsetInEndSection": 278,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8668894",
          "text": " rate two years after treatment; however, this protective effect could not be demonstrated after three years. These recommendations are valid only for",
          "offsetInBeginSection": 564,
          "offsetInEndSection": 714,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29667789",
          "text": "However, even several decades after the initial clinical trials, there remains significant controversy regarding the efficacy and utility of this treatment.",
          "offsetInBeginSection": 503,
          "offsetInEndSection": 659,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25877841",
          "text": "d after any treatment related volume changes have subsided. If the treatment is successful, this form of neuroprotection should improve the recovery f",
          "offsetInBeginSection": 1758,
          "offsetInEndSection": 1908,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25877841",
          "text": "The recent randomised placebo-controlled trial of lamotrigine in secondary progressive MS did not demonstrate a protective effect on brain atrophy, and indeed the opposite effect was observed during the first year of treatment.",
          "offsetInBeginSection": 943,
          "offsetInEndSection": 1170,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10577521",
          "text": "CONCLUSIONS\nFor the affected eye in optic neuritis, the central visual field shows greater abnormalities than the far peripheral visual field.",
          "offsetInBeginSection": 2245,
          "offsetInEndSection": 2387,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26932144",
          "text": "The primary objective is to determine the efficacy of erythropoietin compared to placebo given add-on to methylprednisolone as assessed by measurements of RNFLT-G and low-contrast visual acuity in the affected eye 6 months after randomisation.",
          "offsetInBeginSection": 744,
          "offsetInEndSection": 987,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22742888",
          "text": "ife, fatigue, and depression.\n\n\nDISCUSSION\nIf vision restoration therapy is shown to improve visual function after optic neuritis, this method might b",
          "offsetInBeginSection": 2054,
          "offsetInEndSection": 2204,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8512477",
          "text": "intravenous followed by oral corticosteroids is short term, limited to an accelerated rate of recovery. The decision whether to prescribe this regimen",
          "offsetInBeginSection": 1424,
          "offsetInEndSection": 1574,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22737354",
          "text": "wed by an oral taper accelerates visual recovery, its use does not improve long-term visual outcomes. Long-term treatment with immunomodulating agents",
          "offsetInBeginSection": 610,
          "offsetInEndSection": 760,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31205740",
          "text": "CONCLUSION\nSix weeks of oral lipoic acid supplementation after acute optic neuritis is safe and well tolerated; however, because of insufficient recruitment, we could not conclude that lipoic acid treatment was neuroprotective in acute optic neuritis.",
          "offsetInBeginSection": 1215,
          "offsetInEndSection": 1466,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8668894",
          "text": "The American multicenter study 'A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis' (5) showed how a retrobulbar neuritis should not be treated, Oral steroids (1 mg per kilogram of body weight per day) are not only ineffective but also associated with a higher rate of recurrences compared to high dose i.v.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 347,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052875",
          "text": "When compared with the baseline RNFL thickness of the affected eye, the neuroprotective effects of novel add-on treatments could not be demonstrated.",
          "offsetInBeginSection": 743,
          "offsetInEndSection": 892,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20379464",
          "text": "Therapy with antivirals and steroids may be effective in patients with childhood HZO optic neuritis.",
          "offsetInBeginSection": 545,
          "offsetInEndSection": 645,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8719696",
          "text": " Neuritis Treatment Trial (ONTT). The ONTT was designed to evaluate corticosteroids as a treatment for acute demyelinating optic neuritis and to allow",
          "offsetInBeginSection": 419,
          "offsetInEndSection": 569,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33551721",
          "text": "Our findings in mice further support that corticosteroid treatment alone is not sufficient to prevent eventual axonal loss in ON, and strongly support the potential of DBSI as an in vivo imaging outcome measure to assess optic nerve pathology.",
          "offsetInBeginSection": 1128,
          "offsetInEndSection": 1371,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926853",
          "text": "mary endpoint according to the intention-to-treat protocol. RNFL thinning was less apparent after erythropoietin treatment. Thickness of the RNFL decr",
          "offsetInBeginSection": 1126,
          "offsetInEndSection": 1276,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25605544",
          "text": "CONCLUSION\nUntil more controlled studies are available, the rhEPO is not recommended as an add-on treatment for optic neuritis.",
          "offsetInBeginSection": 1585,
          "offsetInEndSection": 1712,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10577521",
          "text": "In most cases, recovery in optic neuritis can probably be monitored effectively with automated perimetry of the central visual field alone.",
          "offsetInBeginSection": 2668,
          "offsetInEndSection": 2807,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15601662",
          "text": " apoptosis under methylprednisolone therapy, although CNS inflammation was effectively controlled. In the present study, we combined steroid treatment",
          "offsetInBeginSection": 390,
          "offsetInEndSection": 540,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35095131",
          "text": "Our aims were first to find the reported incidence of optic neuritis in different countries and to ascertain what percentage of cases were seropositive for anti-aquaporin 4 and anti-MOG antibodies, and second, to document the presenting features, treatment, and outcomes from a first episode of the different types of optic neuritis from these countries, and to compare the results with the outcomes of the ONTT cohort.",
          "offsetInBeginSection": 648,
          "offsetInEndSection": 1067,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12789593",
          "text": "The recommended treatment for optic neuritis is intravenous steroids, as shown in the Optic Neuritis Treatment Trial (ONTT).",
          "offsetInBeginSection": 1416,
          "offsetInEndSection": 1540,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29667789",
        "http://www.ncbi.nlm.nih.gov/pubmed/22737354",
        "http://www.ncbi.nlm.nih.gov/pubmed/10577521",
        "http://www.ncbi.nlm.nih.gov/pubmed/8512477",
        "http://www.ncbi.nlm.nih.gov/pubmed/31205740",
        "http://www.ncbi.nlm.nih.gov/pubmed/25877841",
        "http://www.ncbi.nlm.nih.gov/pubmed/8719696",
        "http://www.ncbi.nlm.nih.gov/pubmed/12789593",
        "http://www.ncbi.nlm.nih.gov/pubmed/15601662",
        "http://www.ncbi.nlm.nih.gov/pubmed/33735314",
        "http://www.ncbi.nlm.nih.gov/pubmed/10320119",
        "http://www.ncbi.nlm.nih.gov/pubmed/10340796",
        "http://www.ncbi.nlm.nih.gov/pubmed/35095131",
        "http://www.ncbi.nlm.nih.gov/pubmed/8293145",
        "http://www.ncbi.nlm.nih.gov/pubmed/33551721",
        "http://www.ncbi.nlm.nih.gov/pubmed/30151023",
        "http://www.ncbi.nlm.nih.gov/pubmed/22926853",
        "http://www.ncbi.nlm.nih.gov/pubmed/35501141",
        "http://www.ncbi.nlm.nih.gov/pubmed/8614496",
        "http://www.ncbi.nlm.nih.gov/pubmed/22465890",
        "http://www.ncbi.nlm.nih.gov/pubmed/26367086",
        "http://www.ncbi.nlm.nih.gov/pubmed/27706045",
        "http://www.ncbi.nlm.nih.gov/pubmed/22742888",
        "http://www.ncbi.nlm.nih.gov/pubmed/35533337",
        "http://www.ncbi.nlm.nih.gov/pubmed/11033135",
        "http://www.ncbi.nlm.nih.gov/pubmed/20379464",
        "http://www.ncbi.nlm.nih.gov/pubmed/26932144",
        "http://www.ncbi.nlm.nih.gov/pubmed/31425702",
        "http://www.ncbi.nlm.nih.gov/pubmed/8668894",
        "http://www.ncbi.nlm.nih.gov/pubmed/35052875",
        "http://www.ncbi.nlm.nih.gov/pubmed/7749521",
        "http://www.ncbi.nlm.nih.gov/pubmed/30713249",
        "http://www.ncbi.nlm.nih.gov/pubmed/25605544",
        "http://www.ncbi.nlm.nih.gov/pubmed/34800417",
        "http://www.ncbi.nlm.nih.gov/pubmed/7821473",
        "http://www.ncbi.nlm.nih.gov/pubmed/9103884"
      ]
    },
    {
      "id": "6424154d690f196b5100004a",
      "type": "summary",
      "body": "What is the R value with respect to hepatoxicity",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33620007",
          "text": "Overall, 79 cases (76%) had no acute liver injury or hepatotoxicity, and 25 (24%) developed hepatoxicity.",
          "offsetInBeginSection": 1007,
          "offsetInEndSection": 1112,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33620007"
      ]
    },
    {
      "id": "64299b6a57b1c7a315000001",
      "type": "yesno",
      "body": "Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36367927",
          "text": " caused by the Omicron variant in renal transplant recipients (RTRs) is unknown.\n\n\nMETHODS\nInterviews were conducted with 447 RTRs regarding the statu",
          "offsetInBeginSection": 136,
          "offsetInEndSection": 286,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36238984",
          "text": "ronavirus Disease 2019 (COVID-19)\u00a0pandemic in Shanghai, but over 90% of patients were mild. This study included 1139 COVID-19 patients mildly infected",
          "offsetInBeginSection": 119,
          "offsetInEndSection": 269,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35869843",
          "text": "BACKGROUND\nIn the general population, illness after infection with the SARS-CoV-2 Omicron variant is less severe compared with previous variants.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36072085",
          "text": "Unlike the previous two waves, COVID-19 due to the Omicron variant\u00a0was less severe with only 5% of hemodialysis patients\u00a0requiring admission to the intensive care unit compared to 25% during the previous waves.",
          "offsetInBeginSection": 792,
          "offsetInEndSection": 1002,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36072085",
          "text": "Unlike the previous two waves, COVID-19 due to the Omicron variant\u00a0was less severe with only 5% of hemodialysis patients\u00a0requiring admission to the intensive care unit compared to 25% during the previous waves.",
          "offsetInBeginSection": 792,
          "offsetInEndSection": 1002,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36466505",
          "text": "Furthermore, liver damages caused by viral infection of the omicron variant were largely attenuated when compared to those by infection of the wild-type or the delta variant SARS-CoV-2.",
          "offsetInBeginSection": 1292,
          "offsetInEndSection": 1477,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35583528",
          "text": "ly effective in protecting against severe Covid-19 infections.Omicrons may be less severe than other variants of concern. However, its immune evasiven",
          "offsetInBeginSection": 1314,
          "offsetInEndSection": 1464,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36090988",
          "text": "ively protect COVID-19 caused by Delta and Omicron variants but was less effective against Omicron variant infection. One-dose booster immunization co",
          "offsetInBeginSection": 1963,
          "offsetInEndSection": 2113,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36285226",
          "text": "Early reports of Omicron variant confirmed patients indicated less severe disease course compared with the disease caused by previously encountered variants with absence of data regarding cardiac involvement by Omicron.",
          "offsetInBeginSection": 372,
          "offsetInEndSection": 591,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35583528",
          "text": "However, we found that infections by Omicron were significantly less severe than those caused by Delta and other previous variants.",
          "offsetInBeginSection": 772,
          "offsetInEndSection": 903,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35025038",
          "text": "spreads rapidly with an average doubling time of two days. The disease so far has been mild as compared with delta. Though previous infection and vacc",
          "offsetInBeginSection": 445,
          "offsetInEndSection": 595,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35615088",
          "text": "Interpretation\nOur results supported that the viremic effect of the omicron variant became milder than the previous circulating variants, while full vaccination or booster shot was greatly desired for an effective protection against clinical severity.",
          "offsetInBeginSection": 1399,
          "offsetInEndSection": 1650,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35751531",
          "text": "DISCUSSION\nIn this study, symptoms of COVID-19 tended to be milder than described for previous SARS-CoV2 variants.",
          "offsetInBeginSection": 1193,
          "offsetInEndSection": 1307,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35615088",
          "text": "d in this study.\n\n\nInterpretation\nOur results supported that the viremic effect of the omicron variant became milder than the previous circulating var",
          "offsetInBeginSection": 1380,
          "offsetInEndSection": 1530,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35169811",
          "text": "adjusted proportional odds ratio [aPOR] 1.28, 95% CI: 1.11 to 1.46), and lower for Omicron than Delta (aPOR 0.61, 95% CI: 0.49 to 0.77). Compared to u",
          "offsetInBeginSection": 1707,
          "offsetInEndSection": 1857,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35835638",
          "text": "aled multiple cystic cavitations.\n\n\nCONCLUSION\nAlthough COVID-19 is not severe in most children, life-threatening conditions such as COVID-19-associat",
          "offsetInBeginSection": 1182,
          "offsetInEndSection": 1332,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35750265",
          "text": "ess in fragile individuals appears to be lower because of a faster immunity decline. However, the Omicron variant seems to cause less severe COVID-19.",
          "offsetInBeginSection": 1293,
          "offsetInEndSection": 1443,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35835638",
          "text": "INTRODUCTION\nThe coronavirus disease 2019 (COVID-19), including the Omicron variant, is less severe in children than in adults.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36466505",
          "text": "2019 (COVID-19) pandemic, but its clinical characteristics with intrinsic severity and organ tropism remain understudied.\n\n\nMethods\nWe reported 1,001 ",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 295,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36367927",
          "text": "The humoral responses to the Omicron variant before and after the fourth dose were significantly lower than the responses to the wild-type and the Delta variants.",
          "offsetInBeginSection": 1339,
          "offsetInEndSection": 1501,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35404391",
          "text": "BACKGROUND\nThere are limited data assessing coronavirus 2019 (COVID-19) disease severity in children/adolescents infected with the Omicron variant.",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 400,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36050273",
          "text": "CONCLUSION\nThe Omicron wave group had a lower COVID-19 pneumonia prevalence than the previous wave group.",
          "offsetInBeginSection": 1462,
          "offsetInEndSection": 1567,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35236358",
          "text": "This study adds evidence that current vaccination protocols may be less efficient against the Omicron variant.",
          "offsetInBeginSection": 1776,
          "offsetInEndSection": 1886,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36417338",
          "text": "less severe clinical manifestations and decreased hospitalizations. The omicron wave swelled faster than previous waves, completely displacing the delta variant within weeks, and creating worldwide concern about final, successful pandemic control. Some authors contend that symptoms associated to omicron differ from 'traditional' symptoms and more closely resemble those of the common cold. One major COVID-19 symptom frequent with other variants-loss of taste and smell-is rarely present with omicron",
          "offsetInBeginSection": 104,
          "offsetInEndSection": 606,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36296527",
          "text": "However, these drugs have not shown high efficacy in reducing COVID-19 severity, and even antiviral drugs have not shown to be effective.",
          "offsetInBeginSection": 243,
          "offsetInEndSection": 380,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35169811",
          "text": "Among adults hospitalized with COVID-19, Omicron caused less severe disease than Delta, but still resulted in substantial morbidity and mortality.",
          "offsetInBeginSection": 2366,
          "offsetInEndSection": 2512,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35411288",
          "text": "s in its virulence\u00a0and disease severity. Most reports have shown that the Omicron variant causes mild illness. Little is known about the impact of Omi",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 458,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35961786",
          "text": "SARS-CoV-2 Omicron variant seemed to cause milder disease compared to previous predominated variants.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35123975",
          "text": "antly increased vaccine breakthrough rates, and were significantly less likely to be hospitalized. Omicron patients required less intense respiratory ",
          "offsetInBeginSection": 986,
          "offsetInEndSection": 1136,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35751531",
          "text": " variant leads to attenuated disease severity in these patients is currently unknown.\n\n\nMETHODS\nWe assessed clinical and laboratory parameters in 61 p",
          "offsetInBeginSection": 211,
          "offsetInEndSection": 361,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35404391",
          "text": "Omicron variant infection (vs Delta) was associated with significantly lower odds of moderate or severe/critical disease (adjusted odds ratio [AOR], 0.12; 95% confidence interval [CI], .07-.18).",
          "offsetInBeginSection": 1386,
          "offsetInEndSection": 1580,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36453218",
          "text": "Since its emergence in late 2021, Omicron has displaced other circulating variants and caused successive waves of infection worldwide throughout 2022.",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 251,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35143466",
          "text": "In mid-December 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, surpassed the B.1.617.2 (Delta) variant as the predominant strain in California.\u00a7 Initial reports suggest that the Omicron variant is more transmissible and resistant to vaccine neutralization but causes less severe illness compared with previous variants (1-3).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 363,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35846507",
          "text": "However, lung involvement is poorly reported in patients who resulted positive by this new COVID-19 variant.",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 291,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35404391",
          "text": "CONCLUSIONS\nOmicron variant infection in children/adolescents is associated with less severe disease than Delta variant infection as measured by hospitalization rates and need for ICU care or mechanical ventilation.",
          "offsetInBeginSection": 1830,
          "offsetInEndSection": 2045,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35236358",
          "text": "In November 2021, the Omicron variant was discovered and immediately classified as a variant of concern (VOC), since it shows substantially more mutations in the spike protein than any previous variant, especially in the receptor-binding domain (RBD).",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 329,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36075374",
          "text": "He experienced mild symptoms of COVID-19 and was discharged on the ninth day.",
          "offsetInBeginSection": 447,
          "offsetInEndSection": 524,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36116948",
          "text": "The clinical course with Omicron was more severe, leading us to speculate that Omicron may not be any milder among LT patients.",
          "offsetInBeginSection": 200,
          "offsetInEndSection": 327,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35451363",
          "text": "Protection against Omicron symptomatic infections was systematically lower and waned at higher speed than against Delta in those vaccinated.",
          "offsetInBeginSection": 298,
          "offsetInEndSection": 438,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36115649",
          "text": "The Omicron variant may be better adapted for replication in the upper respiratory tract than the Delta variant, in which this is unlikely given its more efficient generation of viral particles.",
          "offsetInBeginSection": 2234,
          "offsetInEndSection": 2428,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36298593",
          "text": "The obtained results indicate that a significantly lower titer was observed in patients with the Omicron variant infection.",
          "offsetInBeginSection": 475,
          "offsetInEndSection": 598,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36339233",
          "text": "On the other hand, our data suggest that vaccination is less effective in preventing infection by the Omicron variant.",
          "offsetInBeginSection": 1150,
          "offsetInEndSection": 1268,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35236358",
          "text": "RESULTS\nSurprisingly, the Omicron RBD showed a somewhat weaker binding to ACE2 compared to Beta and Delta, arguing that improved ACE2 binding is not a likely driver of Omicron evolution.",
          "offsetInBeginSection": 1041,
          "offsetInEndSection": 1227,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35595662",
          "text": "Vaccine effectiveness is lower and wanes faster against infection and symptomatic disease caused by the omicron variant of SARS-CoV-2 than was observed with previous variants.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36453218",
          "text": "Nevertheless, the virus is ever-changing, and public health policies, especially those related to vaccinations, will also have to continually evolve and adapt as COVID-19 transitions to endemicity.",
          "offsetInBeginSection": 1551,
          "offsetInEndSection": 1748,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35675841",
          "text": "This reduced severity could not be explained by differential history of prior infection among individuals with Omicron or Delta variant infection and was starkest among individuals not previously vaccinated against COVID-19 (aHR\u2009=\u20090.40 (0.33-0.49) for any hospital admission and 0.14 (0.07-0.28) for death).",
          "offsetInBeginSection": 1145,
          "offsetInEndSection": 1452,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35595662",
          "text": "howed higher vaccine protection. These approaches might better characterize vaccine performance against severe Covid-19 disease caused by omicron, as ",
          "offsetInBeginSection": 1670,
          "offsetInEndSection": 1820,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35123975",
          "text": " Omicron patients were significantly younger, had significantly increased vaccine breakthrough rates, and were significantly less likely to be hospitalized. Omicron patients required less intense respiratory support and had a shorter length of hospital stay, consistent with on average decreased disease severity",
          "offsetInBeginSection": 928,
          "offsetInEndSection": 1240,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35869843",
          "text": "CONCLUSIONS\nWhile the mortality in immunocompromised patients infected with Omicron was low, hospital admission was frequent and the duration of symptoms often prolonged.",
          "offsetInBeginSection": 1532,
          "offsetInEndSection": 1702,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35675841",
          "text": "Here we show that Omicron variant infections were associated with substantially reduced risk of progression to severe clinical outcomes relative to time-matched Delta (B.1.617.2) variant infections within a large, integrated healthcare system in Southern California.",
          "offsetInBeginSection": 521,
          "offsetInEndSection": 787,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36116948",
        "http://www.ncbi.nlm.nih.gov/pubmed/36050273",
        "http://www.ncbi.nlm.nih.gov/pubmed/35750265",
        "http://www.ncbi.nlm.nih.gov/pubmed/35169811",
        "http://www.ncbi.nlm.nih.gov/pubmed/36367927",
        "http://www.ncbi.nlm.nih.gov/pubmed/36115649",
        "http://www.ncbi.nlm.nih.gov/pubmed/36075374",
        "http://www.ncbi.nlm.nih.gov/pubmed/35025038",
        "http://www.ncbi.nlm.nih.gov/pubmed/35595662",
        "http://www.ncbi.nlm.nih.gov/pubmed/36090988",
        "http://www.ncbi.nlm.nih.gov/pubmed/35404391",
        "http://www.ncbi.nlm.nih.gov/pubmed/35961786",
        "http://www.ncbi.nlm.nih.gov/pubmed/36298593",
        "http://www.ncbi.nlm.nih.gov/pubmed/36285226",
        "http://www.ncbi.nlm.nih.gov/pubmed/35583528",
        "http://www.ncbi.nlm.nih.gov/pubmed/36453218",
        "http://www.ncbi.nlm.nih.gov/pubmed/36072085",
        "http://www.ncbi.nlm.nih.gov/pubmed/36296527",
        "http://www.ncbi.nlm.nih.gov/pubmed/35675841",
        "http://www.ncbi.nlm.nih.gov/pubmed/36238984",
        "http://www.ncbi.nlm.nih.gov/pubmed/35835638",
        "http://www.ncbi.nlm.nih.gov/pubmed/36466505",
        "http://www.ncbi.nlm.nih.gov/pubmed/36417338",
        "http://www.ncbi.nlm.nih.gov/pubmed/35751531",
        "http://www.ncbi.nlm.nih.gov/pubmed/36339233",
        "http://www.ncbi.nlm.nih.gov/pubmed/35869843",
        "http://www.ncbi.nlm.nih.gov/pubmed/35411288",
        "http://www.ncbi.nlm.nih.gov/pubmed/35846507",
        "http://www.ncbi.nlm.nih.gov/pubmed/35451363",
        "http://www.ncbi.nlm.nih.gov/pubmed/35615088",
        "http://www.ncbi.nlm.nih.gov/pubmed/35123975",
        "http://www.ncbi.nlm.nih.gov/pubmed/35143466",
        "http://www.ncbi.nlm.nih.gov/pubmed/35236358"
      ]
    },
    {
      "id": "6432ffdf57b1c7a315000021",
      "type": "summary",
      "body": "What is hereditary angioedema?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3397981",
          "text": "t with hereditary angioedema. Hereditary angioedema, one of the inherited complement deficiencies, has been reported in association with a number of a",
          "offsetInBeginSection": 75,
          "offsetInEndSection": 225,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22179171",
          "text": "In addition to edema of the glottis, hereditary angioedema often results in edema of the gastrointestinal tract, which can be incapacitating.",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 718,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33233873",
          "text": "The disease can either present with hypocomplementemia owing to the presence of pathogenic variants in the gene encoding complement C1 inhibitor (hereditary angioedema with C1-inhibitor deficiency) or present with normocomplementemia and associate with elevated estrogen levels owing to gain-of-function variants in the genes encoding coagulation proteins involved in the kallikrein-kinin system (namely, coagulation FXII [FXII-associated hereditary angioedema], plasminogen [PLG-associated hereditary angioedema], and high-molecular-weight kininogen [KNG1-associated hereditary angioedema]).",
          "offsetInBeginSection": 603,
          "offsetInEndSection": 1195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22195758",
          "text": "Hereditary angioedema is a rare disorder, and patients frequently endure long duration of symptoms, frequent physician visits, and unnecessary procedures prior to a diagnosis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19849675",
          "text": "Hereditary angioedema is a rare genetic disorder resulting from an inherited deficiency or dysfunction of the C1-esterase inhibitor of the classic complement pathway.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22073494",
          "text": "Hereditary angioedema is a rare form of angioedema that can be diagnosed by screening with a C4 level.",
          "offsetInBeginSection": 322,
          "offsetInEndSection": 424,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31283393",
          "text": "Hereditary angioedema is a rare genetic disorder caused by deficiency of C1 esterase inhibitor (C1-INH) and characterized by recurrent episodes of severe swelling that affect the limbs, face, intestinal tract and airway.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34904566",
          "text": "INTRODUCTION\nHereditary angioedema is an infrequent genetic disorder; which mainly manifests with cutaneous and mucosal swelling.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32178893",
          "text": "Hereditary angioedema is an autosomal dominant disorder, presenting as sudden and recurring episodes of variable severity of subcutaneous and mucosa edema that may occur spontaneously or in response to triggers.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22227095",
          "text": "Hereditary angioedema is a rare disease, often diagnosed with delay because of a heterogeneous clinical presentation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22570050",
          "text": "Hereditary Angioedema is a dominantly inherited disease. Routine screening of autoantibodies (AAB) is not recommended for individuals with Hereditary ",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24865240",
          "text": "Hereditary angioedema is a rare disease, which is caused by deficiency of compleman c1 esterase inhibitor regulatory protein in the compleman system.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21251443",
          "text": "Hereditary angioedema is a rare genetic disorder resulting from an inherited deficiency or dysfunction of the C1 inhibitor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2371584",
          "text": "Hereditary angioedema is a rare autosomal dominant disorder due to the deficiency of functionally active C1-inhibitor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166502",
          "text": "They were diagnosed as having hereditary angioedema with C1-INH deficiency (C1-INH hereditary angioedema) for the first time.",
          "offsetInBeginSection": 813,
          "offsetInEndSection": 938,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34983705",
          "text": "Background: Hereditary angioedema is an autosomal dominant disease that presents with recurrent episodic swelling of the submucosal and/or subcutaneous tissues of the cutaneous, gastrointestinal, and respiratory systems.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22014012",
          "text": "Hereditary angioedema is a relatively rare genetic disorder affecting between one in 10,000 and one in 50,000 individuals worldwide.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21623829",
          "text": "BACKGROUND\nHereditary angioedema is an autosomal dominant disease characterized by episodes of subcutaneous and submucosal edema.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22179171",
          "text": "Hereditary angioedema is an autosomal dominant disease characterized by edema attacks with multiple organ involvement.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726426",
          "text": "Hereditary angioedema is a disease associated with acute complement-mediated inflammation and swelling of the airway and other vital organs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18329867",
          "text": "The cause is a quantitative or qualitative congenital deficit in C1 inhibitor.",
          "offsetInBeginSection": 71,
          "offsetInEndSection": 149,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36417927",
          "text": "Hereditary angioedema is a rare, genetic disorder characterized by painful, debilitating and potentially life-threatening angioedema attacks in subcutaneous and submucosal tissue.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24880254",
          "text": "Hereditary angioedema is a genetic disorder typically related to insufficient or dysfunctional C1-esterase inhibitor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26819784",
          "text": "Hereditary angioedema is a rare, but potentially life-threatening genetic disorder that results from an autosomal dominant trait.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15924048",
          "text": "INTRODUCTION\nHereditary angioedema is characterized by episodes of subcutaneous, digestive or laryngeal edema.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23625675",
          "text": "Hereditary angioedema is a rare and potentially fatal autosomal dominant disorder characterised by unpredictable skin, gastrointestinal tract or respiratory tract oedema.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11855162",
          "text": "Hereditary angioedema is a rare autosomal dominant disease characterized by the edema of subcutaneous tissues, respiratory tract and bowel.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29723342",
          "text": "Hereditary angioedema is an autosomal dominant disease characterized by recurrent angioedema attacks with the involvement of multiple organs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33233873",
          "text": "f hereditary angioedema (OMIM#106100). Hereditary angioedema is a rare genetic disease inherited in an autosomal dominant manner and caused by a loss ",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 244,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12572187",
          "text": "Hereditary angioedema is an autosomal dominant condition with a typical presentation of diffuse edematous, painless, and nonpitting swelling of the soft tissues.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11194524",
          "text": "Hereditary angioedema (HAE) is a rare autosomal dominant disorder, which is caused by congenital deficiency of functional C1-inhibitor (C1-INH).",
          "offsetInBeginSection": 284,
          "offsetInEndSection": 428,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166502",
          "text": "BACKGROUND\nHereditary angioedema is a rare autosomal dominantly inherited immunodeficiency disorder characterized by potentially life-threatening angioedema attacks.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34586422",
          "text": "IMPORTANCE\nHereditary angioedema is a rare disease of potentially life-threatening attacks of angioedema that can affect patients of all ages, including women of childbearing age.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21137180",
          "text": "Hereditary angioedema caused by C1 esterase inhibitor deficiency is a rare autosomal dominant inherited disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26849703",
          "text": "INTRODUCTION\nHereditary angioedema is an autosomal dominant primary immunodeficiency caused by a deficiency of the C1 inhibitor protein and characterized by recurrent episodes of subcutaneous and mucosal edema.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25511656",
          "text": "Hereditary angioedema is a rare disease, potentially life-threatening. It requires a specific treatment. Angioedema without wheals associated with abd",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29503044",
          "text": "STUDY OBJECTIVE\nHereditary angioedema is a rare disease associated with unpredictable, recurrent attacks of potentially life-threatening edema.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19526954",
          "text": "BACKGROUND\nHereditary angioedema is an autosomal dominant inherited condition that is characterized by the local development of edema of the skin, subcutaneous tissue, and the walls of almost any organ, including the gastrointestinal and upper respiratory tracts.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26849703",
          "text": "RESULTS\nEighty three percent (83%) of individuals reporting symptoms of the condition exhibited serological criteria of hereditary angioedema type I: low levels of both C4 complement and quantitative (antigenic) and qualitative (functional) C1 inhibitor.",
          "offsetInBeginSection": 841,
          "offsetInEndSection": 1095,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8506211",
          "text": "Hereditary angioedema is an autosomal dominant disorder of the complement system in which there is a deficiency of the inhibitor of the activated first component of complement.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31864442",
          "text": "Angioedema is a clinical entity defined as self-limiting edema localized in the deeper layers of the skin and mucosa and lasting for several days.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24931134",
          "text": "Type III hereditary angioedema is a rare familial disorder that has recently been described as a separate condition.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18851753",
          "text": "INTRODUCTION\nHereditary angioedema is the commonest inherited disorder of the complement system and has been associated with several immune glomerular diseases.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36417927",
          "text": "Hereditary angioedema is diagnosed based on C1-inhibitor level and function.",
          "offsetInBeginSection": 984,
          "offsetInEndSection": 1060,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33034563",
          "text": "BACKGROUND\nHereditary angioedema is a rare genetic condition caused by C1 esterase inhibitor deficiency, dysfunction, or kinin cascade dysregulation, leading to an increased bradykinin plasma concentration.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17427507",
          "text": "Hereditary angioedema was clinically characterized by subcutaneous oedema of extremities, face, neck, throat, gastrointestinal tract and brain.",
          "offsetInBeginSection": 430,
          "offsetInEndSection": 573,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11132070",
          "text": "Hereditary angioedema is a hereditary disorder transmitted as an autosomal dominant trait, characterized by reduced plasma concentration of C1 esterase inhibitor (type 1) or the presence of non functional C1 esterase inhibitor (type 2).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20955596",
          "text": "Hereditary angioedema is characterized by sudden episodes of nonpitting edema that cause discomfort and pain.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26164979",
          "text": "BACKGROUND\nHereditary angioedema, a rare and potentially life-threatening condition, is the result of a defect in the C1 esterase inhibitor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23248378",
          "text": "Hereditary angioedema is a genetic disorder due to a deficiency or malfunction of C1 esterase inhibitor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34904566",
        "http://www.ncbi.nlm.nih.gov/pubmed/22179171",
        "http://www.ncbi.nlm.nih.gov/pubmed/34983705",
        "http://www.ncbi.nlm.nih.gov/pubmed/2371584",
        "http://www.ncbi.nlm.nih.gov/pubmed/11855162",
        "http://www.ncbi.nlm.nih.gov/pubmed/21251443",
        "http://www.ncbi.nlm.nih.gov/pubmed/11194524",
        "http://www.ncbi.nlm.nih.gov/pubmed/8506211",
        "http://www.ncbi.nlm.nih.gov/pubmed/11132070",
        "http://www.ncbi.nlm.nih.gov/pubmed/23625675",
        "http://www.ncbi.nlm.nih.gov/pubmed/15924048",
        "http://www.ncbi.nlm.nih.gov/pubmed/34586422",
        "http://www.ncbi.nlm.nih.gov/pubmed/26849703",
        "http://www.ncbi.nlm.nih.gov/pubmed/3397981",
        "http://www.ncbi.nlm.nih.gov/pubmed/33233873",
        "http://www.ncbi.nlm.nih.gov/pubmed/19849675",
        "http://www.ncbi.nlm.nih.gov/pubmed/24931134",
        "http://www.ncbi.nlm.nih.gov/pubmed/23248378",
        "http://www.ncbi.nlm.nih.gov/pubmed/32178893",
        "http://www.ncbi.nlm.nih.gov/pubmed/26164979",
        "http://www.ncbi.nlm.nih.gov/pubmed/12572187",
        "http://www.ncbi.nlm.nih.gov/pubmed/25511656",
        "http://www.ncbi.nlm.nih.gov/pubmed/24865240",
        "http://www.ncbi.nlm.nih.gov/pubmed/19526954",
        "http://www.ncbi.nlm.nih.gov/pubmed/21623829",
        "http://www.ncbi.nlm.nih.gov/pubmed/18851753",
        "http://www.ncbi.nlm.nih.gov/pubmed/22570050",
        "http://www.ncbi.nlm.nih.gov/pubmed/29166502",
        "http://www.ncbi.nlm.nih.gov/pubmed/21137180",
        "http://www.ncbi.nlm.nih.gov/pubmed/20955596",
        "http://www.ncbi.nlm.nih.gov/pubmed/31864442",
        "http://www.ncbi.nlm.nih.gov/pubmed/26819784",
        "http://www.ncbi.nlm.nih.gov/pubmed/29723342",
        "http://www.ncbi.nlm.nih.gov/pubmed/22073494",
        "http://www.ncbi.nlm.nih.gov/pubmed/22014012",
        "http://www.ncbi.nlm.nih.gov/pubmed/17427507",
        "http://www.ncbi.nlm.nih.gov/pubmed/36417927",
        "http://www.ncbi.nlm.nih.gov/pubmed/22195758",
        "http://www.ncbi.nlm.nih.gov/pubmed/18329867",
        "http://www.ncbi.nlm.nih.gov/pubmed/24880254",
        "http://www.ncbi.nlm.nih.gov/pubmed/11726426",
        "http://www.ncbi.nlm.nih.gov/pubmed/29503044",
        "http://www.ncbi.nlm.nih.gov/pubmed/31283393",
        "http://www.ncbi.nlm.nih.gov/pubmed/33034563",
        "http://www.ncbi.nlm.nih.gov/pubmed/22227095"
      ]
    },
    {
      "id": "64178ec2690f196b51000024",
      "type": "summary",
      "body": "What is viltolarsen's mechanism of action?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
          "text": "In the present study, we posit that normative change is a plausible mechanism and provide a test of this in an eating disorder prevention group program.",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 278,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
          "text": "However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged.",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826604",
          "text": "ivation consistent with left free wall accessory pathway. With induction of tachycardia, beats with LBBB morphology have shorter cycle length than tho",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 305,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283",
          "text": "The role of the mirror mechanism in cognition remains an intriguing and hotly debated topic in cognitive neuroscience.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20735416",
          "text": "mechanism of action of general anaesthetics (GAs) involving membranes and protein receptors. I provide the reasons why the GABA type A receptor, the N",
          "offsetInBeginSection": 227,
          "offsetInEndSection": 377,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "nal heterogeneity in the specific vasoconstrictor involved. Oxygen-induced vasoconstriction may serve as a protective mechanism to reduce the oxidativ",
          "offsetInBeginSection": 1422,
          "offsetInEndSection": 1572,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10029375",
          "text": "These drugs can induce cell cycle arrest and apoptosis in colon cancer cell lines through a mechanism that is fundamentally different from the apoptosis caused by cancer chemotherapeutic agents.",
          "offsetInBeginSection": 1011,
          "offsetInEndSection": 1205,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11068911",
          "text": "ialdehyde antimicrobial agent, the mechanism of action of which has been little studied. The aims of this paper are to examine what is currently known",
          "offsetInBeginSection": 46,
          "offsetInEndSection": 196,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6572387",
          "text": "enylate cyclase activities that are stimulated by human chorionic gonadotropin (hCG) and thyrotropin, respectively. Both cell types also respond to ch",
          "offsetInBeginSection": 96,
          "offsetInEndSection": 246,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19719780",
          "text": "d the position to date and suggested a new mechanistic contender, receptor rebinding. Despite this, they still do not come to any clear conclusion. Mu",
          "offsetInBeginSection": 185,
          "offsetInEndSection": 335,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19719780",
        "http://www.ncbi.nlm.nih.gov/pubmed/20735416",
        "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
        "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
        "http://www.ncbi.nlm.nih.gov/pubmed/6572387",
        "http://www.ncbi.nlm.nih.gov/pubmed/10029375",
        "http://www.ncbi.nlm.nih.gov/pubmed/34826604",
        "http://www.ncbi.nlm.nih.gov/pubmed/11068911",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
        "http://www.ncbi.nlm.nih.gov/pubmed/23089283"
      ]
    },
    {
      "id": "64040bd8201352f04a00000e",
      "type": "yesno",
      "body": "Should be used bexarotene for relapsing-remitting multiple sclerosis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242067",
          "text": "ified as having Relapsing-Remitting Multiple Sclerosis accordingly with Lublin were collected for oxidative stress markers quantification.\n\n\nRESULTS\nN",
          "offsetInBeginSection": 341,
          "offsetInEndSection": 491,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26701666",
          "text": "We here discuss the currently existing options and suggest treatment algorithms for managing relapsing-remitting multiple sclerosis.",
          "offsetInBeginSection": 543,
          "offsetInEndSection": 675,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21975773",
          "text": "y profile of NTZ is warranted. NTZ should be used only by skilled neurologists in MS centres under surveillance programs.All the data in this review c",
          "offsetInBeginSection": 4062,
          "offsetInEndSection": 4212,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23994714",
          "text": "remitting multiple sclerosis was treated with immunomodulatory agents, interferon \u03b2 or glatiramer acetate. The secondary progressive multiple sclerosi",
          "offsetInBeginSection": 703,
          "offsetInEndSection": 853,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14978418",
          "text": "It can also be used in secondary progressive and progressive relapsing remitting multiple sclerosis.",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 210,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28639482",
          "text": "Additionally, a match between being adequately challenged by work, while still having the capacity to meet those work demands, is needed, as is long-term financial stability.",
          "offsetInBeginSection": 1243,
          "offsetInEndSection": 1417,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31099778",
          "text": "The data presented in the current work may be used for the construction of a biomarker panel, to differentiate primary progressive and relapsing-remitting courses of multiple sclerosis on the initial stages of the disease.",
          "offsetInBeginSection": 1032,
          "offsetInEndSection": 1254,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35652121",
          "text": "Myelin-sensitive MRI such as magnetization transfer imaging has been widely used in multiple sclerosis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30042638",
          "text": "Thus, it is consequential to emphasize the value of tailored intervention for attending to these factors in the treatment and rehabilitation agendas for improvement of health-related quality of life in relapsing-remitting multiple sclerosis.",
          "offsetInBeginSection": 1809,
          "offsetInEndSection": 2050,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31099778",
        "http://www.ncbi.nlm.nih.gov/pubmed/30042638",
        "http://www.ncbi.nlm.nih.gov/pubmed/21975773",
        "http://www.ncbi.nlm.nih.gov/pubmed/23994714",
        "http://www.ncbi.nlm.nih.gov/pubmed/19242067",
        "http://www.ncbi.nlm.nih.gov/pubmed/26701666",
        "http://www.ncbi.nlm.nih.gov/pubmed/28639482",
        "http://www.ncbi.nlm.nih.gov/pubmed/14978418",
        "http://www.ncbi.nlm.nih.gov/pubmed/35652121"
      ]
    },
    {
      "id": "6422e7f0690f196b51000045",
      "type": "list",
      "body": "Hepcidin is a key regulator of what processes?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23531037",
          "text": "BACKGROUND\nHepcidin is a central regulator of iron metabolism. Serum hepcidin levels are increased in patients with renal insufficiency, which may con",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23807042",
          "text": "BACKGROUND\nHepcidin is a key regulator of iron metabolism. It binds to ferroportin and causes the trapping of iron in cells, rendering it unavailable ",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21136948",
          "text": "Hepcidin, a key regulator of iron homeostasis, is known to have three isoforms: hepcidin-20, -22, and -25.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19681654",
          "text": "Hepcidin, a key regulator of iron metabolism, plays a crucial role in the pathogenesis of anemia of chronic disease.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19249912",
          "text": "Hepcidin is a key regulator of iron homeostasis, while hemojuvelin is an important component of the hepcidin regulation pathway.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293278",
          "text": "Hepcidin, which is mainly produced by the liver, is the key regulator in iron homeostasis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15886319",
          "text": "Hepatic peptide hormone hepcidin is the key regulator of iron metabolism and the mediator of anemia of inflammation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25782630",
          "text": "Hepcidin is the key regulator of iron absorption and recycling, and its expression is suppressed by red blood cell production.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16198622",
          "text": "Hepcidin is thought to be a key regulator in iron metabolism and has been implicated in ACD.",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16497104",
          "text": "Hepcidin, a key regulator of iron metabolism, decreases intestinal absorption of iron and its release from macrophages.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852110",
          "text": "Hepcidin is a key regulator of iron homeostasis and plays a role in the pathogenesis of anaemia of chronic disease.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30530987",
          "text": "Hepcidin is the master regulator of iron metabolism. It plays a key role in the regulation of iron transport across the duodenal epithelium, which in ",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24123375",
          "text": "The expression of hepcidin is significantly induced by iron overload, inflammation, and infection of pathogens.",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33820875",
          "text": "ved in postmenopausal osteoporosis. Hepcidin is a key regulator of iron homeostasis. However, the exact role of hepcidin in bone metabolism and the un",
          "offsetInBeginSection": 223,
          "offsetInEndSection": 373,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24356737",
          "text": "central role in hepcidin regulation. Hepcidin is a key regulator ofiron homeostasis and has now been suggested as a central mediator ofiron metabolism",
          "offsetInBeginSection": 70,
          "offsetInEndSection": 220,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30798808",
          "text": "Hepcidin is a main regulator of iron metabolism, of which abnormal expression affects intestinal absorption and reticuloendothelial sequestration of iron by interacting with ferroportin.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15797999",
          "text": "Hepcidin, a key regulator of iron metabolism, is synthesized by the liver. Hepcidin binds to the iron exporter ferroportin to regulate the release of ",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21415870",
          "text": "BACKGROUND\nHepcidin, a key regulator of iron metabolism, is synthesized by the liver.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17768112",
          "text": "Hepcidin is the key regulator of systemic iron homeostasis. We describe the modulation of hepcidin production induced by plasma transfusions in a pati",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18936232",
          "text": "The discovery of hepcidin as a key regulator of iron homeostasis has advanced our current knowledge of this field.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22160085",
          "text": "is synthesized by the liver, has emerged as a key regulator of systemic iron homeostasis. Hepcidin inhibits the absorption of dietary iron from the in",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 308,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21439478",
          "text": "The peptide hormone hepcidin is a key homeostatic regulator of iron metabolism and involved in pathological regulation of iron in response to infection, inflammation, hypoxia, and anemia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16604073",
          "text": "Hepcidin deficiency induces iron overload, whereas hepcidin excess induces anemia.",
          "offsetInBeginSection": 58,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31280251",
          "text": "The latest studies in iron metabolism, especially the involvement of hepcidin, which is the main regulator of iron homeostasis, broadened our knowledge in many medical fields (immunology, nephrology, hematology, gastrology).",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 407,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17331760",
          "text": "se antimicrobial peptide that has emerged as a central regulator of iron absorption. Circulating hepcidin levels have been shown to affect iron uptake",
          "offsetInBeginSection": 33,
          "offsetInEndSection": 183,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30374287",
          "text": "Hepcidin is the major regulator of systemic iron metabolism, while the role of this peptide in the brain has just recently been elucidated.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28652306",
          "text": "Although hepcidin has been recognized as the key regulator of iron metabolism, in some infections its levels remain unaffected, suggesting the involvement of other players in iron metabolism deregulation.",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 430,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24385536",
          "text": "The hepatic hormone hepcidin is a key regulator of systemic iron metabolism.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12469120",
          "text": "peptide hepcidin (HAMP; OMIM 606464) is probably a key regulator of iron absorption in mammals. Here we report the identification of two mutations (93",
          "offsetInBeginSection": 46,
          "offsetInEndSection": 196,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16009323",
          "text": "Hepcidin, originally discovered in urine as a bactericidal peptide synthesized by hepatocytes was later proved to be a key regulator of iron metabolism at the whole body level, namely, in conditions of altered iron demand such as the increased or decreased total amount of body iron, inflammation, hypoxia and anemia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 317,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16325907",
          "text": "ptide antibiotic produced in the liver, is a key regulator of iron balance and recycling in humans and mice. Closely related hepcidin genes and peptid",
          "offsetInBeginSection": 53,
          "offsetInEndSection": 203,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16627878",
          "text": "Hepcidin is a proposed mammalian host defense peptide that was identified on the basis of its antimicrobial activity, but it was later shown to be a crucial regulator of iron homeostasis and a mediator of the anemia of chronic inflammation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29958400",
          "text": "derived peptide hepcidin has been recognized as a key regulator of iron homeostasis. Since iron metabolism is crucially linked to cardiovascular healt",
          "offsetInBeginSection": 87,
          "offsetInEndSection": 237,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16755911",
          "text": "Recently, several lines of evidence have suggested that hepcidin is a key regulator of iron metabolism at the whole body level and is relative to inflammation, infection, hypoxia and anemia.",
          "offsetInBeginSection": 162,
          "offsetInEndSection": 352,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18951868",
          "text": "Hepcidin is a peptide hormone that functions as a key regulator of mammalian iron metabolism.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15486069",
          "text": "The hepatic peptide hepcidin is the key regulator of iron metabolism in mammals.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30469435",
          "text": "Hepcidin is a key hormonal regulator of systemic iron homeostasis and its expression is induced by iron or inflammatory stimuli.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28054602",
          "text": "Hepcidin, a peptide hormone, is a key regulator in mammalian iron homeostasis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34755647",
          "text": "The liver synthesized peptide hormone hepcidin is a master regulator of systemic iron metabolism.",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 286,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19338078",
          "text": "The small liver peptide hepcidin is a major regulator of systemic iron homeostasis in mammals, adapting iron absorption to the body's demands.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21136948",
          "text": "We believe our method will facilitate quantitative investigation of the role hepcidin plays in iron homeostasis.",
          "offsetInBeginSection": 1197,
          "offsetInEndSection": 1309,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18333366",
          "text": "Recently discovered peptide hormone hepcidin is the key regulator of systemic iron homeostasis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23897622",
          "text": "The peptide hormone hepcidin is a key regulator of iron homeostasis in vertebrates.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17557118",
          "text": "Hepcidin, a small peptide synthesized in the liver, is a key regulator of iron absorption and homeostasis in mammals.",
          "offsetInBeginSection": 113,
          "offsetInEndSection": 230,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16755911",
          "text": "The subject of this paper is to summarize the regulation of hepcidin gene expression and the understanding of functions of hepcidin.",
          "offsetInBeginSection": 1157,
          "offsetInEndSection": 1289,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836059",
          "text": " production and antimicrobial defense. Hepcidin is a key regulator of iron levels within the body. Under conditions of iron deficiency, hepcidin expre",
          "offsetInBeginSection": 164,
          "offsetInEndSection": 314,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22544439",
          "text": "Hepcidin is a key regulator of iron recycling by macrophages that is synthesized mainly by hepatocytes but also by macrophages.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12433676",
          "text": "Hepcidin is a liver-made peptide proposed to be a central regulator of intestinal iron absorption and iron recycling by macrophages.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16627878",
          "text": "The results support a role for hepcidin as a key regulator of mammalian iron metabolism and chronic inflammation, whose expression correlates with the degree of stainable iron in BA.",
          "offsetInBeginSection": 1357,
          "offsetInEndSection": 1539,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16009323",
          "text": "Utilizing this mechanism, hepcidin regulates serum iron levels during inflammation, infection and possibly also in cancer.",
          "offsetInBeginSection": 806,
          "offsetInEndSection": 928,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18951868",
        "http://www.ncbi.nlm.nih.gov/pubmed/28652306",
        "http://www.ncbi.nlm.nih.gov/pubmed/30469435",
        "http://www.ncbi.nlm.nih.gov/pubmed/17331760",
        "http://www.ncbi.nlm.nih.gov/pubmed/30530987",
        "http://www.ncbi.nlm.nih.gov/pubmed/16198622",
        "http://www.ncbi.nlm.nih.gov/pubmed/23897622",
        "http://www.ncbi.nlm.nih.gov/pubmed/24123375",
        "http://www.ncbi.nlm.nih.gov/pubmed/18333366",
        "http://www.ncbi.nlm.nih.gov/pubmed/24293278",
        "http://www.ncbi.nlm.nih.gov/pubmed/21415870",
        "http://www.ncbi.nlm.nih.gov/pubmed/16627878",
        "http://www.ncbi.nlm.nih.gov/pubmed/25852110",
        "http://www.ncbi.nlm.nih.gov/pubmed/21136948",
        "http://www.ncbi.nlm.nih.gov/pubmed/30798808",
        "http://www.ncbi.nlm.nih.gov/pubmed/29958400",
        "http://www.ncbi.nlm.nih.gov/pubmed/30374287",
        "http://www.ncbi.nlm.nih.gov/pubmed/23531037",
        "http://www.ncbi.nlm.nih.gov/pubmed/24356737",
        "http://www.ncbi.nlm.nih.gov/pubmed/17557118",
        "http://www.ncbi.nlm.nih.gov/pubmed/34755647",
        "http://www.ncbi.nlm.nih.gov/pubmed/28054602",
        "http://www.ncbi.nlm.nih.gov/pubmed/33820875",
        "http://www.ncbi.nlm.nih.gov/pubmed/15486069",
        "http://www.ncbi.nlm.nih.gov/pubmed/16497104",
        "http://www.ncbi.nlm.nih.gov/pubmed/16325907",
        "http://www.ncbi.nlm.nih.gov/pubmed/12433676",
        "http://www.ncbi.nlm.nih.gov/pubmed/19338078",
        "http://www.ncbi.nlm.nih.gov/pubmed/18936232",
        "http://www.ncbi.nlm.nih.gov/pubmed/22160085",
        "http://www.ncbi.nlm.nih.gov/pubmed/25782630",
        "http://www.ncbi.nlm.nih.gov/pubmed/23807042",
        "http://www.ncbi.nlm.nih.gov/pubmed/16009323",
        "http://www.ncbi.nlm.nih.gov/pubmed/22544439",
        "http://www.ncbi.nlm.nih.gov/pubmed/23836059",
        "http://www.ncbi.nlm.nih.gov/pubmed/16755911",
        "http://www.ncbi.nlm.nih.gov/pubmed/31280251",
        "http://www.ncbi.nlm.nih.gov/pubmed/19681654",
        "http://www.ncbi.nlm.nih.gov/pubmed/16604073",
        "http://www.ncbi.nlm.nih.gov/pubmed/24385536",
        "http://www.ncbi.nlm.nih.gov/pubmed/15886319",
        "http://www.ncbi.nlm.nih.gov/pubmed/17768112",
        "http://www.ncbi.nlm.nih.gov/pubmed/21439478",
        "http://www.ncbi.nlm.nih.gov/pubmed/12469120",
        "http://www.ncbi.nlm.nih.gov/pubmed/15797999",
        "http://www.ncbi.nlm.nih.gov/pubmed/19249912"
      ]
    },
    {
      "id": "6429ee7457b1c7a31500000b",
      "type": "yesno",
      "body": "Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35738594",
          "text": "The COVID-19 vaccination can cause specific side-effects, such as axillary lymph node swelling; therefore, breast oncologists should pay attention to such occurrences.",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 311,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36276167",
          "text": "when given to Saudi Arabian adults. All reported side-effects were mild to moderate. The findings will likely persuade vaccine-hesitant individuals an",
          "offsetInBeginSection": 1264,
          "offsetInEndSection": 1414,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35952506",
          "text": "tients with BECTS reported having side effects; all effects were mild that could be relieved themselves. For Sinopharm (Beijing): BBIBP-CorV (Vero cel",
          "offsetInBeginSection": 860,
          "offsetInEndSection": 1010,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34940894",
          "text": "The most common observed side effects were mild to moderate pain at the injection site (40%), followed by fatigue (24%).",
          "offsetInBeginSection": 1062,
          "offsetInEndSection": 1182,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35775049",
          "text": "etween 30 and 40 years old, only after the first vaccination dose. None of the DMTs predisposed for particular side effects.\n\n\nConclusions\nAccording t",
          "offsetInBeginSection": 1514,
          "offsetInEndSection": 1664,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35334998",
          "text": "cination among Arab populations are usually non-life-threatening; flu-like symptoms and injection site pain. Certain predisposing factors have greater",
          "offsetInBeginSection": 2211,
          "offsetInEndSection": 2361,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34197678",
          "text": "The common side effects reported following Covid-19 vaccination were mostly self-restricted local reactions that resolved quickly.",
          "offsetInBeginSection": 261,
          "offsetInEndSection": 391,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34767100",
          "text": "The efficacy of the COVID-19 vaccines seems to be further reduced by immunosuppressive medications, such as glucocorticoids (GC), methotrexate (MTX), mycophenolate/mycophenolic acid (MMF), and rituximab (RTX).",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 921,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35383912",
          "text": "d individuals with DS (median age = 19.5\u00a0years), with 50% reporting no side effects from COVID-19 vaccination. Increased seizures following COVID-19 v",
          "offsetInBeginSection": 943,
          "offsetInEndSection": 1093,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35244157",
          "text": "period of 3-13 days after COVID-19 vaccination. None was under immunosuppressive therapy. The 3 patients recovered in a few weeks and the subsequent d",
          "offsetInBeginSection": 709,
          "offsetInEndSection": 859,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36006991",
          "text": "CONCLUSIONS\nImmunization stress-related responses presenting as stroke-like symptoms can develop after COVID-19 vaccination.",
          "offsetInBeginSection": 1813,
          "offsetInEndSection": 1937,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35236842",
          "text": "Analgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain.",
          "offsetInBeginSection": 137,
          "offsetInEndSection": 278,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34199053",
          "text": "Therefore, here, we aimed to evaluate AEs and early NAb production in relatively healthy Asians who received the ChAdOx1 vaccine and determine the effect of AEs and antipyretics on early NAb production against COVID-19.",
          "offsetInBeginSection": 371,
          "offsetInEndSection": 590,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35099852",
          "text": "Side effects were reported in 335 (81.1%) of patients, of which the most common were injection site pain or swelling (66.3%), fatigue (57.1%), fever (19.9%), and headache (19.6%).",
          "offsetInBeginSection": 607,
          "offsetInEndSection": 786,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34707073",
          "text": "Because of this pharmacological property, the use of NSAIDs should be more effective in reducing the vaccine-induced systemic side effects that are caused primarily by the enhanced cellular immunity.",
          "offsetInBeginSection": 822,
          "offsetInEndSection": 1021,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35720324",
          "text": "o-inflammatory cytokine responses, these cytokines might mediate autoimmune responses after COVID-19 vaccination. Here we report a case with new-onset",
          "offsetInBeginSection": 706,
          "offsetInEndSection": 856,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35099852",
          "text": "There was no difference in risk of side effects between specific rheumatic diseases or drug therapies.",
          "offsetInBeginSection": 1446,
          "offsetInEndSection": 1548,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34866090",
          "text": "ve been approved and administered. However, their side effects remain poorly elucidated. This paper presents two cases of immune thrombocytopenia (ITP",
          "offsetInBeginSection": 313,
          "offsetInEndSection": 463,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35099852",
          "text": "In contrast, patients with hypertension (OR\u2009=\u20090.73; p\u2009=\u2009.04), systemic lupus erythematous (OR\u2009=\u20090.53; p\u2009<\u2009.001), stroke (OR\u2009=\u20090.29; p\u2009=\u2009.01), steroid therapy (OR\u2009=\u20090.59; p\u2009=\u2009.01), and leflunomide therapy (OR\u2009=\u20090.45; p\u2009=\u2009.05) were significantly less likely to be vaccinated.",
          "offsetInBeginSection": 1037,
          "offsetInEndSection": 1310,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34073382",
          "text": "Most of the post-vaccination side effects are mild to moderate, which are signs that body's immune system is building protection.",
          "offsetInBeginSection": 2223,
          "offsetInEndSection": 2352,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35746454",
          "text": "cine outcomes, including the development of adverse events and/or COVID-19 infection following COVID-19 vaccination. A cross-sectional study was condu",
          "offsetInBeginSection": 268,
          "offsetInEndSection": 418,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34835228",
          "text": "clinical trials which lasted only for a few days. Side effects were more common after the second dose. Larger epidemiological and molecular studies ar",
          "offsetInBeginSection": 1787,
          "offsetInEndSection": 1937,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34166950",
          "text": "cination against COVID-19 (27 female, 20% seizure free, 96<% on antiseizure medication) and were included in the study. Two-thirds tolerated the vacci",
          "offsetInBeginSection": 514,
          "offsetInEndSection": 664,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35666609",
          "text": " people are concerned about possible cutaneous side-effects, which can delay or prevent them from being vaccinated. The objectives of this systematic ",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 270,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36298612",
          "text": "Demographics, history of an epinephrine autoinjector prescription, allergy history category (e.g., food, vaccine, medication, insect sting, seasonal), prior COVID-19 diagnosis or positive test, and vaccine manufacturer were identified as factors associated with allergic and non-allergic side effects; vaccination time 6:00-10:59 was associated with more non-allergic side effects.",
          "offsetInBeginSection": 860,
          "offsetInEndSection": 1241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35666609",
          "text": "Most reactions are mild and are not contraindications to subsequent vaccination except for anaphylaxis, which rarely occurs.",
          "offsetInBeginSection": 1586,
          "offsetInEndSection": 1710,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35759219",
          "text": "=\u20090.024) or rheumatoid arthritis (p\u2009=\u20090.023), and participants who take NSAIDs regularly (p\u2009=\u20090.029). Short-term side effects of COVID-19 vaccines see",
          "offsetInBeginSection": 1286,
          "offsetInEndSection": 1436,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35666609",
          "text": "COVID-19 vaccination may also be associated with flares of pre-existing dermatoses and delayed inflammatory reactions to tissue filler.",
          "offsetInBeginSection": 1711,
          "offsetInEndSection": 1846,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34940894",
          "text": "However, some precautions should be taken, especially regarding the timing of vaccination and ICI treatment.",
          "offsetInBeginSection": 1531,
          "offsetInEndSection": 1639,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35383912",
          "text": "SIGNIFICANCE\nThese results indicate COVID-19 vaccination is well tolerated by individuals with DS.",
          "offsetInBeginSection": 1662,
          "offsetInEndSection": 1760,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35334998",
          "text": "traZeneca (20.7%), and Sinopharm (14.2%). About 72% of participants experienced post-vaccination side effects. This study reports statistically signif",
          "offsetInBeginSection": 1466,
          "offsetInEndSection": 1616,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36366292",
          "text": "The most frequent renal side effects of COVID-19 vaccination were minimal change disease (52 cases), IgA nephropathy (48 cases), antineutrophil cytoplasmic autoantibody vasculitis (16 cases), and acute interstitial nephritis (12 cases).",
          "offsetInBeginSection": 900,
          "offsetInEndSection": 1136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35738594",
          "text": "CONCLUSION\nAxillary lymph node swelling can occur after a third COVID-19 vaccination.",
          "offsetInBeginSection": 1248,
          "offsetInEndSection": 1333,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36443813",
          "text": "ine access, rheumatologic medication management around vaccination, and vaccine side effects. Themes were identified for the process and context of CO",
          "offsetInBeginSection": 970,
          "offsetInEndSection": 1120,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34853744",
          "text": "However, given the urgent need for vaccine production, some of the side effects may not have been presented during trials and will only appear during the mass vaccination.",
          "offsetInBeginSection": 260,
          "offsetInEndSection": 431,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36345233",
          "text": "ns may trigger new-onset or reactivation of keratitis, though causality cannot be proven. Despite its rarity, clinicians should be aware of this possi",
          "offsetInBeginSection": 929,
          "offsetInEndSection": 1079,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36184535",
          "text": "de effects of mRNA vaccines for coronavirus disease 2019 (COVID-19) remains unclear. Several cases of antineutrophil cytoplasmic antibody (ANCA)-assoc",
          "offsetInBeginSection": 21,
          "offsetInEndSection": 171,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36119236",
          "text": "eneral population.\n\n\nMethodology\nA cross-sectional study was conducted to assess the acceptance and adverse effects following the first dose of COVID-",
          "offsetInBeginSection": 719,
          "offsetInEndSection": 869,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35334998",
        "http://www.ncbi.nlm.nih.gov/pubmed/35383912",
        "http://www.ncbi.nlm.nih.gov/pubmed/34197678",
        "http://www.ncbi.nlm.nih.gov/pubmed/34835228",
        "http://www.ncbi.nlm.nih.gov/pubmed/35759219",
        "http://www.ncbi.nlm.nih.gov/pubmed/36366292",
        "http://www.ncbi.nlm.nih.gov/pubmed/34767100",
        "http://www.ncbi.nlm.nih.gov/pubmed/36345233",
        "http://www.ncbi.nlm.nih.gov/pubmed/34073382",
        "http://www.ncbi.nlm.nih.gov/pubmed/34866090",
        "http://www.ncbi.nlm.nih.gov/pubmed/34940894",
        "http://www.ncbi.nlm.nih.gov/pubmed/35738594",
        "http://www.ncbi.nlm.nih.gov/pubmed/35775049",
        "http://www.ncbi.nlm.nih.gov/pubmed/35952506",
        "http://www.ncbi.nlm.nih.gov/pubmed/35244157",
        "http://www.ncbi.nlm.nih.gov/pubmed/35236842",
        "http://www.ncbi.nlm.nih.gov/pubmed/36184535",
        "http://www.ncbi.nlm.nih.gov/pubmed/34199053",
        "http://www.ncbi.nlm.nih.gov/pubmed/34166950",
        "http://www.ncbi.nlm.nih.gov/pubmed/36006991",
        "http://www.ncbi.nlm.nih.gov/pubmed/36276167",
        "http://www.ncbi.nlm.nih.gov/pubmed/35666609",
        "http://www.ncbi.nlm.nih.gov/pubmed/35720324",
        "http://www.ncbi.nlm.nih.gov/pubmed/34707073",
        "http://www.ncbi.nlm.nih.gov/pubmed/35099852",
        "http://www.ncbi.nlm.nih.gov/pubmed/34853744",
        "http://www.ncbi.nlm.nih.gov/pubmed/35746454",
        "http://www.ncbi.nlm.nih.gov/pubmed/36298612",
        "http://www.ncbi.nlm.nih.gov/pubmed/36119236",
        "http://www.ncbi.nlm.nih.gov/pubmed/36443813"
      ]
    },
    {
      "id": "6433050157b1c7a315000024",
      "type": "factoid",
      "body": "Which drug was the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE)?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24556385",
          "text": "BACKGROUND\nConestat alfa (Ruconest, rhC1INH) is the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22171564",
          "text": "BACKGROUND\nRecombinant human C1-inhibitor (rhC1INH; Ruconest\u00ae) has been developed for treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) due to heterozygous deficiency of C1INH.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30021471",
          "text": " an established treatment for both on demand and prophylaxis of HAE. Conestat alfa is a recombinant form of human C1-INH (rhC1-INH) produced in transg",
          "offsetInBeginSection": 219,
          "offsetInEndSection": 369,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30280305",
          "text": "Fifty (63.3%) attacks were treated with recombinant human C1-INH (rhC1-INH); 17 (21.5%) with plasma-derived, pasteurized, nanofiltered C1-INH (pnfC1-INH); 13 (16.5%) with icatibant; and 1 (1.3%) with plasma-derived, nanofiltered C1-INH (nfC1-INH).",
          "offsetInBeginSection": 694,
          "offsetInEndSection": 941,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32923264",
          "text": "The targeted therapy for HAE consists of plasma-derived or recombinant C1-INH, ecallantide, and icatibant or bradykinin receptor antagonist.",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 717,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21753889",
          "text": "n findings from bench to bedside trials of a new C1-INH replacement, conestat alfa. Conestat alfa is unique among the other C1-INH replacement product",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 358,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
          "text": "tor (C1-INH) or via blocking the production or function of bradykinin. Cinryze\u00ae is a nanofiltered C1-INH, approved in Europe for the acute treatment, ",
          "offsetInBeginSection": 388,
          "offsetInEndSection": 538,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17559913",
          "text": " likely mediator of the swelling and pain characterizing HAE attacks. Ecallantide, a novel, recombinant protein, potently inhibits kallikrein. This is",
          "offsetInBeginSection": 396,
          "offsetInEndSection": 546,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36193964",
          "text": "The effectiveness of recommended drugs as plasma-derived C1-INH, recombinant C1-INH or icatibant confirmed the diagnosis.",
          "offsetInBeginSection": 2019,
          "offsetInEndSection": 2140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17559913",
          "text": "dose level: 10 to ecallantide and 2 to placebo, per cohort.\n\n\nRESULTS\nEcallantide treatment ameliorated the symptoms of HAE attacks: 72.5% (29/40) of ",
          "offsetInBeginSection": 1110,
          "offsetInEndSection": 1260,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20441418",
          "text": "ccessfully used to treat HAE in selected countries, mostly in Europe. Berinert P (CSL Behring, Marburg, Germany), a human plasma-derived C1-INH, was s",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 383,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28687108",
          "text": "Four treatments-plasma-derived C1 inhibitor concentrate, recombinant C1 inhibitor concentrate, ecallantide, and icatibant-are reviewed in this article.",
          "offsetInBeginSection": 430,
          "offsetInEndSection": 581,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25640891",
          "text": "ssociated with acute C1-INH-HAE attacks, particularly with submucosal involvement. However, rhC1INH therapy was not associated with thrombotic events.",
          "offsetInBeginSection": 1609,
          "offsetInEndSection": 1759,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22995741",
          "text": "ted comparable inhibitory potency and specificity. Recently, rhC1INH (Ruconest(\u00ae)) has been approved by the European Medicines Agency for the treatmen",
          "offsetInBeginSection": 1513,
          "offsetInEndSection": 1663,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282867",
          "text": "One preparation, Cinryze, was approved by the U.S. Food & Drug Administration (FDA) for prophylaxis of HAE attacks in October 2008, and the second, Berinert, was approved by the FDA for treatment of acute attacks in October 2009.",
          "offsetInBeginSection": 796,
          "offsetInEndSection": 1025,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36408587",
          "text": "overview of the safety and efficacy of the oral kallikrein inhibitor berotralstat in C1-INH-HAE disease. It provides a comprehensive synopsis of the r",
          "offsetInBeginSection": 523,
          "offsetInEndSection": 673,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22192966",
          "text": "OBJECTIVE\nTo evaluate the efficacy and safety of repeat use of nanofiltered C1 esterase inhibitor (human) (C1 INH-nf) for the short-term treatment of HAE attacks.",
          "offsetInBeginSection": 242,
          "offsetInEndSection": 404,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22909164",
          "text": "CONCLUSIONS AND CLINICAL RELEVANCE\nTreatment with rhC1-INH provides fast-onset relief for an HAE attack, with a high rate of therapeutic response maintained throughout subsequent attacks.",
          "offsetInBeginSection": 1670,
          "offsetInEndSection": 1857,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21950301",
          "text": " with hereditary angioedema with the bradykinin B2 receptor antagonist icatibant.\n\n\nRESULTS\nDuring the entire observation period, efficacy of icatiban",
          "offsetInBeginSection": 403,
          "offsetInEndSection": 553,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24468257",
          "text": "Recombinant human C1INH (rhC1INH) has been shown effective for acute treatment of HAE attacks.",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 288,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17524093",
          "text": "This study was undertaken to investigate the effects of rHuC1INH in the treatment of acute angioedema attacks in patients with a hereditary C1-inhibitor deficiency.",
          "offsetInBeginSection": 250,
          "offsetInEndSection": 414,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17524093",
          "text": "STUDY DESIGN AND METHODS\nPatients with hereditary C1-inhibitor deficiency were treated with rHuC1INH (at a dose of 100 U/kg) within 8 hours after onset of an acute attack.",
          "offsetInBeginSection": 417,
          "offsetInEndSection": 588,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21695090",
          "text": "In December 2009 the FDA approved ecallantide for the treatment of acute HAE attacks.",
          "offsetInBeginSection": 710,
          "offsetInEndSection": 795,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17761272",
          "text": "OBJECTIVE\nTo summarize our experience with hC1-INH concentrate in patients with HAE.",
          "offsetInBeginSection": 539,
          "offsetInEndSection": 623,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23420425",
          "text": "The aim of this study is a comparison of the clinical effectiveness of conestat alfa, human C1 esterase inhibitor (C1INH), and icatibant in the treatment of acute angioedema attacks in adults with HAE.",
          "offsetInBeginSection": 232,
          "offsetInEndSection": 433,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282867",
          "text": "A third preparation, the recombinant human C1 inhibitor Rhucin, is completing clinical trials.",
          "offsetInBeginSection": 1026,
          "offsetInEndSection": 1120,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36193964",
        "http://www.ncbi.nlm.nih.gov/pubmed/30280305",
        "http://www.ncbi.nlm.nih.gov/pubmed/20441418",
        "http://www.ncbi.nlm.nih.gov/pubmed/22192966",
        "http://www.ncbi.nlm.nih.gov/pubmed/28687108",
        "http://www.ncbi.nlm.nih.gov/pubmed/25640891",
        "http://www.ncbi.nlm.nih.gov/pubmed/36408587",
        "http://www.ncbi.nlm.nih.gov/pubmed/21695090",
        "http://www.ncbi.nlm.nih.gov/pubmed/22909164",
        "http://www.ncbi.nlm.nih.gov/pubmed/24556385",
        "http://www.ncbi.nlm.nih.gov/pubmed/17559913",
        "http://www.ncbi.nlm.nih.gov/pubmed/23420425",
        "http://www.ncbi.nlm.nih.gov/pubmed/21753889",
        "http://www.ncbi.nlm.nih.gov/pubmed/17761272",
        "http://www.ncbi.nlm.nih.gov/pubmed/22171564",
        "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
        "http://www.ncbi.nlm.nih.gov/pubmed/32923264",
        "http://www.ncbi.nlm.nih.gov/pubmed/23282867",
        "http://www.ncbi.nlm.nih.gov/pubmed/22995741",
        "http://www.ncbi.nlm.nih.gov/pubmed/21950301",
        "http://www.ncbi.nlm.nih.gov/pubmed/24468257",
        "http://www.ncbi.nlm.nih.gov/pubmed/30021471",
        "http://www.ncbi.nlm.nih.gov/pubmed/17524093"
      ]
    },
    {
      "id": "6417900b690f196b5100002a",
      "type": "factoid",
      "body": "What type of DMD can viltolarsen be used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
          "text": "Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\u00a0for the treatment of Duchenne muscular dystrophy (DMD), one of the most common lethal genetic disorders characterized by progressive degeneration of skeletal muscles and cardiomyopathy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 305,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32519222",
          "text": "nter of Neurology and Psychiatry (NCNP), for the treatment of Duchenne muscular dystrophy (DMD). Viltolarsen binds to exon 53 of the dystrophin mRNA p",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 317,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
          "text": "be used to monitor the efficacy of experimental therapies for Duchenne Muscular Dystrophy (DMD) in clinical trials. Identification of novel protein bi",
          "offsetInBeginSection": 58,
          "offsetInEndSection": 208,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29579701",
          "text": "BACKGROUND\nAlthough prolonged ambulation is considered important in children with Duchenne muscular dystrophy (DMD), articles describing gait deviations in DMD are scarce.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33285037",
          "text": "n gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD). We investigated viltolarsen's ability to induce dystr",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 251,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12692454",
          "text": "This study examined Three Wishes (a projective technique commonly used with children) in boys with Duchenne muscular dystrophy (DMD), a fatal, progressive illness (n = 74).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36449321",
          "text": "disease progression and therapeutic response in patients with Duchenne muscular dystrophy (DMD). This study evaluates whether quantitative muscle ultr",
          "offsetInBeginSection": 77,
          "offsetInEndSection": 227,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25365558",
          "text": "A readily available animal model is essential for rapidly identifying effective treatments for Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder caused by the lack of dystrophin protein, which results from frame-disrupting mutations in the DMD gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
          "text": "en for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years. We are witnessing the sta",
          "offsetInBeginSection": 420,
          "offsetInEndSection": 570,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
          "text": "Viltolarsen, an AON for DMD exon 53 skipping, was approved in Japan earlier this year.",
          "offsetInBeginSection": 483,
          "offsetInEndSection": 569,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26037351",
          "text": "OBJECTIVE\nTo optimize the methods for genetic detection and prenatal diagnosis of Duchenne muscular dystrophy (DMD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
          "text": "ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33610829",
          "text": "ntisense oligonucleotides (AONs) is a promising treatment for Duchenne muscular dystrophy (DMD). Several exon-skipping drugs, including viltolarsen (N",
          "offsetInBeginSection": 27,
          "offsetInEndSection": 177,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24332447",
          "text": "Ways of testing this hypothesis and its potential topical use are discussed.",
          "offsetInBeginSection": 452,
          "offsetInEndSection": 528,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16528755",
          "text": "ethical issues regarding screening newborns (and infants) for Duchenne muscular dystrophy (DMD). First, what are the risks and benefits of expanding n",
          "offsetInBeginSection": 58,
          "offsetInEndSection": 208,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1459673",
          "text": "This information can be useful for genetic counselling with particular reference to prenatal diagnosis and carrier analysis.",
          "offsetInBeginSection": 329,
          "offsetInEndSection": 453,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1971151",
          "text": "The complete 14-kb cDNA for the gene causing the X-linked recessive muscular dystrophy (MD) type Duchenne (DMD) and Becker (BMD) has recently been cloned and made available for deletion/duplication screening in patients.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29060790",
          "text": "Duchenne Muscular Dystrophy (DMD) is a genetic disorder caused by dystrophin protein deficiency.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25982038",
          "text": "Double-strand DNA (dsDNA) can act as an effective template for the formation of CuNCs, which can be used to distinguish the deletion or duplication genotypes of Duchenne muscular dystrophy (DMD) due to different fluorescent intensities.",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 348,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32453377",
          "text": "Importance\nAn unmet need remains for safe and efficacious treatments for Duchenne muscular dystrophy (DMD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35634851",
          "text": "CONCLUSIONS\nBased on these results at over 2 years, viltolarsen can be a new treatment option for patients with DMD amenable to exon 53 skipping.",
          "offsetInBeginSection": 1654,
          "offsetInEndSection": 1799,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33967607",
          "text": "We explored has_circ_0071106 as a diagnostic marker for type 2 diabetes (T2DM) in south China, and predicted the functional mechanism of the target circRNA.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34938127",
          "text": "Viltolarsen is a mutation-specific drug and will work for 8% of the persons with DMD who carry mutations amenable to exon 53 skipping.",
          "offsetInBeginSection": 991,
          "offsetInEndSection": 1125,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713895",
          "text": "The Cincinnati study reviewed data from 435 males with Duchenne muscular dystrophy, also known as DMD, who were treated at the Cincinnati Children's Hospital Medical Center.",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 351,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33610829",
          "text": "To overcome this limitation, we recently established a direct human somatic cell reprogramming technology and successfully developed a cellular skeletal muscle DMD model by using myogenic differentiation 1 (MYOD1)-transduced urine-derived cells (MYOD1-UDCs).",
          "offsetInBeginSection": 480,
          "offsetInEndSection": 738,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130193",
          "text": "d viltolarsen (VILTEPSO\u00ae) have been approved by the FDA to treat specific types of DMD. SMA is defined by the degeneration of the anterior horn cells ",
          "offsetInBeginSection": 835,
          "offsetInEndSection": 985,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34092651",
          "text": "achieving spectacular success in treating these diseases. For Duchenne muscular dystrophy (DMD), the state-of-the-art is an exon skipping therapy usin",
          "offsetInBeginSection": 661,
          "offsetInEndSection": 811,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637366",
          "text": "A digital micromirror device (DMD) is an array of individually switchable mirrors that can be used in many advanced optical systems as a rapid spatial light modulator.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25198739",
          "text": "Respiratory failure and heart failure are inevitable complications in Duchenne muscular dystrophy (DMD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401026",
          "text": "rom childhood, the earlier treatment is preferred. The canine X-linked muscular dystrophy in Japan (CXMDj), a dog model of DMD, produces no dystrophin",
          "offsetInBeginSection": 556,
          "offsetInEndSection": 706,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25669899",
          "text": "Despite its extensive use in DMD research, no effective treatment has yet been developed for this devastating disease.",
          "offsetInBeginSection": 274,
          "offsetInEndSection": 392,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130193",
          "text": " and viltolarsen (VILTEPSO\u00ae) have been approved by the FDA to treat specific types of DMD. SMA is defined by the degeneration of the anterior horn cel",
          "offsetInBeginSection": 832,
          "offsetInEndSection": 982,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35634851",
          "text": "BACKGROUND\nDuchenne muscular dystrophy (DMD) is a rare, genetic disease caused by mutations in the DMD gene resulting in an absence of functional dystrophin protein.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33239841",
          "text": "Duchenne muscular dystrophy (DMD) is a progressive muscular disorder caused by X-chromosomal DMD gene mutations.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34938127",
          "text": "Duchenne muscular dystrophy (DMD) is a fatal, X-linked recessive disorder characterized by progressive muscle loss and cardiorespiratory complications.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33239841",
          "text": "ed with aging, which is, to some extent, similar to what occurs in humans. Thus, cDMDR could be a valuable model for studying cardiology of human DMD.",
          "offsetInBeginSection": 1512,
          "offsetInEndSection": 1662,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32453377",
          "text": "ntrol: -65.3 m) at the week 25 visit.\n\n\nConclusions and Relevance\nSystemic treatment of participants with DMD with viltolarsen induced de novo dystrop",
          "offsetInBeginSection": 2338,
          "offsetInEndSection": 2488,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28430230",
          "text": "Our results show that DMDs can be used in high-resolution spectroscopy and for Fiber Bragg grating (FBG) interrogation.",
          "offsetInBeginSection": 814,
          "offsetInEndSection": 933,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955503",
          "text": "ng antisense oligonucleotides (AONs) that induce exon skipping. The morpholino AON viltolarsen (code name: NS-065/NCNP-01) has been shown to induce ex",
          "offsetInBeginSection": 314,
          "offsetInEndSection": 464,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
          "text": "es a truncated but functional form of dystrophin. It can treat approximately 8-10% of the DMD patient population.\u00a0This paper aims to summarize the dev",
          "offsetInBeginSection": 780,
          "offsetInEndSection": 930,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24225992",
          "text": "Duchenne and Becker muscular dystrophies (DMD/BMD) are X-linked inherited muscular disorders caused by mutations in the dystrophin gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31720560",
          "text": "Exclusion of exon 53 from the DMD primary transcript can treat 8-10% of DMD patients worldwide.",
          "offsetInBeginSection": 763,
          "offsetInEndSection": 858,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28430230",
        "http://www.ncbi.nlm.nih.gov/pubmed/32453377",
        "http://www.ncbi.nlm.nih.gov/pubmed/32519222",
        "http://www.ncbi.nlm.nih.gov/pubmed/33285037",
        "http://www.ncbi.nlm.nih.gov/pubmed/35713895",
        "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
        "http://www.ncbi.nlm.nih.gov/pubmed/29579701",
        "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
        "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
        "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
        "http://www.ncbi.nlm.nih.gov/pubmed/36449321",
        "http://www.ncbi.nlm.nih.gov/pubmed/33610829",
        "http://www.ncbi.nlm.nih.gov/pubmed/24225992",
        "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
        "http://www.ncbi.nlm.nih.gov/pubmed/31720560",
        "http://www.ncbi.nlm.nih.gov/pubmed/25669899",
        "http://www.ncbi.nlm.nih.gov/pubmed/35634851",
        "http://www.ncbi.nlm.nih.gov/pubmed/36401026",
        "http://www.ncbi.nlm.nih.gov/pubmed/12692454",
        "http://www.ncbi.nlm.nih.gov/pubmed/25198739",
        "http://www.ncbi.nlm.nih.gov/pubmed/34092651",
        "http://www.ncbi.nlm.nih.gov/pubmed/16528755",
        "http://www.ncbi.nlm.nih.gov/pubmed/23637366",
        "http://www.ncbi.nlm.nih.gov/pubmed/25365558",
        "http://www.ncbi.nlm.nih.gov/pubmed/25982038",
        "http://www.ncbi.nlm.nih.gov/pubmed/29060790",
        "http://www.ncbi.nlm.nih.gov/pubmed/34938127",
        "http://www.ncbi.nlm.nih.gov/pubmed/33130193",
        "http://www.ncbi.nlm.nih.gov/pubmed/33239841",
        "http://www.ncbi.nlm.nih.gov/pubmed/1971151",
        "http://www.ncbi.nlm.nih.gov/pubmed/33967607",
        "http://www.ncbi.nlm.nih.gov/pubmed/26037351",
        "http://www.ncbi.nlm.nih.gov/pubmed/32955503",
        "http://www.ncbi.nlm.nih.gov/pubmed/1459673",
        "http://www.ncbi.nlm.nih.gov/pubmed/24332447"
      ]
    },
    {
      "id": "63f57ea133942b094c000005",
      "type": "list",
      "body": "What is the triad of the Cat eye syndrome?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465332",
          "text": "The classic triad of iris coloboma, anorectal malformations, and auricular abnormalities is present in 40% of patients.",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16145841",
          "text": "osome 22q11. The patients demonstrate specific abnormalities of heart, kidney, and eye. Here we attempted to produce a model for this defect by expres",
          "offsetInBeginSection": 84,
          "offsetInEndSection": 234,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3109242",
          "text": "The cat eye syndrome, blepharophimosis or Kohn-Romano syndrome, Rieger syndrome, and other disorders are discussed in relationship to this entity.",
          "offsetInBeginSection": 236,
          "offsetInEndSection": 382,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11332976",
          "text": "riable pattern of multiple congenital anomalies of which coloboma of the iris and anal atresia are the best known. CES is cytogenetically characterise",
          "offsetInBeginSection": 46,
          "offsetInEndSection": 196,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/410302",
          "text": "hniques, we studied a child with typical cat-eye syndrome and ocular retraction syndrome. Although the mother was was chromosomally normal, other mate",
          "offsetInBeginSection": 38,
          "offsetInEndSection": 188,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35911297",
          "text": "The classic clinical triad includes coloboma of the iris, ears, and anal malformations.",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 188,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2072964",
          "text": "In a cyanotic newborn with characteristic features of Cat-Eye-Syndrome, cytogenetic examination disclosed a supernumerary small bisatellited chromosome.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928108",
          "text": "e 22, with a variable phenotype comprising anal atresia, coloboma of the iris and preauricular tags or pits. We report a girl with cat eye syndrome, p",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 279,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31034246",
          "text": "Most of the sample was assigned moderate or high risk for Triad CRA and RED-S CAT (Triad: 54.7% moderate and 7.9% high; RED-S: 63.2% moderate and 33.0% high).",
          "offsetInBeginSection": 964,
          "offsetInEndSection": 1122,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648072",
          "text": "Individuals with cat-eye syndrome are characterized by the presence of preauricular pits and/or tags, anal atresia, and iris coloboma.",
          "offsetInBeginSection": 67,
          "offsetInEndSection": 201,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2258543",
          "text": "ns, neoplasms of the eye surface and the orbit and finally neuro-ophthalmological anomalies. This study was realised at the university clinic of Mont ",
          "offsetInBeginSection": 499,
          "offsetInEndSection": 649,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465332",
          "text": "RESULTS\nThe ophthalmological and systemic evaluation revealed a unilateral iris coloboma and ipsilateral auricular malformations.",
          "offsetInBeginSection": 646,
          "offsetInEndSection": 775,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32362975",
          "text": "The triad of one or more episodes of unilateral orbital pain, paresis of one or more of the cranial nerves, and granulomas by magnetic resonance imaging (MRI) or biopsy is 95-100% sensitive at diagnosing the syndrome; however, our patient did not present with the \"classic\" triad.",
          "offsetInBeginSection": 1215,
          "offsetInEndSection": 1495,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17352276",
          "text": "The cat eye syndrome is a congenital malformation usually associated with anal atresia, ocular coloboma, downward slanting eyes, microphthalmia, hypertelorism, strabismus, preauricular tags or fistulas, congenital heart defect particularly septal defect, urinary tract abnormalities, skeletal anomalies and frequently mental and physical retardation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 350,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17706516",
          "text": "Here, we report a case where there appears to be an association among short segment HD, cat eye syndrome, and anorectal malformation, which has not previously been identified.",
          "offsetInBeginSection": 236,
          "offsetInEndSection": 411,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32362975",
        "http://www.ncbi.nlm.nih.gov/pubmed/23928108",
        "http://www.ncbi.nlm.nih.gov/pubmed/25648072",
        "http://www.ncbi.nlm.nih.gov/pubmed/2072964",
        "http://www.ncbi.nlm.nih.gov/pubmed/410302",
        "http://www.ncbi.nlm.nih.gov/pubmed/11332976",
        "http://www.ncbi.nlm.nih.gov/pubmed/17706516",
        "http://www.ncbi.nlm.nih.gov/pubmed/31034246",
        "http://www.ncbi.nlm.nih.gov/pubmed/33465332",
        "http://www.ncbi.nlm.nih.gov/pubmed/3109242",
        "http://www.ncbi.nlm.nih.gov/pubmed/16145841",
        "http://www.ncbi.nlm.nih.gov/pubmed/2258543",
        "http://www.ncbi.nlm.nih.gov/pubmed/17352276",
        "http://www.ncbi.nlm.nih.gov/pubmed/35911297"
      ]
    },
    {
      "id": "64281a47690f196b5100004f",
      "type": "yesno",
      "body": "Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34258537",
          "text": "INTRODUCTION\nThe therapy to reduce urinary oxalate excretion in primary hyperoxaluria type 1 is still required.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32165440",
          "text": "combined kidney and liver transplantation. There are no therapies approved by the Food and Drug Association. Thus, the Kidney Health Initiative, in pa",
          "offsetInBeginSection": 268,
          "offsetInEndSection": 418,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31580236",
          "text": "order that causes overproduction and urinary excretion of oxalate. Liver transplant has been suggested as a treatment for primary hyperoxaluria type 1",
          "offsetInBeginSection": 69,
          "offsetInEndSection": 219,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35015123",
          "text": "1), with doses and intervals according to body weight. Little is known as to its use in infants; the aim of this study was to describe treatment outco",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 277,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33985991",
          "text": "Lumasiran, an RNA interference therapeutic, suppresses glycolate oxidase, reducing hepatic oxalate production.",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 304,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22215125",
          "text": "The primary disease is treated by combined liver-kidney transplantation, although pathological fracturing also occurs in the posttransplant period.",
          "offsetInBeginSection": 363,
          "offsetInEndSection": 510,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23830800",
          "text": "Aside from combined liver/kidney transplantation, no curative treatment exists.",
          "offsetInBeginSection": 300,
          "offsetInEndSection": 379,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31580236",
          "text": "Combined liver and kidney transplant and preemptive liver transplant could be proper options for these patients.",
          "offsetInBeginSection": 1561,
          "offsetInEndSection": 1673,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35071135",
          "text": "ney failure and systemic oxalosis. Lumasiran, is a liver-directed RNA interference therapeutic agent. It has been shown to reduce hepatic oxalate prod",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 313,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35779234",
          "text": "NA interference medication is now available. Lumasiran\u00ae is already available on prescription and targets the messenger RNA of glycolate oxidase, thus ",
          "offsetInBeginSection": 781,
          "offsetInEndSection": 931,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35592624",
          "text": " kidney function and appropriate dialysis regimens. Liver or combined liver/kidney transplantation is currently the only definitive treatment for prim",
          "offsetInBeginSection": 318,
          "offsetInEndSection": 468,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30907303",
          "text": "Disrupted oxalate metabolism has been implicated in hyperoxaluria and accordingly, an enzymatic disturbance in oxalate biosynthesis can result in the primary hyperoxaluria.",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 267,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33985991",
          "text": "Lumasiran had an acceptable safety profile, with no serious adverse events or study discontinuations attributed to treatment.",
          "offsetInBeginSection": 1412,
          "offsetInEndSection": 1537,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34508834",
          "text": "Fortunately, novel promising targeted therapeutic approaches are on the horizon in patients with primary hyperoxaluria.",
          "offsetInBeginSection": 646,
          "offsetInEndSection": 765,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33985991",
          "text": "CONCLUSIONS\nLumasiran had an acceptable safety profile and reduced urinary oxalate excretion in all patients with primary hyperoxaluria type 1 to near-normal levels.",
          "offsetInBeginSection": 1919,
          "offsetInEndSection": 2084,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35779234",
          "text": "n B6, RNA interference medication is now available. Lumasiran\u00ae is already available on prescription and targets the messenger RNA of glycolate oxidase",
          "offsetInBeginSection": 774,
          "offsetInEndSection": 924,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35731461",
          "text": "Two genes have been targeted with RNA interference; lumasiran targets glycolate oxidase and nedosiran targets lactate dehydrogenase A. Lumasiran was recently approved in the treatment of primary hyperoxaluria type 1 and nedosiran is in the approval process.",
          "offsetInBeginSection": 822,
          "offsetInEndSection": 1079,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33789010",
          "text": "Lumasiran, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase.",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 341,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9604807",
          "text": "Drug therapy receives scant attention as a treatment mode for primary hyperoxaluria (PH).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2210975",
          "text": "revealed the diagnosis of hyperoxaluria. Diagnosis and treatment of primary hyperoxaluria are briefly reviewed and the importance of elevated urinary ",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 319,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2284120",
          "text": "nary oxalate excretion revealed the diagnosis of hyperoxaluria. Diagnosis and treatment of primary hyperoxaluria briefly reviewed and the importance o",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 297,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32165440",
          "text": "Addressing gaps in data will further facilitate testing of promising new treatments, accelerating improved outcomes for patients with primary hyperoxaluria.",
          "offsetInBeginSection": 2066,
          "offsetInEndSection": 2222,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34258537",
          "text": "CONCLUSION\nWe report the lanthanum efficacy in reducing circulating and urinary oxalate levels in type 1 primary hyperoxaluria.",
          "offsetInBeginSection": 843,
          "offsetInEndSection": 970,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33852222",
          "text": "Lumasiran allows to significantly reduce the levels of oxalate both in blood and in urine, halting the course of the disease and preventing serious renal and systemic complications, if the therapy is started at an early stage of the disease.",
          "offsetInBeginSection": 1419,
          "offsetInEndSection": 1660,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2496356",
          "text": "Treatment of the patient with 500 mg pyridoxine daily resulted in a decrease of the excretion of oxalate to normal values.",
          "offsetInBeginSection": 372,
          "offsetInEndSection": 494,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12474639",
          "text": "However options still seem limited in treating the mild hyperoxaluria found in many stone formers.",
          "offsetInBeginSection": 318,
          "offsetInEndSection": 416,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35924494",
          "text": "However, for a few years now, numerous studies are carried out on this subject and promising results have already been published with a new drug, lumasiran.",
          "offsetInBeginSection": 671,
          "offsetInEndSection": 827,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3798070",
          "text": "It is concluded that pyridoxine given to idiopathic hyperoxalurics may correct the disorder, as in primary hyperoxaluria of type I; this is not the case in enteric hyperoxaluria.",
          "offsetInBeginSection": 1489,
          "offsetInEndSection": 1667,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22057078",
          "text": "med the diagnosis of primary hyperoxaluria type 1. This suggests a screening method for ruling out primary hyperoxaluria in suspected cases, especiall",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 862,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34906487",
          "text": "uria type 1 (PH1) is a rare, progressive, genetic disease with limited treatment options. We report the efficacy and safety of lumasiran, an RNA inter",
          "offsetInBeginSection": 25,
          "offsetInEndSection": 175,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33852222",
          "text": "There is an urgent need for drugs able to inhibit the liver production of oxalate and to prevent the disease progression; lumasiran, an innovative molecule based on RNAi interference, is one of the most promising drugs.",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 402,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25949937",
          "text": "studies and if genetic studies prove inconclusive, liver biopsy is undertaken to establish diagnosis. Diagnostic clues pointing towards secondary hype",
          "offsetInBeginSection": 970,
          "offsetInEndSection": 1120,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32165440",
          "text": "Primary hyperoxaluria registry data suggest that eGFR decline in most patients is gradual, but can be unpredictable.",
          "offsetInBeginSection": 1048,
          "offsetInEndSection": 1164,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33910694",
          "text": "By blocking an enzymatic synthesis (glycolate oxidase or lacticodehydrogenase a) upstream of the deficit that causes the disease, oxaluria normalizes and the tolerance of the drug (administered by injection every 1 to 3 months) is good.",
          "offsetInBeginSection": 761,
          "offsetInEndSection": 997,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/2284120",
        "http://www.ncbi.nlm.nih.gov/pubmed/2210975",
        "http://www.ncbi.nlm.nih.gov/pubmed/9604807",
        "http://www.ncbi.nlm.nih.gov/pubmed/12474639",
        "http://www.ncbi.nlm.nih.gov/pubmed/22057078",
        "http://www.ncbi.nlm.nih.gov/pubmed/35592624",
        "http://www.ncbi.nlm.nih.gov/pubmed/30907303",
        "http://www.ncbi.nlm.nih.gov/pubmed/33985991",
        "http://www.ncbi.nlm.nih.gov/pubmed/34258537",
        "http://www.ncbi.nlm.nih.gov/pubmed/33789010",
        "http://www.ncbi.nlm.nih.gov/pubmed/32165440",
        "http://www.ncbi.nlm.nih.gov/pubmed/23830800",
        "http://www.ncbi.nlm.nih.gov/pubmed/34508834",
        "http://www.ncbi.nlm.nih.gov/pubmed/22215125",
        "http://www.ncbi.nlm.nih.gov/pubmed/33910694",
        "http://www.ncbi.nlm.nih.gov/pubmed/35779234",
        "http://www.ncbi.nlm.nih.gov/pubmed/33852222",
        "http://www.ncbi.nlm.nih.gov/pubmed/35015123",
        "http://www.ncbi.nlm.nih.gov/pubmed/35071135",
        "http://www.ncbi.nlm.nih.gov/pubmed/3798070",
        "http://www.ncbi.nlm.nih.gov/pubmed/35924494",
        "http://www.ncbi.nlm.nih.gov/pubmed/2496356",
        "http://www.ncbi.nlm.nih.gov/pubmed/31580236",
        "http://www.ncbi.nlm.nih.gov/pubmed/35731461",
        "http://www.ncbi.nlm.nih.gov/pubmed/34906487",
        "http://www.ncbi.nlm.nih.gov/pubmed/25949937"
      ]
    },
    {
      "id": "6429cfb557b1c7a315000005",
      "type": "yesno",
      "body": "Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34222281",
          "text": "ated with negative COVID-19 related health outcomes. Individuals with COPD should take precautions to limit the risk of COVID-19 exposure to negate th",
          "offsetInBeginSection": 1675,
          "offsetInEndSection": 1825,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34222281",
          "text": "ociated with negative COVID-19 related health outcomes. Individuals with COPD should take precautions to limit the risk of COVID-19 exposure to negate",
          "offsetInBeginSection": 1672,
          "offsetInEndSection": 1822,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34476396",
          "text": "Asthma should be managed as outlined in local and international guidelines.Ensure an adequate supply of medication, and inhaled corticosteroids should not be withdrawnChronic obstructive pulmonary disease (COPD) is associated with severe COVID-19 disease and poor outcomes.",
          "offsetInBeginSection": 330,
          "offsetInEndSection": 603,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12877818",
          "text": "Although inhaled glucocorticoids are highly effective in controlling airway inflammation in asthma, they are ineffective in the small group of patients with glucocorticoid-dependent and -resistant asthma.",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 331,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35747745",
          "text": "ions such as inhaled corticosteroids (ICS) and biologics on COVID-19 is unclear. This systematic literature review analyzed the published evidence on ",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 322,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33248363",
          "text": "Considering what is available in literature, there are no known infection-related hazards to an uninfected patient and also a patient with COVID-19 that preclude the use of a nebulizer at home, but it fundamental that all patients, regardless of whether or not suffering from COVID-19, always follow some practical advices.",
          "offsetInBeginSection": 1066,
          "offsetInEndSection": 1389,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34568369",
          "text": ". 007 \u00b1 0.38; P < 0.05) during the COVID-19 pandemic. In contrast, among COPD patients, there were no significant differences in AE frequency, clinic ",
          "offsetInBeginSection": 1553,
          "offsetInEndSection": 1703,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25750734",
          "text": " also enhance the efficacy of inhaled glucocorticoids in chronic obstructive pulmonary disease (COPD). In both conditions, these drugs are believed to",
          "offsetInBeginSection": 846,
          "offsetInEndSection": 996,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35887681",
          "text": "In addition, the comparison of asthma with COPD patients confirmed the greater frailty of the latter, according to their multiple comorbidities.",
          "offsetInBeginSection": 1791,
          "offsetInEndSection": 1935,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33276252",
          "text": "CONCLUSIONS\nOur study supports the recommendation that patients with chronic pulmonary diseases, including asthma and COPD who require treatment with either inhaled or systemic corticosteroids, should continue their use during the COVID-19 pandemic.",
          "offsetInBeginSection": 1477,
          "offsetInEndSection": 1726,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32979987",
          "text": "INTERPRETATION\nOur results do not support a major role for regular ICS use in protecting against COVID-19-related death among people with asthma or COPD.",
          "offsetInBeginSection": 2891,
          "offsetInEndSection": 3044,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34472524",
          "text": "The doses of inhaled corticosteroids in asthma management were not affected.",
          "offsetInBeginSection": 1386,
          "offsetInEndSection": 1462,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34472524",
        "http://www.ncbi.nlm.nih.gov/pubmed/34476396",
        "http://www.ncbi.nlm.nih.gov/pubmed/33248363",
        "http://www.ncbi.nlm.nih.gov/pubmed/35887681",
        "http://www.ncbi.nlm.nih.gov/pubmed/25750734",
        "http://www.ncbi.nlm.nih.gov/pubmed/34222281",
        "http://www.ncbi.nlm.nih.gov/pubmed/33276252",
        "http://www.ncbi.nlm.nih.gov/pubmed/32979987",
        "http://www.ncbi.nlm.nih.gov/pubmed/34568369",
        "http://www.ncbi.nlm.nih.gov/pubmed/35747745",
        "http://www.ncbi.nlm.nih.gov/pubmed/12877818"
      ]
    },
    {
      "id": "6432f75757b1c7a31500001d",
      "type": "yesno",
      "body": "Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34276674",
          "text": "At present, three different covalent BTKis, ibrutinib, acalabrutinib and zanubrutinib, are FDA-approved and many new inhibitors are under development.",
          "offsetInBeginSection": 406,
          "offsetInEndSection": 556,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
          "text": "As compared to first-generation ibrutinib, zanubrutinib has higher BTK selectivity which may result in fewer off-target effects and improved potential for combination with other targeted therapies.",
          "offsetInBeginSection": 798,
          "offsetInEndSection": 995,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32484067",
          "text": "-fold for 26-weeks and 39-weeks of treatment, respectively. Zanubrutinib was not genotoxic. Fertility studies showed no abnormal findings in both male",
          "offsetInBeginSection": 832,
          "offsetInEndSection": 982,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35993294",
          "text": "TKi-related adverse events, but major rates of neutropenia, and its approval is awaited. With the aim of overcoming drug resistance, noncovalent BTKi ",
          "offsetInBeginSection": 676,
          "offsetInEndSection": 826,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32484067",
          "text": "Zanubrutinib an oral irreversible Bruton's tyrosine kinase (BTK) inhibitor, is under development for the treatment of a variety of B-cell malignancies and has received accelerated approval by the US Food and Drug Administration for treatment of adult patients with mantel cell lymphoma who have received at least one prior therapy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 331,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32731259",
          "text": ", a first-generation BTK inhibitor, with zanubrutinib, a novel highly selective BTK inhibitor, in patients with WM. Patients with MYD88L265P disease w",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 348,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "ewer patients experience side effects and quit treatment. Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have",
          "offsetInBeginSection": 3152,
          "offsetInEndSection": 3302,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "ater selectivity was developed. In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle",
          "offsetInBeginSection": 511,
          "offsetInEndSection": 661,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35507054",
          "text": "labrutinib, and zanubrutinib (the latter not yet approved for this disease but included in the NCCN guidelines). In this review, we will elucidate our",
          "offsetInBeginSection": 165,
          "offsetInEndSection": 315,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31420873",
          "text": "Whether zanubrutinib, a second-generation selective BTK inhibitor, has similar effects as ibrutinib remains to be determined.",
          "offsetInBeginSection": 203,
          "offsetInEndSection": 328,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35680835",
          "text": "Zanubrutinib is a highly selective second-generation BTK inhibitor developed in China and first approved by the U.S. Food and Drug Administration (FDA) as a novel antineoplastic drug.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31933167",
          "text": " for the treatment of B-cell malignancies. Zanubrutinib received accelerated approval in the USA on 14 November 2019 for the treatment of adult patien",
          "offsetInBeginSection": 118,
          "offsetInEndSection": 268,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34858810",
          "text": "ow incidence of atrial fibrillation. Zanubrutinib, a selective next-generation covalent BTK inhibitor, is approved by the FDA to treat adult patients ",
          "offsetInBeginSection": 1119,
          "offsetInEndSection": 1269,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32613545",
          "text": "These drugs have been recently FDA-approved for relapsed or refractory mantle cell lymphoma.",
          "offsetInBeginSection": 1747,
          "offsetInEndSection": 1839,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35303070",
          "text": "Zanubrutinib, a highly selective BTK inhibitor, is approved for patients with MCL who have received \u22651 prior therapy.",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 242,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33216986",
          "text": "Acalabrutinib is a highly selective, next-generation BTK inhibitor, which was granted accelerated approval by the US Food and Drug Administration in 2017 for the treatment of adult patients with MCL who have received at least one prior therapy.",
          "offsetInBeginSection": 699,
          "offsetInEndSection": 943,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "from growing and spreading. Patients experience extended survival with ibrutinib, the first-generation BTK inhibitor approved by US Food and Drug Admi",
          "offsetInBeginSection": 1968,
          "offsetInEndSection": 2118,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35966045",
          "text": "Ibrutinib, acalabrutinib, and zanubrutinib are Food and Drug Administration (FDA)-approved BTK inhibitors that have all demonstrated progression-free survival (PFS) benefit compared with chemoimmunotherapy.",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 367,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753893",
          "text": "resistant disease. In addition to ibrutinib and acalabrutinib, the FDA recently approved zanubrutinib for the treatment of patients with relapsed/refr",
          "offsetInBeginSection": 395,
          "offsetInEndSection": 545,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32207333",
          "text": "ought to contribute to its adverse events. Zanubrutinib is a next-generation BTK inhibitor with minimal off-target effects, sustained BTK occupancy in",
          "offsetInBeginSection": 254,
          "offsetInEndSection": 404,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34491123",
          "text": "Translation of PK/PD attributes into clinical effects was demonstrated in a randomized, phase 3 head-to-head study comparing it with ibrutinib in patients with Waldenstr\u00f6m macroglobulinemia.Expert opinion: Among the approved BTK inhibitors, zanubrutinib is less prone to PK modulation by intrinsic and extrinsic factors, leading to more consistent, sustained therapeutic exposures and improved dosing convenience.",
          "offsetInBeginSection": 885,
          "offsetInEndSection": 1298,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29869556",
          "text": "n those with MYD88L265P and CXCR4WT disease. Zanubrutinib, a next-generation BTK inhibitor with potent preclinical activity in WM and minimal off-targ",
          "offsetInBeginSection": 388,
          "offsetInEndSection": 538,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35950210",
          "text": "Zanubrutinib, one such second-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients.",
          "offsetInBeginSection": 337,
          "offsetInEndSection": 463,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35770040",
          "text": "se 3 ASPEN (NCT03053440) trial, the Food and Drug Administration (FDA) approved zanubrutinib for treating WM. This trial directly compared zanubrutini",
          "offsetInBeginSection": 1196,
          "offsetInEndSection": 1346,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32869675",
          "text": "EXPERT OPINION\nTwo BTK inhibitors are currently Food and Drug Administration (FDA) approved for use in CLL, and multiple additional agents are in development.",
          "offsetInBeginSection": 542,
          "offsetInEndSection": 700,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33297772",
          "text": "Zanubrutinib is a selective, potent BTK inhibitor with the potential to reduce toxicity and improve efficacy.",
          "offsetInBeginSection": 349,
          "offsetInEndSection": 458,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32869675",
          "text": "EXPERT OPINION\nTwo BTK inhibitors are currently Food and Drug Administration (FDA) approved for use in CLL, and multiple additional agents are in development.",
          "offsetInBeginSection": 542,
          "offsetInEndSection": 700,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35770040",
          "text": "T03053440) trial, the Food and Drug Administration (FDA) approved zanubrutinib for treating WM. This trial directly compared zanubrutinib to ibrutinib",
          "offsetInBeginSection": 1210,
          "offsetInEndSection": 1360,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753893",
          "text": "This review article summarizes data from clinical trials of currently FDA-approved BTK inhibitors in MCL with a focus on zanubrutinib.",
          "offsetInBeginSection": 893,
          "offsetInEndSection": 1027,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35957865",
          "text": "Zanubrutinib, a next-generation non-covalent Bruton's tyrosine kinase (BTK) inhibitor, shows great efficacy in the treatment of B cell malignancies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36402930",
          "text": "In November 2021, zanubrutinib became the first of these agents to be approved by the European Medicines Agency for the treatment of WM.",
          "offsetInBeginSection": 796,
          "offsetInEndSection": 932,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36395435",
          "text": "PURPOSE\nZanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34123480",
          "text": "Currently, there are three BTK inhibitors approved by the U.S. Food and Drug Administration: ibrutinib, acalabrutinib, and zanubrutinib.",
          "offsetInBeginSection": 390,
          "offsetInEndSection": 526,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33427570",
          "text": "Based on the results of two key phase 3 trials (ELEVATE-TN in patients with previously untreated chronic lymphocytic leukemia [CLL] and ASCEND in patients with relapsed or refractory CLL), which demonstrated superior progression-free survival while maintaining favorable tolerability, acalabrutinib was granted US Food and Drug Administration (FDA) approval in 2019 for the treatment of patients with CLL.",
          "offsetInBeginSection": 325,
          "offsetInEndSection": 730,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33688166",
          "text": "Zanubrutinib is a second-generation non-covalent BTK inhibitor with higher potency, allowing for inhibition of BTK with fewer off target effects.",
          "offsetInBeginSection": 673,
          "offsetInEndSection": 818,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33777941",
          "text": "Next-generation inhibitors, acalabrutinib and zanubrutinib, are approved both in the United States and in Europe, and zanubrutinib also in China, while tirabrutinib is currently only registered in Japan.",
          "offsetInBeginSection": 490,
          "offsetInEndSection": 693,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32644193",
          "text": "The US Food and Drug Administration granted acalabrutinib approval as the second Bruton tyrosine kinase (BTK) inhibitor to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma as monotherapy or in combination with obinutuzumab.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35507054",
        "http://www.ncbi.nlm.nih.gov/pubmed/31933167",
        "http://www.ncbi.nlm.nih.gov/pubmed/34276674",
        "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
        "http://www.ncbi.nlm.nih.gov/pubmed/36395435",
        "http://www.ncbi.nlm.nih.gov/pubmed/33427570",
        "http://www.ncbi.nlm.nih.gov/pubmed/32644193",
        "http://www.ncbi.nlm.nih.gov/pubmed/33216986",
        "http://www.ncbi.nlm.nih.gov/pubmed/35770040",
        "http://www.ncbi.nlm.nih.gov/pubmed/35957865",
        "http://www.ncbi.nlm.nih.gov/pubmed/32613545",
        "http://www.ncbi.nlm.nih.gov/pubmed/32484067",
        "http://www.ncbi.nlm.nih.gov/pubmed/34123480",
        "http://www.ncbi.nlm.nih.gov/pubmed/33688166",
        "http://www.ncbi.nlm.nih.gov/pubmed/34491123",
        "http://www.ncbi.nlm.nih.gov/pubmed/35680835",
        "http://www.ncbi.nlm.nih.gov/pubmed/32731259",
        "http://www.ncbi.nlm.nih.gov/pubmed/33297772",
        "http://www.ncbi.nlm.nih.gov/pubmed/35966045",
        "http://www.ncbi.nlm.nih.gov/pubmed/34858810",
        "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
        "http://www.ncbi.nlm.nih.gov/pubmed/36402930",
        "http://www.ncbi.nlm.nih.gov/pubmed/35993294",
        "http://www.ncbi.nlm.nih.gov/pubmed/29869556",
        "http://www.ncbi.nlm.nih.gov/pubmed/31420873",
        "http://www.ncbi.nlm.nih.gov/pubmed/32869675",
        "http://www.ncbi.nlm.nih.gov/pubmed/35303070",
        "http://www.ncbi.nlm.nih.gov/pubmed/35950210",
        "http://www.ncbi.nlm.nih.gov/pubmed/32207333",
        "http://www.ncbi.nlm.nih.gov/pubmed/32753893",
        "http://www.ncbi.nlm.nih.gov/pubmed/33777941"
      ]
    },
    {
      "id": "64178fea690f196b51000028",
      "type": "factoid",
      "body": "What types of DMD can eteplirsen be used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907995",
          "text": "OBJECTIVE\nIn prior open-label studies, eteplirsen, a phosphorodiamidate morpholino oligomer, enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic mutations amenable to skipping exon 51.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30526286",
          "text": "Eteplirsen was approved for the treatment of eligible patients with Duchenne muscular dystrophy (DMD) in September 2016 in one of the most, if not the most, controversial approvals ever made by the Food and Drug Administration of the United States.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086232",
          "text": "We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.)",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 371,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
          "text": "ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29907124",
          "text": "BACKGROUND\nExon skipping has been considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34120909",
          "text": "BackgroundEteplirsen received accelerated FDA approval for treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping, based on demonstrated dystrophin production.ObjectiveTo report results from PROMOVI, a phase 3, multicenter, open-label study evaluating efficacy and safety of eteplirsen in a larger cohort.MethodsAmbulatory patients aged 7-16 years, with confirmed mutations amenable to exon 51 skipping, received eteplirsen 30\u200amg/kg/week intravenously for 96 weeks.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 501,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31261494",
          "text": "This analysis aims to describe the outcomes of two nonambulatory patients with Duchenne muscular dystrophy (DMD) who participated in two clinical studies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
          "text": "Intravenous eteplirsen has received accelerated approval from the US FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping.",
          "offsetInBeginSection": 135,
          "offsetInEndSection": 346,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
          "text": "However, several new personalized therapies, including antisense oligonucleotides eteplirsen for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years.",
          "offsetInBeginSection": 330,
          "offsetInEndSection": 544,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29752304",
          "text": "OBJECTIVE\nTo describe the quantification of novel dystrophin production in patients with Duchenne muscular dystrophy (DMD) after long-term treatment with eteplirsen.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30856119",
          "text": "HS) controls.\n\n\nMETHODS\nEteplirsen studies 201/202 evaluated eligible ambulatory DMD patients for at least 4 years, study 204 evaluated primarily non-",
          "offsetInBeginSection": 499,
          "offsetInEndSection": 649,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33610829",
          "text": "ntisense oligonucleotides (AONs) is a promising treatment for Duchenne muscular dystrophy (DMD). Several exon-skipping drugs, including viltolarsen (N",
          "offsetInBeginSection": 27,
          "offsetInEndSection": 177,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865998",
          "text": "oligomer (morpholino)-based AO drug, eteplirsen, developed for DMD exon 51 skipping. Eteplirsen remains controversial with insufficient evidence of it",
          "offsetInBeginSection": 435,
          "offsetInEndSection": 585,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29035327",
          "text": "he first AO-based drug, eteplirsen (Exondys 51), developed for DMD exon 51 skipping. An accurate and reproducible method to quantify exon skipping eff",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 636,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
          "text": "Eteplirsen and golodirsen, AONs for DMD exons 51 and 53 skipping, have been recently approved by the FDA.",
          "offsetInBeginSection": 377,
          "offsetInEndSection": 482,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26573217",
          "text": "holino oligomer designed to skip DMD exon 51 in patients with Duchenne muscular dystrophy (DMD). Three-year progression of eteplirsen-treated patients",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 260,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29771942",
          "text": "erapeutic platform in recent years, especially in the case of Duchenne muscular dystrophy (DMD). Despite FDA approval of eteplirsen-the first-ever ant",
          "offsetInBeginSection": 70,
          "offsetInEndSection": 220,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27854228",
          "text": "mise for treatment of the degenerative neuromuscular disease, Duchenne musculardystrophy (DMD).\n\n\nOBJECTIVE\nToxicity studies in non-human primates (NH",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 297,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28208626",
          "text": "After accelerated US approval of eteplirsen (Exondys 51), which targets dystrophin exon 51 for skipping, efforts are now focused on targeting other exons.",
          "offsetInBeginSection": 390,
          "offsetInEndSection": 544,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29907124",
          "text": "RESULTS\nFive studies involving 322 participants were included, investigating eteplirsen in one and drisapersen in four studies.",
          "offsetInBeginSection": 985,
          "offsetInEndSection": 1112,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29067661",
          "text": "In 2016, the US Food and Drug Administration (FDA)-approved Exondys 51 (eteplirsen) and Spinraza (nusinersen), the first exon skipping and exon inclusion drugs, to treat patients with Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), respectively.",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 449,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35715998",
          "text": "Eteplirsen is a United States-approved treatment for patients with DMD and exon 51 skip-amenable mutations.",
          "offsetInBeginSection": 105,
          "offsetInEndSection": 212,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29301272",
          "text": "Multiple exon skipping, which is theoretically applicable to 80-90% of DMD patients in total, have been demonstrated in animal models, including dystrophic mice and dogs, using cocktail antisense oligonucleotides (AOs).",
          "offsetInBeginSection": 477,
          "offsetInEndSection": 696,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32691988",
          "text": "ies. In this year's neuromuscular Year in Review, we focus on Duchenne muscular dystrophy (DMD), reviewing studies that evaluate the respiratory effec",
          "offsetInBeginSection": 165,
          "offsetInEndSection": 315,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29339778",
          "text": "d splicing modulation is a promising therapeutic approach for Duchenne muscular dystrophy (DMD). Recently, eteplirsen, a phosphorodiamidate morpholino",
          "offsetInBeginSection": 23,
          "offsetInEndSection": 173,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28280301",
          "text": "Eteplirsen is applicable for approximately 14% of patients with DMD mutations.",
          "offsetInBeginSection": 663,
          "offsetInEndSection": 741,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33610829",
          "text": "sed AONs, including eteplirsen in differentiated MYOD1-UDCs (UDC-myotubes) and rhabdomyosarcoma cells. Exon skipping was induced more efficiently in U",
          "offsetInBeginSection": 1011,
          "offsetInEndSection": 1161,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27936976",
          "text": "Exon skipping is a therapeutic approach for Duchenne muscular dystrophy (DMD) that has been in development for close to two decades.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32417793",
          "text": "t FDA-approved RNA-modifying therapy for DMD, is applicable to \u223c13% of patients with DMD. Because multiple exonic deletions are amenable to exon 51 sk",
          "offsetInBeginSection": 31,
          "offsetInEndSection": 181,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907995",
          "text": "of sarcoglycans and neuronal nitric oxide synthase at the sarcolemma. Ambulation-evaluable eteplirsen-treated patients experienced a 67.3 m benefit co",
          "offsetInBeginSection": 1352,
          "offsetInEndSection": 1502,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171538",
          "text": "s currently one of the most promising approaches for treating Duchenne muscular dystrophy (DMD). While we now have a number of AO drug candidates in c",
          "offsetInBeginSection": 67,
          "offsetInEndSection": 217,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27936976",
          "text": "Areas covered: In this review the authors explain the antisense-mediated exon skipping approach, outline how it needs be tailored for different DMD mutation types and describe the challenges and opportunities for each mutation type.",
          "offsetInBeginSection": 551,
          "offsetInEndSection": 783,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171533",
          "text": "Eteplirsen (brand name Exondys 51), is the first approved antisense therapy for DMD in the USA, and provides a treatment option for ~14% of all DMD patients, who are amenable to exon 51 skipping.",
          "offsetInBeginSection": 650,
          "offsetInEndSection": 845,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33523015",
          "text": "BACKGROUND\nDuchenne muscular dystrophy (DMD) is a rare, X-linked, fatal, degenerative neuromuscular disease caused by DMD gene mutations.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34797383",
          "text": "in gene, is considered especially promising. Applicable to approximately 14% of DMD patients, a phosphorodiamidate morpholino oligomer (PMO) antisense",
          "offsetInBeginSection": 424,
          "offsetInEndSection": 574,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171554",
          "text": " exon-skipping AON, called eteplirsen (brand name ExonDys51), targeting exon 51 of the DMD gene, in late 2016. Using a cocktail of AONs, multiple exon",
          "offsetInBeginSection": 385,
          "offsetInEndSection": 535,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28661408",
          "text": "It is the first drug to be approved to treat the underlying causes of the disease.",
          "offsetInBeginSection": 738,
          "offsetInEndSection": 820,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130193",
          "text": "\u2122), and viltolarsen (VILTEPSO\u00ae) have been approved by the FDA to treat specific types of DMD. SMA is defined by the degeneration of the anterior horn ",
          "offsetInBeginSection": 829,
          "offsetInEndSection": 979,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29843823",
          "text": "Perpetuating this line could allow for preclinical testing of genetic therapies targeted to this area of the DMD gene.",
          "offsetInBeginSection": 1448,
          "offsetInEndSection": 1566,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29301272",
          "text": "d eteplirsen, which skips DMD exon 51 and is applicable to approximately 13% of DMD patients. Multiple exon skipping, which is theoretically applicabl",
          "offsetInBeginSection": 383,
          "offsetInEndSection": 533,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24282529",
          "text": "133a,b, miR-206 and miR-31 in serum from patients with DMD, BMD, UCMD and healthy controls. MiR-1, miR-133a,b and miR-206 were upregulated in DMD, but",
          "offsetInBeginSection": 480,
          "offsetInEndSection": 630,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186594",
          "text": "Highly anticipated as new disease-modifying treatments for Duchenne muscular dystrophy (DMD), therapeutics by BioMarin Pharmaceutical (Kyndrisa\u2122; drisapersen) and Sarepta Therapeutics (eteplirsen; AVI-4658) both recently received negative FDA reviews and are now facing battles for approval in the U.S. At present, BioMarin is committed to working with the FDA to forge a pathway to approval following the failure of its NDA, while Sarepta awaits the formal decision on its NDA, which is expected by late May 2016.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 514,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30556126",
          "text": "WHAT THIS PAPER ADDS: Updated standards of care covering most clinical aspects of Duchenne muscular dystrophy (DMD) are available.",
          "offsetInBeginSection": 1227,
          "offsetInEndSection": 1357,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33523015",
          "text": "CONCLUSION\nIn this retrospective matched control study, eteplirsen treatment resulted in attenuation of ambulatory decline over a 4-year observation period, supporting long-term benefit in patients with DMD.",
          "offsetInBeginSection": 1603,
          "offsetInEndSection": 1810,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34797383",
          "text": "The most common events observed are balance disorder, vomiting, and skin rash.",
          "offsetInBeginSection": 806,
          "offsetInEndSection": 884,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24282529",
          "text": "Specific muscle miRNAs (dystromirs) are potential non-invasive biomarkers for monitoring the outcome of therapeutic interventions and disease progression.",
          "offsetInBeginSection": 300,
          "offsetInEndSection": 454,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35213020",
          "text": "Several exon skipping antisense oligonucleotides (eteplirsen, golodirsen, viltolarsen, and casimersen) have been approved for the treatment of Duchenne muscular dystrophy, but many more are in development targeting an array of different DMD exons.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30396145",
          "text": "The 30-mer PMO eteplirsen (EXONDYS51) developed for exon 51 skipping is the first dystrophin-restoring, conditionally FDA-approved drug in history.",
          "offsetInBeginSection": 342,
          "offsetInEndSection": 489,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33610829",
          "text": "These findings underscore the importance of AON sequence optimization by our cellular system, which enables highly sensitive screening of exon skipping drugs that target different types of DMD mutations.",
          "offsetInBeginSection": 1613,
          "offsetInEndSection": 1816,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865998",
          "text": "Here, we designed morpholino AOs targeting DMD exon 51 using the in\u00a0silico tool and quantitatively evaluated the effects in immortalized DMD muscle cells in\u00a0vitro.",
          "offsetInBeginSection": 719,
          "offsetInEndSection": 882,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28661408",
        "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
        "http://www.ncbi.nlm.nih.gov/pubmed/35715998",
        "http://www.ncbi.nlm.nih.gov/pubmed/34120909",
        "http://www.ncbi.nlm.nih.gov/pubmed/22086232",
        "http://www.ncbi.nlm.nih.gov/pubmed/31261494",
        "http://www.ncbi.nlm.nih.gov/pubmed/29301272",
        "http://www.ncbi.nlm.nih.gov/pubmed/28865998",
        "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
        "http://www.ncbi.nlm.nih.gov/pubmed/28280301",
        "http://www.ncbi.nlm.nih.gov/pubmed/29843823",
        "http://www.ncbi.nlm.nih.gov/pubmed/24282529",
        "http://www.ncbi.nlm.nih.gov/pubmed/30171538",
        "http://www.ncbi.nlm.nih.gov/pubmed/35213020",
        "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
        "http://www.ncbi.nlm.nih.gov/pubmed/27936976",
        "http://www.ncbi.nlm.nih.gov/pubmed/32691988",
        "http://www.ncbi.nlm.nih.gov/pubmed/28208626",
        "http://www.ncbi.nlm.nih.gov/pubmed/30556126",
        "http://www.ncbi.nlm.nih.gov/pubmed/33610829",
        "http://www.ncbi.nlm.nih.gov/pubmed/23907995",
        "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
        "http://www.ncbi.nlm.nih.gov/pubmed/33523015",
        "http://www.ncbi.nlm.nih.gov/pubmed/26573217",
        "http://www.ncbi.nlm.nih.gov/pubmed/29771942",
        "http://www.ncbi.nlm.nih.gov/pubmed/29035327",
        "http://www.ncbi.nlm.nih.gov/pubmed/29339778",
        "http://www.ncbi.nlm.nih.gov/pubmed/34797383",
        "http://www.ncbi.nlm.nih.gov/pubmed/27186594",
        "http://www.ncbi.nlm.nih.gov/pubmed/30396145",
        "http://www.ncbi.nlm.nih.gov/pubmed/29067661",
        "http://www.ncbi.nlm.nih.gov/pubmed/32417793",
        "http://www.ncbi.nlm.nih.gov/pubmed/30171533",
        "http://www.ncbi.nlm.nih.gov/pubmed/30171554",
        "http://www.ncbi.nlm.nih.gov/pubmed/30526286",
        "http://www.ncbi.nlm.nih.gov/pubmed/29752304",
        "http://www.ncbi.nlm.nih.gov/pubmed/33130193",
        "http://www.ncbi.nlm.nih.gov/pubmed/27854228",
        "http://www.ncbi.nlm.nih.gov/pubmed/29907124",
        "http://www.ncbi.nlm.nih.gov/pubmed/30856119"
      ]
    },
    {
      "id": "63eef94ff36125a426000010",
      "type": "yesno",
      "body": "Is Cinpanemab effective for Parkinson\u2019s Disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921450",
          "text": "The trial was stopped after the week 72 interim analysis owing to lack of efficacy.",
          "offsetInBeginSection": 1215,
          "offsetInEndSection": 1298,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23223310",
          "text": "Nevertheless, this well established therapeutic intervention loses efficacy with the progression of the disease and patients develop invalidating side effects, known in their complex as L-DOPA-induced dyskinesia (LID).",
          "offsetInBeginSection": 105,
          "offsetInEndSection": 323,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921450",
          "text": "Cinpanemab, a human-derived monoclonal antibody that binds to \u03b1-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35500112",
          "text": "in patients with Parkinson\u2019s disease (PD). However, its therapeutic mechanism of action is unknown. The healthy striatum exhibits rich dynamics result",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 267,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29874003",
          "text": "The present therapeutic drugs for PD can only alleviate the patients\u2019 symptoms, but cannot prevent or delay progression of the disease.",
          "offsetInBeginSection": 114,
          "offsetInEndSection": 249,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26236796",
          "text": "Current treatment cannot stop the progression of the disease, although there is definite therapeutic effect.",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 416,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31731332",
          "text": "Conclusion\nAs detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG treatment in many aspects of the disease.",
          "offsetInBeginSection": 1067,
          "offsetInEndSection": 1241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35404466",
          "text": " associated with neurodegeneration  but  have  failed  to  identify  preventive  or  curative  therapies.  This  failure  mainly  originates  from  th",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 383,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26464310",
          "text": "The current drug treatment for PD is palliative and does not meet the clinical challenges of the disease, such as levodopa-induced dyskinesia, non-motor symptoms, and neuroprotection.",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 330,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29714967",
          "text": "Parkinson\u2019s disease(PD)diagnosis based on speech data has been proved to be an effective way in recent years.There are still some problems on preprocessing samples,ensemble learning,and so on.The problems can further cause misleading of classifiers,unsatisfactory classification accuracy and stability.This paper proposed a new diagnosis algorithm of PD by combining multi-edit sample selection method and random forest.At the end of it,this paper presents a group of experiments carried out with the newest public datasets.Experimental results showed that this proposed algorithm realized the classification of the samples and the subjects of PD.Furthermore,it achieved average classification accuracy of 100% and obtained improvement of up to 29.44% compared to those provided by the subjects.This paper proposes a new speech diagnosis algorithm for PD based on instance selection;and the method algorithm has a higher and more stable classification accuracy,compared with the other algorithms.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 996,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26296199",
          "text": "Reducing long-term care utilization by patients with PDP may significantly lower the overall economic burden associated with PDP.",
          "offsetInBeginSection": 1704,
          "offsetInEndSection": 1833,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32613752",
          "text": "054), a monoclonal antibody targeting aggregated \u03b1-synuclein, for a phase II study in Parkinson's disease (PD). Doses and regimens were proposed based",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 236,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26464310",
          "text": "In summary, exercise improved dopaminergic neurotransmission and enhanced cognition in a preclinical animal model of PD.",
          "offsetInBeginSection": 954,
          "offsetInEndSection": 1074,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32718129",
          "text": "Conclusion\nLCIG is an efficient treatment modality in the management of Turkish patients with advanced Parkinson\u2019s disease.",
          "offsetInBeginSection": 1904,
          "offsetInEndSection": 2027,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32718129",
          "text": "gnificant increase in hallucination among patients.\n\n\nConclusion\nLCIG is an efficient treatment modality in the management of Turkish patients with ad",
          "offsetInBeginSection": 1850,
          "offsetInEndSection": 2000,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29708714",
          "text": "The effect of deep brain stimulation(DBS)surgery treatment for Parkinson\u2019s disease is determined by the accuracy of the electrodes placement and localization.The subthalamic nuclei(STN)as the implant target is small and has no clear boundary on the images.In addition,the intra-operative magnetic resonance images(MRI)have such a low resolution that the artifacts of the electrodes impact the observation.The three-dimensional(3D)visualization of STN and other nuclei nearby is able to provide the surgeons with direct and accurate localizing information.In this study,pre-and intra-operative MRIs of the Parkinson\u2019s disease patients were used to realize the 3Dvisualization.After making a co-registration between the high-resolution pre-operative MRIs and the low-resolution intraoperative MRIs,we normalized the MRIs into a standard atlas space.We used a special threshold mask to search the lead trajectories in each axial slice.After checking the location of the electrode contacts with the coronal MRIs of the patients,we reconstructed the whole lead trajectories.Then the STN and other nuclei nearby in the standard atlas space were visualized with the grey images of the standard atlas,accomplishing the lead reconstruction and nerve nuclei visualization near STN of all patients.This study provides intuitive and quantitative information to identify the accuracy of the DBS electrode implantation,which could help decide the post-operative programming setting.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1468,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23797465",
          "text": "orders have been made during the past few decades, the success rates are still moderate if not poor. The blood\u2013brain barrier (BBB) hampers the access ",
          "offsetInBeginSection": 221,
          "offsetInEndSection": 371,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28459950",
          "text": "To date no validated neurophysiological technique is available that has proven to have good classification performance, and the diagnostic gold standard is the clinical evaluation made by a movement disorders expert.",
          "offsetInBeginSection": 192,
          "offsetInEndSection": 408,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24822250",
          "text": "Genetic studies have provided increasing evidence that ceramide homeostasis plays a role in neurodegenerative diseases including Parkinson\u2019s disease (PD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29953178",
          "text": "Pharmacotherapy in Parkinson\u2019s disease is complex and requires expertise in all health-care professions.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34878820",
          "text": "In Parkinson\u2019s disease (PD), SWS appears to be closely linked with disease symptoms and progression.",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 210,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28468476",
          "text": "BACKGROUND\nMany patients with Parkinson\u2019s disease with severe motor fluctuations benefit from advanced therapies \u2013 either deep brain stimulation or continuous infusion therapy with levodopa-carbidopa intestinal gel or apomorphine.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28468476",
          "text": "INTERPRETATION\nAdvanced therapies for Parkinson\u2019s disease are offered throughout Norway, but there are significant geographical differences in the type of therapy initiated.",
          "offsetInBeginSection": 1449,
          "offsetInEndSection": 1622,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921450",
          "text": "CONCLUSIONS\nIn participants with early Parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in DaT-SPECT imaging did not differ from those of placebo over a 52-week period.",
          "offsetInBeginSection": 2318,
          "offsetInEndSection": 2540,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29953182",
          "text": "Finding the balance between controlling symptoms and provoking psychotic adverse drug reactions is a typical clinical challenge in the treatment of Parkinson\u2019s disease.",
          "offsetInBeginSection": 252,
          "offsetInEndSection": 420,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191267",
          "text": ", a number of recent studies have reported that this drug has \"non-cholinergic\" effects on AD. Most important among these is the protective effect of ",
          "offsetInBeginSection": 505,
          "offsetInEndSection": 655,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23128888",
          "text": "On the other hand, there is increasing evidence for a role of histamine as a neuromodulator in the mammalian central nervous system.",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 427,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24822250",
          "text": "Identifying the regulatory mechanisms precipitating this change may provide novel targets for future therapeutics.",
          "offsetInBeginSection": 1553,
          "offsetInEndSection": 1667,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25457181",
          "text": " it is being considered as an important target for the treatment of Parkinson\u2019s disease and other neuropsychiatric disorders. However, the physiological factors that control its distinctive biochemical properties are still unknown",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 360,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31731332",
          "text": "Background/aim\nOur purpose was to determine the efficacy of levodopa carbidopa intestinal gel (LCIG) in a series of Turkish patients with Parkinson\u2019s disease (PD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29715417",
          "text": "Quantitative assessment of the symptoms of Parkinson\u2019s disease is the key for precise diagnosis and treatment and essential for long term management over years.The challenges of quantitative assessment on Parkinson\u2019s disease are rich information,ultra-low load,long term and large range monitoring in free-moving condition.In this paper,we developed wearable devices with multiple sensors to monitor and quantify the movement symptoms of Parkinson\u2019s disease.Five wearable sensors were used to record motion signals from bilateral forearms,legs and waist.A local area network based on low power Wi-Fi technology was built for long distance wireless data transmission.A software was developed for signal recording and analyzing.The size of each sensor was 39mm\u00d733mm\u00d716mm and the weight was 18 g.The sensors were rechargeable and able to run 12 hours.The wireless transmission radius is about 45 m.The wearable devices were tested in patients and normal subjects.The devices were reliable and accurate for movement monitoring in hospital.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1035,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28459950",
          "text": "Tremor stability index with a cut-off of 1.05 gave good classification performance for Parkinson\u2019s disease tremor and essential tremor, in both test and validation datasets.",
          "offsetInBeginSection": 1476,
          "offsetInEndSection": 1649,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29547091",
          "text": "CONCLUSIONS\nIn PD patients, bilateral GPi and STN DBS using the asleep method resulted in motor, quality-of-life, and medication reduction outcomes that were comparable to those of the awake method.",
          "offsetInBeginSection": 1665,
          "offsetInEndSection": 1863,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29709151",
          "text": "Excessive microglial activation and subsequent neuroinflammation lead to neuronal cell death,which are involved in the pathogenesis and progression of several neurodegenerative diseases such as Parkinson\u2019s disease.The objective of this study was to determine the involvement of chlorpyrifos(CPF)in the activation of microglia and production of inflammatory factors in response to CPF stimulation and the influence on the viability of dopaminergic(DA)neurons.We detected the change of BV-2cells morphology and expression of inducible nitric oxide(iNOS),cyclooxygenase-2(COX-2)mRNA and protein level upon CPF stimulation(0,1,3,6,12,24h)in BV-2(mouse brain microglia)cells by reverse transcription polymerase chain reaction(RT-PCR)or Western blot.We randomly assigned BV-2cells into CPF,menstruum dimethysulfoxide(DMSO)and normal saline(NS)groups.We stimulated The BV-2cells in the CPF group with CPF,and we stimulated the two control groups with DMSO or NS for 12 hours,respectively.We then collected the used culture media from the culture dishes and centrifuged it to remove the detached cells.Then,we used the supernatants as microglial conditioned media.We treated SH-SY5 Yneurons with various groups of microglial conditioned media for 24 hours.We observed the effect of conditioned media collected from BV-2cell on the viability of dopaminergic cell lines SH-SY5 Yusing MTT assay.We found that inflammatory factors iNOS,COX-2mRNA and protein levels were up-regulated upon CPF stimulation.Conditioned media from BV-2upon CPF stimulation is toxic to SH-SY5 Y.It might be concluded that the exposure to CPF may induce dopaminergic neuronal damage by the activation of inflammatory response,and a mechanism may be involved in Parkinson\u2019s disease pathogenesis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1759,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32364361",
          "text": "Now, it is known that mitochondrial dysfunction in Parkinson's disease plays a key role in the loss of dopaminergic neurons in the substantia nigra.",
          "offsetInBeginSection": 373,
          "offsetInEndSection": 521,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32613752",
        "http://www.ncbi.nlm.nih.gov/pubmed/34878820",
        "http://www.ncbi.nlm.nih.gov/pubmed/23128888",
        "http://www.ncbi.nlm.nih.gov/pubmed/28459950",
        "http://www.ncbi.nlm.nih.gov/pubmed/29714967",
        "http://www.ncbi.nlm.nih.gov/pubmed/23797465",
        "http://www.ncbi.nlm.nih.gov/pubmed/26236796",
        "http://www.ncbi.nlm.nih.gov/pubmed/24822250",
        "http://www.ncbi.nlm.nih.gov/pubmed/29874003",
        "http://www.ncbi.nlm.nih.gov/pubmed/29708714",
        "http://www.ncbi.nlm.nih.gov/pubmed/35921450",
        "http://www.ncbi.nlm.nih.gov/pubmed/25191267",
        "http://www.ncbi.nlm.nih.gov/pubmed/32718129",
        "http://www.ncbi.nlm.nih.gov/pubmed/31731332",
        "http://www.ncbi.nlm.nih.gov/pubmed/29547091",
        "http://www.ncbi.nlm.nih.gov/pubmed/32364361",
        "http://www.ncbi.nlm.nih.gov/pubmed/29953182",
        "http://www.ncbi.nlm.nih.gov/pubmed/25457181",
        "http://www.ncbi.nlm.nih.gov/pubmed/28468476",
        "http://www.ncbi.nlm.nih.gov/pubmed/35404466",
        "http://www.ncbi.nlm.nih.gov/pubmed/29715417",
        "http://www.ncbi.nlm.nih.gov/pubmed/35500112",
        "http://www.ncbi.nlm.nih.gov/pubmed/29953178",
        "http://www.ncbi.nlm.nih.gov/pubmed/23223310",
        "http://www.ncbi.nlm.nih.gov/pubmed/29709151",
        "http://www.ncbi.nlm.nih.gov/pubmed/26296199",
        "http://www.ncbi.nlm.nih.gov/pubmed/26464310"
      ]
    },
    {
      "id": "6426d131690f196b5100004e",
      "type": "factoid",
      "body": "In what organ would you find the Ashwell receptor?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20816169",
          "text": "The Ashwell-Morell receptor (AMR) of hepatocytes, originally termed the hepatic asialoglycoprotein receptor, was the first cellular receptor to be identified and isolated and the first lectin to be detected in mammals.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18488037",
          "text": "The Ashwell receptor, the major lectin of hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose and N-acetylgalactosamine.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27207430",
          "text": "This review will focus on the mechanisms of platelet senescence with specific emphasis on the role of post-translational modifications in platelet life-span and thrombopoietin production downstream of the hepatic Ashwell-Morrell receptor.",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 479,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20816169",
          "text": "Among these components, clearance by the liver's AMR is enhanced by exposure of terminal galactose on the glycan chains.",
          "offsetInBeginSection": 968,
          "offsetInEndSection": 1088,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18488037",
        "http://www.ncbi.nlm.nih.gov/pubmed/20816169",
        "http://www.ncbi.nlm.nih.gov/pubmed/27207430"
      ]
    },
    {
      "id": "6429e17657b1c7a315000007",
      "type": "list",
      "body": "What histone marks are indicative of enhancers in the chromatin landscape of a given cell?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28649883",
          "text": "or instance, active enhancers are commonly occupied by both marks H3K4me1 and H3K27ac. The traditional bottom-up MS strategy identifies and quantifies",
          "offsetInBeginSection": 417,
          "offsetInEndSection": 567,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32058623",
          "text": "In silico analysis and integration of DNA methylation data with chondrogenesis chromatin states revealed that enhancers marked by histone marks H3K4me1 and H3K27ac were de-methylated during in vitro chondrogenesis.",
          "offsetInBeginSection": 725,
          "offsetInEndSection": 939,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28981749",
          "text": "The intersection of the proteomics data with ChIP-seq and RNA-seq analyses revealed the existence of novel subpopulations of enhancers, marked by specific histone modification signatures: specifically, H3K4me1/K36me2 marks transcribed enhancers, while H3K4me1/K36me3 and H3K4me1/K79me2 combinations mark distinct classes of intronic enhancers.",
          "offsetInBeginSection": 996,
          "offsetInEndSection": 1339,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26957309",
          "text": "We tested 40 chromatin signatures on this unbiased enhancer set and identified H2BK20ac, a little-studied histone modification, as the most predictive mark of active enhancers.",
          "offsetInBeginSection": 347,
          "offsetInEndSection": 523,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32058623",
          "text": "In silico analysis and integration of DNA methylation data with chondrogenesis chromatin states revealed that enhancers marked by histone marks H3K4me1 and H3K27ac were de-methylated during in vitro chondrogenesis.",
          "offsetInBeginSection": 725,
          "offsetInEndSection": 939,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29089515",
          "text": "These elements are characterized by distinct epigenomic profiles, such as expanded deposition of histone marks H3K27ac for super enhancers and H3K4me3 for broad domains, however little is known about how they interact with each other and the rest of the genome in three-dimensional chromatin space.",
          "offsetInBeginSection": 152,
          "offsetInEndSection": 450,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32286315",
          "text": "Here, we present chromatin immunoprecipitation sequencing (ChIP-Seq) data for the oncogenic transcription factors, MYCN and MYC, as well as regulatory histone marks H3K4me1, H3K4me3, H3K27Ac, and H3K27me3 in ten commonly used human neuroblastoma-derived cell line models.",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 479,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21106759",
          "text": "stem cells and several adult tissues in the mouse. We find that histone H3K27ac distinguishes active enhancers from inactive/poised enhancer elements ",
          "offsetInBeginSection": 667,
          "offsetInEndSection": 817,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955985",
          "text": "all types of chromatin marks examined, including promoter, enhancer, elongation, and repressive marks. The fine-resolution signal shapes discovered by",
          "offsetInBeginSection": 1403,
          "offsetInEndSection": 1553,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955985",
          "text": "digestion and high-depth sequencing. Here we relate 14 chromatin signals (12 histone marks, DNase, and nucleosome positioning) to the binding sites of",
          "offsetInBeginSection": 453,
          "offsetInEndSection": 603,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23526891",
          "text": "We show that RFECS not only leads to more accurate and precise prediction of enhancers than previous methods, but also helps identify the most informative and robust set of three chromatin marks for enhancer prediction.",
          "offsetInBeginSection": 1030,
          "offsetInEndSection": 1249,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25106691",
          "text": " well as in fully differentiated adipocytes. Interestingly, activating H3K4me1/2 histone marks were enriched at these sites when the associated genes ",
          "offsetInBeginSection": 760,
          "offsetInEndSection": 910,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916725",
          "text": "Here we use ChIP sequencing (ChIP-seq) to identify domains enriched for the histone marks histone H3 lysine 4 trimethylation, histone H3 lysine 4 monomethylation, and histone H3 lysine 27 acetylation (H3K4me3, H3K4me1, and H3K27ac) and define, for the first time, the super enhancers and typical enhancers active in primary human corneal epithelial cells.",
          "offsetInBeginSection": 421,
          "offsetInEndSection": 776,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22328731",
          "text": "The combined results indicate that ChromaGenSVM comfortably outperforms previously published methods and that enhancers are best predicted by specific combinations of histone methylation and acetylation marks.",
          "offsetInBeginSection": 1225,
          "offsetInEndSection": 1434,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22759587",
          "text": "CONCLUSIONS\nThe analysis presented here provides a systematic characterization of combinatorial histone codes of enhancers across three human cell types using a novel semi-supervised biclustering algorithm.",
          "offsetInBeginSection": 1471,
          "offsetInEndSection": 1677,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22491032",
          "text": " of specific transcription factors to enhancers and existing histone modifications. In this review, we present insights into the mechanisms of enhance",
          "offsetInBeginSection": 716,
          "offsetInEndSection": 866,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30755522",
          "text": "Furthermore, we observed possible feedbacks to control chromatin dynamics as the found motifs appear in the promoters or enhancers associated with various histone modification enzymes.",
          "offsetInBeginSection": 1306,
          "offsetInEndSection": 1490,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27617035",
          "text": "ChIP-seq studies using chromatin prepared from mouse lens and cultured lens cells demonstrate that Pax6-bound regions are mostly enriched with H3K4me2 and H3K4me1 in enhancers and promoters, though H3K4me3 marks only Pax6-containing promoters.",
          "offsetInBeginSection": 1189,
          "offsetInEndSection": 1432,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27540855",
          "text": "important roles in balancing transcriptional output. The discovery of acyl marks, besides histone acetylation, has added to the functional diversity o",
          "offsetInBeginSection": 31,
          "offsetInEndSection": 181,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789687",
          "text": "We introduce a novel computational framework, PEDAL, for distinguishing effectively transcriptional profiles of promoters and enhancers using solely histone modification marks, chromatin accessibility and binding sites of transcription factors and co-activators.",
          "offsetInBeginSection": 520,
          "offsetInEndSection": 782,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29754476",
          "text": "on of regulatory DNA and are densely occupied by transcription factors, active histone marks, and co-activators. Accumulating evidence points to the c",
          "offsetInBeginSection": 425,
          "offsetInEndSection": 575,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27617035",
          "text": "Enhancers are distinguished from bulk chromatin by specific modifications of core histone H3, including H3K4me1 and H3K27ac, while promoters show increased H3K4me3 PTM.",
          "offsetInBeginSection": 397,
          "offsetInEndSection": 565,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21847099",
          "text": "The concomitant presence of the three H3K4 methylation states (H3K4me1/2/3) was found to clearly reflect the activity of bona fide T-cell gene enhancers.",
          "offsetInBeginSection": 592,
          "offsetInEndSection": 745,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30532006",
          "text": "Here we find that the ubiquitous nucleosome binding proteins HMGN1 and HMGN2 preferentially colocalize with epigenetic marks of active chromatin, and with cell-type specific enhancers.",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 392,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22593555",
          "text": "atin landscape marked by histone H3 lysine 4 mono-methylation (H3K4me1) and histone H3 lysine 27 acetylation (H3K27ac). Nevertheless, little is known ",
          "offsetInBeginSection": 394,
          "offsetInEndSection": 544,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30755522",
          "text": "oadly mapped. We have analyzed 6 histone marks (H3K4me1, H3K4me3, H3K27ac, H3K27me3, K3H9me3, H3K36me3) across 121 human cell types and tissues from t",
          "offsetInBeginSection": 371,
          "offsetInEndSection": 521,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29141961",
          "text": "cape throughout organismal development. We find that over 5000 distal noncoding regions exhibit dynamic changes in chromatin accessibility between dev",
          "offsetInBeginSection": 682,
          "offsetInEndSection": 832,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30905748",
          "text": "With the trained model, optimized virtual input histone marks was generated to provide a deeper insight into how histone modification marks can represent enhancer regions in which histone marks indicate active or repressed enhancers.",
          "offsetInBeginSection": 1123,
          "offsetInEndSection": 1356,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24038352",
          "text": "eRNAs and H3K27ac to discriminate enhancer activity. We demonstrate that eRNA is more indicative of enhancer activity. Finally, we apply our fibroblas",
          "offsetInBeginSection": 1122,
          "offsetInEndSection": 1272,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33190371",
          "text": "In contrast, active transcription-associated chromatin marks such as DOT1L-catalyzed H3K79 methylation, FACT-mediated histone turnover, active enhancer SUMOylation, and EP300/CBP bromodomain-mediated interactions act to maintain somatic-specific gene expression programs.",
          "offsetInBeginSection": 920,
          "offsetInEndSection": 1191,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28981749",
          "text": "The intersection of the proteomics data with ChIP-seq and RNA-seq analyses revealed the existence of novel subpopulations of enhancers, marked by specific histone modification signatures: specifically, H3K4me1/K36me2 marks transcribed enhancers, while H3K4me1/K36me3 and H3K4me1/K79me2 combinations mark distinct classes of intronic enhancers.",
          "offsetInBeginSection": 996,
          "offsetInEndSection": 1339,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32058623",
          "text": "Similarity analysis between hMSC and chondrocyte chromatin states defined in this study with epigenomes of cell-types defined by the Roadmap Epigenomics project revealed that enhancers are more distinct between cell-types compared to other chromatin states.",
          "offsetInBeginSection": 940,
          "offsetInEndSection": 1197,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32286315",
          "text": "Finally, we show with H3K27Ac ChIP-Seq that these cell lines retain expression of key neuroblastoma super-enhancers (SE).",
          "offsetInBeginSection": 735,
          "offsetInEndSection": 856,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27617035",
          "text": "CONCLUSIONS\nOur study supports a general model of Pax6-mediated recruitment of histone methyltransferases Mll1 and Mll2 to lens chromatin, especially at distal enhancers.",
          "offsetInBeginSection": 1852,
          "offsetInEndSection": 2022,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916725",
          "text": "Here we use ChIP sequencing (ChIP-seq) to identify domains enriched for the histone marks histone H3 lysine 4 trimethylation, histone H3 lysine 4 monomethylation, and histone H3 lysine 27 acetylation (H3K4me3, H3K4me1, and H3K27ac) and define, for the first time, the super enhancers and typical enhancers active in primary human corneal epithelial cells.",
          "offsetInBeginSection": 421,
          "offsetInEndSection": 776,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30593493",
          "text": "We observe that stretch and super enhancers cover cell type-specific enhancer \"chromatin states,\" whereas HOT regions and broad domains comprise more ubiquitous promoter states.",
          "offsetInBeginSection": 642,
          "offsetInEndSection": 819,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23473601",
          "text": "Here we give an overview of enhancer-associated modifications of histones and DNA and discuss enzymatic activities involved in their dynamic deposition and removal.",
          "offsetInBeginSection": 668,
          "offsetInEndSection": 832,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30073529",
          "text": "matin formation and chromosome segregation. Key factors, known as histone chaperones, have been involved in escorting histones, thereby contributing t",
          "offsetInBeginSection": 328,
          "offsetInEndSection": 478,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32912294",
          "text": "CONCLUSIONS\nIn conclusion, loci identified as active by STARR-seq often overlap with those identified by chromatin accessibility and active epigenetic marking, yet a significant fraction is epigenetically repressed or display condition-specific enhancer activity.",
          "offsetInBeginSection": 1366,
          "offsetInEndSection": 1629,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24885402",
          "text": "correlated with enhancer status (poised or active), defined by surrounding histone marks. Furthermore, about fifty percent of poised and active enhanc",
          "offsetInBeginSection": 759,
          "offsetInEndSection": 909,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35801925",
          "text": "Here, we analyzed genome-wide profiles of active enhancer and promoter marks in colorectal cancer cells and report DBC1 as a critical positive regulator of histone epigenetic writers KMT2D (H3K4 methyltransferase) and p300 (histone acetyltransferase).",
          "offsetInBeginSection": 407,
          "offsetInEndSection": 658,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24038352",
          "text": " acetyltransferase P300 and the histone modification H3K4me1, indicate the presence of enhancers, only a fraction of enhancers are functionally active. Individual chromatin marks, such as H3K27ac and H3K27me3",
          "offsetInBeginSection": 135,
          "offsetInEndSection": 343,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33190371",
          "text": "In contrast, active transcription-associated chromatin marks such as DOT1L-catalyzed H3K79 methylation, FACT-mediated histone turnover, active enhancer SUMOylation, and EP300/CBP bromodomain-mediated interactions act to maintain somatic-specific gene expression programs.",
          "offsetInBeginSection": 920,
          "offsetInEndSection": 1191,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29507293",
          "text": "hierarchically organized, containing both hub and non-hub enhancers. Hub enhancers share similar histone marks with non-hub enhancers, but are distinc",
          "offsetInBeginSection": 285,
          "offsetInEndSection": 435,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22593555",
          "text": "We find that (1) changes in H3K27ac enrichment at enhancers accompany the shift from pluripotency to tissue-specific gene expression, (2) in early embryos, the peaks of H3K27ac enrichment are bound by pluripotent factors such as Nanog, and (3) the degree of evolutionary conservation is higher for enhancers that become marked by H3K27ac at the end of gastrulation, suggesting their implication in the establishment of the most conserved (phylotypic) transcriptome that is known to occur later at the pharyngula stage.",
          "offsetInBeginSection": 794,
          "offsetInEndSection": 1312,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28514649",
          "text": "Enhancers of stem cell-related genes are bookmarked by both H3K27ac and the master regulators OCT4, SOX2, and KLF4, while promoters of housekeeping genes retain high levels of mitotic H3K27ac in a cell-type invariant manner.",
          "offsetInBeginSection": 441,
          "offsetInEndSection": 665,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19129543",
          "text": "tin conformation linked to a shift of the epigenetic signature toward repressive histone marks. Importantly, these sites are not correlated with gene ",
          "offsetInBeginSection": 581,
          "offsetInEndSection": 731,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25715743",
          "text": "with transcription factors, co-activators, histone chromatin marks, and lncRNAs. Alterations in enhancers lead to misregulation of gene expression, ca",
          "offsetInBeginSection": 423,
          "offsetInEndSection": 573,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33334884",
          "text": "At present, histone marks are used to identify and define enhancers but do not consider the endogenous role of an enhancer in the context of native chromatin.",
          "offsetInBeginSection": 165,
          "offsetInEndSection": 323,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27089178",
          "text": "Moreover, we find a new class of active functional enhancers that is marked by H3K122ac but lacks H3K27ac.",
          "offsetInBeginSection": 760,
          "offsetInEndSection": 866,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28981749",
        "http://www.ncbi.nlm.nih.gov/pubmed/21106759",
        "http://www.ncbi.nlm.nih.gov/pubmed/27617035",
        "http://www.ncbi.nlm.nih.gov/pubmed/29141961",
        "http://www.ncbi.nlm.nih.gov/pubmed/29754476",
        "http://www.ncbi.nlm.nih.gov/pubmed/28649883",
        "http://www.ncbi.nlm.nih.gov/pubmed/32912294",
        "http://www.ncbi.nlm.nih.gov/pubmed/25715743",
        "http://www.ncbi.nlm.nih.gov/pubmed/26957309",
        "http://www.ncbi.nlm.nih.gov/pubmed/23473601",
        "http://www.ncbi.nlm.nih.gov/pubmed/29089515",
        "http://www.ncbi.nlm.nih.gov/pubmed/30755522",
        "http://www.ncbi.nlm.nih.gov/pubmed/24885402",
        "http://www.ncbi.nlm.nih.gov/pubmed/27789687",
        "http://www.ncbi.nlm.nih.gov/pubmed/27089178",
        "http://www.ncbi.nlm.nih.gov/pubmed/22759587",
        "http://www.ncbi.nlm.nih.gov/pubmed/35801925",
        "http://www.ncbi.nlm.nih.gov/pubmed/27540855",
        "http://www.ncbi.nlm.nih.gov/pubmed/23526891",
        "http://www.ncbi.nlm.nih.gov/pubmed/32058623",
        "http://www.ncbi.nlm.nih.gov/pubmed/30532006",
        "http://www.ncbi.nlm.nih.gov/pubmed/30073529",
        "http://www.ncbi.nlm.nih.gov/pubmed/22955985",
        "http://www.ncbi.nlm.nih.gov/pubmed/24038352",
        "http://www.ncbi.nlm.nih.gov/pubmed/33334884",
        "http://www.ncbi.nlm.nih.gov/pubmed/28916725",
        "http://www.ncbi.nlm.nih.gov/pubmed/33190371",
        "http://www.ncbi.nlm.nih.gov/pubmed/29507293",
        "http://www.ncbi.nlm.nih.gov/pubmed/19129543",
        "http://www.ncbi.nlm.nih.gov/pubmed/32286315",
        "http://www.ncbi.nlm.nih.gov/pubmed/30905748",
        "http://www.ncbi.nlm.nih.gov/pubmed/21847099",
        "http://www.ncbi.nlm.nih.gov/pubmed/25106691",
        "http://www.ncbi.nlm.nih.gov/pubmed/30593493",
        "http://www.ncbi.nlm.nih.gov/pubmed/22328731",
        "http://www.ncbi.nlm.nih.gov/pubmed/22491032",
        "http://www.ncbi.nlm.nih.gov/pubmed/28514649",
        "http://www.ncbi.nlm.nih.gov/pubmed/22593555"
      ]
    },
    {
      "id": "643306cc57b1c7a315000027",
      "type": "yesno",
      "body": "Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35719360",
          "text": "0 min), and CRISPR/Cas12a-mediated detection (37\u00b0C, 8 min), can be completed within 70 min. A fluorescence reader (for fluorescence CRISPR-CLA) or a l",
          "offsetInBeginSection": 1652,
          "offsetInEndSection": 1802,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32486913",
          "text": "These results indicate that Cas12a is able to detect both DNA and RNA targets, making it an appropriate and convenient tool to detect all types of pathogens.",
          "offsetInBeginSection": 1008,
          "offsetInEndSection": 1165,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33159392",
          "text": "However, whether single-stranded DNA in CRISPR system can cause false positives remains undetermined.",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 303,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31413315",
          "text": "h attomolar sensitivity but, to our knowledge, it has not been used for the detection of small molecules. Bacterial allosteric transcription factors (",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 245,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32093010",
          "text": "This proof of principle study demonstrates that the CRISPR-Cas12a system could rapidly and sensitively detect circulating EGFR mutations, and thus, has potential prognostic or therapeutic implications.",
          "offsetInBeginSection": 1361,
          "offsetInEndSection": 1562,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33329659",
          "text": "By using this simple and high-efficiency CRISPR/Cas12a system, multiple targets can be modified to obtain multigene simultaneous knockout mutants in tree species, which will provide powerful tools with which to facilitate genetic studies of forest trees.",
          "offsetInBeginSection": 1212,
          "offsetInEndSection": 1466,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33991961",
          "text": "ns-cleaves ssDNA and this feature has been widely harnessed for nucleic acid detection. Herein, we introduce a new type of Cas12a reporter, G-triplex ",
          "offsetInBeginSection": 24,
          "offsetInEndSection": 174,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34794559",
          "text": "By means of the unique combination of Cas12a with ECL technique based on BPE, it can convert the recognition of target ATP into a detectable ECL signal.",
          "offsetInBeginSection": 720,
          "offsetInEndSection": 872,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36214815",
          "text": "e degraded, leaving the single-stranded DNA (ssDNA). The CRISPR/Cas12a can accurately locate ssDNA without PAM, then initiating its trans-cleavage act",
          "offsetInBeginSection": 868,
          "offsetInEndSection": 1018,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34653714",
          "text": "Although CRISPR-Cas12a and CRISPR-Cas13a systems work individually effective on gene detection, their multiplex detection capability is limited due to the lack of specific probe cleavage mechanism.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32682455",
          "text": "the targeted EGFR gene in a cancer-specific manner, without detectable off-target nuclease activity. Importantly, oAd/Cas12a/crEGFR elicits a potent a",
          "offsetInBeginSection": 765,
          "offsetInEndSection": 915,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33076176",
          "text": "Herein, by combining aptamers that specifically bind to protein targets on TEVs, PCR-based exponential amplification and CRISPR/Cas12a real-time DNA detection, we developed a novel technique, termed the aptamer-CRISPR/Cas12a assay, to detect CD109+ and EGFR+ TEVs from cell lines and complex biofluids.",
          "offsetInBeginSection": 293,
          "offsetInEndSection": 595,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32786346",
          "text": "Our results indicate that the CRISPR-Cas12a enhanced fluorescence assay coupled with nucleic acid amplification is robust, convenient, specific, confirmatory, affordable, and potentially adaptable for ASF diagnosis.",
          "offsetInBeginSection": 1220,
          "offsetInEndSection": 1435,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33076176",
          "text": "Given that the aptamer-CRISPR/Cas12a assay rapidly and conveniently detects ultralow concentrations of CD109+ and EGFR+ TEVs directly in serum, it could be useful in NPC diagnosis and prognosis.",
          "offsetInBeginSection": 1313,
          "offsetInEndSection": 1507,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34074403",
          "text": "avage ability of CRISPR/Cas12a was established to ultra-sensitively detect gene-PIK3CAH1047R mutation. The mutated gene-PIK3CAH1047R can combine with ",
          "offsetInBeginSection": 230,
          "offsetInEndSection": 380,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33329659",
          "text": "CRISPR/Cas12a is a novel CRISPR effector protein that not only broadens the CRISPR/Cas targeting range but also enables the generation of large-fragment deletions.",
          "offsetInBeginSection": 203,
          "offsetInEndSection": 366,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36318504",
          "text": "The current method can broaden the CRISPR-Cas12a-based applications for multiple biomarkers detection and precise disease diagnosis.",
          "offsetInBeginSection": 1355,
          "offsetInEndSection": 1487,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32478351",
          "text": "Among the different classes of CRISPR/Cas-Dx, the class based on the Cas12a enzyme (i.e., CRISPR/Cas12a-Dx or simply Cas12a-Dx), is predominantly employed for detecting DNA targets.",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 301,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35481381",
          "text": "It is a simple and rapid assay that can monitor and track the circulating SARS-CoV-2 variants and the dynamics of the coronavirus disease 2019 (COVID-19) pandemic and can be easily implemented in resource-limited settings.",
          "offsetInBeginSection": 1813,
          "offsetInEndSection": 2035,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35727982",
          "text": "Based on this strategy, recombinase polymerase amplification (RPA) and CRISPR-Cas12a detection systems can be integrated into a completely closed test tube.",
          "offsetInBeginSection": 271,
          "offsetInEndSection": 427,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30936531",
          "text": "How these inhibitors disable Cas12a by preventing programmed DNA cleavage is unknown.",
          "offsetInBeginSection": 322,
          "offsetInEndSection": 407,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34533940",
          "text": " detection method remains lacking. CRISPR-Cas12a has recently emerged as a promising tool in biosensing applications with the characteristic of fast d",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 296,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36318259",
          "text": "With this mode, we discriminated all mismatch types and detected the EGFR T790M and L858R mutations in very low abundance.",
          "offsetInBeginSection": 758,
          "offsetInEndSection": 880,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35670376",
          "text": " compared with the crRNA sequence, the CRISPR-Cas12a system can still recognize and cleave the target dsDNA sequence. We conclude that the tolerance o",
          "offsetInBeginSection": 455,
          "offsetInEndSection": 605,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35857897",
          "text": "Therefore, detection signals are accumulated without amplification, which augments the conventional detection limit.",
          "offsetInBeginSection": 938,
          "offsetInEndSection": 1054,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36277631",
          "text": "The programmability of CRISPR/Cas12a, a powerful toolbox for genome editing, is used to activate the responsive release of captured CTCs from the DNA network.",
          "offsetInBeginSection": 1154,
          "offsetInEndSection": 1312,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33107304",
          "text": "Overall, our outcomes advance our mechanistic understanding of CRISPR-Cas12a and provide grounds for novel engineering efforts to improve genome editing and viral detection.",
          "offsetInBeginSection": 1503,
          "offsetInEndSection": 1676,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32687187",
          "text": "We developed a CRISPR-Cas12a that can induce mutations in target DNA sequences in a highly specific and effective manner by partially substituting the (cr)RNA with DNA to change the energy potential of base pairing to the target DNA.",
          "offsetInBeginSection": 732,
          "offsetInEndSection": 965,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30936531",
          "text": "These distinct mechanisms equip bacteriophages with tools to evade CRISPR-Cas12a and support biotechnological applications for which multiple-turnover enzymatic inhibition of Cas12a is desirable.",
          "offsetInBeginSection": 887,
          "offsetInEndSection": 1082,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36399094",
          "text": "However, the potential of these CRISPR/Cas12a strategies for POC molecular diagnostics is often compromised due to the complex labeling, high cost, and low signal-to-noise ratio.",
          "offsetInBeginSection": 256,
          "offsetInEndSection": 434,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31403279",
          "text": "Herein, we found Cas12a can also recognize another PAM sequence of UUUN resulting in activation of its ssDNA collateral cleavage effect.",
          "offsetInBeginSection": 242,
          "offsetInEndSection": 378,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34087725",
          "text": "We show that our strategy can allow the detection of an EGFR gene mutation in sub-femtomolar concentrations up to 0.1% variant allele frequency using either fluorescence or electrochemical readouts.",
          "offsetInBeginSection": 921,
          "offsetInEndSection": 1119,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31460749",
          "text": "By integrating recombinase polymerase amplification (RPA) with Cas12a cleavage in a single reaction system, the detection can be accomplished in 30 min and uncapping contamination can be avoided.",
          "offsetInBeginSection": 510,
          "offsetInEndSection": 705,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35671698",
          "text": "We believe that this work not only extends the application scope of CRISPR/Cas12a, but also devotes a new approach for clinical diagnosis.",
          "offsetInBeginSection": 1353,
          "offsetInEndSection": 1491,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35605545",
          "text": "CRISPR/Cas12a system can nonspecifically cleave single-stranded DNA after specific recognition of target DNA, showing tremendous potential in molecular diagnostics.",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 323,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32786346",
        "http://www.ncbi.nlm.nih.gov/pubmed/35481381",
        "http://www.ncbi.nlm.nih.gov/pubmed/35671698",
        "http://www.ncbi.nlm.nih.gov/pubmed/31403279",
        "http://www.ncbi.nlm.nih.gov/pubmed/31413315",
        "http://www.ncbi.nlm.nih.gov/pubmed/34533940",
        "http://www.ncbi.nlm.nih.gov/pubmed/33076176",
        "http://www.ncbi.nlm.nih.gov/pubmed/33159392",
        "http://www.ncbi.nlm.nih.gov/pubmed/35670376",
        "http://www.ncbi.nlm.nih.gov/pubmed/35605545",
        "http://www.ncbi.nlm.nih.gov/pubmed/36399094",
        "http://www.ncbi.nlm.nih.gov/pubmed/35719360",
        "http://www.ncbi.nlm.nih.gov/pubmed/30936531",
        "http://www.ncbi.nlm.nih.gov/pubmed/36318504",
        "http://www.ncbi.nlm.nih.gov/pubmed/33329659",
        "http://www.ncbi.nlm.nih.gov/pubmed/33107304",
        "http://www.ncbi.nlm.nih.gov/pubmed/36214815",
        "http://www.ncbi.nlm.nih.gov/pubmed/32478351",
        "http://www.ncbi.nlm.nih.gov/pubmed/36318259",
        "http://www.ncbi.nlm.nih.gov/pubmed/32093010",
        "http://www.ncbi.nlm.nih.gov/pubmed/34087725",
        "http://www.ncbi.nlm.nih.gov/pubmed/32682455",
        "http://www.ncbi.nlm.nih.gov/pubmed/31460749",
        "http://www.ncbi.nlm.nih.gov/pubmed/35857897",
        "http://www.ncbi.nlm.nih.gov/pubmed/33991961",
        "http://www.ncbi.nlm.nih.gov/pubmed/35727982",
        "http://www.ncbi.nlm.nih.gov/pubmed/34794559",
        "http://www.ncbi.nlm.nih.gov/pubmed/34074403",
        "http://www.ncbi.nlm.nih.gov/pubmed/32486913",
        "http://www.ncbi.nlm.nih.gov/pubmed/36277631",
        "http://www.ncbi.nlm.nih.gov/pubmed/32687187",
        "http://www.ncbi.nlm.nih.gov/pubmed/34653714"
      ]
    },
    {
      "id": "64178ffb690f196b51000029",
      "type": "factoid",
      "body": "What type of DMD can casimersen be used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33861387",
          "text": "Casimersen (Amondys 45\u2122) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a mutation in the DMD gene that is amenable to exon\u00a045 skipping.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 286,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
          "text": "ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
          "text": "be used to monitor the efficacy of experimental therapies for Duchenne Muscular Dystrophy (DMD) in clinical trials. Identification of novel protein bi",
          "offsetInBeginSection": 58,
          "offsetInEndSection": 208,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12692454",
          "text": "This study examined Three Wishes (a projective technique commonly used with children) in boys with Duchenne muscular dystrophy (DMD), a fatal, progressive illness (n = 74).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29791760",
          "text": "of dystrophin-deficient muscle. We tested the hypothesis that Duchenne muscular dystrophy (DMD) patients would have elevated levels of the macrophage-",
          "offsetInBeginSection": 882,
          "offsetInEndSection": 1032,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29579701",
          "text": "BACKGROUND\nAlthough prolonged ambulation is considered important in children with Duchenne muscular dystrophy (DMD), articles describing gait deviations in DMD are scarce.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36449321",
          "text": "disease progression and therapeutic response in patients with Duchenne muscular dystrophy (DMD). This study evaluates whether quantitative muscle ultr",
          "offsetInBeginSection": 77,
          "offsetInEndSection": 227,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25365558",
          "text": "A readily available animal model is essential for rapidly identifying effective treatments for Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder caused by the lack of dystrophin protein, which results from frame-disrupting mutations in the DMD gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34105177",
          "text": "Casimersen was well tolerated in participants with DMD amenable to exon 45 skipping. Most TEAEs were mild, nonserious, and unrelated to casimersen. Pl",
          "offsetInBeginSection": 1478,
          "offsetInEndSection": 1628,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7599358",
          "text": "sed as potential treatments for inherited myopathies, such as Duchenne muscular dystrophy (DMD). The success of myoblast implantation in mouse models,",
          "offsetInBeginSection": 63,
          "offsetInEndSection": 213,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29791760",
          "text": "t, we then identified a potential role for 7,8-dihydroneopterin in disease pathology. We assessed whether 7,8-dihydroneopterin could: (i) protect agai",
          "offsetInBeginSection": 1467,
          "offsetInEndSection": 1617,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29791760",
          "text": "-synthesized antioxidant 7,8-dihydroneopterin was elevated in Duchenne muscular dystrophy (DMD) patients. We then examined whether 7,8-dihydroneopteri",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33967607",
          "text": "We explored has_circ_0071106 as a diagnostic marker for type 2 diabetes (T2DM) in south China, and predicted the functional mechanism of the target circRNA.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24332447",
          "text": "Ways of testing this hypothesis and its potential topical use are discussed.",
          "offsetInBeginSection": 452,
          "offsetInEndSection": 528,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1971151",
          "text": "The complete 14-kb cDNA for the gene causing the X-linked recessive muscular dystrophy (MD) type Duchenne (DMD) and Becker (BMD) has recently been cloned and made available for deletion/duplication screening in patients.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33239841",
          "text": "ed with aging, which is, to some extent, similar to what occurs in humans. Thus, cDMDR could be a valuable model for studying cardiology of human DMD.",
          "offsetInBeginSection": 1512,
          "offsetInEndSection": 1662,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16528755",
          "text": "ethical issues regarding screening newborns (and infants) for Duchenne muscular dystrophy (DMD). First, what are the risks and benefits of expanding n",
          "offsetInBeginSection": 58,
          "offsetInEndSection": 208,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26037351",
          "text": "OBJECTIVE\nTo optimize the methods for genetic detection and prenatal diagnosis of Duchenne muscular dystrophy (DMD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33861387",
          "text": ", for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon\u00a045 skipping. The approval, granted under",
          "offsetInBeginSection": 638,
          "offsetInEndSection": 788,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35213020",
          "text": "Several exon skipping antisense oligonucleotides (eteplirsen, golodirsen, viltolarsen, and casimersen) have been approved for the treatment of Duchenne muscular dystrophy, but many more are in development targeting an array of different DMD exons.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34105177",
          "text": "INTRODUCTION/AIMS\nDuchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene resulting in the absence of dystrophin.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25982038",
          "text": "Double-strand DNA (dsDNA) can act as an effective template for the formation of CuNCs, which can be used to distinguish the deletion or duplication genotypes of Duchenne muscular dystrophy (DMD) due to different fluorescent intensities.",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 348,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25669899",
          "text": "Despite its extensive use in DMD research, no effective treatment has yet been developed for this devastating disease.",
          "offsetInBeginSection": 274,
          "offsetInEndSection": 392,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637366",
          "text": "The DMD can also be used as a real-time optical processor for applications such as the programmable array microscope and compressive sensing.",
          "offsetInBeginSection": 302,
          "offsetInEndSection": 443,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401026",
          "text": "rom childhood, the earlier treatment is preferred. The canine X-linked muscular dystrophy in Japan (CXMDj), a dog model of DMD, produces no dystrophin",
          "offsetInBeginSection": 556,
          "offsetInEndSection": 706,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713895",
          "text": "The Cincinnati study reviewed data from 435 males with Duchenne muscular dystrophy, also known as DMD, who were treated at the Cincinnati Children's Hospital Medical Center.",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 351,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1459673",
          "text": "This information can be useful for genetic counselling with particular reference to prenatal diagnosis and carrier analysis.",
          "offsetInBeginSection": 329,
          "offsetInEndSection": 453,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29173172",
          "text": "CONCLUSIONS\nRestoration of the wild type and shorter form of dystrophin highlights the therapeutic potential of CRISPR technology for DMD.",
          "offsetInBeginSection": 1585,
          "offsetInEndSection": 1723,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28430230",
          "text": "Our results show that DMDs can be used in high-resolution spectroscopy and for Fiber Bragg grating (FBG) interrogation.",
          "offsetInBeginSection": 814,
          "offsetInEndSection": 933,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34909800",
          "text": "Casimersen targets exon 45 of the dystrophin gene and is expected to treat ~8% of the DMD patient population.",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 821,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29060790",
          "text": "Duchenne Muscular Dystrophy (DMD) is a genetic disorder caused by dystrophin protein deficiency.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26290039",
          "text": "SCs that recapitulate the primary pathology and can be used for DMD drug screening. Skeletal myotubes generated from hiPSCs are intact, which allows t",
          "offsetInBeginSection": 390,
          "offsetInEndSection": 540,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24225992",
          "text": "Duchenne and Becker muscular dystrophies (DMD/BMD) are X-linked inherited muscular disorders caused by mutations in the dystrophin gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30028534",
          "text": "Screening for erectile dysfunction before screening for Type 2 diabetes seems to improve the accuracy of well-known risk scores for undiagnosed Type 2 diabetes.",
          "offsetInBeginSection": 1713,
          "offsetInEndSection": 1873,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25198739",
          "text": " and angiotensin II type 1 receptor blockers (ARB) are used as the first line drugs. Beta-blockers (BB) are usually added to ACEI/ARB, when they canno",
          "offsetInBeginSection": 516,
          "offsetInEndSection": 666,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16528755",
          "text": "Rather, I propose that screening for DMD should be offered only on a voluntary basis beyond the newborn period.",
          "offsetInBeginSection": 832,
          "offsetInEndSection": 943,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10935423",
          "text": "Although infants and children are affected by many acute and chronic diseases, nearly 80% of the drugs approved in the US for use in adults have not been labelled for paediatric use.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26290039",
          "text": "These results suggest that the early pathogenesis of DMD can be effectively modelled in skeletal myotubes induced from patient-derived iPSCs, thereby enabling the development and evaluation of novel drugs.",
          "offsetInBeginSection": 986,
          "offsetInEndSection": 1191,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28430230",
        "http://www.ncbi.nlm.nih.gov/pubmed/35713895",
        "http://www.ncbi.nlm.nih.gov/pubmed/29579701",
        "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
        "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
        "http://www.ncbi.nlm.nih.gov/pubmed/35213020",
        "http://www.ncbi.nlm.nih.gov/pubmed/7599358",
        "http://www.ncbi.nlm.nih.gov/pubmed/26290039",
        "http://www.ncbi.nlm.nih.gov/pubmed/36449321",
        "http://www.ncbi.nlm.nih.gov/pubmed/24225992",
        "http://www.ncbi.nlm.nih.gov/pubmed/30028534",
        "http://www.ncbi.nlm.nih.gov/pubmed/25669899",
        "http://www.ncbi.nlm.nih.gov/pubmed/36401026",
        "http://www.ncbi.nlm.nih.gov/pubmed/12692454",
        "http://www.ncbi.nlm.nih.gov/pubmed/25198739",
        "http://www.ncbi.nlm.nih.gov/pubmed/16528755",
        "http://www.ncbi.nlm.nih.gov/pubmed/23637366",
        "http://www.ncbi.nlm.nih.gov/pubmed/34105177",
        "http://www.ncbi.nlm.nih.gov/pubmed/34909800",
        "http://www.ncbi.nlm.nih.gov/pubmed/25365558",
        "http://www.ncbi.nlm.nih.gov/pubmed/25982038",
        "http://www.ncbi.nlm.nih.gov/pubmed/29060790",
        "http://www.ncbi.nlm.nih.gov/pubmed/33239841",
        "http://www.ncbi.nlm.nih.gov/pubmed/1971151",
        "http://www.ncbi.nlm.nih.gov/pubmed/33967607",
        "http://www.ncbi.nlm.nih.gov/pubmed/26037351",
        "http://www.ncbi.nlm.nih.gov/pubmed/10935423",
        "http://www.ncbi.nlm.nih.gov/pubmed/33861387",
        "http://www.ncbi.nlm.nih.gov/pubmed/29173172",
        "http://www.ncbi.nlm.nih.gov/pubmed/1459673",
        "http://www.ncbi.nlm.nih.gov/pubmed/24332447",
        "http://www.ncbi.nlm.nih.gov/pubmed/29791760"
      ]
    },
    {
      "id": "63eeefc5f36125a426000009",
      "type": "factoid",
      "body": "What is targeted by CIS43LS?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34511592",
          "text": " dose of the CIS43LS monoclonal antibody resulted in protection against malaria. These new findings have implications for the seasonal control of mala",
          "offsetInBeginSection": 1100,
          "offsetInEndSection": 1250,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
          "text": "ody with an extended half-life, and its efficacy against infection with Plasmodium falciparum. Part A of the trial assessed the safety, initial side-e",
          "offsetInBeginSection": 248,
          "offsetInEndSection": 398,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
          "text": "administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection. (Funded by the National Institute of Aller",
          "offsetInBeginSection": 1993,
          "offsetInEndSection": 2143,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36317783",
          "text": "BACKGROUND\nCIS43LS is a monoclonal antibody that was shown to protect against controlled <i>Plasmodium falciparum</i> infection in a phase 1 clinical trial.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36317783",
          "text": "falciparum</i> infection over a 6-month malaria season in Mali without evident safety concerns.",
          "offsetInBeginSection": 1837,
          "offsetInEndSection": 1932,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33332286",
          "text": "CIS43 is a potent neutralizing human mAb that targets a highly conserved \"junctional\" epitope in the Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33332286",
        "http://www.ncbi.nlm.nih.gov/pubmed/34511592",
        "http://www.ncbi.nlm.nih.gov/pubmed/36317783",
        "http://www.ncbi.nlm.nih.gov/pubmed/34379916"
      ]
    },
    {
      "id": "6415b422690f196b5100000a",
      "type": "summary",
      "body": "What does Cal-light do?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28650460",
          "text": "We present a dual-protein switch system, Cal-Light, that translates neuronal-activity-mediated calcium signaling into gene expression in a light-dependent manner.",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 292,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28650460"
      ]
    },
    {
      "id": "64172bb2690f196b5100001e",
      "type": "factoid",
      "body": "To which region of a gene does an RNA polymerase bind to initiate transcription?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31863129",
          "text": "RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase.",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 363,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8065261",
          "text": "Furthermore, two proteins (M(r) 12,000 and 35,000) which interact with and may activate transcription from the ndh promoter under these conditions were detected by gel retardation analysis.",
          "offsetInBeginSection": 1234,
          "offsetInEndSection": 1423,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6382259",
          "text": "The RNA polymerase from bacteriophage T4-infected Escherichia coli, which specifically initiates transcription at phage T4 late promoters, is extensively modified by ADP-ribosylation of core subunits and by binding several virus-encoded subunits.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9603525",
          "text": "Initiation of transcription of a gene from a core promoter region by RNA polymerase II requires the assembly of several initiation factors to form a preinitiation complex.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24600005",
          "text": "from a reduced ability of RNA polymerase II to be recruited to the promoter-proximal regions of these genes. In contrast, depletion of hPaf1 reduces t",
          "offsetInBeginSection": 639,
          "offsetInEndSection": 789,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7022450",
          "text": "nscription at certain promoters recognized by unmodified enzyme. In the T4tRNA gene region, only one of the two promoters is active with the modified ",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 376,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6194892",
          "text": "A sensitive hybridization technique was used to demonstrate that the purified polymerase, even when supplemented with a transcription factor that binds specifically to the 5S RNA gene internal control region, is unable to initiate synthesis at the start site of the 5S RNA gene.",
          "offsetInBeginSection": 246,
          "offsetInEndSection": 524,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3380786",
          "text": "kurstaki HD-1-Dipel that directs transcription from the promoter region of an insecticidal crystal protein gene.",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 213,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2648001",
          "text": " facilitates binding of the RNA polymerase to the proper region of the promoter. The Ada protein possesses two known methyl acceptor sites, Cys69 and ",
          "offsetInBeginSection": 1617,
          "offsetInEndSection": 1767,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8496187",
          "text": "actor responsible for the assembly of a transcription complex on the 5 S RNA gene. We have analyzed the effect of deleting various regions of yeast TF",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 270,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16798040",
          "text": "During transcription initiation by bacterial RNA polymerase, the sigma subunit recognizes the -35 and -10 promoter elements; free sigma, however, does not bind DNA.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9765583",
          "text": "Our results show that (i) only one RNA polymerase molecule can bind to the DNA fragment carrying the aroP regulatory region, (ii) RNA polymerase has a higher affinity for P1 than for either P2 or P3 and binds to P1 in the absence of TyrR protein, (iii) in the presence of TyrR protein and its cofactor, phenylalanine or tyrosine, RNA polymerase preferentially binds to P3, and (iv) RNA polymerase does not respond to the activation-defective mutant TyrR protein TyrR-RQ10 and remains bound to P1 in the presence of TyrR-RQ10 and either of the cofactors.",
          "offsetInBeginSection": 815,
          "offsetInEndSection": 1368,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2648001",
          "text": "RNA polymerase did bind to the promoter once the methylated Ada protein had bound to the upstream sequence.",
          "offsetInBeginSection": 980,
          "offsetInEndSection": 1087,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27558998",
          "text": "In a canonical \u03c3 factor, region 2.3 amino acids bind non-template strand DNA, trapping the promoter in a single-stranded state required for initiation of transcription.",
          "offsetInBeginSection": 834,
          "offsetInEndSection": 1002,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24600005",
          "text": " a reduced ability of RNA polymerase II to be recruited to the promoter-proximal regions of these genes. In contrast, depletion of hPaf1 reduces the o",
          "offsetInBeginSection": 643,
          "offsetInEndSection": 793,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17998332",
          "text": "The Wdr82 component of the Setd1A complex interacts with the RNA recognition motif of Setd1A and additionally binds to the Ser5-phosphorylated C-terminal domain of RNA polymerase II, which is involved in initiation of transcription, but does not bind to an unphosphorylated or Ser2-phosphorylated C-terminal domain.",
          "offsetInBeginSection": 320,
          "offsetInEndSection": 635,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10799081",
          "text": "Eukaryotic gene transcription involves several different RNA polymerases that interact with a host of transcription factors to initiate transcription.",
          "offsetInBeginSection": 115,
          "offsetInEndSection": 265,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3465670",
          "text": "We conclude that RNA polymerase II can initiate transcription at the cap site in isolated nuclei.",
          "offsetInBeginSection": 1097,
          "offsetInEndSection": 1194,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11222621",
          "text": "nce of an IS box in order to bind to and initiate transcription from pvd promoters. These results indicate that IS box elements participate in sequenc",
          "offsetInBeginSection": 606,
          "offsetInEndSection": 756,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9526497",
          "text": "ally, the cyanobacterial RNA polymerase could initiate transcription at PlacUV5, but not from wild-type Plac promoters. The different behaviours of th",
          "offsetInBeginSection": 1043,
          "offsetInEndSection": 1193,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3865211",
          "text": "The binding of a species-specific transcription initiation factor (TIF) and purified RNA polymerase I to the promoter region of the 39S ribosomal RNA gene from Acanthamoeba were studied by using DNase I \"footprinting.\"",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11562354",
          "text": "RNA Pol II does not bind to HO until late G1, when HO is actively transcribed, and binding occurs exclusively to the TATA region.",
          "offsetInBeginSection": 1269,
          "offsetInEndSection": 1398,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6263495",
          "text": "ta beta alpha 2-sigma able selectively to initiate transcription at promoter sites. It is proposed that beta beta' alpha 2-nusA and beta beta' alpha 2",
          "offsetInBeginSection": 610,
          "offsetInEndSection": 760,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9765583",
          "text": "Our results show that (i) only one RNA polymerase molecule can bind to the DNA fragment carrying the aroP regulatory region, (ii) RNA polymerase has a higher affinity for P1 than for either P2 or P3 and binds to P1 in the absence of TyrR protein, (iii) in the presence of TyrR protein and its cofactor, phenylalanine or tyrosine, RNA polymerase preferentially binds to P3, and (iv) RNA polymerase does not respond to the activation-defective mutant TyrR protein TyrR-RQ10 and remains bound to P1 in the presence of TyrR-RQ10 and either of the cofactors.",
          "offsetInBeginSection": 815,
          "offsetInEndSection": 1368,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8496187",
          "text": "We speculate that the ninth zinc finger serves to anchor the carboxyl-terminal portion of TFIIIA on the 5 S RNA gene, correctly orienting the 81-amino acid domain to serve its role in promoting transcription.",
          "offsetInBeginSection": 1209,
          "offsetInEndSection": 1417,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20300884",
          "text": "The mammalian core promoter is a sophisticated and crucial component for the regulation of transcription mediated by the RNA polymerase II.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10593606",
          "text": "d action of transcription factors binding to the gene-internal and gene-external parts of its promoter. Here, we investigated which transcription fact",
          "offsetInBeginSection": 85,
          "offsetInEndSection": 235,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7556074",
          "text": "a binding site for RNA polymerase. RNA polymerase is able to bind the -40 to -60 region of the ada and the aidB promoters in the absence of meAda, and",
          "offsetInBeginSection": 402,
          "offsetInEndSection": 552,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31863129",
          "text": "Here, we describe experiments to determine whether the prototype T7 RNAP is able to recognize and initiate at truncated promoters similar to mitochondrial promoters.",
          "offsetInBeginSection": 604,
          "offsetInEndSection": 769,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9990859",
          "text": "In bacteria, association of the specialized sigmaN protein with the core RNA polymerase subunits forms a holoenzyme able to bind promoter DNA, but unable to melt DNA and initiate transcription unless acted on by an activator protein.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8703091",
          "text": "e II. Sequence analysis of the 50-amino-acid region thought to bind alpha-amanitin shows that this region of the trichomonad RNA polymerase II lacks m",
          "offsetInBeginSection": 599,
          "offsetInEndSection": 749,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3380786",
          "text": " however, this form of RNA polymerase does direct transcription from a promoter for the 27-kDa crystal protein of B. thuringiensis subsp. israelensis ",
          "offsetInBeginSection": 752,
          "offsetInEndSection": 902,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9526497",
          "text": "Addition of RcaA, a protein that binds to the promoter region of the phycobiliprotein cpeBA operon, restored accurate initiation of transcription in the in vitro system for three phycobiliprotein promoters.",
          "offsetInBeginSection": 524,
          "offsetInEndSection": 730,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6537904",
          "text": "f DNA surrounding the start point of transcription of the histone H3, H4, and actin 5C genes. Included in this binding region is the TATA box, the sta",
          "offsetInBeginSection": 480,
          "offsetInEndSection": 630,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10593606",
          "text": "onstrate that TFIIIC is required for human 7SL transcription. The gene-external part of the promoter includes an authentic cAMP-responsive element pre",
          "offsetInBeginSection": 708,
          "offsetInEndSection": 858,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8703091",
          "text": "entical to the mouse RNA polymerase II. Sequence analysis of the 50-amino-acid region thought to bind alpha-amanitin shows that this region of the tri",
          "offsetInBeginSection": 565,
          "offsetInEndSection": 715,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3865211",
          "text": "The close apposition of the regions protected by TIF and polymerase provides evidence that accurate transcription of the ribosomal gene may be achieved through protein-protein contacts as well as through DNA-protein interactions.",
          "offsetInBeginSection": 1176,
          "offsetInEndSection": 1405,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2497942",
          "text": "The binding region of the RNA polymerase extends from 30 base pairs (bp) upstream (-30) to 20 bp downstream (+20) from the in vivo transcription start site.",
          "offsetInBeginSection": 275,
          "offsetInEndSection": 431,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2550316",
          "text": "a H has been shown to bind specifically to DNA in the intergenic region upstream of the purE gene cloned from this species. The RNAP binding site has ",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 281,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7226225",
          "text": "A transcription factor binds specifically to a region within the 5S ribosomal RNA gene that is known to be required for accurate initiation of transcription of the gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2676999",
          "text": "nal protein factors and two regions within the tRNA gene (the 5'-internal control region (ICR) or A-box and the 3'-ICR or B-box). Using a reconstitute",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1736538",
          "text": "The RNA polymerase can initiate transcription in vitro with gamma-thio-GTP, whose thiophosphate group is found on the 5' terminus of transcripts.",
          "offsetInBeginSection": 243,
          "offsetInEndSection": 388,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7556074",
          "text": "da does not act by enhancing RNA polymerase binding affinity to the promoter region. Instead, Ada stimulates transcription by modifying the nature of ",
          "offsetInBeginSection": 838,
          "offsetInEndSection": 988,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2648001",
          "text": "These results are compatible with the notion that methylation of the cysteine residue at position 69 causes a conformational change of the Ada protein, thereby facilitating binding of the protein to the upstream regulatory sequence.",
          "offsetInBeginSection": 2201,
          "offsetInEndSection": 2433,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2497942",
          "text": "According to the specific binding of the enzyme to only DNA-fragments harbouring this motif, we propose the sequence TTTATATA as the major recognition signal of the Methanococcus RNA polymerase.",
          "offsetInBeginSection": 752,
          "offsetInEndSection": 946,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3652209",
          "text": "Competition experiments show that at least the distal sequence elements of the two promoters bind to a common factor both in vivo and in vitro.",
          "offsetInBeginSection": 659,
          "offsetInEndSection": 802,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11433282",
          "text": "onsists of a minimal promoter and other upstream cis elements. The minimal promoter is essentially a TATA box region where RNA polymerase II, TATA-bin",
          "offsetInBeginSection": 31,
          "offsetInEndSection": 181,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10369763",
          "text": "esidues in the functionally dispensable region of the RNA polymerase beta' subunit. We investigated the effect of gp2 on transcription at a -10/-35 pr",
          "offsetInBeginSection": 196,
          "offsetInEndSection": 346,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27558998",
          "text": "In a canonical \u03c3 factor, region 2.3 amino acids bind non-template strand DNA, trapping the promoter in a single-stranded state required for initiation of transcription.",
          "offsetInBeginSection": 834,
          "offsetInEndSection": 1002,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22999857",
          "text": "ithin the SL RNA gene locus mainly within a 220-nt long region that straddles the transcription start site. tTFIIB does not bind within the small subu",
          "offsetInBeginSection": 825,
          "offsetInEndSection": 975,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/2497942",
        "http://www.ncbi.nlm.nih.gov/pubmed/1736538",
        "http://www.ncbi.nlm.nih.gov/pubmed/16798040",
        "http://www.ncbi.nlm.nih.gov/pubmed/11222621",
        "http://www.ncbi.nlm.nih.gov/pubmed/6537904",
        "http://www.ncbi.nlm.nih.gov/pubmed/3652209",
        "http://www.ncbi.nlm.nih.gov/pubmed/9603525",
        "http://www.ncbi.nlm.nih.gov/pubmed/8496187",
        "http://www.ncbi.nlm.nih.gov/pubmed/6263495",
        "http://www.ncbi.nlm.nih.gov/pubmed/10799081",
        "http://www.ncbi.nlm.nih.gov/pubmed/3465670",
        "http://www.ncbi.nlm.nih.gov/pubmed/10593606",
        "http://www.ncbi.nlm.nih.gov/pubmed/6194892",
        "http://www.ncbi.nlm.nih.gov/pubmed/7226225",
        "http://www.ncbi.nlm.nih.gov/pubmed/2676999",
        "http://www.ncbi.nlm.nih.gov/pubmed/31863129",
        "http://www.ncbi.nlm.nih.gov/pubmed/17998332",
        "http://www.ncbi.nlm.nih.gov/pubmed/3380786",
        "http://www.ncbi.nlm.nih.gov/pubmed/9990859",
        "http://www.ncbi.nlm.nih.gov/pubmed/27558998",
        "http://www.ncbi.nlm.nih.gov/pubmed/24600005",
        "http://www.ncbi.nlm.nih.gov/pubmed/11562354",
        "http://www.ncbi.nlm.nih.gov/pubmed/2550316",
        "http://www.ncbi.nlm.nih.gov/pubmed/8065261",
        "http://www.ncbi.nlm.nih.gov/pubmed/10369763",
        "http://www.ncbi.nlm.nih.gov/pubmed/8703091",
        "http://www.ncbi.nlm.nih.gov/pubmed/9526497",
        "http://www.ncbi.nlm.nih.gov/pubmed/11433282",
        "http://www.ncbi.nlm.nih.gov/pubmed/3865211",
        "http://www.ncbi.nlm.nih.gov/pubmed/9765583",
        "http://www.ncbi.nlm.nih.gov/pubmed/22999857",
        "http://www.ncbi.nlm.nih.gov/pubmed/20300884",
        "http://www.ncbi.nlm.nih.gov/pubmed/6382259",
        "http://www.ncbi.nlm.nih.gov/pubmed/7022450",
        "http://www.ncbi.nlm.nih.gov/pubmed/2648001",
        "http://www.ncbi.nlm.nih.gov/pubmed/7556074"
      ]
    },
    {
      "id": "63f9ccdc33942b094c00000f",
      "type": "yesno",
      "body": "Is PRP-40 involved in microexon splicing?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142",
          "text": "ion of neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dep",
          "offsetInBeginSection": 527,
          "offsetInEndSection": 677,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142",
          "text": "f neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dependen",
          "offsetInBeginSection": 532,
          "offsetInEndSection": 682,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7935475",
          "text": "However, any such splicing factor containing the helicase motifs in vertebrates has not been identified.",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 390,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026070",
          "text": "ated by fPACAP-38 in a concentration-dependent manner, but was not regulated by fPRP-45. Results from real-time quantitative polymerase chain reaction",
          "offsetInBeginSection": 1307,
          "offsetInEndSection": 1457,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18945809",
          "text": "Our findings suggest that in addition to its important regulatory function in the C. elegans germ line, prp-8(rr40) may provide further insight into the etiology of this splicing-associated human disorder.",
          "offsetInBeginSection": 1520,
          "offsetInEndSection": 1725,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026070",
          "text": "ulated by fPACAP-38 in a concentration-dependent manner, but was not regulated by fPRP-45. Results from real-time quantitative polymerase chain reacti",
          "offsetInBeginSection": 1305,
          "offsetInEndSection": 1455,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34348142",
        "http://www.ncbi.nlm.nih.gov/pubmed/23026070",
        "http://www.ncbi.nlm.nih.gov/pubmed/18945809",
        "http://www.ncbi.nlm.nih.gov/pubmed/7935475"
      ]
    },
    {
      "id": "641790d6690f196b5100002d",
      "type": "factoid",
      "body": "At what range of ages usually occurs the loss of independent ambulation in Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22115006",
          "text": "f corticosteroids slowed the loss of ambulation that develops in mid to late childhood. Corticosteroids, however, frequently produce unacceptable side",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 376,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12363102",
          "text": "nsuing year that resulted in loss of independent ambulation at the age of 10. Both boys remained around the 50th centile for height and weight, and sh",
          "offsetInBeginSection": 622,
          "offsetInEndSection": 772,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31588416",
          "text": "The impact of the disease presents as early as infancy with significant developmental delays, and ultimately loss of ambulation and respiratory insufficiency.",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 300,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35625891",
          "text": "wasting during early childhood, and loss of ambulation and death by early adulthood. Chronic inflammation due to myofiber instability leads to fibrosi",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 273,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21784636",
          "text": "Patients with Duchenne muscular dystrophy (DMD) lose ambulation by age 12. Long-term steroids have lengthened ambulation by 2-5 years. Ischial weight-",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12466073",
          "text": "Loss of independent gait occurred at similar ages in both groups (10.3 vs. 10.5 years).",
          "offsetInBeginSection": 971,
          "offsetInEndSection": 1058,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17388226",
          "text": "Subsequently, the disease immobilizes the patient (ages 9 to 14 years) and severe respiratory failure occurs due to chest and vertebral column deformity.",
          "offsetInBeginSection": 261,
          "offsetInEndSection": 414,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25643053",
          "text": "ents with Duchenne muscular dystrophy aged 17.1 \u00b1 4.8 years (range: 9 - 28.1 years). The average Brooke functional score of these patients was 4.6 \u00b1 1",
          "offsetInBeginSection": 641,
          "offsetInEndSection": 791,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23440719",
          "text": "Glucocorticoid-treated patients who were IAAM homozygotes lost ambulation at 12.5 \u00b1 3.3 years compared to 10.7 \u00b1 2.1 years for treated VTTT heterozygotes or homozygotes.",
          "offsetInBeginSection": 787,
          "offsetInEndSection": 956,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19834452",
          "text": "Historically, DMD has resulted in loss of ambulation between ages 7 and 13 years and death in the teens or 20s.",
          "offsetInBeginSection": 303,
          "offsetInEndSection": 414,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3198893",
          "text": "ot orthoses at the point of loss of ambulation, between the ages of 6 and 12 years. There was an inverse relationship between the severity of the scol",
          "offsetInBeginSection": 152,
          "offsetInEndSection": 302,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3632394",
          "text": "f Duchenne muscular dystrophy, comparing the age at which 16 treated patients and 38 controls lost the ability to ambulate. Survival curve analysis an",
          "offsetInBeginSection": 87,
          "offsetInEndSection": 237,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
          "text": "it disturbance, and historically has led to the loss of ambulation by age 12. It is important for the practicing pediatrician, however, to be aware of",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 376,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32195737",
          "text": "Eighty-one percent were older than 9 yrs at first fracture and 36.4% became nonambulatory after fracture.",
          "offsetInBeginSection": 590,
          "offsetInEndSection": 695,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12026233",
          "text": "trophies, resulting in early loss of ambulation between the ages of 7 and 13 years and death in the teens and twenties. Despite the phenomenal advance",
          "offsetInBeginSection": 93,
          "offsetInEndSection": 243,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16322188",
          "text": "ked by progressive skeletal muscle weakness with loss of ambulation by 12 years of age. Death occurs in early adulthood secondary to respiratory or ca",
          "offsetInBeginSection": 211,
          "offsetInEndSection": 361,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31922454",
          "text": "Results: Median ages at loss of ambulation were 15.6 and 13.5\u00a0years among deflazacort- and prednisone-initiated patients, respectively.",
          "offsetInBeginSection": 326,
          "offsetInEndSection": 461,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33215271",
          "text": "childhood with loss of ambulation usually occurring around the age of 9-11\u00a0years.\n\n\nOBJECTIVE, MATERIAL AND METHODS\nBased on current guidelines and cl",
          "offsetInBeginSection": 99,
          "offsetInEndSection": 249,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34605048",
          "text": "8816 earnings loss in 2020\u2009U.S. dollars. Caregivers of boys with DMD with \u22654\u2009y of ambulation loss had a predicted loss in annualized earnings of $23,9",
          "offsetInBeginSection": 1138,
          "offsetInEndSection": 1288,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27382620",
          "text": "Duchenne muscular dystrophy is a progressive disease with loss of ambulation at around 9-10 years of age, followed, if untreated, by development of scoliosis, respiratory insufficiency, and death in the second decade of life.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30275245",
          "text": " weakness, loss of ambulation, and cardiopulmonary compromise by the second decade of life. Life expectancy has improved from mid-teenage years to mid",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 339,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
          "text": " walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, medical, su",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 328,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29067658",
          "text": "Dystrophinopathies are multi-systems disorders that are characterized by severe skeletal muscle wasting, with loss of independent ambulation in the early teenage years, followed by cardio-respiratory complications and premature death.",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 412,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27221372",
          "text": "ctively, accelerating around the time of ambulation loss (mean age 11.8 \u00b1 2.7 years). Chronic corticosteroid therapy was utilized in 69% of patients a",
          "offsetInBeginSection": 389,
          "offsetInEndSection": 539,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17257866",
          "text": "Age at loss of ambulation in KAFOs was 12.3+/-1.9 years and at loss of standing 12.8+/-2.1 years.",
          "offsetInBeginSection": 1073,
          "offsetInEndSection": 1170,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36397889",
          "text": "kness, respiratory impairment, and loss of ambulation.\u00a0A case study of a nine-year-old male diagnosed with DMD is presented. The patient had difficult",
          "offsetInBeginSection": 200,
          "offsetInEndSection": 350,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27927595",
          "text": "ages were obtained from 26 patients and 19 age-matched controls (ages 8-18 years) on a 3 tesla MRI scanner. Group comparisons of cerebral blood flow w",
          "offsetInBeginSection": 859,
          "offsetInEndSection": 1009,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11961461",
          "text": "The mean age at cessation of ambulation for those who had surgery was 11.2 years versus 10.3 years for those who did not have surgery.",
          "offsetInBeginSection": 709,
          "offsetInEndSection": 843,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25635234",
          "text": " deflazacort prolonged ambulation longer than prednisone (median 14 years and 13 years, respectively). Further, use of Vitamin D and Coenzyme Q10, ins",
          "offsetInBeginSection": 981,
          "offsetInEndSection": 1131,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32195738",
          "text": "We describe the clinical deterioration of a 26-yr-old man with Duchenne muscular dystrophy on oral daily high-dose deflazacort.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12026233",
          "text": "From this review, it is clear that until a definitive treatment for Duchenne muscular dystrophy is available, the use of deflazacort and prednisone with judicious dietary control and close clinical monitoring for side effects seems the best intervention for interim preservation of function in such a common devastating disorder of young growing boys.",
          "offsetInBeginSection": 851,
          "offsetInEndSection": 1202,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18974549",
          "text": "Patients usually become wheelchair-bound by the age of 12 years, and die of cardiorespiratory complications in their late teens to early twenties.",
          "offsetInBeginSection": 223,
          "offsetInEndSection": 369,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25414237",
          "text": "nual risk of losing ambulation 82% lower than the untreated, up to age 11 years; after which the risks were not statistically different. The relations",
          "offsetInBeginSection": 678,
          "offsetInEndSection": 828,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29174484",
          "text": "METHODS\nFor this prospective cohort study, we enrolled male patients aged 2-28 years with Duchenne muscular dystrophy at 20 centres in nine countries.",
          "offsetInBeginSection": 357,
          "offsetInEndSection": 507,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10382913",
          "text": "Loss of walking ability occurred in the control group at an average of 9.29 years (5.85-13.63, SD 1.98) and in the operated group at an average of 10.55 years (8.17-14.39, SD 1.76).",
          "offsetInBeginSection": 635,
          "offsetInEndSection": 816,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26966795",
          "text": "PURPOSE\nWe investigated the prognostic utility of onset age at first signs and symptoms (SS) to predict onset age at loss of ambulation (LOA) for childhood-onset Duchenne and Becker Muscular Dystrophies (DBMD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17257866",
          "text": "OBJECTIVE\nScoliosis is a frequent complication (68-90%) of Duchenne muscular dystrophy (DMD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25752877",
          "text": "Untreated boys become wheelchair bound by the age of 12 years and die of cardiorespiratory complications in their late teens to early 20s.",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 289,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36397889",
        "http://www.ncbi.nlm.nih.gov/pubmed/35625891",
        "http://www.ncbi.nlm.nih.gov/pubmed/12363102",
        "http://www.ncbi.nlm.nih.gov/pubmed/34605048",
        "http://www.ncbi.nlm.nih.gov/pubmed/3198893",
        "http://www.ncbi.nlm.nih.gov/pubmed/17388226",
        "http://www.ncbi.nlm.nih.gov/pubmed/32195737",
        "http://www.ncbi.nlm.nih.gov/pubmed/21784636",
        "http://www.ncbi.nlm.nih.gov/pubmed/31588416",
        "http://www.ncbi.nlm.nih.gov/pubmed/3632394",
        "http://www.ncbi.nlm.nih.gov/pubmed/32195738",
        "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
        "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
        "http://www.ncbi.nlm.nih.gov/pubmed/25752877",
        "http://www.ncbi.nlm.nih.gov/pubmed/17257866",
        "http://www.ncbi.nlm.nih.gov/pubmed/18974549",
        "http://www.ncbi.nlm.nih.gov/pubmed/27382620",
        "http://www.ncbi.nlm.nih.gov/pubmed/22115006",
        "http://www.ncbi.nlm.nih.gov/pubmed/16322188",
        "http://www.ncbi.nlm.nih.gov/pubmed/23440719",
        "http://www.ncbi.nlm.nih.gov/pubmed/27927595",
        "http://www.ncbi.nlm.nih.gov/pubmed/30275245",
        "http://www.ncbi.nlm.nih.gov/pubmed/27221372",
        "http://www.ncbi.nlm.nih.gov/pubmed/25414237",
        "http://www.ncbi.nlm.nih.gov/pubmed/12466073",
        "http://www.ncbi.nlm.nih.gov/pubmed/12026233",
        "http://www.ncbi.nlm.nih.gov/pubmed/25643053",
        "http://www.ncbi.nlm.nih.gov/pubmed/26966795",
        "http://www.ncbi.nlm.nih.gov/pubmed/31922454",
        "http://www.ncbi.nlm.nih.gov/pubmed/10382913",
        "http://www.ncbi.nlm.nih.gov/pubmed/29067658",
        "http://www.ncbi.nlm.nih.gov/pubmed/25635234",
        "http://www.ncbi.nlm.nih.gov/pubmed/29174484",
        "http://www.ncbi.nlm.nih.gov/pubmed/11961461",
        "http://www.ncbi.nlm.nih.gov/pubmed/19834452",
        "http://www.ncbi.nlm.nih.gov/pubmed/33215271"
      ]
    },
    {
      "id": "6404199d201352f04a000019",
      "type": "yesno",
      "body": "Is ocrelizumab effective for primary progressive multiple sclerosis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31354720",
          "text": "Ocrelizumab was the first medication to be approved for primary progressive MS.",
          "offsetInBeginSection": 720,
          "offsetInEndSection": 799,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32920498",
          "text": "ary progressive multiple sclerosis (PPMS) with efficacy proven in a phase 3 randomised controlled trial. Eleven months prior to the European regulator",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 332,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33519676",
          "text": "Conclusions: Our real-world study supports the tolerability, safety, and effectiveness of ocrelizumab in clinical practice.",
          "offsetInBeginSection": 1453,
          "offsetInEndSection": 1576,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32777270",
          "text": " remitting and primary progressive multiple sclerosis with evidence of inflammatory activity. Guidelines suggest assessing vaccination status and even",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 233,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33519676",
          "text": "of RMS patients who were followed for at least 1 year. Ocrelizumab was generally well-tolerated; the most common adverse events were infusion-related ",
          "offsetInBeginSection": 1249,
          "offsetInEndSection": 1399,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456175",
          "text": "In conclusion, our study highlighted that early ocrelizumab treatment is effective in modifying the disability accrual in MS patients.",
          "offsetInBeginSection": 2061,
          "offsetInEndSection": 2195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36454397",
          "text": "OBJECTIVES\nOcrelizumab demonstrated significant clinical benefit for the treatment of relapsing (RMS) and primary progressive (PPMS) multiple sclerosis (MS), an incurable disease characterized by disability progression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33868559",
          "text": "BACKGROUND\nOcrelizumab is an anti-CD20 monoclonal antibody that has been shown to reduce disability progression in primary progressive multiple sclerosis (MS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32607256",
          "text": "CONCLUSION\nOcrelizumab can stabilize disability progression in patients with PPMS.",
          "offsetInBeginSection": 1108,
          "offsetInEndSection": 1190,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30160679",
          "text": "lizumab, are widely coming to multiple sclerosis (MS) therapy. Its clinical-MRI efficacy in MS with relapses as well in primary progressive MS (PPMS) ",
          "offsetInBeginSection": 71,
          "offsetInEndSection": 221,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30677733",
          "text": "rve (SUCRA) values.\n\n\nRESULTS\nResults suggest that ocrelizumab has superior efficacy to 10 of the 17 treatments in the 12-week confirmed disability pr",
          "offsetInBeginSection": 1412,
          "offsetInEndSection": 1562,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30008443",
          "text": "Here, we review the evidence for the safety and effectiveness of ocrelizumab.",
          "offsetInBeginSection": 327,
          "offsetInEndSection": 404,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33352355",
          "text": "ng therapy (DMT) for primary progressive multiple sclerosis (MS). Although effective, adverse infusion-related reactions (IRR), such as erythema, prur",
          "offsetInBeginSection": 77,
          "offsetInEndSection": 227,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35079395",
          "text": "Ocrelizumab is a recombinant humanized antibody targeted against CD-20\u00a0molecule, which was approved for the treatment of relapsing and primary progressive multiple sclerosis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35964555",
          "text": "Ocrelizumab is an effective treatment for relapsing and primary-progressive multiple sclerosis (MS). However, the effect of ocrelizumab on leptomeningeal (LM) inflammation is unknown",
          "offsetInBeginSection": 11,
          "offsetInEndSection": 193,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35964555",
          "text": " in one patient at first dose.\n\n\nCONCLUSIONS\nTreatment with ocrelizumab was safe and clinically effective. Brain volume loss and accumulation of T1-LV",
          "offsetInBeginSection": 1426,
          "offsetInEndSection": 1576,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33450528",
          "text": "Ocrelizumab is a humanized monoclonal anti-CD20 antibody approved for treatment of relapsing-remitting and primary progressive multiple sclerosis (MS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35583174",
          "text": "progressive multiple sclerosis (PPMS). Ocrelizumab is the only disease-modifying therapy (DMT) approved for PPMS. In November 2017, the European Medic",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 429,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32607256",
          "text": "Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32470856",
          "text": "Ocrelizumab is a humanized monoclonal anti-CD20 antibody approved for treatment of relapsing-remitting and primary progressive multiple sclerosis (MS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34449289",
          "text": "Ocrelizumab is a humanized monoclonal antibody that targets the CD20 antigen on B cells, which is approved for the treatment of both relapsing-remitting multiple sclerosis (RRMS) and primary-progressive multiple sclerosis (PPMS).",
          "offsetInBeginSection": 88,
          "offsetInEndSection": 317,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33948072",
          "text": "Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34644452",
          "text": "e free of magnetic resonance imaging activity. Ocrelizumab was generally well tolerated, as side effects were only reported for 10% of patients, mostl",
          "offsetInBeginSection": 1382,
          "offsetInEndSection": 1532,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33356643",
          "text": "INTRODUCTION\nOcrelizumab is the first approved drug for primary progressive multiple sclerosis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33369288",
          "text": "INTERPRETATION\nThe preliminary results in our real-world setting show that ocrelizumab presented excellent results in suppressing disease activity with a favorable and consistent safety profile.",
          "offsetInBeginSection": 1186,
          "offsetInEndSection": 1380,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36454397",
          "text": "8.38), interferon \u03b2-1a (8.33) and glatiramer acetate (8.18). As the most effective option, with quality-adjusted life year (QALY) gains between 0.3 an",
          "offsetInBeginSection": 1077,
          "offsetInEndSection": 1227,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30632834",
          "text": "slowdown progression in primary progressive MS (PPMS). The treatment is generally well tolerated, with manageable adverse events related to infusion r",
          "offsetInBeginSection": 572,
          "offsetInEndSection": 722,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31783427",
          "text": "New medications are the B-cell depleting antibody ocrelizumab, authorized for primary progressive MS with inflammatory activity and the sphingosine-1-receptor modulator siponimod, which is under development for secondary-progressive MS.\u200aPathomechanisms of progressive MS comprise chronic inflammation with activation of T and B cells and microglia with release of reactive oxygen species, age-dependent accumulation of iron and neurodegeneration.",
          "offsetInBeginSection": 244,
          "offsetInEndSection": 690,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28695471",
          "text": "ents with a disease that had no proven therapy. Ocrelizumab is generally well tolerated, with the most common adverse events experienced being infusio",
          "offsetInBeginSection": 422,
          "offsetInEndSection": 572,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35583174",
          "text": "For PPMS, compared with placebo, ocrelizumab was associated with: 1. a lower number of participants with disability progression (HR 0.75, 95% CI 0.58 to 0.98; 1 study, 731 participants; low-certainty evidence); 2. a higher number of participants with any adverse events (RR 1.06, 95% CI 1.01 to 1.11; 1 study, 725 participants; moderate-certainty evidence); 3. little to no difference in the number of participants with any serious adverse event (RR 0.92, 95% CI 0.68 to 1.23; 1 study, 725 participants; low-certainty evidence); 4. little to no difference in the number of participants experiencing treatment discontinuation caused by adverse events (RR 1.23, 95% CI 0.55 to 2.75; 1 study, 725 participants; low-certainty evidence) for at least 120 weeks.",
          "offsetInBeginSection": 3170,
          "offsetInEndSection": 3925,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36007299",
          "text": "the basis of previous phase III studies. However, limited data were available on ocrelizumab efficacy in RMS according to the Lublin definition of act",
          "offsetInBeginSection": 232,
          "offsetInEndSection": 382,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35583174",
          "text": "For RRMS, compared with interferon beta-1a, ocrelizumab was associated with: 1. lower relapse rate (risk ratio (RR) 0.61, 95% confidence interval (CI) 0.52 to 0.73; 2 studies, 1656 participants; moderate-certainty evidence); 2. a lower number of participants with disability progression (hazard ratio (HR) 0.60, 95% CI 0.43 to 0.84; 2 studies, 1656 participants; low-certainty evidence); 3. little to no difference in the number of participants with any adverse event (RR 1.00, 95% CI 0.96 to 1.04; 2 studies, 1651 participants; moderate-certainty evidence); 4. little to no difference in the number of participants with any serious adverse event (RR 0.79, 95% CI 0.57 to 1.11; 2 studies, 1651 participants; low-certainty evidence); 5. a lower number of participants experiencing treatment discontinuation caused by adverse events (RR 0.58, 95% CI 0.37 to 0.91; 2 studies, 1651 participants; low-certainty evidence); 6. a lower number of participants with gadolinium-enhancing T1 lesions on magnetic resonance imaging (MRI) (RR 0.27, 95% CI 0.22 to 0.35; 2 studies, 1656 participants; low-certainty evidence); 7. a lower number of participants with new or enlarging T2-hyperintense lesions on MRI (RR 0.63, 95% CI 0.57 to 0.69; 2 studies, 1656 participants; low-certainty evidence) at 96 weeks.",
          "offsetInBeginSection": 1875,
          "offsetInEndSection": 3169,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31821962",
          "text": "mary progressive multiple sclerosis (PPMS). Its increasing use for MS has been due in part to its efficacy, unique indication for PPMS, and convenient",
          "offsetInBeginSection": 135,
          "offsetInEndSection": 285,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34497472",
          "text": "Ocrelizumab is a humanized CD20 monoclonal antibody which was approved for management of Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS) in 2017.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456175",
          "text": "In conclusion, our study highlighted that early ocrelizumab treatment is effective in modifying the disability accrual in MS patients.",
          "offsetInBeginSection": 2061,
          "offsetInEndSection": 2195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32920498",
          "text": "e patient cohort in Germany, supporting that ocrelizumab is generally well-tolerated in clinical practice. Physicians should be vigilant for early sym",
          "offsetInBeginSection": 2823,
          "offsetInEndSection": 2973,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30597851",
          "text": "Ocrelizumab, a humanized monoclonal anti-CD20 antibody, has shown pronounced effects in reduction of disease activity in multiple sclerosis (MS) patients and has recently been approved for the treatment of patients with relapsing MS (RMS) and primary progressive MS (PPMS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 273,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36007299",
          "text": "CONCLUSION\nThese data confirm the efficacy of ocrelizumab in a pragmatic setting and its favorable benefit-risk profile in patients with RMS.",
          "offsetInBeginSection": 2491,
          "offsetInEndSection": 2632,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35107597",
          "text": "INTERPRETATION\nWe provide real-world evidence of effectiveness of ocrelizumab and rituximab in pwPPMS.",
          "offsetInBeginSection": 1534,
          "offsetInEndSection": 1636,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35741088",
          "text": "Response to ocrelizumab was linked to lower total and gray matter cerebellar volume loss over time.",
          "offsetInBeginSection": 1229,
          "offsetInEndSection": 1328,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34553320",
          "text": "Our findings suggest that ocrelizumab is an effective treatment in real-world patients with RRMS and PMS, with a manageable safety profile.",
          "offsetInBeginSection": 1629,
          "offsetInEndSection": 1768,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33795953",
          "text": "mitting MS (RRMS), 18 (35.3%) with secondary progressive MS (SPMS) and 7 (13.7%) with primary progressive MS (PPMS). The mean lymphocyte value one day",
          "offsetInBeginSection": 902,
          "offsetInEndSection": 1052,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33795953",
          "text": "CONCLUSION\nFrom our data, it is evident that ocrelizumab is safe in the short term.",
          "offsetInBeginSection": 1431,
          "offsetInEndSection": 1514,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32524163",
          "text": "Recently published phase\u00a03 studies confirmed that ocrelizumab is effective in the treatment of both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).",
          "offsetInBeginSection": 175,
          "offsetInEndSection": 360,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456175",
          "text": "Pivotal trials showed the effectiveness of the monoclonal antibody ocrelizumab in relapsing and progressive multiple sclerosis (MS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34735301",
          "text": "Under guidance of neurology, we had initiated treatment with ocrelizumab with stability of ocular inflammation for the past 24 months.Conclusion: Six-monthly 600mg ocrelizumab infusions may be effective as a steroid sparing option for patients with severe, recurrent bilateral panuveitis secondary to primary progressive multiple sclerosis.",
          "offsetInBeginSection": 656,
          "offsetInEndSection": 996,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29897610",
          "text": "The clinical trials conducted for both the relapsing forms (OPERA I/II) and the progressive forms of the disease (ORATORIO) have demonstrated its efficacy.",
          "offsetInBeginSection": 380,
          "offsetInEndSection": 535,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35289375",
          "text": "Current therapeutic options for the treatment of PMS remain inadequate, although ocrelizumab, a B-cell-depleting antibody, is now available as the first approved therapeutic option for primary progressive MS.",
          "offsetInBeginSection": 284,
          "offsetInEndSection": 492,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34354358",
          "text": "ng-remitting multiple sclerosis (RRMS). It is also the first proven therapy able to slow disability progression in primary progressive multiple sclero",
          "offsetInBeginSection": 402,
          "offsetInEndSection": 552,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35192158",
          "text": "rogressive multiple sclerosis (PPMS). The efficacy of ocrelizumab in reducing relapse rates and disease activity in patients with RMS was demonstrated",
          "offsetInBeginSection": 195,
          "offsetInEndSection": 345,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32920498",
        "http://www.ncbi.nlm.nih.gov/pubmed/33450528",
        "http://www.ncbi.nlm.nih.gov/pubmed/34354358",
        "http://www.ncbi.nlm.nih.gov/pubmed/34735301",
        "http://www.ncbi.nlm.nih.gov/pubmed/35192158",
        "http://www.ncbi.nlm.nih.gov/pubmed/35583174",
        "http://www.ncbi.nlm.nih.gov/pubmed/32524163",
        "http://www.ncbi.nlm.nih.gov/pubmed/31354720",
        "http://www.ncbi.nlm.nih.gov/pubmed/33868559",
        "http://www.ncbi.nlm.nih.gov/pubmed/30008443",
        "http://www.ncbi.nlm.nih.gov/pubmed/31821962",
        "http://www.ncbi.nlm.nih.gov/pubmed/34449289",
        "http://www.ncbi.nlm.nih.gov/pubmed/32470856",
        "http://www.ncbi.nlm.nih.gov/pubmed/31783427",
        "http://www.ncbi.nlm.nih.gov/pubmed/28695471",
        "http://www.ncbi.nlm.nih.gov/pubmed/29897610",
        "http://www.ncbi.nlm.nih.gov/pubmed/30677733",
        "http://www.ncbi.nlm.nih.gov/pubmed/34497472",
        "http://www.ncbi.nlm.nih.gov/pubmed/36007299",
        "http://www.ncbi.nlm.nih.gov/pubmed/33795953",
        "http://www.ncbi.nlm.nih.gov/pubmed/33369288",
        "http://www.ncbi.nlm.nih.gov/pubmed/35289375",
        "http://www.ncbi.nlm.nih.gov/pubmed/32607256",
        "http://www.ncbi.nlm.nih.gov/pubmed/36454397",
        "http://www.ncbi.nlm.nih.gov/pubmed/35964555",
        "http://www.ncbi.nlm.nih.gov/pubmed/34644452",
        "http://www.ncbi.nlm.nih.gov/pubmed/30597851",
        "http://www.ncbi.nlm.nih.gov/pubmed/33519676",
        "http://www.ncbi.nlm.nih.gov/pubmed/35456175",
        "http://www.ncbi.nlm.nih.gov/pubmed/35107597",
        "http://www.ncbi.nlm.nih.gov/pubmed/30632834",
        "http://www.ncbi.nlm.nih.gov/pubmed/35741088",
        "http://www.ncbi.nlm.nih.gov/pubmed/30160679",
        "http://www.ncbi.nlm.nih.gov/pubmed/33948072",
        "http://www.ncbi.nlm.nih.gov/pubmed/32777270",
        "http://www.ncbi.nlm.nih.gov/pubmed/33356643",
        "http://www.ncbi.nlm.nih.gov/pubmed/34553320",
        "http://www.ncbi.nlm.nih.gov/pubmed/35079395",
        "http://www.ncbi.nlm.nih.gov/pubmed/33352355"
      ]
    },
    {
      "id": "641b7bba690f196b5100003e",
      "type": "summary",
      "body": "How is Indocyanine green (ICG) used?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35874138",
          "text": "s an operation burdened with severe postoperative complications. Fluorescence imaging, particularly using indocyanine green (ICG), offers the ability ",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 262,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12140046",
          "text": "PURPOSE\nTo report an altered uptake and possible complication associated with the use of indocyanine green (ICG) dye, internal limiting membrane (ILM) peeling, and infrared diode laser.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33965600",
          "text": "We describe a case using indocyanine green (ICG) fluorescence imaging for diagnosis of postoperative gastrointestinal fistula.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28316935",
          "text": "Indocyanine Green (ICG) is frequently used during urologic robotic procedures and is generally considered to be safe.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9018428",
          "text": "Indocyanine green (ICG) is a fluorescent dye that can be used to image both retinal and choroidal vessels.",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 237,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7553712",
          "text": "Systemic indocyanine green (ICG) clearance has been used to estimate splanchnic blood flow, but the results may be compromised by altered hepatic dye extraction.",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 306,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35668312",
          "text": "Indocyanine green (ICG) is one of the methods used to assess vascularization, but this assessment is usually subjective.",
          "offsetInBeginSection": 152,
          "offsetInEndSection": 272,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12963458",
          "text": "We examined Indocyanine green (ICG) which is widely used in medical testing and is highly unstable.",
          "offsetInBeginSection": 90,
          "offsetInEndSection": 189,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35601636",
          "text": "ntly available in Korea. Indocyanine green (ICG) can be applied as an alternative agent. However, studies on colonoscopic tattooing by the direct inje",
          "offsetInBeginSection": 157,
          "offsetInEndSection": 307,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35662771",
          "text": "Using indocyanine green (ICG), a standard reagent used in liver function tests, bile leaks from exfoliated liver sections can be detected with higher sensitivity than naked-eye observation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12880353",
          "text": "Its complex spectral behavior and low quantum yield limits some applications.",
          "offsetInBeginSection": 71,
          "offsetInEndSection": 148,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12617707",
          "text": "Indocyanine green is therefore potentially of interest for use in experimental neurophysiological studies.",
          "offsetInBeginSection": 1327,
          "offsetInEndSection": 1433,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30582975",
          "text": "anine green (ICG) is an FDA-approved, inexpensive, and widely available NIR dye. We hypothesized that axillary lymphatic mapping with ICG is equivalen",
          "offsetInBeginSection": 133,
          "offsetInEndSection": 283,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31129192",
          "text": "Indocyanine green (ICG) is a dye used for fluorescent-guided surgery. This review article addresses the recent surge in reported uses of ICG in variou",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28579357",
          "text": "OBJECTIVE\nIndocyanine green fluorescence-guided surgery (ICG-FGS) has emerged as a potential new imaging modality for improving the detection of hepatic, lymph node (LN), and peritoneal metastases in colorectal cancer (CRC) patients.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27544892",
          "text": "(Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque [BRIGHT-CEA]; NCT01873716).",
          "offsetInBeginSection": 2431,
          "offsetInEndSection": 2528,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15871512",
          "text": "OBJECT\nRecently, intraoperative fluorescence angiography in which indocyanine green (ICG) is used as a tracer has been introduced as a novel technique to confirm successful aneurysm clipping.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19065196",
          "text": "Indocyanine green (ICG) is a fluorescent probe used in clinical imaging. However, its utility remains limited by optical instability, rapid circulatio",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11084282",
          "text": "Indocyanine green was used to better visualize the anterior capsule before capsulotomy.",
          "offsetInBeginSection": 522,
          "offsetInEndSection": 609,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17964824",
          "text": "OBJECTIVE\nTo introduce our preliminary experience with indocyanine green (ICG) fluorescence angiography for the assessment of lower leg bypasses.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34555944",
          "text": "Indocyanine green angiography was utilized to visualize better skin paddle during flap reconstruction if needed.",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 894,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35308965",
          "text": "g stacks enables non-invasive quantification of perfusion by using fluorescent dyes, typically Indocyanine Green (ICG). Due to their often leaky and c",
          "offsetInBeginSection": 85,
          "offsetInEndSection": 235,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12617707",
          "text": "plication of indocyanine green (ICG) over the retinal surface is followed by prolonged staining of the optic disc. This study was performed to analyze",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 198,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8235110",
          "text": "Indocyanine green (ICG)-enhanced laser therapy was evaluated for the treatment of experimental intraocular melanoma.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23727789",
          "text": "The nanoparticles could be activated from \"OFF\" to \"ON\" of NIR fluorescence in an intracellular environment and used for NIR imaging and photothermal therapy.",
          "offsetInBeginSection": 199,
          "offsetInEndSection": 357,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15871512",
          "text": "Indocyanine green videoangiography was used to identify four nonfunctioning STA-MCA bypasses, which could be revised successfully in all cases.",
          "offsetInBeginSection": 1464,
          "offsetInEndSection": 1607,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27544892",
          "text": "METHODS\nEight patients were enrolled in the BRIGHT-CEA (Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque) trial.",
          "offsetInBeginSection": 684,
          "offsetInEndSection": 816,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34188987",
          "text": "raphy is a real-time imaging modality that can be used to assess intraoperative tissue perfusion. ICG dye has proven to be feasible, safe, and cost-ef",
          "offsetInBeginSection": 30,
          "offsetInEndSection": 180,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10946079",
          "text": "Indocyanine green (ICG) is a fluorescent dye that has been used for the imaging of retinal and choroidal vasculatures for more than 30 years.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25698588",
          "text": "Near-infrared fluorescence (NIRF) imaging with intraoperative administration of indocyanine green (ICG) is a technology with emerging applications in urologic surgery.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25379674",
          "text": "d approximately by 40% even at 4 mm depth from liver surfaces. Photoacoustic tomography using indocyanine green also failed to identify any hepatocell",
          "offsetInBeginSection": 1416,
          "offsetInEndSection": 1566,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30582975",
          "text": "CONCLUSIONS\nIndocyanine green with NIR fluorescence imaging can be safely and efficiently used for real-time intraoperative lymphatic mapping in breast cancer patients.",
          "offsetInBeginSection": 1395,
          "offsetInEndSection": 1563,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10048369",
          "text": "BACKGROUND\nIndocyanine green (ICG) angiography detects the infrared fluorescence of ICG through the retinal pigment epithelium, providing visualization of the choroidal vascular network.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34589458",
          "text": "Conclusion: Indocyanine green fluorescence angiography is a safe imaging technology and its use is increasing rapidly in pediatric surgical specialties.",
          "offsetInBeginSection": 1633,
          "offsetInEndSection": 1785,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19790157",
          "text": "Indocyanine green clearance (Cl-ICG) has been used to assess liver function and hepatic blood flow mainly before and after hepatic surgery.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7553712",
          "text": "CONCLUSIONS\nThe prerequisites for the method of primed, constant infusion of indocyanine green with hepatic vein catheterization are achieved in intensive care patients.",
          "offsetInBeginSection": 1510,
          "offsetInEndSection": 1679,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28477043",
          "text": "n fluorescence (m-ICG) has been widely used for assessing real-time blood flow during aneurysm surgery. More recently, an endoscope-integrated indocya",
          "offsetInBeginSection": 64,
          "offsetInEndSection": 214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36357227",
          "text": "y and safety of the use of indocyanine green technology during pediatric intestinal resections. While indocyanine green fluorescence angiography (ICG-",
          "offsetInBeginSection": 64,
          "offsetInEndSection": 214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7553712",
          "text": "CONCLUSIONS\nThe prerequisites for the method of primed, constant infusion of indocyanine green with hepatic vein catheterization are achieved in intensive care patients.",
          "offsetInBeginSection": 1510,
          "offsetInEndSection": 1679,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27051499",
          "text": "We describe the utilization of indocyanine green (ICG) dye to facilitate combined/en bloc removal of epiretinal membranes (ERM) along with internal limiting membranes (ILM).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32021082",
          "text": " with fluorescein or indocyanine green (ICG) is a diagnostic procedure commonly used in ophthalmology. Adverse reactions to fluorescein and ICG are ra",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 198,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27544892",
          "text": "OBJECTIVES\nThis study sought to determine whether indocyanine green (ICG)-enhanced near-infrared fluorescence (NIRF) imaging can illuminate high-risk histologic plaque features of human carotid atherosclerosis, and in coronary atheroma of living swine, using intravascular NIRF-optical coherence tomography (OCT) imaging.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 321,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32360873",
          "text": "line for the use of indocyanine green (ICG) in the localization of pulmonary nodules before surgery. How long ICG can remain in\u00a0vivo is unknown. Accor",
          "offsetInBeginSection": 36,
          "offsetInEndSection": 186,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30903392",
          "text": "METHODS\nA narrative mini-review was performed in November 2018 using PubMed, Scopus, EMBASE, and Web of Science databases utilizing the following search phrase: \"indocyanine green fluorescence robotic surgery\" resulting in 104 articles of which 30 articles had urologic-pertinent applications.",
          "offsetInBeginSection": 424,
          "offsetInEndSection": 717,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34589458",
          "text": "Conclusion: Indocyanine green fluorescence angiography is a safe imaging technology and its use is increasing rapidly in pediatric surgical specialties.",
          "offsetInBeginSection": 1633,
          "offsetInEndSection": 1785,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36055879",
          "text": " chemical injected intraoperatively which can be used to visualize dermal blood flow in real time. There is little objective data available to help gu",
          "offsetInBeginSection": 334,
          "offsetInEndSection": 484,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36114496",
          "text": "BACKGROUND\nIndocyanine green (ICG) when injected intravenously into the bloodstream allows us to show stomach vascularity in real time.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11351215",
          "text": "INTRODUCTION\nSince early 90th, infra-red angiography using indocyanine green, is an additional examination done after fluorescein angiography (FA) very often used in ARMD allowing deep retinal layers and choroid analysis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24710988",
          "text": "Indocyanine green (ICG) is a fluorescent dye largely used as functional indicator, fluorescent imaging contrast agent and recently as enhancer during diode laser photocoagulation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33884231",
          "text": "Indocyanine green (ICG) angiography is a procedure that uses a fluorescent dye for a variety of medical diagnostics, including the real-time examination of blood flow in tissue.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25698588",
        "http://www.ncbi.nlm.nih.gov/pubmed/7553712",
        "http://www.ncbi.nlm.nih.gov/pubmed/12617707",
        "http://www.ncbi.nlm.nih.gov/pubmed/30582975",
        "http://www.ncbi.nlm.nih.gov/pubmed/17964824",
        "http://www.ncbi.nlm.nih.gov/pubmed/34555944",
        "http://www.ncbi.nlm.nih.gov/pubmed/35874138",
        "http://www.ncbi.nlm.nih.gov/pubmed/27544892",
        "http://www.ncbi.nlm.nih.gov/pubmed/36357227",
        "http://www.ncbi.nlm.nih.gov/pubmed/23727789",
        "http://www.ncbi.nlm.nih.gov/pubmed/10946079",
        "http://www.ncbi.nlm.nih.gov/pubmed/35662771",
        "http://www.ncbi.nlm.nih.gov/pubmed/10048369",
        "http://www.ncbi.nlm.nih.gov/pubmed/27051499",
        "http://www.ncbi.nlm.nih.gov/pubmed/35308965",
        "http://www.ncbi.nlm.nih.gov/pubmed/34589458",
        "http://www.ncbi.nlm.nih.gov/pubmed/12880353",
        "http://www.ncbi.nlm.nih.gov/pubmed/34188987",
        "http://www.ncbi.nlm.nih.gov/pubmed/28579357",
        "http://www.ncbi.nlm.nih.gov/pubmed/19065196",
        "http://www.ncbi.nlm.nih.gov/pubmed/8235110",
        "http://www.ncbi.nlm.nih.gov/pubmed/35601636",
        "http://www.ncbi.nlm.nih.gov/pubmed/33965600",
        "http://www.ncbi.nlm.nih.gov/pubmed/11351215",
        "http://www.ncbi.nlm.nih.gov/pubmed/31129192",
        "http://www.ncbi.nlm.nih.gov/pubmed/33884231",
        "http://www.ncbi.nlm.nih.gov/pubmed/28477043",
        "http://www.ncbi.nlm.nih.gov/pubmed/25379674",
        "http://www.ncbi.nlm.nih.gov/pubmed/19790157",
        "http://www.ncbi.nlm.nih.gov/pubmed/36114496",
        "http://www.ncbi.nlm.nih.gov/pubmed/12140046",
        "http://www.ncbi.nlm.nih.gov/pubmed/15871512",
        "http://www.ncbi.nlm.nih.gov/pubmed/32360873",
        "http://www.ncbi.nlm.nih.gov/pubmed/28316935",
        "http://www.ncbi.nlm.nih.gov/pubmed/12963458",
        "http://www.ncbi.nlm.nih.gov/pubmed/24710988",
        "http://www.ncbi.nlm.nih.gov/pubmed/9018428",
        "http://www.ncbi.nlm.nih.gov/pubmed/11084282",
        "http://www.ncbi.nlm.nih.gov/pubmed/30903392",
        "http://www.ncbi.nlm.nih.gov/pubmed/35668312",
        "http://www.ncbi.nlm.nih.gov/pubmed/32021082",
        "http://www.ncbi.nlm.nih.gov/pubmed/36055879"
      ]
    },
    {
      "id": "6428da74690f196b51000052",
      "type": "factoid",
      "body": "What is the process that generates multiple transcripts from the same gene?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29074233",
          "text": "Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome diversity and regulate mRNA levels.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22961303",
          "text": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscriptional regulatory mechanism for expanding proteomic diversity and functional complexity in higher eukaryotes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28402429",
          "text": "Alternative splicing generates multiple transcript and protein isoforms from the same gene and thus is important in gene expression regulation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30852095",
          "text": "Alternative splicing (AS) generates multiple transcripts from the same gene, however, AS contribution to proteome complexity remains elusive in plants.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20396891",
          "text": "We have shown earlier that this sunflower gene is interrupted by nine introns and generates multiple mRNAs by alternative splicing of its primary transcript (Lazarescu et al.",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 382,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29368663",
          "text": "ranscriptional regulation of gene expression. Selection of transcript cleavage and polyadenylation sites is a dynamic process that produces multiple t",
          "offsetInBeginSection": 82,
          "offsetInEndSection": 232,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1508684",
          "text": "The chicken beta tropomyosin gene generates three major transcripts by alternative splicing.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968750",
          "text": "on can occur at multiple locations through a process known as alternative polyadenylation (APA). Therefore, APA is a form of co-transcriptional gene r",
          "offsetInBeginSection": 255,
          "offsetInEndSection": 405,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33793927",
          "text": "nt accordingly by regulating gene expression at multiple levels. Alternative splicing (AS), a widespread mechanism in eukaryotes that post-transcripti",
          "offsetInBeginSection": 80,
          "offsetInEndSection": 230,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34383135",
          "text": "Alternative splicing is a widespread phenomenon, which generates multiple isoforms of the gene product.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28942592",
          "text": "Alternative polyadenylation is an important and pervasive mechanism that generates heterogeneous 3'-termini of mRNA and is considered an important regulator of gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35821097",
          "text": "at give rise to phenotypic diversity in multicellular organisms. Alternative splicing generates multiple transcripts from a single gene, enriching the",
          "offsetInBeginSection": 79,
          "offsetInEndSection": 229,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10964921",
          "text": "ogous with only one of the upstream exons found in the mouse. The downstream promoter generates an array of transcripts, some of which do not produce ",
          "offsetInBeginSection": 608,
          "offsetInEndSection": 758,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064309",
          "text": "Alternative splicing of pre-mRNA is one of the main mechanisms regulating gene expression that generates multiple transcripts from one gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11868989",
          "text": "ervening noncoding sequences, introns, from primary transcripts. Alternative splicing generates an enormous repertoire of functional diversity by prod",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 332,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23494411",
          "text": " cases with multiple EWSR1-ETS fusion transcripts.\n\n\nCONCLUSIONS\nAlternative splicing may frequently affect the process of EFT-associated fusion gene ",
          "offsetInBeginSection": 1246,
          "offsetInEndSection": 1396,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10799306",
          "text": "ogenase (sdh2). Two transcripts are generated from this locus by alternative splicing. One transcript encodes a precursor for a functional SDH2 protei",
          "offsetInBeginSection": 228,
          "offsetInEndSection": 378,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7665564",
          "text": "gene, and their relative abundance is developmentally regulated. Alternative splicing of the primary Sty transcript generates mRNAs encoding full-leng",
          "offsetInBeginSection": 339,
          "offsetInEndSection": 489,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18817741",
          "text": "Alternative splicing of messenger RNA (mRNA) precursors generates multiple transcripts from a single primary transcript.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1967836",
          "text": "In contrast to vertebrate sarcomeric MHCs, which generate diversity through the expression of members of a multigene family, an alternative polyadenylylation site is used in the nonmuscle MHC gene to generate multiple transcripts that encode the same protein.",
          "offsetInBeginSection": 620,
          "offsetInEndSection": 879,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33294436",
          "text": "The human SOX2-OT gene comprises multiple exons and has multiple transcription start sites and generates hundreds of transcripts.",
          "offsetInBeginSection": 231,
          "offsetInEndSection": 360,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7565599",
          "text": "a gene (exu) functions in both oogenesis and spermatogenesis. Alternative RNA processing and promoter usage generates sex-specific transcripts which d",
          "offsetInBeginSection": 25,
          "offsetInEndSection": 175,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33569514",
          "text": "Alternative polyadenylation (APA) is a molecular process that generates diversity at the 3' end of RNA polymerase II transcripts from over 60% of human genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34440445",
          "text": "Alternative pre-mRNA splicing plays a very important role in expanding protein diversity as it generates numerous transcripts from a single protein-coding gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33434218",
          "text": "s of tips from the same species with improbably short branch lengths. treeinform is a method that uses phylogenetic information across species to refi",
          "offsetInBeginSection": 304,
          "offsetInEndSection": 454,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11274164",
          "text": "Differential splicing from the bcl-X gene generates several isoforms with opposite effects on the apoptotic response.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24130571",
          "text": "ent transcripts yielding mature mRNAs, in a process known as spliced leader trans-splicing (SLTS). The best described function for SLTS is to solve po",
          "offsetInBeginSection": 220,
          "offsetInEndSection": 370,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14764596",
          "text": "factor-A (VEGF) gene locus contains eight exons that span 14 kb. Alternative splicing generates multiple, different mRNAs that in turn translate into ",
          "offsetInBeginSection": 32,
          "offsetInEndSection": 182,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29368663",
          "text": "promotes nucleolar dissolution in oocytes. We show that the RNA-binding protein NCL-1/Brat is a posttranscriptional regulator of numerous ribosome-rel",
          "offsetInBeginSection": 1053,
          "offsetInEndSection": 1203,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24139801",
          "text": "Alternative splicing generates multiple transcripts from a single gene, and cell-type-specific splicing profiles are important for the properties and functions of the cells.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955028",
          "text": "PARK2 primary transcript undergoes an extensive alternative splicing, which enhances transcriptomic diversification and protein diversity in tissues and cells.",
          "offsetInBeginSection": 808,
          "offsetInEndSection": 967,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955028",
          "text": "The completion of the Human Genome Project aroused renewed interest in alternative splicing, an efficient and widespread mechanism that generates multiple protein isoforms from individual genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35269461",
          "text": "ntia, Huntington's disease, progressive supranuclear palsy, etc. Alternative splicing is a physiological process by which cells generate several trans",
          "offsetInBeginSection": 252,
          "offsetInEndSection": 402,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18466458",
          "text": "We first grouped mRNA transcripts according to their functions annotated in biological process of gene ontology (GO).",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30277515",
          "text": "Alternative pre-mRNA splicing generates functionally distinct transcripts from the same gene and is involved in the control of multiple cellular processes, with its dysregulation being associated with a variety of pathologies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10421436",
          "text": "Although the COLQ gene produces multiple transcripts, it does not generate the hydrophobic tail.",
          "offsetInBeginSection": 1423,
          "offsetInEndSection": 1519,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8626590",
          "text": "Genomic 5'-flanking regions containing the three putative PRLR gene promoters (PI, PII, and PIII) that initiate the transcription of E11, E12, and E13, respectively, were identified.",
          "offsetInBeginSection": 1071,
          "offsetInEndSection": 1253,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23298867",
          "text": "e transcript variants from a single AKR gene. However, since multiple transcript variants could give rise to either the same or multiple protein isofo",
          "offsetInBeginSection": 717,
          "offsetInEndSection": 867,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30852095",
        "http://www.ncbi.nlm.nih.gov/pubmed/35269461",
        "http://www.ncbi.nlm.nih.gov/pubmed/22961303",
        "http://www.ncbi.nlm.nih.gov/pubmed/24130571",
        "http://www.ncbi.nlm.nih.gov/pubmed/34440445",
        "http://www.ncbi.nlm.nih.gov/pubmed/14764596",
        "http://www.ncbi.nlm.nih.gov/pubmed/23494411",
        "http://www.ncbi.nlm.nih.gov/pubmed/10799306",
        "http://www.ncbi.nlm.nih.gov/pubmed/28942592",
        "http://www.ncbi.nlm.nih.gov/pubmed/18466458",
        "http://www.ncbi.nlm.nih.gov/pubmed/11274164",
        "http://www.ncbi.nlm.nih.gov/pubmed/34383135",
        "http://www.ncbi.nlm.nih.gov/pubmed/8626590",
        "http://www.ncbi.nlm.nih.gov/pubmed/29074233",
        "http://www.ncbi.nlm.nih.gov/pubmed/28402429",
        "http://www.ncbi.nlm.nih.gov/pubmed/18817741",
        "http://www.ncbi.nlm.nih.gov/pubmed/28064309",
        "http://www.ncbi.nlm.nih.gov/pubmed/7665564",
        "http://www.ncbi.nlm.nih.gov/pubmed/33569514",
        "http://www.ncbi.nlm.nih.gov/pubmed/24955028",
        "http://www.ncbi.nlm.nih.gov/pubmed/33793927",
        "http://www.ncbi.nlm.nih.gov/pubmed/33294436",
        "http://www.ncbi.nlm.nih.gov/pubmed/1508684",
        "http://www.ncbi.nlm.nih.gov/pubmed/24139801",
        "http://www.ncbi.nlm.nih.gov/pubmed/11868989",
        "http://www.ncbi.nlm.nih.gov/pubmed/33434218",
        "http://www.ncbi.nlm.nih.gov/pubmed/1967836",
        "http://www.ncbi.nlm.nih.gov/pubmed/23298867",
        "http://www.ncbi.nlm.nih.gov/pubmed/7565599",
        "http://www.ncbi.nlm.nih.gov/pubmed/10964921",
        "http://www.ncbi.nlm.nih.gov/pubmed/20396891",
        "http://www.ncbi.nlm.nih.gov/pubmed/28968750",
        "http://www.ncbi.nlm.nih.gov/pubmed/30277515",
        "http://www.ncbi.nlm.nih.gov/pubmed/10421436",
        "http://www.ncbi.nlm.nih.gov/pubmed/35821097",
        "http://www.ncbi.nlm.nih.gov/pubmed/29368663"
      ]
    },
    {
      "id": "63f9cdcc33942b094c000013",
      "type": "yesno",
      "body": "Does silencing of SRRM4 inhibit tumor growth across cancers?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30100395",
          "text": "Whether SRRM4 can also regulate a stem-cell gene network for NEPC development remains unclear.",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 531,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30100395",
          "text": "dependent manners in DU145 cells, RNA depletion of SOX2 compromises SRRM4-mediated stimulation of pluripotency genes. More importantly, this SRRM4-SOX",
          "offsetInBeginSection": 1553,
          "offsetInEndSection": 1703,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346347",
          "text": "quently occurs in cancer, but the mechanism and functional role of this silencing in oncogenesis are not fully understood. Here, we show that oncogeni",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 242,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27180064",
          "text": "ated adenocarcinoma cells to express NEPC biomarkers, and this effect was exacerbated by ARPI. ARPI combined with a gain of SRRM4-induced adenocarcino",
          "offsetInBeginSection": 1388,
          "offsetInEndSection": 1538,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27180064",
        "http://www.ncbi.nlm.nih.gov/pubmed/30100395",
        "http://www.ncbi.nlm.nih.gov/pubmed/27346347"
      ]
    },
    {
      "id": "64179aac690f196b51000037",
      "type": "factoid",
      "body": "What is the life expectancy for Duchenne muscular dystrophy patients?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6696607",
          "text": "eater Los Angeles area. Regardless of their ages, which ranged from 12 years to 21, the majority of the patients, as well as the majority of the paren",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 408,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27234309",
          "text": "A total of 85 boys with Duchenne muscular dystrophy aged 8-18 years and 136 age, sex and living place matched healthy controls were included in this study.",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 314,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10193393",
          "text": "tients with Duchenne muscular dystrophy (DMD). Life expectancy is less than one year once diurnal hypercapnia develops. This study examines the effect",
          "offsetInBeginSection": 68,
          "offsetInEndSection": 218,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19078632",
          "text": "ION\nLong-term steroid treatment in Duchenne muscular dystrophy (average. 65 mo) proved beneficial m terms of muscle strength, function, and tolerable ",
          "offsetInBeginSection": 1328,
          "offsetInEndSection": 1478,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33075081",
          "text": "lar dystrophy (DMD) is a childhood onset muscular dystrophy leading to shortened life expectancy. There are gaps in published DMD care guidelines rega",
          "offsetInBeginSection": 27,
          "offsetInEndSection": 177,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34053847",
          "text": "As a result of progressive muscle weakness, pulmonary function decreases during the second decade of life and lung disease contributes significantly to morbidity and mortality in these patients.",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 277,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28099279",
          "text": "and clinical history of Duchenne muscular dystrophy who is currently 53 years old. Because of improvements in cardiopulmonary care, there has been a g",
          "offsetInBeginSection": 45,
          "offsetInEndSection": 195,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17939910",
          "text": "RESULTS\nThe mean (SD) age was 26 (6) years and the mean age at which mechanical ventilation had initiated in the patients was 21 (5) years.",
          "offsetInBeginSection": 429,
          "offsetInEndSection": 568,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34645707",
          "text": "Median life expectancy was 22.0 years (95% confidence interval [CI] 21.2, 22.4).",
          "offsetInBeginSection": 1005,
          "offsetInEndSection": 1085,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
          "text": "RESULTS\nSurvey respondents included 52 people with Duchenne muscular dystrophy with a median age of 17 years (range: 14, 40) and 183 parents/guardians.",
          "offsetInBeginSection": 734,
          "offsetInEndSection": 885,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30796500",
          "text": "trophy-associated cardiomyopathy, a nearly consistent feature in the third decade of life. A 26-year-old patient with Duchenne muscular dystrophy expe",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 300,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2739342",
          "text": "The mean of the constant c in the group of Duchenne patients (n = 88) was -0.29/year, in Beckers dystrophy (n = 7) -0.14/year and in limb girdle dystrophy (n = 12) -0.21/year.",
          "offsetInBeginSection": 1605,
          "offsetInEndSection": 1780,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
          "text": " walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, medical, su",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 328,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11506211",
          "text": "Thirty-one patients with Duchenne muscular dystrophy of age four years and above were studied.",
          "offsetInBeginSection": 261,
          "offsetInEndSection": 355,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1450492",
          "text": "f the patients with progressive muscular dystrophy from 15.8 years to 20.4 years over the last 20 years. Various new drug trials for muscular dystroph",
          "offsetInBeginSection": 77,
          "offsetInEndSection": 227,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30275245",
          "text": "Life expectancy has improved from mid-teenage years to mid-20s with the use of glucocorticoids and beyond the third decade with ventilator support and multidisciplinary care.",
          "offsetInBeginSection": 281,
          "offsetInEndSection": 455,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26140505",
          "text": "There is currently no cure, and despite exhaustive palliative care, patients are restricted to a wheelchair by the age of 12 years and usually succumb to cardiac or respiratory complications in their late 20s.",
          "offsetInBeginSection": 979,
          "offsetInEndSection": 1188,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26799743",
          "text": "Five ambulatory, genetically confirmed Duchenne muscular dystrophy patients aged between 7\u201310 years were treated with L-arginine (3 x 2.5 g/d) and metformin (2 x 250 mg/d) for 16 weeks.",
          "offsetInBeginSection": 433,
          "offsetInEndSection": 618,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34420127",
          "text": "ation Duchenne muscular dystrophy, in ambulatory individuals aged two years and older. This study explored the symptoms and impacts of nonsense mutati",
          "offsetInBeginSection": 196,
          "offsetInEndSection": 346,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802771",
          "text": "equent muscular dystrophy in childhood, with a worldwide incidence of one in 5000 live male births. It is due to mutations in the dystrophin gene lead",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 198,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2739342",
          "text": "w an increase during the first three years of life, a maximum between the age of 3 and 4 and an asymptotic decline thereafter. Taking the blood sample",
          "offsetInBeginSection": 438,
          "offsetInEndSection": 588,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21482750",
          "text": "Caregivers (21 mothers and 6 fathers; mean age, 40.04 years) of 27 Duchenne muscular dystrophy patients (mean age, 11.26 years) completed the validated Children Health Questionnaire-Parent Form 50 and the Family Strain Questionnaire.",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 519,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34374872",
          "text": "e mutation Duchenne muscular dystrophy, in ambulatory individuals aged two years and older. This study explored the impact of caring for an ambulatory",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 341,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802771",
          "text": "The association of Duchenne Muscular Dystrophy with seizures has been reported, and there is a higher prevalence of epilepsy in Duchenne Muscular Dystrophy patients (between 6.3% and 12.3%) than in the general pediatric population (0.5-1%).",
          "offsetInBeginSection": 443,
          "offsetInEndSection": 683,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17939910",
          "text": "ge at which mechanical ventilation had initiated in the patients was 21 (5) years. Sixty-two percent had undergone tracheostomy and invasive mechanica",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 636,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3694224",
          "text": "Analysis of 176 autopsy cases of Duchenne muscular dystrophy (DMD) demonstrated that (1) hospitalized patients showed longer life spans than their non-hospitalized affected maternal uncles, (2) patients hospitalized recently lived longer than those hospitalized in the past, and (3) pulmonary infection has become a less frequent cause of death in recent years, whereas dystrophic changes of the cardiac and respiratory muscles are more closely related with recent fatal cases.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 477,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7985396",
          "text": "Progressive scolioses in 20 wheelchair patients with an age between 10.5-18.3 years (mean 14.6 years) were treated by CDI.",
          "offsetInBeginSection": 227,
          "offsetInEndSection": 349,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34420127",
          "text": "RESULTS\nTen interviews were conducted with parents of individuals aged 4-19\u2009years.",
          "offsetInBeginSection": 627,
          "offsetInEndSection": 709,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23876223",
          "text": "RESULTS\nLife expectancy without or with ventilatory assistance was 22.16 and 36.23 years, respectively.",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 540,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29984652",
          "text": "The deletion of exons 51 and 52 in the DMD gene, which has been proposed as one of the therapeutic strategies for Duchenne, is consistent with a normal life expectancy and the absence of myopathic symptoms in hemizygous males.",
          "offsetInBeginSection": 1225,
          "offsetInEndSection": 1451,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19078632",
          "text": "Results of an average follow-up period of 65 months (range, 49-79 mo) are described.",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 233,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25752877",
          "text": "Untreated boys become wheelchair bound by the age of 12 years and die of cardiorespiratory complications in their late teens to early 20s.",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 289,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18974549",
          "text": "2 years, and die of cardiorespiratory complications in their late teens to early twenties. Advances in the management of DMD, including treatment with",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 429,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31311695",
          "text": "f infarction ranged from 4 to 31 years (n\u202f=\u202f19). Most patients were 16-21 years old (14 of 19; 73.7%). Eighteen patients (90%) had dilated cardiomyopa",
          "offsetInBeginSection": 541,
          "offsetInEndSection": 691,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744411",
          "text": "ease that requires comprehensive, multidisciplinary care. This care, at minimum, should include neuromuscular, respiratory, cardiac, orthopedic, endoc",
          "offsetInBeginSection": 96,
          "offsetInEndSection": 246,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23876223",
        "http://www.ncbi.nlm.nih.gov/pubmed/31311695",
        "http://www.ncbi.nlm.nih.gov/pubmed/19078632",
        "http://www.ncbi.nlm.nih.gov/pubmed/17939910",
        "http://www.ncbi.nlm.nih.gov/pubmed/11506211",
        "http://www.ncbi.nlm.nih.gov/pubmed/34374872",
        "http://www.ncbi.nlm.nih.gov/pubmed/28802771",
        "http://www.ncbi.nlm.nih.gov/pubmed/28744411",
        "http://www.ncbi.nlm.nih.gov/pubmed/34420127",
        "http://www.ncbi.nlm.nih.gov/pubmed/27234309",
        "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
        "http://www.ncbi.nlm.nih.gov/pubmed/25752877",
        "http://www.ncbi.nlm.nih.gov/pubmed/3694224",
        "http://www.ncbi.nlm.nih.gov/pubmed/1450492",
        "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
        "http://www.ncbi.nlm.nih.gov/pubmed/18974549",
        "http://www.ncbi.nlm.nih.gov/pubmed/29984652",
        "http://www.ncbi.nlm.nih.gov/pubmed/10193393",
        "http://www.ncbi.nlm.nih.gov/pubmed/28099279",
        "http://www.ncbi.nlm.nih.gov/pubmed/2739342",
        "http://www.ncbi.nlm.nih.gov/pubmed/26140505",
        "http://www.ncbi.nlm.nih.gov/pubmed/21482750",
        "http://www.ncbi.nlm.nih.gov/pubmed/7985396",
        "http://www.ncbi.nlm.nih.gov/pubmed/30275245",
        "http://www.ncbi.nlm.nih.gov/pubmed/33075081",
        "http://www.ncbi.nlm.nih.gov/pubmed/30796500",
        "http://www.ncbi.nlm.nih.gov/pubmed/6696607",
        "http://www.ncbi.nlm.nih.gov/pubmed/26799743",
        "http://www.ncbi.nlm.nih.gov/pubmed/34053847",
        "http://www.ncbi.nlm.nih.gov/pubmed/34645707"
      ]
    },
    {
      "id": "64041e97201352f04a00001e",
      "type": "yesno",
      "body": "Is daridorexant effective for insomnia?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306405",
          "text": "BACKGROUND\nThe dual orexin receptor antagonist daridorexant did not impact nighttime respiratory function as assessed by the apnea/hypopnea index (AHI) and nocturnal oxygen saturation (SpO2) and improved sleep in patients with mild to moderate obstructive sleep apnea (OSA).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
          "text": "were the most officious doses. Treatment with daridorexant has resulted in a slightly higher incidence of adverse events [risk ratio (RR)\u2009=\u20091.19; 95% ",
          "offsetInBeginSection": 861,
          "offsetInEndSection": 1011,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32341187",
          "text": "OBJECTIVE\nTo assess the dose-response of daridorexant, a new dual orexin receptor antagonist, on wake after sleep onset (WASO).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36054921",
          "text": "in the two placebo-controlled phase III trials that evaluated the efficacy and safety of daridorexant. The DCE design was informed by a two-phase qual",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 429,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36098753",
          "text": "e events were nasopharyngitis and headache.\n\n\nCONCLUSION\nDaridorexant was efficacious and safe. Studies that evaluate the long-term safety and compare",
          "offsetInBeginSection": 936,
          "offsetInEndSection": 1086,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36309969",
          "text": "Morning administration is not relevant for daridorexant use by insomnia patients.",
          "offsetInBeginSection": 1246,
          "offsetInEndSection": 1327,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35065036",
          "text": " p=0\u00b7012 at month 3). Compared with the placebo group, no significant differences were observed among participants in the daridorexant 10 mg group for",
          "offsetInBeginSection": 4108,
          "offsetInEndSection": 4258,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35065036",
          "text": "th 1; -1\u00b70 [-2\u00b70 to 0\u00b701], p=0\u00b7053 at month 3). In study 2, WASO was significantly reduced among participants in the daridorexant 25 mg group compared",
          "offsetInBeginSection": 3306,
          "offsetInEndSection": 3456,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
          "text": " (RR\u2009=\u20092.01; 95% CI, 1.21-3.36; P\u2009=\u20090.007). Daridorexant is superior to placebo in improving sleep quality. However, the drug resulted in a slightly h",
          "offsetInBeginSection": 1116,
          "offsetInEndSection": 1266,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34331678",
          "text": "Daridorexant was safe and well tolerated and its pharmacokinetics were consistent with previous data.",
          "offsetInBeginSection": 1528,
          "offsetInEndSection": 1629,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33305817",
          "text": "In this randomized, double-blind, placebo-controlled, two-period crossover study, the effect of the dual orexin receptor antagonist daridorexant was evaluated on nighttime respiratory function and sleep in 28 patients with mild and moderate obstructive sleep apnea (OSA).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35065036",
          "text": " Compared with placebo, participants in the daridorexant 50 mg group had significantly improved self-reported total sleep time at month 1 (LSM differe",
          "offsetInBeginSection": 2627,
          "offsetInEndSection": 2777,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32937014",
          "text": "Herein we describe our efforts leading to the identification of a promising set of dual orexin receptor antagonists (DORAs) which subsequently went through physiology-based pharmacokinetic and pharmacodynamic modelling>[1] and finally led to the selection of daridorexant, currently in phase 3 clinical trials for the treatment of insomnia disorders.",
          "offsetInBeginSection": 399,
          "offsetInEndSection": 749,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36045942",
          "text": "It was shown to be effective in reducing insomnia symptoms, increasing daytime functioning, and improving the overall quality of sleep.",
          "offsetInBeginSection": 759,
          "offsetInEndSection": 894,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36144776",
          "text": "logy-based pharmacodynamic and pharmacokinetic model. The use of daridorexant is considered safe, with no clinically significant side-effects includin",
          "offsetInBeginSection": 409,
          "offsetInEndSection": 559,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21453740",
          "text": "Melatonin can be effective for improving sleep quality without the adverse effects associated with hypnotic-sedatives.",
          "offsetInBeginSection": 750,
          "offsetInEndSection": 868,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36309969",
          "text": "The results indicate that differences between subjects do not require dose adjustments.",
          "offsetInBeginSection": 1864,
          "offsetInEndSection": 1951,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31953863",
          "text": "OBJECTIVE\nTo evaluate the dose-response relationship of daridorexant, a new dual orexin receptor antagonist, on sleep variables in subjects with insomnia disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843245",
          "text": "Many licensed drugs (including benzodiazepines, daridorexant, suvorexant, and trazodone) can be effective in the acute treatment of insomnia but are associated with poor tolerability, or information about long-term effects is not available.",
          "offsetInBeginSection": 3896,
          "offsetInEndSection": 4136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33305817",
          "text": "These results indicate that single and repeated doses of 50 mg daridorexant do not impair nighttime respiratory function and improve sleep in patients with mild and moderate OSA.",
          "offsetInBeginSection": 1556,
          "offsetInEndSection": 1734,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32341187",
          "text": "CLASSIFICATION OF EVIDENCE\nThis study provides Class I evidence that, for elderly people with insomnia, daridorexant reduced WASO.",
          "offsetInBeginSection": 1590,
          "offsetInEndSection": 1720,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32778207",
          "text": " dual orexin receptor antagonist. Daridorexant successfully passed first pivotal phase 3 clinical trial in April 2020 for the treatment of insomnia di",
          "offsetInBeginSection": 553,
          "offsetInEndSection": 703,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32603512",
          "text": "Daridorexant is a dual orexin receptor antagonist in clinical development for the treatment of insomnia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34121345",
          "text": "The aim of this study was to evaluate the impact of renal impairment on the pharmacokinetics (PKs), safety, and tolerability of daridorexant, a dual orexin receptor antagonist intended for the treatment of insomnia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
          "text": "We assess the safety and efficacy of this novel drug in the treatment of insomnia.",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 249,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31953863",
          "text": "INTERPRETATION\nDaridorexant induced a dose-dependent reduction in wake time after sleep onset in subjects with insomnia disorder (Clinicaltrials.gov NCT02839200).",
          "offsetInBeginSection": 1576,
          "offsetInEndSection": 1738,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36045942",
          "text": "Summary\nIn this article, we review the most recent data on insomnia treatments and summarize the safety and efficacy of daridorexant in treating insomnia.",
          "offsetInBeginSection": 1070,
          "offsetInEndSection": 1224,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32134851",
          "text": "Daridorexant dose-dependently reduced vigilance, attention, visuomotor coordination, and postural stability.",
          "offsetInBeginSection": 1241,
          "offsetInEndSection": 1349,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34994734",
          "text": "In the treatment of insomnia, trazodone is less effective than hypnotics in the treatment of sleep onset insomnia (i.e., disorders of falling asleep).",
          "offsetInBeginSection": 695,
          "offsetInEndSection": 845,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36046352",
          "text": "Objective: To review the safety, efficacy, and tolerability of daridorexant in treating insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34098518",
          "text": "Doses up to 50\u00a0mg daridorexant can be safely co-administered with citalopram.",
          "offsetInBeginSection": 1729,
          "offsetInEndSection": 1806,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32733587",
          "text": "CONCLUSIONS\nCurrently, findings support that CBT-I seems to be effective and safe for insomnia comorbid with depression to improve the insomnia condition, while it is unsure whether CBT-I could improve depression condition.",
          "offsetInBeginSection": 1733,
          "offsetInEndSection": 1956,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34480579",
          "text": "e, Drug-liking VAS scores were greater than placebo. Both control drugs and daridorexant were safe and the pharmacokinetics of daridorexant was consis",
          "offsetInBeginSection": 1335,
          "offsetInEndSection": 1485,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36046352",
          "text": "In addition, daridorexant appears to be as safe and effective in treating insomnia in patients of all ages including those \u226565 years of age.",
          "offsetInBeginSection": 1390,
          "offsetInEndSection": 1530,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36366844",
          "text": "anagement of insomnia. Beyond the effectiveness in insomnia, it has been successfully used in patients suffering from Obstructive sleep apnoea, Chroni",
          "offsetInBeginSection": 891,
          "offsetInEndSection": 1041,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34415378",
          "text": "Daridorexant is a new DORA that exhibited in phase 3 trials in insomnia not only a beneficial effect on sleep variables, measured objectively and assessed subjectively, but also an improvement in daytime functioning.",
          "offsetInBeginSection": 212,
          "offsetInEndSection": 428,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33305817",
          "text": "O2 during TST was 0.16% [90% CI: -0.21, 0.53]. Overall, there was no clinically relevant effect of daridorexant on AHI or SpO2-related data after sing",
          "offsetInBeginSection": 919,
          "offsetInEndSection": 1069,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35426136",
          "text": "llowing administration of daridorexant, a new dual orexin receptor antagonist developed to treat insomnia. Sixty healthy male and female subjects (50-",
          "offsetInBeginSection": 257,
          "offsetInEndSection": 407,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33417730",
          "text": "r sleep onset), reached expected plasma concentrations, and was safe and well tolerated. In conclusion, single and multiple doses of 50\u00a0mg daridorexan",
          "offsetInBeginSection": 1489,
          "offsetInEndSection": 1639,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35762946",
          "text": "r insomnia (CBTi) might be an effective treatment, no controlled studies had been conducted to date. This randomised controlled trial evaluated the be",
          "offsetInBeginSection": 139,
          "offsetInEndSection": 289,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306405",
          "text": "CONCLUSION\nThese results suggest safe use of daridorexant in patients with mild to moderate OSA.",
          "offsetInBeginSection": 1569,
          "offsetInEndSection": 1665,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34371524",
          "text": ".73), respectively. tmax remained unaffected. All treatments containing daridorexant were well tolerated.\n\n\nCONCLUSION\nDaridorexant 50\u2009mg can be admin",
          "offsetInBeginSection": 1411,
          "offsetInEndSection": 1561,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843245",
          "text": "nce in network meta-analysis (CINeMA) framework. Primary outcomes were efficacy (ie, quality of sleep measured by any self-rated scale), treatment dis",
          "offsetInBeginSection": 928,
          "offsetInEndSection": 1078,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33205362",
          "text": "BACKGROUND\nDaridorexant\u00a0(ACT-541468) is a potent dual orexin receptor antagonist under development for the treatment of sleep disorders.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32134851",
          "text": "lopment for the treatment of sleep disorders. Thus far, it has not yet been studied in Japanese subjects. Study objectives were to evaluate the pharma",
          "offsetInBeginSection": 76,
          "offsetInEndSection": 226,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36098936",
          "text": "CONCLUSIONS\nIn older patients with insomnia, as in younger patients, the efficacy of daridorexant is maximal on night-time and daytime variables at the higher dose of 50 mg.",
          "offsetInBeginSection": 2998,
          "offsetInEndSection": 3171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36098936",
          "text": "CONCLUSIONS\nIn older patients with insomnia, as in younger patients, the efficacy of daridorexant is maximal on night-time and daytime variables at the higher dose of 50 mg.",
          "offsetInBeginSection": 2998,
          "offsetInEndSection": 3171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32901578",
          "text": "Dual orexin receptor antagonists (DORAs) have been approved for the treatment of insomnia disorders (suvorexant, lemborexant) and drugs with a distinctive profile (daridorexant) or orexin-2 receptor selectivity (seltorexant) are in development.",
          "offsetInBeginSection": 179,
          "offsetInEndSection": 423,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31029189",
          "text": "Cognitive behavioral treatment for insomnia (CBTI) is an effective treatment of insomnia; however, there are insufficient CBTI providers for the 10% to 25% of the population who have insomnia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35972717",
          "text": "nsomnia, while lemborexant and daridorexant were still being validated in primary insomnia. Almorexant is now mainly used as a commercial specific inh",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 413,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33417730",
        "http://www.ncbi.nlm.nih.gov/pubmed/35972717",
        "http://www.ncbi.nlm.nih.gov/pubmed/33205362",
        "http://www.ncbi.nlm.nih.gov/pubmed/34994734",
        "http://www.ncbi.nlm.nih.gov/pubmed/36309969",
        "http://www.ncbi.nlm.nih.gov/pubmed/35065036",
        "http://www.ncbi.nlm.nih.gov/pubmed/33305817",
        "http://www.ncbi.nlm.nih.gov/pubmed/32937014",
        "http://www.ncbi.nlm.nih.gov/pubmed/21453740",
        "http://www.ncbi.nlm.nih.gov/pubmed/35306405",
        "http://www.ncbi.nlm.nih.gov/pubmed/35843245",
        "http://www.ncbi.nlm.nih.gov/pubmed/32778207",
        "http://www.ncbi.nlm.nih.gov/pubmed/34480579",
        "http://www.ncbi.nlm.nih.gov/pubmed/34121345",
        "http://www.ncbi.nlm.nih.gov/pubmed/31029189",
        "http://www.ncbi.nlm.nih.gov/pubmed/34098518",
        "http://www.ncbi.nlm.nih.gov/pubmed/36098936",
        "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
        "http://www.ncbi.nlm.nih.gov/pubmed/32134851",
        "http://www.ncbi.nlm.nih.gov/pubmed/35762946",
        "http://www.ncbi.nlm.nih.gov/pubmed/35426136",
        "http://www.ncbi.nlm.nih.gov/pubmed/34371524",
        "http://www.ncbi.nlm.nih.gov/pubmed/36098753",
        "http://www.ncbi.nlm.nih.gov/pubmed/34415378",
        "http://www.ncbi.nlm.nih.gov/pubmed/32733587",
        "http://www.ncbi.nlm.nih.gov/pubmed/36366844",
        "http://www.ncbi.nlm.nih.gov/pubmed/36144776",
        "http://www.ncbi.nlm.nih.gov/pubmed/32603512",
        "http://www.ncbi.nlm.nih.gov/pubmed/36054921",
        "http://www.ncbi.nlm.nih.gov/pubmed/36046352",
        "http://www.ncbi.nlm.nih.gov/pubmed/32341187",
        "http://www.ncbi.nlm.nih.gov/pubmed/32901578",
        "http://www.ncbi.nlm.nih.gov/pubmed/34331678",
        "http://www.ncbi.nlm.nih.gov/pubmed/36045942",
        "http://www.ncbi.nlm.nih.gov/pubmed/31953863"
      ]
    },
    {
      "id": "6422ee03690f196b51000046",
      "type": "factoid",
      "body": "What cells produce erythroferrone?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31723763",
          "text": "Here the hormone erythroferrone, produced by erythroblasts, acts on hepatocytes to suppress hepcidin production, and thereby increase dietary iron absorption and mobilization from stores.",
          "offsetInBeginSection": 825,
          "offsetInEndSection": 1012,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30097509",
          "text": "Erythropoietin (EPO) enhances erythroferrone (ERFE) synthesis by erythroblasts, and ERFE suppresses hepatic hepcidin production through an unknown mechanism.",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 274,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28739636",
          "text": "Erythroferrone (ERFE) is a glycoprotein hormone secreted by erythroblasts in response to stimulation by erythropoietin (EPO).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35464433",
          "text": "Erythroferrone is a recently identified erythroid regulator produced by erythroblasts in the mammalian bone marrow and extramedullary sites, known to be induced in conditions of anemia or blood loss.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24880340",
          "text": "pcidin suppression during stress erythropoiesis. ERFE is produced by erythroblasts in response to erythropoietin. ERFE-deficient mice fail to suppress",
          "offsetInBeginSection": 305,
          "offsetInEndSection": 455,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28629515",
          "text": "Among the number of factors proposed as mediators linking erythropoiesis with liver hepcidin suppression, erythroferrone, a hormone produced and secreted by erythroid precursors, appears the best candidate.",
          "offsetInBeginSection": 1033,
          "offsetInEndSection": 1239,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35628152",
          "text": "Erythroferrone, a factor produced and secreted by erythroid precursors in response to erythropoietin, has been identified and characterized as a suppressor of hepcidin synthesis to allow iron mobilization and facilitate erythropoiesis.",
          "offsetInBeginSection": 894,
          "offsetInEndSection": 1129,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31846624",
          "text": " blood islands where initial erythropoiesis occurs and later in circulating blood cells. ERFE knockdown does not alter the expression of etv.2, aplnr ",
          "offsetInBeginSection": 624,
          "offsetInEndSection": 774,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27161430",
          "text": "ency, hypoxia and EPO treatment. Erythroferrone, produced by EPO-stimulated erythropoiesis, inhibits hepcidin only when the activity of BMP/SMAD pathw",
          "offsetInBeginSection": 1315,
          "offsetInEndSection": 1465,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31808893",
          "text": "Furthermore, hepcidin regulation by erythropoiesis is attributed in large part to a bone marrow-derived hormone erythroferrone.",
          "offsetInBeginSection": 494,
          "offsetInEndSection": 621,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29073189",
          "text": "The lack of effect of erythropoietin on hepcidin expression in mask mice can not be explained by changes in erythroferrone synthesis, as splenic erythroferrone content increased after erythropoietin administration in both C57BL/6 and mask mice.",
          "offsetInBeginSection": 1657,
          "offsetInEndSection": 1901,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26494918",
          "text": "In this issue of Blood, Kautz et al show that the ablation of the erythroid-derived factor erythroferrone (ERFE), which has been shown to be highly expressed in \u03b2-thalassemic mice, restores hepcidin levels and corrects iron overload.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34827208",
          "text": "Intense physical activity contributes to an increased demand for red blood cells, which transport oxygen to working muscles.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33888681",
          "text": "Differentially expressed LIF affects the metabolism of Schwann cells and negatively regulates ERFE (Erythroferrone).",
          "offsetInBeginSection": 817,
          "offsetInEndSection": 933,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28438754",
          "text": "Epoetin alfa (EPO) robustly induced bone marrow erythroferrone (Fam132b) mRNA in control and Smad1;Smad5;Cre mice but suppressed hepcidin only in control mice.",
          "offsetInBeginSection": 1228,
          "offsetInEndSection": 1387,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34538261",
          "text": "BACKGROUND\nIn ineffective erythropoiesis, hepcidin synthesis is suppressed by erythroid regulators, namely erythroferrone and growth differentiation factor-15.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978826",
          "text": "In mice, erythroferrone, secreted from erythroblasts, suppresses hepcidin expression.",
          "offsetInBeginSection": 655,
          "offsetInEndSection": 740,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31649559",
          "text": "The paradigm is non-transfusion-dependent thalassemia where the release of erythroferrone from the expanded pool of immature erythroid cells results in hepcidin suppression and secondary iron overload that in turn worsens ineffective erythropoiesis and anemia.",
          "offsetInBeginSection": 1704,
          "offsetInEndSection": 1964,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33372284",
          "text": "When the release of erythropoietin from the kidney stimulates the production of new red blood cells, it also increases the synthesis of ERFE in bone marrow erythroblasts.",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 313,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30232784",
          "text": "In CKD mice, levels of erythroferrone mRNA in BM and splenic cells were significantly decreased, and MafB protein levels in BM cells were significantly increased.",
          "offsetInBeginSection": 674,
          "offsetInEndSection": 836,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28666715",
          "text": "This review summarizes the current knowledge on the role of erythroferrone in iron metabolism, starting from experimental results, obtained mainly on mouse models, and related to iron overload in \u03b2-thalassemia, iron disturbances during anemia of chronic diseases and chronic renal failure.",
          "offsetInBeginSection": 883,
          "offsetInEndSection": 1172,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26494918",
        "http://www.ncbi.nlm.nih.gov/pubmed/28629515",
        "http://www.ncbi.nlm.nih.gov/pubmed/34538261",
        "http://www.ncbi.nlm.nih.gov/pubmed/35464433",
        "http://www.ncbi.nlm.nih.gov/pubmed/28666715",
        "http://www.ncbi.nlm.nih.gov/pubmed/28438754",
        "http://www.ncbi.nlm.nih.gov/pubmed/24880340",
        "http://www.ncbi.nlm.nih.gov/pubmed/30232784",
        "http://www.ncbi.nlm.nih.gov/pubmed/35628152",
        "http://www.ncbi.nlm.nih.gov/pubmed/31808893",
        "http://www.ncbi.nlm.nih.gov/pubmed/34827208",
        "http://www.ncbi.nlm.nih.gov/pubmed/27161430",
        "http://www.ncbi.nlm.nih.gov/pubmed/31649559",
        "http://www.ncbi.nlm.nih.gov/pubmed/33888681",
        "http://www.ncbi.nlm.nih.gov/pubmed/28978826",
        "http://www.ncbi.nlm.nih.gov/pubmed/31723763",
        "http://www.ncbi.nlm.nih.gov/pubmed/33372284",
        "http://www.ncbi.nlm.nih.gov/pubmed/30097509",
        "http://www.ncbi.nlm.nih.gov/pubmed/29073189",
        "http://www.ncbi.nlm.nih.gov/pubmed/28739636",
        "http://www.ncbi.nlm.nih.gov/pubmed/31846624"
      ]
    },
    {
      "id": "6429f86657b1c7a31500000d",
      "type": "summary",
      "body": "What is the role of the Mediator in gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10611325",
          "text": "Therefore, the gene-specific function of Mediator as an integrator of transcriptional regulatory signals is evolutionarily conserved and is essential for C. elegans development.",
          "offsetInBeginSection": 771,
          "offsetInEndSection": 948,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21854862",
          "text": "The Mediator complex serves a crucial function in gene regulation, forming a link between gene-specific transcription factors and RNA polymerase II.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16885160",
          "text": "ChREBP and Mlx dimerize and function together as a glucose-responsive transcription factor to regulate target genes, such as liver-type pyruvate kinase, acetyl-CoA carboxylase 1, and fatty acid synthase.",
          "offsetInBeginSection": 204,
          "offsetInEndSection": 407,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21854862",
        "http://www.ncbi.nlm.nih.gov/pubmed/10611325",
        "http://www.ncbi.nlm.nih.gov/pubmed/16885160"
      ]
    },
    {
      "id": "6415c0df690f196b51000010",
      "type": "factoid",
      "body": "What does FBDD stand for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23410157",
          "text": " the chances of identifying active molecules. Among them, the Fragment Based Drug Design (FBDD) is surely worth noting. The FBDD entails the screening",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 319,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20345344",
          "text": "In the last decade, fragment-based drug discovery (FBDD) has evolved from a novel approach in the search of new hits to a valuable alternative to the high-throughput screening (HTS) campaigns of many pharmaceutical companies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348623",
          "text": "Fragment-Based Drug Discovery (FBDD) is a strategy to develop potent lead molecules and is frequently used in drug discovery projects of the pharmaceutical industry.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25420726",
          "text": "Fragment-based drug discovery (FBDD) has caused a revolution in the process of drug discovery and design, with many FBDD leads being developed into clinical trials or approved in the past few years.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36044560",
          "text": "The technique of Fragment-Based Drug Design (FBDD) considers the interactions of different moieties of molecules with biological targets for the rational construction of potential drugs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32339336",
          "text": "Fragment-based drug discovery (FBDD) has become an established approach for the generation of early lead candidates.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22459076",
          "text": "Fragment-based drug discovery (FBDD) has become established in both industry and academia as an alternative approach to high-throughput screening for the generation of chemical leads for drug targets.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21482811",
          "text": "Fragment-based drug discovery (FBDD) has proven to be an effective means of producing high-quality chemical ligands as starting points for drug-discovery pursuits.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32133344",
          "text": "Fragment-based drug (or lead) discovery (FBDD or FBLD) has developed in the last two decades to become a successful key technology in the pharmaceutical industry for early stage drug discovery and development.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32850968",
          "text": "Fragment-based drug discovery (FBDD) is a powerful method to develop potent small-molecule compounds starting from fragments binding weakly to targets.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20190516",
          "text": "Fragment-Based Drug Discovery (FBDD) has been recognized as a newly emerging lead discovery methodology that involves biophysical fragment screening and chemistry-driven fragment-to-lead stages.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35749608",
          "text": "Fragment-based drug discovery (FBDD) is now established as a complementary approach to high-throughput screening (HTS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35234147",
          "text": "Over the last two decades, fragment-based drug discovery (FBDD) has emerged as an effective and efficient method to identify new chemical scaffolds for the development of lead compounds.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32592867",
          "text": "Fragment-based drug discovery (FBDD) is an innovative approach, progressively more applied in the academic and industrial context, to enhance hit identification for previously considered undruggable biological targets.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22827744",
          "text": "WHAT THE READER WILL GAIN\nThe reader is introduced to various computational methods that are used for in silico FBDD, the fragment library composition for this technique, special applications used to identify binding sites on the surface of proteins and how to assess the druggability of these sites.",
          "offsetInBeginSection": 598,
          "offsetInEndSection": 898,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27124799",
          "text": "Fragment-based drug discovery (FBDD) is well suited for discovering both drug leads and chemical probes of protein function; it can cover broad swaths of chemical space and allows the use of creative chemistry.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21371601",
          "text": "Fragment-based drug discovery (FBDD) has become increasingly popular over the last decade as an alternate lead generation tool to HTS approaches.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31387220",
          "text": "Fragment-based drug discovery (FBDD) has become a major strategy to derive novel lead candidates for various therapeutic targets, as it promises efficient exploration of chemical space by employing fragment-sized (MW < 300) compounds.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34123246",
          "text": "Fragment-based drug discovery (FBDD) is a powerful strategy for the identification of new bioactive molecules.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18510103",
          "text": "Fragment-based drug discovery (FBDD) is established as an alternative approach to high-throughput screening for generating novel small molecule drug candidates.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28240184",
          "text": "Fragment-based drug discovery (FBDD) is a broadly used strategy in structure-guided ligand design, whereby low-molecular weight hits move from lead-like to drug-like compounds.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21428828",
          "text": "The use of fragment-based drug discovery (FBDD) has increased in the last decade due to the encouraging results obtained to date.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19443265",
          "text": "Fragment-based drug discovery (FBDD) represents a logical and efficient approach to lead discovery and optimisation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27417849",
          "text": "After 20 years of sometimes quiet growth, fragment-based drug discovery (FBDD) has become mainstream.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22430881",
          "text": "Computational FBDD can be used independently or in parallel with experimental FBDD for efficiently generating and optimizing leads.",
          "offsetInBeginSection": 842,
          "offsetInEndSection": 973,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26372893",
          "text": "The recent literature reveals that fragment-based drug design/discovery (FBDD) has become an effective alternative to conventional high-throughput screening strategies for drug discovery.",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 364,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34916022",
          "text": "Fragment-based drug discovery (FBDD) emerged as a disruptive technology and became established during the last two decades.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32345095",
          "text": "Fragment-based drug discovery (FBDD) has come of age in the last decade with the FDA approval of four fragment-derived drugs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22430881",
          "text": "Fragment-based drug design (FBDD) is a promising approach for the discovery and optimization of lead compounds.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33226222",
          "text": "These include covalent FBDD, FBDD for the stabilization of proteins or protein-protein interactions, FBDD for enzyme activators, new screening technologies, and advances in library design and chemical synthesis.",
          "offsetInBeginSection": 576,
          "offsetInEndSection": 787,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27452339",
          "text": "Fragment-based drug design (FBDD) has emerged as a mainstream approach for the rapid and efficient identification of building blocks that can be used to develop high-affinity ligands against protein targets.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21378847",
          "text": "FBDD identifies low-molecular-weight ligands (\u223c150 Da) that bind to biologically important macromolecules.",
          "offsetInBeginSection": 436,
          "offsetInEndSection": 542,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18510103",
        "http://www.ncbi.nlm.nih.gov/pubmed/32345095",
        "http://www.ncbi.nlm.nih.gov/pubmed/20345344",
        "http://www.ncbi.nlm.nih.gov/pubmed/27124799",
        "http://www.ncbi.nlm.nih.gov/pubmed/32592867",
        "http://www.ncbi.nlm.nih.gov/pubmed/22459076",
        "http://www.ncbi.nlm.nih.gov/pubmed/34348623",
        "http://www.ncbi.nlm.nih.gov/pubmed/27452339",
        "http://www.ncbi.nlm.nih.gov/pubmed/23410157",
        "http://www.ncbi.nlm.nih.gov/pubmed/32850968",
        "http://www.ncbi.nlm.nih.gov/pubmed/20190516",
        "http://www.ncbi.nlm.nih.gov/pubmed/34123246",
        "http://www.ncbi.nlm.nih.gov/pubmed/28240184",
        "http://www.ncbi.nlm.nih.gov/pubmed/32339336",
        "http://www.ncbi.nlm.nih.gov/pubmed/36044560",
        "http://www.ncbi.nlm.nih.gov/pubmed/31387220",
        "http://www.ncbi.nlm.nih.gov/pubmed/26372893",
        "http://www.ncbi.nlm.nih.gov/pubmed/21371601",
        "http://www.ncbi.nlm.nih.gov/pubmed/27417849",
        "http://www.ncbi.nlm.nih.gov/pubmed/34916022",
        "http://www.ncbi.nlm.nih.gov/pubmed/21378847",
        "http://www.ncbi.nlm.nih.gov/pubmed/35234147",
        "http://www.ncbi.nlm.nih.gov/pubmed/25420726",
        "http://www.ncbi.nlm.nih.gov/pubmed/22430881",
        "http://www.ncbi.nlm.nih.gov/pubmed/21482811",
        "http://www.ncbi.nlm.nih.gov/pubmed/21428828",
        "http://www.ncbi.nlm.nih.gov/pubmed/35749608",
        "http://www.ncbi.nlm.nih.gov/pubmed/19443265",
        "http://www.ncbi.nlm.nih.gov/pubmed/33226222",
        "http://www.ncbi.nlm.nih.gov/pubmed/22827744",
        "http://www.ncbi.nlm.nih.gov/pubmed/32133344"
      ]
    },
    {
      "id": "64041dae201352f04a00001d",
      "type": "yesno",
      "body": "Is deucravacitinib effective for psoriasis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34239295",
          "text": "The latest IL-17 and IL-23 inhibitors include bimekizumab, netakimab and mirikizumab as well as oral small molecules, such as deucravacitinib, a tyrosine kinase 2 selective inhibitor, and piclidenoson, an agonist of the Gi protein-associated A3 adenosine receptor.",
          "offsetInBeginSection": 1260,
          "offsetInEndSection": 1524,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36369798",
          "text": " (OR 1.6 [95% CI 0.8, 2.9]; nominal P\u00a0=\u00a00.08 versus placebo). Response rates were higher with deucravacitinib treatment for BICLA, CLASI-50, LLDAS, an",
          "offsetInBeginSection": 1188,
          "offsetInEndSection": 1338,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36369798",
          "text": "OBJECTIVE\nTo assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in a phase II trial in adult patients with active systemic lupus erythematosus (SLE).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36115523",
          "text": "vs 8.6% and 33.9%; P < 0.0001 for both). Efficacy was maintained until Week 52 with continuous deucravacitinib. The most frequent adverse event (AE) w",
          "offsetInBeginSection": 832,
          "offsetInEndSection": 982,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35820547",
          "text": " oral psoriasis treatments are needed.\n\n\nOBJECTIVE\nTo compare the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibit",
          "offsetInBeginSection": 36,
          "offsetInEndSection": 186,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35960487",
          "text": "so reported by patients, with greater impact on itch. Deucravacitinib was well tolerated and safe. There were no reports of serious infections, thromb",
          "offsetInBeginSection": 1115,
          "offsetInEndSection": 1265,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36469536",
          "text": "Deucravacitinib was generally well tolerated and safe compared to placebo and apremilast.",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 710,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35241426",
          "text": "OBJECTIVE\nTo evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34767869",
          "text": "of deucravacitinib versus lower doses or placebo.\n\n\nCONCLUSION\nRobust clinical efficacy with deucravacitinib treatment was associated with decreases i",
          "offsetInBeginSection": 1563,
          "offsetInEndSection": 1713,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35820547",
          "text": "CONCLUSION\nDeucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.",
          "offsetInBeginSection": 1191,
          "offsetInEndSection": 1347,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35820547",
          "text": "and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < 0.0001). Efficacy improved beyond Week 16 and was maintained through Week 52. Adverse event ",
          "offsetInBeginSection": 902,
          "offsetInEndSection": 1052,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15655140",
          "text": "CONCLUSIONS\nThe combination of 0.1% tacrolimus ointment and 6% salicylic acid gel is an effective treatment for psoriasis.",
          "offsetInBeginSection": 1468,
          "offsetInEndSection": 1590,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34471993",
          "text": "s the closely related Janus kinases (JAKs) 1/2/3. Deucravacitinib was efficacious in phase 2 and 3 psoriasis trials, without clinical or laboratory pa",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 436,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21221197",
          "text": "nts' quality of life, and physical and mental function. Established treatments can be effective but are also limited by tolerability, convenience, cos",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 322,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36115523",
          "text": "CONCLUSION\nDeucravacitinib demonstrated superiority versus placebo and apremilast and was well tolerated in adults with moderate to severe plaque psoriasis.",
          "offsetInBeginSection": 1200,
          "offsetInEndSection": 1356,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35747941",
          "text": "It is unclear whether recent safety concerns (ie, elevated rates of lung cancer and lymphoma) related to similar medications (ie, other JAK inhibitors) are shared with this novel TYK2 inhibitor.",
          "offsetInBeginSection": 153,
          "offsetInEndSection": 347,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35001782",
          "text": "Deucravacitinib, an allosteric TYK2 inhibitor discovered by BMS, is the most advanced molecule in clinical development and in 2021, it received positive phase 3 data for the treatment of plaque psoriasis. .",
          "offsetInBeginSection": 849,
          "offsetInEndSection": 1055,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35280877",
          "text": "Conclusion\nThere is increasing evidence on the use of drugs targeting the JAK/STAT pathway as a treatment for psoriasis, although they are in the early phases of development.",
          "offsetInBeginSection": 2930,
          "offsetInEndSection": 3104,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36373503",
          "text": "rather than other members of this kinase family. Deucravacitinib has demonstrated safety and efficacy in moderate to severe plaque psoriasis in clinic",
          "offsetInBeginSection": 637,
          "offsetInEndSection": 787,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35280877",
          "text": "funding or by those related to them. Only tofacitinib and deucravacitinib have undergone phase III clinical trials, being the only ones tested with ac",
          "offsetInBeginSection": 1847,
          "offsetInEndSection": 1997,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36453809",
          "text": " deucravacitinib, a new oral drug which selectively inhibits TYK2, granting it a low risk of off-target effects. Two phase 3, 52-week trials evaluated",
          "offsetInBeginSection": 465,
          "offsetInEndSection": 615,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35025062",
          "text": "INTRODUCTION\nDeucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35592052",
          "text": "There is no cure for psoriasis. A psoriasis patient was treated with Histobulin\u2122. The patient's clinical symptoms and signs disappeared after the eigh",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36115523",
          "text": "BACKGROUND\nDeucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, inhibits cytokine signaling in psoriasis pathogenesis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36369798",
          "text": "CONCLUSION\nDeucravacitinib treatment elicited higher response rates for SRI-4 and other end points compared with placebo, with an acceptable safety profile, in adult patients with active SLE.",
          "offsetInBeginSection": 1725,
          "offsetInEndSection": 1916,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33419149",
          "text": "Oral vitamin D supplementation might be effective as an adjuvant treatment option in psoriasis.",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 190,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401743",
          "text": "The Marketing Authorisation Application for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis has been validated in the EU, and clinical development of the drug for the treatment of multiple immune-mediated diseases is underway in numerous countries worldwide.",
          "offsetInBeginSection": 853,
          "offsetInEndSection": 1148,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15090021",
          "text": "CONCLUSION\nInfliximab is not only an effective agent in the treatment of psoriasis but appears to have a very rapid onset of action.",
          "offsetInBeginSection": 950,
          "offsetInEndSection": 1082,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36325947",
          "text": "h favorable PK and safety profiles. Deucravacitinib is a promising therapeutic option for immune-mediated diseases, including Crohn's disease, psorias",
          "offsetInBeginSection": 995,
          "offsetInEndSection": 1145,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34224773",
          "text": "n receptors. Deucravacitinib, which is an oral, selective inhibitor that binds to the regulatory domain of TYK2, and brepocitinib (PF-06700841) and PF",
          "offsetInBeginSection": 762,
          "offsetInEndSection": 912,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35566756",
          "text": "However, little evidence is available on the use of this biologic in psoriasis in difficult-to-treat locations.",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 236,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16164712",
          "text": "CONCLUSIONS\nThese results confirm that synchronous balneophototherapy is an effective treatment modality for different clinical types of psoriasis.",
          "offsetInBeginSection": 1991,
          "offsetInEndSection": 2138,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35960487",
          "text": "This article aims to review the current knowledge on deucravacitinib, a new oral drug that selectively inhibits TYK2, granting it a low risk of off-target effects.",
          "offsetInBeginSection": 328,
          "offsetInEndSection": 491,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34767869",
          "text": "Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, blocks IL-23, IL-12, and type I IFN signaling in cellular assays.",
          "offsetInBeginSection": 188,
          "offsetInEndSection": 318,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23515267",
          "text": "Newer biological agents have been shown to be more effective than traditional therapies.",
          "offsetInBeginSection": 225,
          "offsetInEndSection": 313,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35182043",
          "text": "Deucravacitinib had no clinically relevant effect on other parameters and was generally well tolerated.",
          "offsetInBeginSection": 988,
          "offsetInEndSection": 1091,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15655140",
          "text": "BACKGROUND\nWhile oral tacrolimus is effective for the treatment of psoriasis, tacrolimus ointment has shown only spotty efficacy in the treatment of plaque psoriasis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22016273",
          "text": "CONCLUSION\nPTU significantly clears the lesions in psoriasis with minimal adverse effects.",
          "offsetInBeginSection": 1346,
          "offsetInEndSection": 1436,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36453809",
          "text": "Deucravacitinib has the potential to become a safe, effective, and well-tolerated treatment for patients with moderate-to-severe disease.",
          "offsetInBeginSection": 1181,
          "offsetInEndSection": 1318,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35025062",
          "text": "Deucravacitinib has the potential to become a promising new oral therapy for this condition.",
          "offsetInBeginSection": 1687,
          "offsetInEndSection": 1779,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34471993",
          "text": "highly selective inhibition of TYK2 and not JAK 1/2/3. Tofacitinib, upadacitinib, and baricitinib variably inhibit JAK 1/2/3 but not TYK2. These results indicate that deucravacitinib is a distinct class of kinase inhibitor",
          "offsetInBeginSection": 1913,
          "offsetInEndSection": 2135,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25227750",
          "text": "Therefore there is still a need for new therapies with better efficacy and less adverse effects.",
          "offsetInBeginSection": 357,
          "offsetInEndSection": 453,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35280877",
          "text": "The development of drugs targeting the JAK/STAT signaling pathway presents new treatment opportunities for psoriasis.",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 308,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818503",
          "text": "Therefore, a rapid and effective agent must be utilized to treat the acute phase, followed by safe long-term therapy for maintenance.",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 441,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35182043",
          "text": "therapeutic dose) had a clinically relevant effect on the corrected QT interval and other electrocardiographic (ECG) parameters. Subjects received 1 o",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 445,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22016273",
          "text": "In this scenario, propylthiouracil (PTU), an antithyroid thioureylene has been shown to be effective in psoriasis which satisfies the above criteria.",
          "offsetInBeginSection": 388,
          "offsetInEndSection": 537,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35960487",
          "text": "Despite advances in the treatment of psoriasis, namely among biologic agents, an oral, effective and safe new drug can bring several advantages to prescribers and patients.",
          "offsetInBeginSection": 1443,
          "offsetInEndSection": 1615,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267724",
          "text": "Biologics for psoriasis are directed at more specific targets, have a better safety profile, are better tolerated, and are more effective than conventional systemic agents.",
          "offsetInBeginSection": 157,
          "offsetInEndSection": 329,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35182043",
          "text": "This study demonstrated that a single oral dose of deucravacitinib 12 or 36 mg did not produce a clinically relevant effect on the corrected QT interval or other measured ECG parameters in healthy adults.",
          "offsetInBeginSection": 1364,
          "offsetInEndSection": 1568,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267735",
          "text": "The findings demonstrate that methotrexate is a relatively well-tolerated and effective treatment for palmoplantar psoriasis, amenable as either monotherapy or in combination with other systemic agents.",
          "offsetInBeginSection": 276,
          "offsetInEndSection": 478,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36469536",
        "http://www.ncbi.nlm.nih.gov/pubmed/34239295",
        "http://www.ncbi.nlm.nih.gov/pubmed/36369798",
        "http://www.ncbi.nlm.nih.gov/pubmed/35820547",
        "http://www.ncbi.nlm.nih.gov/pubmed/34767869",
        "http://www.ncbi.nlm.nih.gov/pubmed/34471993",
        "http://www.ncbi.nlm.nih.gov/pubmed/16164712",
        "http://www.ncbi.nlm.nih.gov/pubmed/35592052",
        "http://www.ncbi.nlm.nih.gov/pubmed/36325947",
        "http://www.ncbi.nlm.nih.gov/pubmed/26267735",
        "http://www.ncbi.nlm.nih.gov/pubmed/35182043",
        "http://www.ncbi.nlm.nih.gov/pubmed/22016273",
        "http://www.ncbi.nlm.nih.gov/pubmed/36373503",
        "http://www.ncbi.nlm.nih.gov/pubmed/35747941",
        "http://www.ncbi.nlm.nih.gov/pubmed/36453809",
        "http://www.ncbi.nlm.nih.gov/pubmed/26267724",
        "http://www.ncbi.nlm.nih.gov/pubmed/35025062",
        "http://www.ncbi.nlm.nih.gov/pubmed/23515267",
        "http://www.ncbi.nlm.nih.gov/pubmed/36401743",
        "http://www.ncbi.nlm.nih.gov/pubmed/35001782",
        "http://www.ncbi.nlm.nih.gov/pubmed/35241426",
        "http://www.ncbi.nlm.nih.gov/pubmed/15655140",
        "http://www.ncbi.nlm.nih.gov/pubmed/35960487",
        "http://www.ncbi.nlm.nih.gov/pubmed/36115523",
        "http://www.ncbi.nlm.nih.gov/pubmed/35280877",
        "http://www.ncbi.nlm.nih.gov/pubmed/15090021",
        "http://www.ncbi.nlm.nih.gov/pubmed/21221197",
        "http://www.ncbi.nlm.nih.gov/pubmed/34224773",
        "http://www.ncbi.nlm.nih.gov/pubmed/33419149",
        "http://www.ncbi.nlm.nih.gov/pubmed/21818503",
        "http://www.ncbi.nlm.nih.gov/pubmed/25227750",
        "http://www.ncbi.nlm.nih.gov/pubmed/35566756"
      ]
    },
    {
      "id": "6415b6eb690f196b5100000b",
      "type": "list",
      "body": "What processes do orexin/hypocretin neurons regulate?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32314734",
          "text": "e in the hypothalamus and project throughout the brain to regulate sleep/wakefulness. Ablation of orexin neurons decreases wakefulness and results in ",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 251,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34052808",
          "text": "However, cellular-resolution calcium imaging and optogenetic studies show that orexin neurons regulate self-generated and sensory-evoked movement on rapid, subsecond timescales.",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 410,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12106679",
          "text": "ypothalamic orexin/hypocretin-containing neurons in the control of sleep-wakefulness. To help determine if adenosine might play a role in the control ",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 272,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16731510",
          "text": "ote wakefulness (their loss causes narcolepsy) and also regulate metabolism and reward. Here we demonstrate that their inhibition by glucose is mediat",
          "offsetInBeginSection": 214,
          "offsetInEndSection": 364,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16054072",
          "text": " have emerged as instrumental in triggering arousal and regulating energy metabolism. The lack of hypocretin signaling is the cause of narcolepsy whil",
          "offsetInBeginSection": 64,
          "offsetInEndSection": 214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11532254",
          "text": "This peptide is believed to be involved in regulating feeding and wakefulness.",
          "offsetInBeginSection": 264,
          "offsetInEndSection": 342,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20307612",
          "text": "is a critical regulator of physiological processes including sleep/wakefulness and feeding. Using organotypic slice culture of rat hypothalamus, we fo",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 198,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10624957",
          "text": "Orexin (hypocretin) appears to play a role in the regulation of energy balances.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12495630",
          "text": "Neurons that release hypocretin/orexin modulate sleep, arousal, and energy homeostasis; the absence of hypocretin results in narcolepsy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22813966",
          "text": "hrough interactions with neuronal systems that regulate emotion, reward, and energy homeostasis. Here, we briefly summarize the progress of orexin/hyp",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 587,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32135427",
          "text": " to orchestrate diverse functions including sleep, reward processing, food intake, thermogenesis, and mood. Since the hypocretins/orexins were discove",
          "offsetInBeginSection": 97,
          "offsetInEndSection": 247,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17563364",
          "text": "These results suggest a new mechanism of how orexin/hypocretin networks generate homeostatically appropriate firing patterns.",
          "offsetInBeginSection": 1258,
          "offsetInEndSection": 1383,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20861370",
          "text": "Orexin neurons (hypocretin neurons) have a critical role in the regulation of sleep/wakefulness, especially in the maintenance of arousal.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10876067",
          "text": "tin-2) are hypothalamic peptides that regulate feeding behavior, energy metabolism, and sleep-wake cycle. We determined the distribution of orexin-A a",
          "offsetInBeginSection": 61,
          "offsetInEndSection": 211,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28025809",
          "text": "ntral nervous system to control sleep and arousal, circadian rhythms, metabolism, reward pathways, and other behaviors. Dysfunction of orexin/hypocret",
          "offsetInBeginSection": 298,
          "offsetInEndSection": 448,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30348769",
          "text": "in the hypothalamus play an essential role in sleep-wake control, feeding, reward, and energy homeostasis. The likelihood of anesthesia and sleep shar",
          "offsetInBeginSection": 42,
          "offsetInEndSection": 192,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454841",
          "text": "Compelling evidence indicates that hypocretin/orexin signaling regulates arousal, stress and reward-seeking behaviors.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20467915",
          "text": "ulated by various factors involved in regulation of energy homeostasis and sleep/wakefulness states. Bombesin receptor subtype 3 (BRS3) is an orphan r",
          "offsetInBeginSection": 265,
          "offsetInEndSection": 415,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26724374",
          "text": " are two neuropeptides that influence many behaviours, such as feeding, sleep or arousal. Orexin A/hypocretin-1 (OXA) and orexin B/hypocretin-2 (OXB) ",
          "offsetInBeginSection": 19,
          "offsetInEndSection": 169,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10191330",
          "text": "s and has been reported to increase food intake and regulate the neuroendocrine system. In the present paper, long descending axonal projections that ",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 222,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32804153",
          "text": "nance of arousal and contribute to the regulation of multiple homeostatic and behavioral processes. In this issue of the JCI, Tan and Hang et al. repo",
          "offsetInBeginSection": 96,
          "offsetInEndSection": 246,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19926811",
          "text": "These simulation results support the concept of state-dependent alterations of hypocretin/orexin effects as an important homeostatic process in sleep-wake regulation, although additional mechanisms can be involved.",
          "offsetInBeginSection": 1261,
          "offsetInEndSection": 1475,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15066149",
          "text": "These results demonstrate that orexins directly regulate NPY, POMC and glucose-responsive neurons in the ARC and VMH, in a manner reciprocal to leptin.",
          "offsetInBeginSection": 1428,
          "offsetInEndSection": 1579,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15066149",
          "text": "Here we show the effector neurons and signaling mechanisms for the orexigenic action of orexins in rats.",
          "offsetInBeginSection": 90,
          "offsetInEndSection": 194,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9920670",
          "text": "nism of action for hypocretin in the central regulation of metabolic and endocrine processes. The excitatory actions of hypocretin could increase NPY ",
          "offsetInBeginSection": 593,
          "offsetInEndSection": 743,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17563364",
          "text": "They are critical for normal stimulation of wakefulness and breathing: Orexin loss causes narcolepsy and compromises vital ventilatory adaptations.",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 264,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15848807",
          "text": "These neuroanatomical findings provide important insights into the neural pathways that regulate sleep/wakefulness states.",
          "offsetInBeginSection": 1026,
          "offsetInEndSection": 1148,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22256611",
          "text": " has close interactions with systems that regulate emotion, energy homeostasis, reward, and arousal. These observations suggest that orexin neurons ar",
          "offsetInBeginSection": 543,
          "offsetInEndSection": 693,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12946712",
          "text": "Hypocretin/orexin modulates sleep-wake state via actions across multiple terminal fields.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18784290",
          "text": "wn to participate in sleep regulation, energy homeostasis, drug addiction, motor regulation, stress response, and social behaviors. The elucidation of",
          "offsetInBeginSection": 237,
          "offsetInEndSection": 387,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21056546",
          "text": "exin) neuropeptide system coordinates the regulation of various physiological processes. A reduction in Nr6a1 expression was observed in hypocretin ne",
          "offsetInBeginSection": 32,
          "offsetInEndSection": 182,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36457878",
          "text": "Introduction\nIntroduction: Several studies have demonstrated that orexins may regulate different forms of affective and cognitive processes during wakefulness.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36457878",
          "text": "l hypothalamus (LH) in driving the reward pathway, sleep and awake circuits, decision making and psychotic disorders. But our knowledge towards the fu",
          "offsetInBeginSection": 1927,
          "offsetInEndSection": 2077,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10447804",
          "text": " that are synthesized in neurones of the lateral hypohalamus and stimulate food intake in rats. To clarify whether leptin may interact with hypocretin",
          "offsetInBeginSection": 55,
          "offsetInEndSection": 205,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28620314",
          "text": "Interestingly, orexinergic neurons show connections to regions involved in cognition and mood regulation, including hippocampus.",
          "offsetInBeginSection": 1238,
          "offsetInEndSection": 1366,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15978010",
          "text": "Orexin/hypocretin neurons in the lateral hypothalamus and adjacent perifornical area (LH/PFA) innervate midbrain dopamine (DA) neurons that project to corticolimbic sites and subserve psychostimulant-induced locomotor activity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11330208",
          "text": "Recent work indicates that the orexin/hypocretin-containing neurons of the lateral hypothalamus are involved in control of REM sleep phenomena, but site-specific actions in control of wakefulness have been less studied.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12211415",
          "text": "lassically involved in the control of feeding behavior, blood pressure and central regulation of immune function. Orexin-/hypocretin-containing neuron",
          "offsetInBeginSection": 519,
          "offsetInEndSection": 669,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17093123",
          "text": "At the cell body of the hypocretin/orexin neurons, adenosine inhibits voltage-dependent calcium currents without the induction of GIRK current.",
          "offsetInBeginSection": 1391,
          "offsetInEndSection": 1534,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16364191",
          "text": "Hypocretin/orexin neurons may thus directly translate rises and falls in body energy levels into different states of consciousness.",
          "offsetInBeginSection": 892,
          "offsetInEndSection": 1023,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28620314",
          "text": "Orexin neurons are \"multi-tasking\" neurons regulating a set of vital body functions, including sleep/wake states, feeding behavior, energy homeostasis, reward systems, cognition and mood.",
          "offsetInBeginSection": 303,
          "offsetInEndSection": 490,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11988773",
          "text": "Subsequent studies have illuminated many aspects of the circuitry of the hypocretin (also called orexin) system, which also influences hormone secretion and autonomic homeostasis, and have led to the hypothesis that most human narcolepsies result from an autoimmune attack against the hypocretin-producing neurons.",
          "offsetInBeginSection": 249,
          "offsetInEndSection": 563,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26322330",
          "text": "Hypocretin/orexin neurons regulate many behavioral functions, including addiction.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15848807",
          "text": "s hypothalamic neuropeptide plays a crucial role in regulating sleep/wakefulness states. However, very little is known about the synaptic input of ore",
          "offsetInBeginSection": 84,
          "offsetInEndSection": 234,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16904760",
          "text": "We propose that the current evidence indicates a dichotomy in orexin function, such that orexin neurons in the lateral hypothalamus regulate reward processing for both food and abused drugs, whereas those in the perifornical and dorsomedial hypothalamus regulate arousal and response to stress.",
          "offsetInBeginSection": 408,
          "offsetInEndSection": 702,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11532254",
          "text": "In this way, hypocretin, which is implicated in feeding, energy metabolism and wakefulness, serves to influence cognitive processes critical for the animal's survival.",
          "offsetInBeginSection": 1882,
          "offsetInEndSection": 2049,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17093123",
          "text": "ntain hypocretin/orexin have been established as important promoters of arousal. Deficiencies in the hypocretin/orexin system lead to narcolepsy. The ",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 198,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20861370",
          "text": "Together, these results suggest that orexin neurons form a positive-feedback circuit through indirect and direct pathways, which results in the preservation of the orexin neuron network at a high activity level and/or for a longer period.",
          "offsetInBeginSection": 978,
          "offsetInEndSection": 1216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9742163",
          "text": "ning the arcuate nucleus, suggesting a second function of hypocretin in hormone regulation. The widespread distribution of hypocretin axons, coupled w",
          "offsetInBeginSection": 1298,
          "offsetInEndSection": 1448,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19508695",
          "text": "However, orexin neurons from TASK1/3 knockout mice retained typical responses to glucose and pH, and the knockout animals showed normal food-anticipatory locomotor activity.",
          "offsetInBeginSection": 891,
          "offsetInEndSection": 1064,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36457878",
        "http://www.ncbi.nlm.nih.gov/pubmed/20861370",
        "http://www.ncbi.nlm.nih.gov/pubmed/11988773",
        "http://www.ncbi.nlm.nih.gov/pubmed/26322330",
        "http://www.ncbi.nlm.nih.gov/pubmed/10191330",
        "http://www.ncbi.nlm.nih.gov/pubmed/30348769",
        "http://www.ncbi.nlm.nih.gov/pubmed/12211415",
        "http://www.ncbi.nlm.nih.gov/pubmed/16731510",
        "http://www.ncbi.nlm.nih.gov/pubmed/20467915",
        "http://www.ncbi.nlm.nih.gov/pubmed/32804153",
        "http://www.ncbi.nlm.nih.gov/pubmed/34052808",
        "http://www.ncbi.nlm.nih.gov/pubmed/17563364",
        "http://www.ncbi.nlm.nih.gov/pubmed/21056546",
        "http://www.ncbi.nlm.nih.gov/pubmed/22813966",
        "http://www.ncbi.nlm.nih.gov/pubmed/16054072",
        "http://www.ncbi.nlm.nih.gov/pubmed/12106679",
        "http://www.ncbi.nlm.nih.gov/pubmed/10624957",
        "http://www.ncbi.nlm.nih.gov/pubmed/19926811",
        "http://www.ncbi.nlm.nih.gov/pubmed/15066149",
        "http://www.ncbi.nlm.nih.gov/pubmed/12946712",
        "http://www.ncbi.nlm.nih.gov/pubmed/11532254",
        "http://www.ncbi.nlm.nih.gov/pubmed/11330208",
        "http://www.ncbi.nlm.nih.gov/pubmed/26724374",
        "http://www.ncbi.nlm.nih.gov/pubmed/32314734",
        "http://www.ncbi.nlm.nih.gov/pubmed/16904760",
        "http://www.ncbi.nlm.nih.gov/pubmed/28025809",
        "http://www.ncbi.nlm.nih.gov/pubmed/17093123",
        "http://www.ncbi.nlm.nih.gov/pubmed/15848807",
        "http://www.ncbi.nlm.nih.gov/pubmed/20307612",
        "http://www.ncbi.nlm.nih.gov/pubmed/19508695",
        "http://www.ncbi.nlm.nih.gov/pubmed/9742163",
        "http://www.ncbi.nlm.nih.gov/pubmed/10876067",
        "http://www.ncbi.nlm.nih.gov/pubmed/12495630",
        "http://www.ncbi.nlm.nih.gov/pubmed/32135427",
        "http://www.ncbi.nlm.nih.gov/pubmed/18784290",
        "http://www.ncbi.nlm.nih.gov/pubmed/10447804",
        "http://www.ncbi.nlm.nih.gov/pubmed/16364191",
        "http://www.ncbi.nlm.nih.gov/pubmed/29454841",
        "http://www.ncbi.nlm.nih.gov/pubmed/9920670",
        "http://www.ncbi.nlm.nih.gov/pubmed/15978010",
        "http://www.ncbi.nlm.nih.gov/pubmed/28620314",
        "http://www.ncbi.nlm.nih.gov/pubmed/22256611"
      ]
    },
    {
      "id": "6428da47690f196b51000051",
      "type": "yesno",
      "body": "Can the epigenetic status of introns affect gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18319396",
          "text": "However, not all introns affect gene expression, and direct testing is currently the only way to identify stimulatory introns.",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 212,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24213601",
          "text": "Epigenetic modifications affect gene expression and thereby govern a wide range of biological processes such as differentiation, development and tumorigenesis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32187179",
          "text": "n, and their contributions to genetic diversity and evolution, remain poorly understood. In this study, we investigated the genome-wide distribution o",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 519,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15673716",
          "text": "and exons of human genes is shown here to negatively correlate with among-tissues breadth of gene expression. The nucleosome formation potential is al",
          "offsetInBeginSection": 66,
          "offsetInEndSection": 216,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34823400",
          "text": "Epigenetic modifications can affect gene expression and function and can also mediate crosstalk between genes and the environment.",
          "offsetInBeginSection": 264,
          "offsetInEndSection": 394,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24737381",
          "text": "We conclude that alterations in the methylation status of protein-coding genes and various miRNA genes are influenced by HPV infection, the viral genotype, the physical state of the viral DNA, and viral oncogenic risk.",
          "offsetInBeginSection": 829,
          "offsetInEndSection": 1047,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31235724",
          "text": "Introns can increase gene expression levels using a variety of mechanisms collectively referred to as Intron Mediated Enhancement (IME).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22645558",
          "text": "Introns exist in the transcribed DNA and the nascent RNA, and could affect expression from either location.",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24455281",
          "text": "Epigenetic modifications can affect the long-term gene expression without any change in nucleotide sequence of the DNA.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18287520",
          "text": "However, in yeast only 283 of the 6000 genes contain introns and their impact on cell function is not clear.",
          "offsetInBeginSection": 96,
          "offsetInEndSection": 204,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23593031",
          "text": "Epigenetic variation, such as heritable changes of DNA methylation, can affect gene expression and thus phenotypes, but examples of natural epimutations are few and little is known about their stability and frequency in nature.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30010918",
          "text": "uch the same way as intergenic TEs, they are targeted by repressive epigenetic marks for transcriptional silencing. Silenced intragenic TEs generally ",
          "offsetInBeginSection": 217,
          "offsetInEndSection": 367,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25671208",
          "text": ", histone modification and non-coding RNAs, can regulate gene expression and affect progression of disease. Although studies focused on epigenetics ar",
          "offsetInBeginSection": 179,
          "offsetInEndSection": 329,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29513783",
          "text": "Introns are necessary for gene expression and alternative splicing can regulate gene expression in response to environmental cues.",
          "offsetInBeginSection": 228,
          "offsetInEndSection": 358,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34433110",
          "text": " FKBP5 in patients with psychiatric disorders. To date, there are no reports of DNA methylation in introns 2 and 5 of the gene associated with diagnos",
          "offsetInBeginSection": 984,
          "offsetInEndSection": 1134,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30792737",
          "text": "However, introns may be particularly useful in practical applications such as gene therapy because they strongly activate expression but only affect the transcription unit in which they are located.",
          "offsetInBeginSection": 1201,
          "offsetInEndSection": 1399,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34433110",
          "text": "id response elements (GREs) located in introns 2, 5 and 7, which affect its expression. Recent studies have examined GRE activity and the effects of g",
          "offsetInBeginSection": 314,
          "offsetInEndSection": 464,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28673892",
          "text": "In many eukaryotes, including mammals, plants, yeast, and insects, introns can increase gene expression without functioning as a binding site for transcription factors.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32988986",
          "text": "These results show that alternative transposition events are not only able to induce genome rearrangements, but also generate CIs that can control gene expression.",
          "offsetInBeginSection": 1722,
          "offsetInEndSection": 1885,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12702819",
          "text": "However, the extent to which each of these steps contributes to the overall effect of any one intron on gene expression has not been rigorously tested.",
          "offsetInBeginSection": 367,
          "offsetInEndSection": 518,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25765649",
          "text": "While promoter methylation is relatively well characterized, the role of intragenic DNA methylation remains unclear.",
          "offsetInBeginSection": 108,
          "offsetInEndSection": 224,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28768481",
          "text": "It has been observed that the methylation status of certain CpG sites close to or within a gene can directly affect its expression, either by silencing or, in some cases, up-regulating transcription.",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 291,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074130",
          "text": "U12-type introns are spliced somewhat less efficiently than the major introns, and it is believed that this limits the expression of the genes containing such introns.",
          "offsetInBeginSection": 460,
          "offsetInEndSection": 627,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20822493",
          "text": "Changes in epigenetic processes can lead to changes in gene function, cancer formation and progression, as well as other diseases.",
          "offsetInBeginSection": 778,
          "offsetInEndSection": 908,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24038247",
          "text": "Epigenetics can be defined as inheritable and reversible phenomena that affect gene expression without altering the underlying base pair sequence.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31875008",
          "text": "These mechanisms can be affected by environmental factors such as nutrients.",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 206,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32187179",
          "text": "rious biological functions. Transcription of genes bearing intronic heterochromatin is regulated by an epigenetic mechanism involving the conserved fa",
          "offsetInBeginSection": 980,
          "offsetInEndSection": 1130,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27788248",
          "text": "Our study demonstrated that DNA methylation changes may influence gene expression profiles in the hypothalamus of goats during the onset of puberty, which may provide new insights into the mechanisms involved in pubertal onset.",
          "offsetInBeginSection": 1307,
          "offsetInEndSection": 1534,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18630758",
          "text": "Introns can significantly affect gene expression in plants and many other eukaryotes in a variety of ways.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21602587",
          "text": "This review describes the known epigenetic regulation of drug-metabolizing enzymes and other proteins that might affect drug response and compounds that modify the epigenetic status.",
          "offsetInBeginSection": 747,
          "offsetInEndSection": 929,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28673892",
          "text": "It is suggested that there is no sole, definite answer to the question \"how do introns enhance gene expression\".",
          "offsetInBeginSection": 1245,
          "offsetInEndSection": 1357,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11894937",
          "text": "Some intron mutations in this gene affect not only its expression but also that of another mitochondrial gene: oxi3.",
          "offsetInBeginSection": 175,
          "offsetInEndSection": 291,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21913084",
          "text": "y influence the transcriptional processes, leading to silencing or activation of gene expression. A novel technique has been recently explored in our ",
          "offsetInBeginSection": 281,
          "offsetInEndSection": 431,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25104823",
          "text": "ve covalent modifications of DNA and histones, which affect transcriptional activity of chromatin. Since chromatin states can be propagated through mi",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 300,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26759245",
          "text": "ent epigenetic changes, suggesting that genetic and epigenetic alterations could be independent events in ccRCC. Specifically, we found unique DNA met",
          "offsetInBeginSection": 843,
          "offsetInEndSection": 993,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404599",
          "text": "We focus on how metabolic changes, due to diet, genetic mutations, or tumor microenvironment, regulate histone methylation status and, consequently, affect gene expression profiles to promote tumorigenesis.",
          "offsetInBeginSection": 457,
          "offsetInEndSection": 663,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191382",
          "text": "Thus the acetylation/deacetylation status of NF-\u03baB and the glucocorticoid receptor can also affect the overall expression pattern of inflammatory genes and regulate the inflammatory response.",
          "offsetInBeginSection": 1679,
          "offsetInEndSection": 1870,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28768481",
          "text": "By applying different filtering methods, we show that a subset of CpG sites exhibits consistent methylation patterns, and that the status of sites affect the expression of key regulator genes, as well as other genes located downstream in the same pathways.",
          "offsetInBeginSection": 1634,
          "offsetInEndSection": 1890,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29330282",
          "text": "This underscores the need for understanding epigenetic differences in populations and their correlation with breast cancer is an important step toward achieving personalized cancer care.Implications: This research contributes to the understanding of how epigenetic markers in the gene body communicate with the transcriptional machinery to control transcript diversity and differential biological response to changes in methylation status could underlie some of the known, yet unexplained, disparities in certain breast cancer patient populations.",
          "offsetInBeginSection": 1170,
          "offsetInEndSection": 1717,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34764277",
          "text": "Our experimental evidence demonstrates a role for introns in regulating MAE, possibly explaining why some mutations within introns result in disease.",
          "offsetInBeginSection": 899,
          "offsetInEndSection": 1048,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31945283",
          "text": "They seemed to be just \"junk\" DNA, although currently are considered as important genetic elements influencing the genome functions, as they increase the diversity of transcriptome and proteome, perform regulatory activities in the cell, affect gene expression, mRNA processing, degradation and translation.",
          "offsetInBeginSection": 51,
          "offsetInEndSection": 358,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089147",
          "text": "Within two years of their discovery in 1977, introns were found to have a positive effect on gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074130",
          "text": "U12-type introns are spliced somewhat less efficiently than the major introns, and it is believed that this limits the expression of the genes containing such introns.",
          "offsetInBeginSection": 460,
          "offsetInEndSection": 627,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22236027",
          "text": "Recent evidence shows that diabetes-induced epigenetic changes can affect gene expression in vascular endothelial cells and vascular smooth muscles cells.",
          "offsetInBeginSection": 328,
          "offsetInEndSection": 482,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31875008",
          "text": "Dietary supplementation of these three metabolites and the resulting epigenetic modification were important for stability in gene expression.",
          "offsetInBeginSection": 1274,
          "offsetInEndSection": 1415,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18630758",
        "http://www.ncbi.nlm.nih.gov/pubmed/29330282",
        "http://www.ncbi.nlm.nih.gov/pubmed/18319396",
        "http://www.ncbi.nlm.nih.gov/pubmed/22645558",
        "http://www.ncbi.nlm.nih.gov/pubmed/25104823",
        "http://www.ncbi.nlm.nih.gov/pubmed/27788248",
        "http://www.ncbi.nlm.nih.gov/pubmed/15673716",
        "http://www.ncbi.nlm.nih.gov/pubmed/11894937",
        "http://www.ncbi.nlm.nih.gov/pubmed/23074130",
        "http://www.ncbi.nlm.nih.gov/pubmed/12702819",
        "http://www.ncbi.nlm.nih.gov/pubmed/23593031",
        "http://www.ncbi.nlm.nih.gov/pubmed/31945283",
        "http://www.ncbi.nlm.nih.gov/pubmed/24737381",
        "http://www.ncbi.nlm.nih.gov/pubmed/24455281",
        "http://www.ncbi.nlm.nih.gov/pubmed/31875008",
        "http://www.ncbi.nlm.nih.gov/pubmed/22236027",
        "http://www.ncbi.nlm.nih.gov/pubmed/30010918",
        "http://www.ncbi.nlm.nih.gov/pubmed/29513783",
        "http://www.ncbi.nlm.nih.gov/pubmed/32988986",
        "http://www.ncbi.nlm.nih.gov/pubmed/32187179",
        "http://www.ncbi.nlm.nih.gov/pubmed/25765649",
        "http://www.ncbi.nlm.nih.gov/pubmed/34764277",
        "http://www.ncbi.nlm.nih.gov/pubmed/34823400",
        "http://www.ncbi.nlm.nih.gov/pubmed/26759245",
        "http://www.ncbi.nlm.nih.gov/pubmed/31235724",
        "http://www.ncbi.nlm.nih.gov/pubmed/24213601",
        "http://www.ncbi.nlm.nih.gov/pubmed/25671208",
        "http://www.ncbi.nlm.nih.gov/pubmed/21913084",
        "http://www.ncbi.nlm.nih.gov/pubmed/24038247",
        "http://www.ncbi.nlm.nih.gov/pubmed/25191382",
        "http://www.ncbi.nlm.nih.gov/pubmed/18287520",
        "http://www.ncbi.nlm.nih.gov/pubmed/28768481",
        "http://www.ncbi.nlm.nih.gov/pubmed/28404599",
        "http://www.ncbi.nlm.nih.gov/pubmed/21602587",
        "http://www.ncbi.nlm.nih.gov/pubmed/26089147",
        "http://www.ncbi.nlm.nih.gov/pubmed/30792737",
        "http://www.ncbi.nlm.nih.gov/pubmed/20822493",
        "http://www.ncbi.nlm.nih.gov/pubmed/28673892",
        "http://www.ncbi.nlm.nih.gov/pubmed/34433110"
      ]
    },
    {
      "id": "6415c5d4690f196b51000014",
      "type": "list",
      "body": "What was Keytruda originally approved for by the FDA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29209918",
          "text": "ons in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-ce",
          "offsetInBeginSection": 318,
          "offsetInEndSection": 468,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34647523",
          "text": " Drug Administration (FDA) for use in pediatric patients with relapsed or refractory classical Hodgkin's lymphoma. However, there is currently no publ",
          "offsetInBeginSection": 218,
          "offsetInEndSection": 368,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513",
          "text": "rug Administration approval of a checkpoint inhibitor for first-line treatment of lung cancer. This approval expands the pembrolizumab indication in s",
          "offsetInBeginSection": 1937,
          "offsetInEndSection": 2087,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34156377",
          "text": "Pembrolizumab (Keytruda) has been approved to treat metastatic or locally advanced esophageal or gastroesophageal junction cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17280539",
          "text": "Thus, while the circulatory support was initially tolerated for short periods to permit recovery of cardiac function, this technology eventually provided effective circulatory support for increasing periods that permitted the FDA to approve devices for bridging patients in end-stage cardiac failure awaiting transplant and eventually a device for destination therapy where patients in end-stage heart failure are not cardiac transplant candidates.",
          "offsetInBeginSection": 685,
          "offsetInEndSection": 1133,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3477937",
          "text": "Two of the EWCL brands were approved by the United States Food and Drug Administration (FDA) for wear by the public, while two of the brands were uninvestigated.",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 306,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26429199",
          "text": "A total of 130 FDA-approved drugs, originally intended against other diseases, could be repurposed against 78 potential targets in M. tuberculosis.",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 859,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32645193",
          "text": "The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 296,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12179363",
          "text": "The fact that this IUD is approved for 6 years makes it an even more attractive option for women choosing a contraceptive method.\"",
          "offsetInBeginSection": 1104,
          "offsetInEndSection": 1234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28235882",
          "text": "On September 4, 2014, the FDA approved pembrolizumab (KEYTRUDA; Merck Sharp & Dohme Corp.) with a recommended dose of 2 mg/kg every 3 weeks by intravenous infusion for the treatment of patients with unresectable or metastatic melanoma who have progressed following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 345,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27322992",
          "text": " for new indications when a drug has already been approved for use in another condition. Finally, this case demonstrates the importance of employing s",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 587,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30120163",
          "text": "On September 22, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab (Keytruda, Merck & Co., Inc., Whitehouse Station, NJ) for the treatment of patients with recurrent, locally advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after two or more systemic therapies, including fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, HER2/neu-targeted therapy, and whose tumors express programmed death-ligand 1 (PD-L1), as determined by an FDA-approved test.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 584,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513",
          "text": "On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] \u226550%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS \u22651%), with disease progression on or after platinum-containing chemotherapy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 712,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28546286",
          "text": "The FDA has approved one PD-1 checkpoint inhibitor, pembrolizumab, and two PD-L1 checkpoint inhibitors, avelumab and durvalumab, to treat metastatic urothelial carcinoma in patients whose disease continues to progress despite platinum-based chemotherapy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35736598",
          "text": "Pembrolizumab (Keytruda) is now approved as a single agent to treat advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient in those whose disease has progressed following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 315,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30120163",
          "text": "Pembrolizumab was approved concurrently with the PD-L1 immunohistochemistry 22C3 pharmDx test (Dako, Agilent, Santa Clara, CA) for selection of patients with gastric cancer for treatment with pembrolizumab based on PD-L1 tumor expression.",
          "offsetInBeginSection": 1640,
          "offsetInEndSection": 1878,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18421052",
          "text": "more than 10 times more likely to only use agents FDA-approved for colorectal cancer. Three percent of patients were enrolled onto trials enriched for",
          "offsetInBeginSection": 1171,
          "offsetInEndSection": 1321,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24405254",
          "text": "o approved drug in Japan; in 16 of the remaining 32 PGBMs, the aim was efficacy. The largest therapeutic area was oncology (34%, 11/32). Of the 32 PGB",
          "offsetInBeginSection": 1060,
          "offsetInEndSection": 1210,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28235882",
        "http://www.ncbi.nlm.nih.gov/pubmed/18421052",
        "http://www.ncbi.nlm.nih.gov/pubmed/26429199",
        "http://www.ncbi.nlm.nih.gov/pubmed/28546286",
        "http://www.ncbi.nlm.nih.gov/pubmed/32645193",
        "http://www.ncbi.nlm.nih.gov/pubmed/28835513",
        "http://www.ncbi.nlm.nih.gov/pubmed/12179363",
        "http://www.ncbi.nlm.nih.gov/pubmed/35736598",
        "http://www.ncbi.nlm.nih.gov/pubmed/24405254",
        "http://www.ncbi.nlm.nih.gov/pubmed/17280539",
        "http://www.ncbi.nlm.nih.gov/pubmed/27322992",
        "http://www.ncbi.nlm.nih.gov/pubmed/29209918",
        "http://www.ncbi.nlm.nih.gov/pubmed/34647523",
        "http://www.ncbi.nlm.nih.gov/pubmed/3477937",
        "http://www.ncbi.nlm.nih.gov/pubmed/34156377",
        "http://www.ncbi.nlm.nih.gov/pubmed/30120163"
      ]
    },
    {
      "id": "63f5713733942b094c000003",
      "type": "summary",
      "body": "What are clinical features of the Achard-Thiers syndrome?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1201353",
          "text": "The Achard syndrome is a well-defined clinical entity consisting of widespread dysostoses and increased ligament laxity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/518037",
          "text": "The clinical and neuroradiological features in 4 patients with the syndrome of aberrant regeneration of the third nerve are presented.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8166424",
          "text": "ions in two of the boys, confirmed diagnosis. The clinical, hematological and radiological features are discussed in order to better define what appea",
          "offsetInBeginSection": 330,
          "offsetInEndSection": 480,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10560599",
          "text": "ile other manifestations, including clinical features, CSF pressures, and imaging abnormalities, are variables dependent on the CSF volume. The term C",
          "offsetInBeginSection": 1260,
          "offsetInEndSection": 1410,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10560599",
          "text": "What determines the various clinical and imaging features of this syndrome seems to be the loss of CSF volume as the independent variable, while other manifestations, including clinical features, CSF pressures, and imaging abnormalities, are variables dependent on the CSF volume.",
          "offsetInBeginSection": 1119,
          "offsetInEndSection": 1399,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28695356",
          "text": "METHODS\nThe following clinical and MRI findings were assessed: age, gender, pain, pain attributable to lesion, tumour location, tumour length, presence, depth of endosteal scalloping, bone marrow oedema, soft tissue oedema, cortical destruction, periosteal reaction, bone expansion, macroscopic fat, calcification, soft tissue mass, haemorrhage, dynamic contrast-enhanced MRI.",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 548,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24173296",
          "text": "Obesity, hypertension and angiopathy were present in most of these patients.",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 239,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/1201353",
        "http://www.ncbi.nlm.nih.gov/pubmed/8166424",
        "http://www.ncbi.nlm.nih.gov/pubmed/10560599",
        "http://www.ncbi.nlm.nih.gov/pubmed/24173296",
        "http://www.ncbi.nlm.nih.gov/pubmed/518037",
        "http://www.ncbi.nlm.nih.gov/pubmed/28695356"
      ]
    },
    {
      "id": "642d4c9b57b1c7a315000013",
      "type": "yesno",
      "body": "Are Luminopsins a fusion proteins of luminol and Rhodopsin ?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24724832",
          "text": "bunit C-terminal tail, suggesting binding of both proteins to rhodopsin may share some similar underlying mechanisms. We also identify two areas of co",
          "offsetInBeginSection": 330,
          "offsetInEndSection": 480,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2854348",
          "text": "The data obtained indicate that similarity in the primary structure between rhodopsin, muscarinic cholinoreceptor and adrenoreceptor is a consequence of divergent, not convergent, evolution; in other words, these receptor proteins are homologous.",
          "offsetInBeginSection": 1482,
          "offsetInEndSection": 1728,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26733686",
          "text": "Luminopsins are fusion proteins of luciferase and opsin that allow interrogation of neuronal circuits at different temporal and spatial resolutions by choosing either extrinsic physical or intrinsic biological light for its activation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30954887",
          "text": "Currently, three different types of these fusion proteins with an N-terminal type-1 rhodopsin and a C-terminal enzyme domain have been identified, but their physiological relevance is mostly unknown.",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 328,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34281270",
          "text": "Bioluminescent optogenetics (BL-OG) uses luminopsins, fusion proteins of light-generating luciferase and light-sensing ion channels that could be used to increase neuronal excitability if exposed to a suitable substrate.",
          "offsetInBeginSection": 321,
          "offsetInEndSection": 541,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1349018",
          "text": "s. It is concluded that even though arrestin and beta-arrestin are similar proteins, they display marked specificity for their respective receptors an",
          "offsetInBeginSection": 1953,
          "offsetInEndSection": 2103,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24724832",
          "text": "Although this observation at first seems paradoxical, in fact, it provides strong support for recent hypotheses that structural plasticity and conformational changes are involved in the arrestin-rhodopsin binding interface and that the two proteins may be able to interact through multiple docking modes, with arrestin binding to both monomeric and dimeric rhodopsin.",
          "offsetInBeginSection": 1216,
          "offsetInEndSection": 1583,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35836081",
          "text": "BL-OG is realized through opsin-luciferase fusion proteins called luminopsins (LMOs).",
          "offsetInBeginSection": 499,
          "offsetInEndSection": 584,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24591614",
          "text": "Furthermore, two-color TIRFM showed that Rab11a-mCherry was present in rhodopsin-GFP carrier vesicles and was rapidly released upon fusion onset.",
          "offsetInBeginSection": 1465,
          "offsetInEndSection": 1610,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24260336",
          "text": "mol. Vis. Sci. 21, 395-402 1981). In contrast, endogenous rhodopsin did not exhibit such axial variation. Thus, there is an axial inhomogeneity in mem",
          "offsetInBeginSection": 1302,
          "offsetInEndSection": 1452,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28862809",
          "text": "We conclude that these new luminopsins will be useful for bimodal opto- and chemogenetic analyses of brain function.",
          "offsetInBeginSection": 939,
          "offsetInEndSection": 1055,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/47175",
          "text": "epared as prototypes for peptides and proteins with latent, enzyme-activatable chemical reactivity. In the presence of small quantities of activated h",
          "offsetInBeginSection": 99,
          "offsetInEndSection": 249,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7841129",
          "text": "Previous transgenic experiments using rhodopsin promoter/lacZ fusion constructs identified some of the cis-acting DNA elements responsible for photoreceptor cell-specific expression.",
          "offsetInBeginSection": 124,
          "offsetInEndSection": 306,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28862809",
          "text": "Previous work has demonstrated that fusion of a luciferase to an opsin, to create a luminescent opsin or luminopsin, provides a genetically encoded means of manipulating neuronal activity via both chemogenetic and optogenetic approaches.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33398804",
          "text": "Animal and microbial rhodopsins possess 11-cis and all-trans retinal, respectively, to capture light in seven transmembrane \u03b1-helices, and photoisomerizations into all-trans and 13-cis forms, respectively, initiate each function.",
          "offsetInBeginSection": 393,
          "offsetInEndSection": 622,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35836081",
        "http://www.ncbi.nlm.nih.gov/pubmed/28862809",
        "http://www.ncbi.nlm.nih.gov/pubmed/7841129",
        "http://www.ncbi.nlm.nih.gov/pubmed/2854348",
        "http://www.ncbi.nlm.nih.gov/pubmed/47175",
        "http://www.ncbi.nlm.nih.gov/pubmed/24260336",
        "http://www.ncbi.nlm.nih.gov/pubmed/30954887",
        "http://www.ncbi.nlm.nih.gov/pubmed/24724832",
        "http://www.ncbi.nlm.nih.gov/pubmed/34281270",
        "http://www.ncbi.nlm.nih.gov/pubmed/26733686",
        "http://www.ncbi.nlm.nih.gov/pubmed/33398804",
        "http://www.ncbi.nlm.nih.gov/pubmed/1349018",
        "http://www.ncbi.nlm.nih.gov/pubmed/24591614"
      ]
    },
    {
      "id": "6429fe4e57b1c7a31500000f",
      "type": "summary",
      "body": "What are coactivators?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9806345",
          "text": "ent and indicates a dual role for coactivators as bridging factors and chromatin remodeling proteins. The opposites of coactivators are corepressors, ",
          "offsetInBeginSection": 879,
          "offsetInEndSection": 1029,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19843848",
          "text": "Coregulators (coactivators and corepressors) occupy the driving seat for actions of all nuclear receptors, and consequently, selective receptor modulator drugs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9096323",
          "text": "uld be rescued from E1A inhibition by overexpression of CBP or p300. CBP and p300 act as coactivators of p65-driven gene activation and may play an im",
          "offsetInBeginSection": 909,
          "offsetInEndSection": 1059,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10379889",
          "text": "In fact, squelching becomes even more severe when coactivators are abundant.",
          "offsetInBeginSection": 1084,
          "offsetInEndSection": 1160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11893487",
          "text": "Coactivators are diverse and multifunctional proteins that act downstream of DNA-binding activators to stimulate transcription.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17476305",
          "text": "development and physiology. These coactivators are nuclear proteins and transcription co-regulators that function to facilitate the transcription init",
          "offsetInBeginSection": 70,
          "offsetInEndSection": 220,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201947",
          "text": "ogen-sensitive and -insensitive prostate cancer cells. Coactivators p300 and SRC-1 are required for AR activation by interleukin-6 (IL-6), a cytokine ",
          "offsetInBeginSection": 1188,
          "offsetInEndSection": 1338,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14690606",
          "text": "160, p300, and CARM1 coactivators. We identified a coactivator, coiled-coil coactivator (CoCoA), which binds to this domain and thereby enhances trans",
          "offsetInBeginSection": 413,
          "offsetInEndSection": 563,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12376547",
          "text": "Coactivators such as TIF2 and SRC-1 modulate the positioning of the dose-response curve for agonist-bound glucocorticoid receptors (GRs) and the partial agonist activity of antiglucocorticoid complexes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17244199",
          "text": "relevant brain regions coexpress nuclear receptor coactivators and steroid receptors. Confocal analysis revealed that in oestrogen-primed rats, most o",
          "offsetInBeginSection": 1159,
          "offsetInEndSection": 1309,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19463689",
          "text": "To regulate transcription, AR recruits a series of coactivators that modify chromatin and facilitate transcription.",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 273,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16604175",
          "text": "Estrogen receptors are hormone-inducible transcription factors requiring coactivators such as members of the SRC/p160 family to modulate the transcription of their target genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14690606",
          "text": "We identified a coactivator, coiled-coil coactivator (CoCoA), which binds to this domain and thereby enhances transcriptional activation by the estrogen receptor and other nuclear receptors.",
          "offsetInBeginSection": 448,
          "offsetInEndSection": 638,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11108858",
          "text": "Coactivators are a diverse group of molecules that bring multiple structural and enzymatic functions to the promoter.",
          "offsetInBeginSection": 287,
          "offsetInEndSection": 404,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23380592",
          "text": "e transcription and they require the help of coactivators. Several TEAD-interacting coactivators are known and they can be classified into three group",
          "offsetInBeginSection": 382,
          "offsetInEndSection": 532,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28607951",
          "text": "As coordinators of energy demands and nutritional supplies, the PGC-1 family of transcriptional coactivators regulates mitochondrial biogenesis to control the cellular bioenergetic state.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11823864",
          "text": "Our study uncovers a unique mechanism, called 'synergistic folding', through which p160 coactivators recruit CBP/p300 to allow transmission of the hormonal signal to the transcriptional machinery.",
          "offsetInBeginSection": 1174,
          "offsetInEndSection": 1370,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201947",
          "text": "AR coactivators are proteins which interact with one or more regions of the AR thus enhancing its function.",
          "offsetInBeginSection": 459,
          "offsetInEndSection": 566,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21664237",
          "text": "Coactivators are a diverse group of non-DNA binding proteins that induce structural changes in agonist-bound nuclear receptors (NRs) that are essential for NR-mediated transcriptional activation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25024406",
          "text": "Transcriptional coactivators have evolved as an important new class of functional proteins that participate with virtually all transcription factors and nuclear receptors (NRs) to intricately regulate gene expression in response to a wide variety of environmental cues.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19019695",
          "text": "Nuclear receptor (NR) coactivators are recruited to DNA by NRs, potentiating NR-dependent gene transcription.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10454556",
          "text": "We have analyzed the functional interactions between the androgen receptor (AR) and 160-kDa nuclear receptor coactivators.",
          "offsetInBeginSection": 210,
          "offsetInEndSection": 332,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29786798",
          "text": "vators is frequently reported in prostate cancer. Coactivators such as p300/CBP are involved in modulation of androgen receptor activity by increasing",
          "offsetInBeginSection": 51,
          "offsetInEndSection": 201,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27654711",
          "text": "Coactivators represent a large class of proteins that partner with nuclear receptors and other transcription factors to regulate gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16189181",
          "text": "METHODS\nWe determined the localization of these three p160 coactivators in immature and mature rat testis, and epididymis by immunohistochemistry using the specific monoclonal antibodies.",
          "offsetInBeginSection": 525,
          "offsetInEndSection": 712,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14766010",
          "text": "The p160 coactivators, steroid receptor coactivator-1 (SRC-1), transcriptional intermediary factor-2 (TIF2) and receptor-associated coactivator-3 (RAC3), as well as the coactivator/integrator CBP, mediate estrogen receptor-alpha (ERalpha)-dependent gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17046230",
          "text": "Transcriptional coactivators enhance gene expression by associating with sequence-specific transcription factors and serve as the primary targets of developmental and physiological signals in diverse biological processes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11897715",
          "text": "Steroid receptor coactivator (SRC)-1 and transcriptional intermediary factor (TIF)-2 are homologous nuclear receptor coactivators.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9096323",
          "text": "CBP (CREB-binding protein) and p300 are versatile coactivators that link transcriptional activators to the basal transcriptional apparatus.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19052561",
          "text": "These results demonstrate that VDR and coactivators SRC2 and SRC3, which are also involved in other nuclear receptors as well, are critical for epidermis-specific sphingolipid production and barrier formation.",
          "offsetInBeginSection": 1066,
          "offsetInEndSection": 1275,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8571454",
          "text": "Coactivators are a novel class of transcriptional activator required at many eukaryotic promoters.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14973393",
          "text": "Coactivators function as adaptors in a signaling pathway that transmits transcriptional responses from the DNA bound receptor to the basal transcriptional machinery.",
          "offsetInBeginSection": 733,
          "offsetInEndSection": 898,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201947",
          "text": " redundant, specific functions have been identified and analyzed. The p160 group of coactivators, SRC-1, -2, and -3 not only potentiate the activation",
          "offsetInBeginSection": 619,
          "offsetInEndSection": 769,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17244199",
          "text": "In previous studies, we have found that two of these nuclear receptor coactivators, steroid receptor coactivator-1 (SRC-1) and CREB-binding protein (CBP), are important in ER-mediated induction of PR in the VMN and in steroid-dependent behaviours.",
          "offsetInBeginSection": 602,
          "offsetInEndSection": 849,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10454563",
          "text": "C-terminal coactivator fragments lacking AD1 but containing AD2 and the AR AF-1 binding site served as efficient coactivators for full-length AR and AR AF-1.",
          "offsetInBeginSection": 1217,
          "offsetInEndSection": 1374,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11514567",
          "text": "The steroid receptor coactivator (SRC) proteins are coactivators that interact with the AF-2 domain of VDR to augment 1,25-dihydroxyvitamin D3-dependent transcription.",
          "offsetInBeginSection": 205,
          "offsetInEndSection": 372,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12039076",
          "text": "and CREB-binding protein (CBP). Since coactivators function as transcription amplifiers, subtle changes in expression levels of coactivators in certai",
          "offsetInBeginSection": 341,
          "offsetInEndSection": 491,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14973393",
          "text": "diated transcriptional activation. Coactivators function as adaptors in a signaling pathway that transmits transcriptional responses from the DNA boun",
          "offsetInBeginSection": 698,
          "offsetInEndSection": 848,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15814849",
          "text": "e coactivators are differentially used by transcription factors, including NRs, in a cell/tissue type- and promoter-specific manner. However, the mole",
          "offsetInBeginSection": 298,
          "offsetInEndSection": 448,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17018837",
          "text": "One of the best-studied examples of coactivator control of metabolic pathways is the peroxisome proliferator-activated receptor coactivator 1 (PGC-1) family.",
          "offsetInBeginSection": 294,
          "offsetInEndSection": 451,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15016838",
          "text": "es and whether the association of corepressors and coactivators with GR complexes involves competitive equilibrium reactions. In mammalian two-hybrid ",
          "offsetInBeginSection": 584,
          "offsetInEndSection": 734,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23380592",
          "text": "o play a role in development and cancers. Recent studies have shown that TEADs and their coactivators aid in the progression of various cancers, inclu",
          "offsetInBeginSection": 633,
          "offsetInEndSection": 783,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15016838",
          "text": "Corepressors and coactivators can modulate the dose-response curve and partial agonist activity of glucocorticoid receptors (GRs) complexed with agonist and antagonist steroids, respectively, in intact cells.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11893728",
          "text": "Two functionally distinct classes of coactivators are recruited by liganded estrogen receptor, the DRIP/Mediator complex and p160 proteins, although the relative dynamics of recruitment is unclear.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10379889",
          "text": "osed to reflect the titration of coactivators that bind the receptors in a hormone-dependent manner. We have tested whether the coactivators are the o",
          "offsetInBeginSection": 69,
          "offsetInEndSection": 219,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11823864",
          "text": "The hormone response is mediated through recruitment of p160 receptor coactivators and the general transcriptional coactivator CBP/p300, which function synergistically to activate transcription.",
          "offsetInBeginSection": 173,
          "offsetInEndSection": 367,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23795583",
          "text": "understanding steroid action in the brain, the importance of nuclear receptor coactivators in the brain is becoming more apparent. The present review ",
          "offsetInBeginSection": 218,
          "offsetInEndSection": 368,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11818499",
          "text": "uction of estrogen-dependent pS2 gene expression, indicating that SRA and SRC family coactivators can fulfill specific functional roles. Taken togethe",
          "offsetInBeginSection": 1463,
          "offsetInEndSection": 1613,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11514567",
          "text": "The current study examined whether these two distinct classes of coactivators impact functionally on VDR-mediated transcription.",
          "offsetInBeginSection": 495,
          "offsetInEndSection": 623,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21664237",
          "text": "gnostic indicators. With much interest in the development of selective receptor modulators (SRMs), we focus on how these coactivators regulate the int",
          "offsetInBeginSection": 869,
          "offsetInEndSection": 1019,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/14973393",
        "http://www.ncbi.nlm.nih.gov/pubmed/15016838",
        "http://www.ncbi.nlm.nih.gov/pubmed/23380592",
        "http://www.ncbi.nlm.nih.gov/pubmed/14766010",
        "http://www.ncbi.nlm.nih.gov/pubmed/16604175",
        "http://www.ncbi.nlm.nih.gov/pubmed/28607951",
        "http://www.ncbi.nlm.nih.gov/pubmed/10454563",
        "http://www.ncbi.nlm.nih.gov/pubmed/11823864",
        "http://www.ncbi.nlm.nih.gov/pubmed/27654711",
        "http://www.ncbi.nlm.nih.gov/pubmed/10454556",
        "http://www.ncbi.nlm.nih.gov/pubmed/17046230",
        "http://www.ncbi.nlm.nih.gov/pubmed/26201947",
        "http://www.ncbi.nlm.nih.gov/pubmed/9806345",
        "http://www.ncbi.nlm.nih.gov/pubmed/21664237",
        "http://www.ncbi.nlm.nih.gov/pubmed/29786798",
        "http://www.ncbi.nlm.nih.gov/pubmed/17018837",
        "http://www.ncbi.nlm.nih.gov/pubmed/16189181",
        "http://www.ncbi.nlm.nih.gov/pubmed/11818499",
        "http://www.ncbi.nlm.nih.gov/pubmed/19019695",
        "http://www.ncbi.nlm.nih.gov/pubmed/11514567",
        "http://www.ncbi.nlm.nih.gov/pubmed/10379889",
        "http://www.ncbi.nlm.nih.gov/pubmed/23795583",
        "http://www.ncbi.nlm.nih.gov/pubmed/9096323",
        "http://www.ncbi.nlm.nih.gov/pubmed/11897715",
        "http://www.ncbi.nlm.nih.gov/pubmed/17476305",
        "http://www.ncbi.nlm.nih.gov/pubmed/15814849",
        "http://www.ncbi.nlm.nih.gov/pubmed/17244199",
        "http://www.ncbi.nlm.nih.gov/pubmed/19463689",
        "http://www.ncbi.nlm.nih.gov/pubmed/12376547",
        "http://www.ncbi.nlm.nih.gov/pubmed/25024406",
        "http://www.ncbi.nlm.nih.gov/pubmed/8571454",
        "http://www.ncbi.nlm.nih.gov/pubmed/12039076",
        "http://www.ncbi.nlm.nih.gov/pubmed/19843848",
        "http://www.ncbi.nlm.nih.gov/pubmed/14690606",
        "http://www.ncbi.nlm.nih.gov/pubmed/19052561",
        "http://www.ncbi.nlm.nih.gov/pubmed/11108858",
        "http://www.ncbi.nlm.nih.gov/pubmed/11893487",
        "http://www.ncbi.nlm.nih.gov/pubmed/11893728"
      ]
    },
    {
      "id": "6412331b201352f04a000038",
      "type": "factoid",
      "body": "What are PROTACs?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31873151",
          "text": "Proteolysis targeting chimeras (PROTACs) are an emerging strategy for promoting targeted protein degradation by inducing the proximity between targeted proteins and E3 ubiquitin ligases.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34175722",
          "text": "Proteolysis targeting chimeras (PROTACs) have been developed to be an effective technology for targeted protein degradation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34494353",
          "text": "Proteolysis-targeting chimeras (PROTACs), an emerging paradigm-shifting technology, hijacks the ubiquitin-proteasome system for targeted protein degradation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35916511",
          "text": "Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic strategy using small molecules to induce ubiquitin-dependent degradation of proteins.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15876533",
          "text": "PROTACS are small molecule chimera which comprise a ligand and a peptide recognition motif for an E3 ligase.",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 238,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32475992",
          "text": " as a potential therapeutic strategy for cancer. PROTACs are heterobifunctional molecules consisting of one ligand for binding to a protein of interes",
          "offsetInBeginSection": 115,
          "offsetInEndSection": 265,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35533582",
          "text": "Proteolysis-targeting chimeras (PROTACs), bifunctional molecules consisting of a ligand of protein of interest (POI), an E3 ligase ligand and a linker, have been developed to hijack the ubiquitin-proteasome system (UPS) to induce different POIs degradation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35001407",
          "text": "Proteolysis targeting chimaeras (PROTACs) is a cutting edge and rapidly growing technique for new drug discovery and development.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34034148",
          "text": "Chemical knockdown of therapeutic targets using proteolysis targeting chimeras (PROTACs) is a rapidly developing field in drug discovery, but PROTACs are bifunctional molecules that generally show poor bioavailability due to their relatively high molecular weight.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31538491",
          "text": "h the potential to revolutionize drug discovery. PROTACs are heterobifunctional molecules comprising of a ligand targeting a protein of interest, a li",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31873151",
          "text": "A quantitative proteomic analysis further revealed that VHL-CRBN heterodimerizing PROTACs induced the degradation of CRBN, but not the well-known immunomodulatory drug (IMiD) neo-substrates, IKAROS family zinc finger 1 (IKZF1) and -3 (IZKF3).",
          "offsetInBeginSection": 517,
          "offsetInEndSection": 759,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28595007",
          "text": "The design of proteolysis-targeting chimeras (PROTACs) is a powerful small-molecule approach for inducing protein degradation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35589670",
          "text": "ive technology for targeted protein degradation. PROTACs are heterobifunctional molecules that can trigger the polyubiquitination of proteins of inter",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 224,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35702041",
          "text": "Proteolysis-targeting chimaeras (PROTACs) have been developed to be an emerging technology for targeted protein degradation and attracted the favour of academic institutions, large pharmaceutical enterprises, and biotechnology companies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36120561",
          "text": "PROTACs are small molecule, protein degraders that function by hijacking the built-in Ubiquitin-Proteasome pathway.",
          "offsetInBeginSection": 254,
          "offsetInEndSection": 369,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34411892",
          "text": "Protease-targeted chimeras (PROTACs) are a new technology that is receiving much attention in the treatment of diseases.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32871345",
          "text": "PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules that trigger the poly-ubiquitination of the protein of interest (POI) inducing its degradation via the recruitment of the ubiquitin-proteasome system, thus suppressing the POI's intracellular levels and indirectly all its functions.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 306,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28595007",
          "text": "sing different polyethylene glycol linkers to VHL ligand VH032. Triazolodiazepine PROTACs exhibited positive cooperativities of ternary complex format",
          "offsetInBeginSection": 395,
          "offsetInEndSection": 545,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33970635",
          "text": "PROTACs (proteolysis targeting chimeras) are an emerging class of promising therapeutic modalities that degrade intracellular protein targets by hijacking the cellular ubiquitin-proteasome system.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30706727",
          "text": "y reducing or eliminating disease-causing proteins. PROTACs are bifunctional molecules that consist of a target protein ligand, a linker and an E3 lig",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 242,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33959589",
          "text": "Proteolysis Targeting Chimeras (PROTACs) are heterobifunctional degraders that specifically eliminate targeted proteins by hijacking the ubiquitin-proteasome system (UPS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33970635",
          "text": " in cancer cells versus noncancerous normal cells. We show that our folate-PROTACs, including BRD PROTAC (folate-ARV-771), MEK PROTAC (folate-MS432), ",
          "offsetInBeginSection": 693,
          "offsetInEndSection": 843,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32255606",
          "text": "grade intracellular disease-associated proteins. PROTACs are heterobifunctional molecules composed of a target protein ligand, E3 ubiquitin ligase lig",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 317,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35471699",
          "text": "In this review, we provide an overview of these new smart activatable PROTACs, which exert protein degradation action only in response to internal or external stimuli.",
          "offsetInBeginSection": 574,
          "offsetInEndSection": 741,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33010159",
          "text": "Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted proteins by the ubiquitin-proteasome system, have emerged as a novel therapeutic technology with potential advantages over traditional inhibition strategies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33369705",
          "text": "Since its development in 2001, the field of targeted protein degradation, in which PROTACs are used, has expanded rapidly.",
          "offsetInBeginSection": 649,
          "offsetInEndSection": 771,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35763424",
          "text": "Proteolysis-targeting chimeras (PROTACs) is a fast-growing technology providing many strengths over inhibition of protein activity directly and is attracting increasing interest in new drug discovery and development.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33369705",
          "text": "PROteolysis Targeting Chimeras (PROTACs) are a family of heterobifunctional small molecules that specifically target cellular proteins for degradation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32270707",
          "text": "uitin-proteasome system. PROTAC molecules (PROTACs) are a class of heterobifunctional molecules, which contain a ligand targeting the protein of inter",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32718354",
          "text": "Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that utilize the ubiquitin proteasome system (UPS) to degrade proteins of interest (POI).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32431173",
          "text": "Proteolysis targeting chimeras (PROTACs) are small molecules that can recruit an E3 ligase and a protein of interest (POI) into proximity, leading to induced ubiquitination and degradation of the POI by the proteasome system.",
          "offsetInBeginSection": 114,
          "offsetInEndSection": 339,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34411892",
          "text": "and RNF114-based PROTACs) have been identified so far. In particular, CRBN-based PROTACs (e.g., ARV-110 and ARV-471) have received more attention for ",
          "offsetInBeginSection": 458,
          "offsetInEndSection": 608,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35410300",
          "text": "Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein degradation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35471699",
          "text": "Proteolysis-targeting chimeras (PROTACs) are heterobifunctional chemicals that degrade proteins at the post-translational level, which represent an emerging therapeutic modality to fight cancer and other diseases.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35927805",
          "text": "eins by targeting protein degradation. PROTACs molecules are bifunctional small molecules that simultaneously bind to the protein of interest (POIs) a",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 233,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29473971",
          "text": "Proteolysis-targeting chimeric molecules (PROTACs) represent an emerging technique that is receiving much attention for therapeutic intervention.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33081540",
          "text": "INTRODUCTION\nPROTACs represent a novel class of heterobifunctional molecules that simultaneously bind to a target protein and to an E3 ligase complex, resulting in the transfer of ubiquitin and initiating a process ultimately causing the proteasomal degradation of the target protein.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 284,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30631068",
          "text": "PROteolysis-TArgeting Chimeras (PROTACs) are hetero-bifunctional molecules that recruit an E3 ubiquitin ligase to a given substrate protein resulting in its targeted degradation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32866456",
          "text": "Proteolysis-targeting chimeras (PROTACs), the hetero-bifunctional compounds containing a specific ligand to bind the target protein, a suitable linker, and an E3 ubiquitin ligase substrate, are being developed for therapeutic applications.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 239,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32939229",
          "text": "Proteolysis targeting chimeras (PROTACs) are catalytic heterobifunctional molecules that can selectively degrade a protein of interest by recruiting a ubiquitin E3 ligase to the target, leading to its ubiquitylation and degradation by the proteasome.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33088687",
          "text": "Proteolysis targeting chimeras (PROTACs) are dual-functional hybrid molecules that can selectively recruit an E3 ubiquitin ligase to a target protein to direct the protein into the ubiquitin-proteasome system (UPS), thereby selectively reducing the target protein level by the ubiquitin-proteasome pathway.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 306,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31047748",
          "text": "Proteolysis targeting chimeras (PROTACs) are heterobifunctional compounds with molecular weights and other properties that lie outside the classic 'rule-of-five' space.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36041010",
          "text": "Proteolysis-targeting chimeras (PROTACs) are a promising new class of drugs that selectively degrade cellular proteins of interest.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33634757",
          "text": "The concept of PROTACs involves the reduction in the disease-causing protein by its degradation through the ubiquitin-proteasomal enzyme system.",
          "offsetInBeginSection": 418,
          "offsetInEndSection": 562,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31538491",
          "text": "Specific types such as homoPROTACs, PROTACs targeting Tau protein and the first PROTACs recently entering clinical trials are examined.",
          "offsetInBeginSection": 623,
          "offsetInEndSection": 758,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36232374",
          "text": "Proteolysis-targeting chimeras (PROTACs) are molecules that selectively degrade a protein of interest (POI).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32698111",
          "text": "PROTACs are made up of ligands of target proteins, E3 ligase recruiting elements and linkers.",
          "offsetInBeginSection": 133,
          "offsetInEndSection": 226,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31064868",
          "text": "Proteolysis-targeting chimeras (PROTAC) are bifunctional molecules that hijack endogenous E3 ubiquitin ligases to induce ubiquitination and subsequent degradation of protein of interest.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32475992",
          "text": "PROTACs have been developed to degrade a variety of cancer targets with unprecedented efficacy against a multitude of tumor types.",
          "offsetInBeginSection": 494,
          "offsetInEndSection": 624,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28378579",
          "text": "Proteolysis targeting chimeras (PROTACs) are bispecific molecules containing a target protein binder and an ubiquitin ligase binder connected by a linker.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32866456",
        "http://www.ncbi.nlm.nih.gov/pubmed/34411892",
        "http://www.ncbi.nlm.nih.gov/pubmed/28595007",
        "http://www.ncbi.nlm.nih.gov/pubmed/36041010",
        "http://www.ncbi.nlm.nih.gov/pubmed/33634757",
        "http://www.ncbi.nlm.nih.gov/pubmed/35533582",
        "http://www.ncbi.nlm.nih.gov/pubmed/31538491",
        "http://www.ncbi.nlm.nih.gov/pubmed/28378579",
        "http://www.ncbi.nlm.nih.gov/pubmed/35589670",
        "http://www.ncbi.nlm.nih.gov/pubmed/33369705",
        "http://www.ncbi.nlm.nih.gov/pubmed/30631068",
        "http://www.ncbi.nlm.nih.gov/pubmed/33088687",
        "http://www.ncbi.nlm.nih.gov/pubmed/32871345",
        "http://www.ncbi.nlm.nih.gov/pubmed/33959589",
        "http://www.ncbi.nlm.nih.gov/pubmed/15876533",
        "http://www.ncbi.nlm.nih.gov/pubmed/32475992",
        "http://www.ncbi.nlm.nih.gov/pubmed/32431173",
        "http://www.ncbi.nlm.nih.gov/pubmed/33010159",
        "http://www.ncbi.nlm.nih.gov/pubmed/32718354",
        "http://www.ncbi.nlm.nih.gov/pubmed/36120561",
        "http://www.ncbi.nlm.nih.gov/pubmed/35471699",
        "http://www.ncbi.nlm.nih.gov/pubmed/35410300",
        "http://www.ncbi.nlm.nih.gov/pubmed/32270707",
        "http://www.ncbi.nlm.nih.gov/pubmed/32255606",
        "http://www.ncbi.nlm.nih.gov/pubmed/34175722",
        "http://www.ncbi.nlm.nih.gov/pubmed/34494353",
        "http://www.ncbi.nlm.nih.gov/pubmed/35702041",
        "http://www.ncbi.nlm.nih.gov/pubmed/32939229",
        "http://www.ncbi.nlm.nih.gov/pubmed/30706727",
        "http://www.ncbi.nlm.nih.gov/pubmed/35763424",
        "http://www.ncbi.nlm.nih.gov/pubmed/33970635",
        "http://www.ncbi.nlm.nih.gov/pubmed/35916511",
        "http://www.ncbi.nlm.nih.gov/pubmed/33081540",
        "http://www.ncbi.nlm.nih.gov/pubmed/35927805",
        "http://www.ncbi.nlm.nih.gov/pubmed/31064868",
        "http://www.ncbi.nlm.nih.gov/pubmed/32698111",
        "http://www.ncbi.nlm.nih.gov/pubmed/31047748",
        "http://www.ncbi.nlm.nih.gov/pubmed/35001407",
        "http://www.ncbi.nlm.nih.gov/pubmed/36232374",
        "http://www.ncbi.nlm.nih.gov/pubmed/34034148",
        "http://www.ncbi.nlm.nih.gov/pubmed/29473971",
        "http://www.ncbi.nlm.nih.gov/pubmed/31873151"
      ]
    },
    {
      "id": "62008022c9dfcb9c0900001b",
      "type": "list",
      "body": "Which variables are included in the ALBI grade?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30026834",
          "text": "A newly developed scoring system called albumin-bilirubin grade (ALBI grade), consists of albumin and bilirubin to assess liver function reserve objectively.",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 410,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33788758",
          "text": "RESULTS\nALBI grade 2/3 was significantly associated with older age, male sex, advanced pT status, and histological type.",
          "offsetInBeginSection": 556,
          "offsetInEndSection": 676,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30077606",
          "text": "The albumin-bilirubin (ALBI) grade, a measure of liver function based on albumin and bilirubin, has the potential to detect Child-Pugh grade A HCC patients with poor prognosis.",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 331,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33392490",
          "text": "Here we have used a validated approach to assess liver function using 2 laboratory parameters, serum albumin and bilirubin (ALBI), both before and during treatment with ramucirumab in 2 phase III placebo-controlled studies.",
          "offsetInBeginSection": 2136,
          "offsetInEndSection": 2359,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31191834",
          "text": "Patient's age, gender, cause of cirrhosis, ALBI Grade along with the site, size and number of tumors were recorded.",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 612,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688815",
          "text": "Serum albumin, bilirubin, and platelet values were used to determine ALBI and PALBI grades.",
          "offsetInBeginSection": 734,
          "offsetInEndSection": 825,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33392490",
          "text": "BACKGROUND & AIMS\nThe albumin-bilirubin (ALBI) grade/score is derived from a validated nomogram to objectively assess prognosis and liver function in patients with hepatocellular carcinoma (HCC).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32411593",
          "text": "Multivariate analysis suggested that the ALBI grade, AAPR, CA19-9, tumor number, and microvascular invasion were independent prognostic predictors for OS.",
          "offsetInBeginSection": 1048,
          "offsetInEndSection": 1202,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26462681",
          "text": "METHODS\nWe evaluated the correlations between the ALBI grade and Child-Pugh score, adverse events, and survival in 89 patients with advanced HCC who were prospectively treated with sorafenib.",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 432,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36411535",
          "text": "BACKGROUND\nAlbumin-bilirubin (ALBI) grade is an index of liver function based on total bilirubin (T-BIL) and albumin levels, and its usefulness has been widely reported.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27038686",
          "text": "BI grade provided distinct survival curves for C-P B (P = .02), BCLC B (P = .001), and BCLC C (P = .02). When substratified by BCLC stage, ALBI grade ",
          "offsetInBeginSection": 1241,
          "offsetInEndSection": 1391,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31540447",
          "text": "We sought to elucidate the relationship between albumin-bilirubin (ALBI) grade and non-protein respiratory quotient (npRQ) calculated by indirect calorimetry in chronic liver disease (CLD) patients (n = 601, median age = 63 years).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 231,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28295594",
          "text": "This study aimed to elucidate the application of ALBI grade in baseline and sorafenib-end in advanced HCC patients who received sorafenib.",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 307,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33442542",
          "text": "Unlike the Child-Pugh score, the ALBI score uses only objective parameters, albumin (Alb) and total bilirubin (T.Bil), enabling a better evaluation.",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 299,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31284682",
          "text": "p < 0.05). Multivariate analysis identified ALBI grade 1 and baseline AFP level <200 ng/mL as the significant predictors of a high objective response ",
          "offsetInBeginSection": 1338,
          "offsetInEndSection": 1488,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32411593",
          "text": "It remains unclear whether the albumin-bilirubin (ALBI) grade and albumin-to-alkaline phosphatase ratio (AAPR) can predict long-term outcomes of surgically treated patients with intrahepatic cholangiocarcinoma (ICC).",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 307,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33392490",
          "text": "ected by baseline ALBI grade, macrovascular invasion, tumour response, geographical region, or prior locoregional therapy. Baseline ALBI grades 2 and ",
          "offsetInBeginSection": 1366,
          "offsetInEndSection": 1516,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27038686",
          "text": "ation for hepatocellular carcinoma.\n\n\nMATERIALS AND METHODS\nBaseline albumin and bilirubin values of 765 consecutive patients treated with conventiona",
          "offsetInBeginSection": 132,
          "offsetInEndSection": 282,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31908896",
          "text": "Multivariate analysis results showed age, \u03b1-fetoprotein level, tumor number, platelet count, location, Child-Turcotte-Pugh (CTP) and ALBI grade were associated with OS, which generated the nomograms.",
          "offsetInBeginSection": 1177,
          "offsetInEndSection": 1376,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33346079",
          "text": "Increasing ALBI grade was significantly associated with mortality (ALBI grade 2: odds ratio [OR] 5.24; p < 0.001; ALBI grade 3: OR 25.6; p < 0.001) and morbidity (ALBI grade 2: OR 2.15; p < 0.001; ALBI grade 3: OR 6.12; p < 0.001).",
          "offsetInBeginSection": 1256,
          "offsetInEndSection": 1487,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30842180",
          "text": "Multivariate analysis revealed that the ALBI grade combined with the CA19-9 concentration, served as an independent prognostic indicator.",
          "offsetInBeginSection": 1200,
          "offsetInEndSection": 1337,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30588524",
          "text": "RESULTS\nA total of 465 HCC patients were enrolled; multivariate analysis identified ALBI grade \u22652 (p=0.003) as a risk factor for ER, in addition to hepatitis B virus surface antigen (HBsAg)-positive status (p<0.001), tumor size \u22653.5cm (p\u22640.001), lymph-vascular invasion (p=0.001), and the presence of satellite lesions (p=0.009).",
          "offsetInBeginSection": 580,
          "offsetInEndSection": 909,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28116800",
          "text": "nuation identifies a subset of patients with prolonged stability of hepatic reserve and superior survival. This may allow improved patient selection f",
          "offsetInBeginSection": 1404,
          "offsetInEndSection": 1554,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32350365",
          "text": "The impact of the pre- and post-operative ALBI grades on overall survival (OS) and recurrence-free survival (RFS) were analyzed by multivariate analysis.",
          "offsetInBeginSection": 347,
          "offsetInEndSection": 500,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30077606",
          "text": "Post-operative ALBI grade was associated with patients' surgical factors of repeated hepatic resection (P\u202f=\u202f0.012), intra-operative bleeding (P\u202f=\u202f0.006), and surgery duration (P\u202f=\u202f0.033).",
          "offsetInBeginSection": 994,
          "offsetInEndSection": 1181,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32411593",
          "text": "Multivariate analysis suggested that the ALBI grade, AAPR, CA19-9, tumor number, and microvascular invasion were independent prognostic predictors for OS.",
          "offsetInBeginSection": 1048,
          "offsetInEndSection": 1202,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35211856",
          "text": "Furthermore, the association between the ALBI grade and skeletal muscle-related indices is unclear.",
          "offsetInBeginSection": 209,
          "offsetInEndSection": 308,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27214151",
          "text": "ALBI grade 1 vs 2 were proposed as stratification factors within the Child Pugh (CP) A class.",
          "offsetInBeginSection": 164,
          "offsetInEndSection": 257,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30819473",
          "text": "e identified as significant risk factors. The ALBI grade and CTP score based on nomograms were established separately and showed similar prognostic pe",
          "offsetInBeginSection": 1089,
          "offsetInEndSection": 1239,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26462681",
          "text": "Thus, ALBI grade 2B was an independent predictor of poor prognosis in addition to elevated serum aspartate aminotransferase levels, increased serum alpha-fetoprotein level, and macrovascular invasion.",
          "offsetInBeginSection": 1095,
          "offsetInEndSection": 1295,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33627573",
          "text": "These results suggested incorporating CSPH into the ALBI grade could strengthen its prognostic power.",
          "offsetInBeginSection": 1422,
          "offsetInEndSection": 1523,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36291867",
          "text": "In patients receiving curative therapy (radiofrequency ablation and surgical resection), the mALBI grade (grade 2 vs. 1 and grade 3 vs. 2) was an independent predictor of OS.",
          "offsetInBeginSection": 1018,
          "offsetInEndSection": 1192,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30842180",
          "text": "Herein we investigated the prognostic significance of the combination of the ALBI grade with serum carbohydrate antigen 19-9 (CA 19-9) concentration, the most frequently used tumor marker in pancreatic cancer (PC) in resected patients with PC.",
          "offsetInBeginSection": 132,
          "offsetInEndSection": 375,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647219",
          "text": "ng hepatocellular carcinoma (HCC) patients based on hepatic function and predicting their prognosis.\n\n\nMETHOD\nFrom 2000 to 2014, 2584 na\u00efve HCC [69.0\u2009",
          "offsetInBeginSection": 322,
          "offsetInEndSection": 472,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31025380",
          "text": "dentified using an international multi-institutional database. Clinicopathologic factors including ALBI score were assessed using bivariate and multiv",
          "offsetInBeginSection": 285,
          "offsetInEndSection": 435,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32411762",
          "text": "This study aimed to assess and compare the capability of ALBI grade and Child-Pugh score in predicting overall survival (OS).",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 411,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29976502",
          "text": "Similarly, when the ALBI score was included as a binary variable, the ALBI grade, tumor thrombus, and trial were significant predictors of OS.",
          "offsetInBeginSection": 1623,
          "offsetInEndSection": 1765,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29138913",
          "text": "sion analyses were used to determine the factors that influence recurrence and survival.\n\n\nRESULTS\nDuring the follow-up, 130 patients experienced recu",
          "offsetInBeginSection": 870,
          "offsetInEndSection": 1020,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30588524",
          "text": "RESULTS\nA total of 465 HCC patients were enrolled; multivariate analysis identified ALBI grade \u22652 (p=0.003) as a risk factor for ER, in addition to hepatitis B virus surface antigen (HBsAg)-positive status (p<0.001), tumor size \u22653.5cm (p\u22640.001), lymph-vascular invasion (p=0.001), and the presence of satellite lesions (p=0.009).",
          "offsetInBeginSection": 580,
          "offsetInEndSection": 909,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33609383",
          "text": " the combined APRI/ALBI score for clinically relevant outcomes such as mortality was demonstrated. An evidence-based smartphone application will allow",
          "offsetInBeginSection": 1726,
          "offsetInEndSection": 1876,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31191834",
          "text": "Patient's age, gender, cause of cirrhosis, ALBI Grade along with the site, size and number of tumors were recorded.",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 612,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32411762",
          "text": " this retrospective study. The prognostic values of ALBI grade and Child-Pugh score in predicting postoperative OS were respectively estimated using t",
          "offsetInBeginSection": 507,
          "offsetInEndSection": 657,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27214151",
          "text": "(HR) = 1.60 (95%CI: 1.35-1.89, P < 0.001) for A6 vs A5. Median OS was 10.9, 6.6 and 3.0 months for ALBI grade 1, 2 and 3, respectively (P < 0.001), HR",
          "offsetInBeginSection": 1081,
          "offsetInEndSection": 1231,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34942439",
          "text": "at the ALBI grade was significantly associated with progression-free survival and overall survival. Moreover, Cox regression analysis revealed that th",
          "offsetInBeginSection": 1228,
          "offsetInEndSection": 1378,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34621044",
          "text": "ALBI scores were retrospectively calculated based on baseline serum albumin and total bilirubin, with an ALBI grade of 1 defined as\u2009 \u2264\u2009-2.60 score and a grade of 2 as a score of\u2009>\u2009-2.60 to \u2009\u2264\u2009-1.39.",
          "offsetInBeginSection": 634,
          "offsetInEndSection": 832,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30026834",
          "text": "nd 10 (2.5%) patients were correspondingly classified into ALBI grade 1, 2 and 3. The areas under the curves of ALBI-CLIP, CLIP and TNM systems were 0",
          "offsetInBeginSection": 1494,
          "offsetInEndSection": 1644,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27038686",
          "text": "led different survival outcomes for C-P B (P = .001), BCLC A (P < .001), BCLC B (P = .001), and BCLC C (P < .001). When substratified by BCLC stage, A",
          "offsetInBeginSection": 826,
          "offsetInEndSection": 976,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29168098",
          "text": "orodeoxyglucose-positron emission tomography (18F-FDG-PET) and the albumin-bilirubin (ALBI) grade.\n\n\nMETHODS\nThis study included 207 consecutive patie",
          "offsetInBeginSection": 349,
          "offsetInEndSection": 499,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33609383",
          "text": "BACKGROUND\nAspartate aminotransferase/platelet ratio index (APRI) and albumin-bilirubin grade (ALBI) are validated prognostic indices implicated as predictors of postoperative liver dysfunction after hepatic resection.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31284682",
          "text": "The correlations of baseline liver function according to the Child-Pugh score and ALBI grade with treatment outcomes, including objective response rate per mRECIST (modified Response Evaluation Criteria in the Solid Tumor), time to treatment failure, treatment duration, and likelihood of treatment discontinuation due to adverse events, were assessed in patients with hepatocellular carcinoma treated with lenvatinib.",
          "offsetInBeginSection": 305,
          "offsetInEndSection": 723,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28688815",
        "http://www.ncbi.nlm.nih.gov/pubmed/33627573",
        "http://www.ncbi.nlm.nih.gov/pubmed/36291867",
        "http://www.ncbi.nlm.nih.gov/pubmed/31540447",
        "http://www.ncbi.nlm.nih.gov/pubmed/31025380",
        "http://www.ncbi.nlm.nih.gov/pubmed/29976502",
        "http://www.ncbi.nlm.nih.gov/pubmed/35211856",
        "http://www.ncbi.nlm.nih.gov/pubmed/34942439",
        "http://www.ncbi.nlm.nih.gov/pubmed/29168098",
        "http://www.ncbi.nlm.nih.gov/pubmed/31284682",
        "http://www.ncbi.nlm.nih.gov/pubmed/28295594",
        "http://www.ncbi.nlm.nih.gov/pubmed/30026834",
        "http://www.ncbi.nlm.nih.gov/pubmed/33609383",
        "http://www.ncbi.nlm.nih.gov/pubmed/32411593",
        "http://www.ncbi.nlm.nih.gov/pubmed/33442542",
        "http://www.ncbi.nlm.nih.gov/pubmed/28116800",
        "http://www.ncbi.nlm.nih.gov/pubmed/26462681",
        "http://www.ncbi.nlm.nih.gov/pubmed/30077606",
        "http://www.ncbi.nlm.nih.gov/pubmed/31908896",
        "http://www.ncbi.nlm.nih.gov/pubmed/30819473",
        "http://www.ncbi.nlm.nih.gov/pubmed/33346079",
        "http://www.ncbi.nlm.nih.gov/pubmed/30588524",
        "http://www.ncbi.nlm.nih.gov/pubmed/31191834",
        "http://www.ncbi.nlm.nih.gov/pubmed/33788758",
        "http://www.ncbi.nlm.nih.gov/pubmed/34621044",
        "http://www.ncbi.nlm.nih.gov/pubmed/30842180",
        "http://www.ncbi.nlm.nih.gov/pubmed/32411762",
        "http://www.ncbi.nlm.nih.gov/pubmed/36411535",
        "http://www.ncbi.nlm.nih.gov/pubmed/29138913",
        "http://www.ncbi.nlm.nih.gov/pubmed/27214151",
        "http://www.ncbi.nlm.nih.gov/pubmed/32350365",
        "http://www.ncbi.nlm.nih.gov/pubmed/26647219",
        "http://www.ncbi.nlm.nih.gov/pubmed/27038686",
        "http://www.ncbi.nlm.nih.gov/pubmed/33392490"
      ]
    },
    {
      "id": "64240f33690f196b51000049",
      "type": "list",
      "body": "What drugs are used to treat FIP, Feline Infectious Peritonitis in cats?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19482534",
          "text": "fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive a",
          "offsetInBeginSection": 52,
          "offsetInEndSection": 202,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33799985",
          "text": "ed, and most of the affected cats die or are euthanized. Anecdotally, doxycycline has been used to treat FIP-affected cats, but there are currently no",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 341,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/793459",
          "text": "Serum antibodies to the feline infectious peritonitis (FIP) virus were measured in cats, using an indirect fluorescent antibody procedure.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31375588",
          "text": "Our recombinant FCoVs are powerful tools for increasing our understanding of the viral life cycle and pathogenesis of FIP-inducing type I FCoV.IMPORTANCE Feline coronavirus (FCoV) is one of the most significant coronaviruses, because this virus induces feline infectious peritonitis (FIP), which is a lethal disease in cats.",
          "offsetInBeginSection": 1498,
          "offsetInEndSection": 1822,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36002137",
          "text": "Research has demonstrated efficacy of new antivirals in FIP treatment, but these products are not legally available in many countries at this time.",
          "offsetInBeginSection": 1694,
          "offsetInEndSection": 1841,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36387398",
          "text": "ive and no relapse was observed.\n\n\nConclusions and relevance\nGS-441524 combined with GC376 can be safely and effectively used to treat FIP and reduces",
          "offsetInBeginSection": 1427,
          "offsetInEndSection": 1577,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19058829",
          "text": "The lethal pathology associated with FIP (granulomatous inflammation and T-cell lymphopenia) is thought to be mediated by aberrant modulation of the immune system due to infection of cells such as monocytes and macrophages.",
          "offsetInBeginSection": 188,
          "offsetInEndSection": 411,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15123155",
          "text": "ritonitis (FIP) were treated with a combination of recombinant feline interferon and glucocorticoid. A complete remission (over 2 years) and a partial",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18196725",
          "text": "All cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin.",
          "offsetInBeginSection": 620,
          "offsetInEndSection": 736,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20180212",
          "text": "Current treatments are crude and involve supportive care and immunosuppression.",
          "offsetInBeginSection": 439,
          "offsetInEndSection": 518,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458025",
          "text": "s slightly better in specific pathogen-free cats treated with NP7 and NP8 with fCpG-ODNs. However, immune tolerance was suggested to be induced by the",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 771,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8588340",
          "text": "Feline infectious peritonitis (FIP) virus antigen was demonstrated after methanol, ethanol or formalin fixation in paraffin-embedded tissues by means of monoclonal and polyclonal antibodies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14623149",
          "text": "The possible role of some acute phase proteins (APPs) and immunoglobulins in both the pathogenesis and diagnosis of feline infectious peritonitis (FIP) has been investigated.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33644160",
          "text": "For the treatment of FIP, several effective antivirals were recently reported, but many of these are not available for practical use.",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 275,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36297266",
          "text": "This study provides a proof of principle for the use of molnupiravir in cats and supports the need for future studies to further evaluate molnupiravir as a potentially safe and effective therapy for FIP.",
          "offsetInBeginSection": 1089,
          "offsetInEndSection": 1292,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36015002",
          "text": " cats that presented with these laboratory changes. This study shows that PI is beneficial in the treatment of FIP, and more studies are needed to est",
          "offsetInBeginSection": 1229,
          "offsetInEndSection": 1379,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31375588",
          "text": "es derived from type I FCoV that retained its virulence. Our recombinant FCoVs are powerful tools for increasing our understanding of the viral life c",
          "offsetInBeginSection": 1441,
          "offsetInEndSection": 1591,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33799985",
          "text": "ration 50% (IC50) 4.1 \u00b5g/mL and IC90 5.4 \u00b5g/mL. Our data suggest that doxycycline has some inhibitory effect on FIPV replication in vitro, which suppo",
          "offsetInBeginSection": 1099,
          "offsetInEndSection": 1249,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32441826",
          "text": "spite a variety of historically used treatments. Recently developed antiviral drugs have shown promise in treatment of nonneurological FIP, but data f",
          "offsetInBeginSection": 317,
          "offsetInEndSection": 467,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9330474",
          "text": "The potential value of raised levels of the acute phase reactants, alpha 1-acid glycoprotein (AGP) and haptoglobin in the diagnosis of the disease was investigated.",
          "offsetInBeginSection": 236,
          "offsetInEndSection": 400,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36387398",
          "text": "Objectives\nThe main objectives of this study were to investigate the efficacy of the nucleotide analog GS-441524 in combination with the 3C-like protease inhibitor GC376 for the treatment of naturally aquired feline infectious peritonitis (FIP) and to test whether their combination shortens the dosing period and improves the cure rate.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 337,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32456286",
          "text": "Our study suggested that HCQ and rfIFN-\u03c9 are applicable for treatment of FIP.",
          "offsetInBeginSection": 882,
          "offsetInEndSection": 959,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35281564",
          "text": "ole in mediating viral replication and transcription. An Mpro inhibitor, GC376, has been shown to treat feline infectious peritonitis (FIP), a fatal i",
          "offsetInBeginSection": 288,
          "offsetInEndSection": 438,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22092616",
          "text": "All cats received additional treatment with glucocorticoids, antibiotics, and low molecular weight heparin according to methods.",
          "offsetInBeginSection": 569,
          "offsetInEndSection": 697,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11033870",
          "text": "Treatment of ocular FIP is symptomatic, and the mainstay of palliative therapy is topical or systemic corticosteroids or both.",
          "offsetInBeginSection": 535,
          "offsetInEndSection": 661,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34406859",
          "text": "ty in adult cats), which will be powerful tools to study pathogenesis, antiviral drugs, and vaccines for FCoV. IMPORTANCE Tissue- or cell culture-adap",
          "offsetInBeginSection": 1558,
          "offsetInEndSection": 1708,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31846702",
          "text": "d reiterated the urgent need to develop effective anti-FIP therapeutic agents and anti-FIPV vaccines. As pet cats are household animals, risk communic",
          "offsetInBeginSection": 1517,
          "offsetInEndSection": 1667,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34406859",
          "text": "Importantly, the wild-type FIPV replicase skeleton of serotype I will greatly facilitate the screening of antiviral drugs, both in vivo and in vitro.",
          "offsetInBeginSection": 2357,
          "offsetInEndSection": 2506,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36015002",
          "text": "An ineffective immune response is an important component of FIP pathophysiology; hence treatment with an immune stimulant such as Polyprenyl Immunostimulant\u2122 (PI), which enhances cell-mediated immunity by upregulating the innate immune response via Toll-like receptors, is a rational approach.",
          "offsetInBeginSection": 107,
          "offsetInEndSection": 400,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777454",
          "text": "The appearance of a case of FIP in the cattery was associated with an increased expression of cytokines, in particular there was an increased production of IL-1beta and IFN-gamma, suggesting that these cytokines might protect infected cats from the disease.",
          "offsetInBeginSection": 650,
          "offsetInEndSection": 907,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19058829",
          "text": "e production was inhibited by the pyridinyl imidazole inhibitors SB 203580 and SC 409 in a dose-dependent manner. FIPV-induced p38 MAPK activation was",
          "offsetInBeginSection": 997,
          "offsetInEndSection": 1147,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32441826",
          "text": "cranial and caudal segment disease with ocular imaging. Treatment with GS-441524 shows clinical efficacy and may result in clearance and long-term res",
          "offsetInBeginSection": 1459,
          "offsetInEndSection": 1609,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36297266",
          "text": "Feline infectious peritonitis (FIP) is a complex and historically fatal disease, though recent advances in antiviral therapy have uncovered potential treatments.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26850532",
          "text": "Progression to FIP was prevented in 2 out of 3 cats treated with mAb 2-4, whereas all 3 cats developed FIP in the placebo control group.",
          "offsetInBeginSection": 602,
          "offsetInEndSection": 738,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18395801",
          "text": "Some veterinarians prescribe immune modulators to treat cats with FIP with no documented controlled evidence of efficacy.",
          "offsetInBeginSection": 624,
          "offsetInEndSection": 745,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29542369",
          "text": "OBJECTIVES\nThe amino acid substitutions M1058L and S1060A in the spike protein of feline coronavirus (FCoV) have been postulated to be responsible for the development of the pathogenic feline infectious peritonitis virus (FIPV), which causes feline infectious peritonitis (FIP).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 278,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26656689",
          "text": " most important fatal infectious diseases of cats worldwide. No specific vaccines or drugs have been approved to treat FIP. CoV main proteases (M(pro)",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 439,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9637307",
          "text": "We tried to evaluate the effect of thromboxane (Tx) synthetase inhibitor, ozagrel hydrochloride, on the progression of symptoms and clinicopathologic data characteristic to FIP.",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 278,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24886103",
          "text": "Currently, no protective vaccine or effective treatment for the disease is available.",
          "offsetInBeginSection": 128,
          "offsetInEndSection": 213,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26592814",
          "text": "f cats in multi-cat households per year. In an effort to develop small molecule drugs targeting FIP for the treatment of cats, we screened a small set",
          "offsetInBeginSection": 326,
          "offsetInEndSection": 476,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26850532",
          "text": "In the present study, we investigated whether mAb 2-4 improved the FIP symptoms and survival rate of experimentally FIPV-inoculated SPF cats.",
          "offsetInBeginSection": 460,
          "offsetInEndSection": 601,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30658691",
          "text": "Feline coronaviruses (FCoVs) are the causative agents of severe systemic disease (feline infectious peritonitis: FIP) in domestic and wild cats.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33138721",
          "text": "Historically, three major pharmacological approaches have been employed to treat FIP: (1) immunomodulators to stimulate the patient's immune system non-specifically to reduce the clinical effects of the virus through a robust immune response, (2) immunosuppressive agents to dampen clinical signs temporarily, and (3) re-purposed human antiviral drugs, all of which have been unsuccessful to date in providing reliable efficacious treatment options for FIPV.",
          "offsetInBeginSection": 205,
          "offsetInEndSection": 663,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264736",
          "text": "rmed to have fTNF-alpha neutralization activity. Purified mouse mAb 2-4 and chimeric mAb 2-4 were repeatedly administered to cats, and the changes in ",
          "offsetInBeginSection": 703,
          "offsetInEndSection": 853,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14623149",
          "text": "These results suggest that changes in the electrophoretic motility of APPs or APPs other than Hp, SAA and AGP might be involved in the pathogenesis of FIP or in protecting cats from the disease.",
          "offsetInBeginSection": 912,
          "offsetInEndSection": 1106,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14960820",
          "text": "To investigate the usefulness of ascites as a material for viral tests in cats with effusive feline infectious peritonitis (FIP), we attempted to detect anti-feline coronavirus antibody, anti-feline immunodeficiency virus antibody, and feline leukemia virus antigen in ascites from 88 cats clinically suspected with effusive FIP.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 329,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1319173",
          "text": "Anti-idiotypic antibodies (Ab2s) generated against neutralizing antibodies (Ab1s) specific for feline infectious peritonitis virus (FIPV) were shown to be specific for paratope-associated idiotopes of the Ab1s and not against isotypic determinants.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9330474",
          "text": "Serum samples from feline immunodeficiency virus-infected cats were also analysed for these proteins and their concentrations were significantly elevated, illustrating that raised levels of AGP and haptoglobin are not pathognomonic for FIP.",
          "offsetInBeginSection": 1006,
          "offsetInEndSection": 1246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219425",
          "text": "Previously, we reported the generation of broad-spectrum peptidyl inhibitors against viruses that possess a 3C or 3CL protease.",
          "offsetInBeginSection": 865,
          "offsetInEndSection": 992,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34406859",
          "text": "Currently, there are no clinically approved drugs or effective vaccines for FIP.",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 238,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16777454",
        "http://www.ncbi.nlm.nih.gov/pubmed/18196725",
        "http://www.ncbi.nlm.nih.gov/pubmed/36015002",
        "http://www.ncbi.nlm.nih.gov/pubmed/27264736",
        "http://www.ncbi.nlm.nih.gov/pubmed/34406859",
        "http://www.ncbi.nlm.nih.gov/pubmed/24886103",
        "http://www.ncbi.nlm.nih.gov/pubmed/36297266",
        "http://www.ncbi.nlm.nih.gov/pubmed/22092616",
        "http://www.ncbi.nlm.nih.gov/pubmed/26592814",
        "http://www.ncbi.nlm.nih.gov/pubmed/33644160",
        "http://www.ncbi.nlm.nih.gov/pubmed/36002137",
        "http://www.ncbi.nlm.nih.gov/pubmed/33799985",
        "http://www.ncbi.nlm.nih.gov/pubmed/32441826",
        "http://www.ncbi.nlm.nih.gov/pubmed/26850532",
        "http://www.ncbi.nlm.nih.gov/pubmed/26656689",
        "http://www.ncbi.nlm.nih.gov/pubmed/35281564",
        "http://www.ncbi.nlm.nih.gov/pubmed/23219425",
        "http://www.ncbi.nlm.nih.gov/pubmed/31846702",
        "http://www.ncbi.nlm.nih.gov/pubmed/33138721",
        "http://www.ncbi.nlm.nih.gov/pubmed/32456286",
        "http://www.ncbi.nlm.nih.gov/pubmed/14960820",
        "http://www.ncbi.nlm.nih.gov/pubmed/19058829",
        "http://www.ncbi.nlm.nih.gov/pubmed/18395801",
        "http://www.ncbi.nlm.nih.gov/pubmed/29542369",
        "http://www.ncbi.nlm.nih.gov/pubmed/24458025",
        "http://www.ncbi.nlm.nih.gov/pubmed/30658691",
        "http://www.ncbi.nlm.nih.gov/pubmed/31375588",
        "http://www.ncbi.nlm.nih.gov/pubmed/8588340",
        "http://www.ncbi.nlm.nih.gov/pubmed/20180212",
        "http://www.ncbi.nlm.nih.gov/pubmed/36387398",
        "http://www.ncbi.nlm.nih.gov/pubmed/9637307",
        "http://www.ncbi.nlm.nih.gov/pubmed/19482534",
        "http://www.ncbi.nlm.nih.gov/pubmed/793459",
        "http://www.ncbi.nlm.nih.gov/pubmed/11033870",
        "http://www.ncbi.nlm.nih.gov/pubmed/14623149",
        "http://www.ncbi.nlm.nih.gov/pubmed/15123155",
        "http://www.ncbi.nlm.nih.gov/pubmed/9330474",
        "http://www.ncbi.nlm.nih.gov/pubmed/1319173"
      ]
    },
    {
      "id": "6428da98690f196b51000053",
      "type": "yesno",
      "body": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32511488",
          "text": "Few studies have compared these clinical features and outcomes of COVID-19 to other acute respiratory illnesses.",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33947345",
          "text": "million cases have occurred worldwide as of June 16, 2020. However, it is important to distinguish COVID-19 from other respiratory infectious diseases",
          "offsetInBeginSection": 88,
          "offsetInEndSection": 238,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33821230",
          "text": " hospitalized patients with other viral pneumonias such as influenza is unknown.\n\n\nObjectives\nTo assess the incidence of venous and arterial thromboti",
          "offsetInBeginSection": 327,
          "offsetInEndSection": 477,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33907612",
          "text": "n most\u00a0other contagious respiratory illnesses. The\u00a0mechanisms underlying this difference remain unclear.\n\n\nMETHODS\nWe compared the immunological lands",
          "offsetInBeginSection": 79,
          "offsetInEndSection": 229,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32832306",
          "text": "COVID-19) are both contagious respiratory illnesses, but they are caused by different viruses. COVID-19 pandemic is caused by a novel virus - severe a",
          "offsetInBeginSection": 40,
          "offsetInEndSection": 190,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34111501",
          "text": "Although COVID-19 is often compared to other respiratory viral illnesses, few formal comparisons of these viruses on kidney health exist.",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 306,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090987",
          "text": "Data that examine all in-hospital complications of COVID-19 and that compare these complications with those associated with other viral respiratory pathogens, such as influenza, are lacking.",
          "offsetInBeginSection": 214,
          "offsetInEndSection": 404,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36410319",
          "text": "ose with dengue or influenza, adjusting for age, subregion, and days from illness onset to presentation for clinical care. Among 13,431 participants, ",
          "offsetInBeginSection": 697,
          "offsetInEndSection": 847,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34728719",
          "text": "other respiratory viral infections, such as Influenza, has not hitherto been extensively studied. We aimed to compare the prognostic value of NLR in C",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 313,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34484383",
          "text": "CONCLUSION\nDuring influenza season, differentiating other causes of respiratory illness from COVID-19 is difficult, because common clinical manifestations of COVID-19 mimic those of influenza.",
          "offsetInBeginSection": 694,
          "offsetInEndSection": 886,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33623450",
          "text": "CONCLUSION\nMachine learning provides a tool that can rapidly and accurately distinguish between COVID-19 and influenza cases.",
          "offsetInBeginSection": 1426,
          "offsetInEndSection": 1551,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33615750",
          "text": "However, as the treatments and prognoses of COVID-19 and influenza are different, it is important to accurately differentiate these two different respiratory tract infections on the basis of their respective early-stage characteristics.",
          "offsetInBeginSection": 247,
          "offsetInEndSection": 483,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32511543",
          "text": "evere respiratory distress, such as influenza virus infection, are not fully understood. Here we addressed this by developing a prospective observatio",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 340,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34900356",
          "text": "However, unlike other viral respiratory tract infections such as influenza, bacterial coinfection in COVID-19 patients has uncommonly been described in adult and pediatric patients.",
          "offsetInBeginSection": 316,
          "offsetInEndSection": 497,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34016619",
          "text": "BACKGROUND\nInfluenza epidemics were initially considered to be a suitable model for the COVID-19 epidemic, but there is a lack of data concerning patients with chronic respiratory diseases (CRDs), who were supposed to be at risk of severe forms of COVID-19.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33869239",
          "text": " be the cough sound, which comes in different types and forms. A reliable lab-free tool for early and accurate diagnosis, which can differentiate betw",
          "offsetInBeginSection": 733,
          "offsetInEndSection": 883,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33038391",
          "text": "Future work is needed to validate this histopathologic finding and, if confirmed, elucidate the mechanistic underpinnings and characterize any associations with clinically important outcomes.",
          "offsetInBeginSection": 1661,
          "offsetInEndSection": 1852,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32881022",
          "text": "With our findings, we emphasize that epidemiological risk factors and clinical symptoms are more useful than laboratory and radiological abnormalities in differentiating COVID-19 from other respiratory viral infections.",
          "offsetInBeginSection": 1173,
          "offsetInEndSection": 1392,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090987",
          "text": "These findings highlight the higher risk for most complications associated with COVID-19 compared with influenza and might aid clinicians and researchers in recognizing, monitoring, and managing the spectrum of COVID-19 manifestations.",
          "offsetInBeginSection": 2499,
          "offsetInEndSection": 2734,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33901185",
          "text": "At clinical presentation, nine basic clinical and epidemiological indicators may help to distinguish COVID-19 or dengue from each other and other febrile illnesses.",
          "offsetInBeginSection": 2027,
          "offsetInEndSection": 2191,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590732",
          "text": "The success and efficacy of vaccination campaigns for other respiratory illnesses, such as influenza, may help inform messaging around COVID-19 vaccinations.",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 298,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33995342",
          "text": "he factors distinguishing SARS-CoV-2 from other respiratory viruses are unknown. Here, we compared the clinical, histopathological, and immunological ",
          "offsetInBeginSection": 290,
          "offsetInEndSection": 440,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33623450",
          "text": "However, there is no available tool that can rapidly and precisely distinguish between these two diseases in the absence of laboratory evidence of specific pathogens.",
          "offsetInBeginSection": 206,
          "offsetInEndSection": 372,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33128444",
          "text": "th the combined threat of influenza and COVID-19. Ensuring that this approach is optimal will be key as we move from a reactive pandemic response towa",
          "offsetInBeginSection": 1416,
          "offsetInEndSection": 1566,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32497283",
          "text": "some other respiratory pathogens. However, the information of COVID-19 and influenza coinfection is limited. In this study, we reported our coinfected",
          "offsetInBeginSection": 265,
          "offsetInEndSection": 415,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35411212",
          "text": "break of COVID-19. Therefore, testing for respiratory viruses should be performed in all patients with flu-like symptoms for effective surveillance of",
          "offsetInBeginSection": 1542,
          "offsetInEndSection": 1692,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33135801",
          "text": "It is difficult to distinguish coronavirus disease-2019 (COVID-19) from other viral respiratory tract infections owing to the similarities in clinical and radiological findings.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33907612",
          "text": "munity-L, respectively. These data indicate that most COVID-19 patients have weaker immune signatures than influenza and RSV patients, as evidenced by",
          "offsetInBeginSection": 812,
          "offsetInEndSection": 962,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33970449",
          "text": "This study is aimed to compare the clinical and laboratory characteristics of COVID-19 and H1N1 influenza infections.",
          "offsetInBeginSection": 319,
          "offsetInEndSection": 436,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33901185",
          "text": "Factors independently associated with COVID-19 or with dengue were sought using multinomial logistic regression models, taking other febrile illnesses (OFIs) as controls.",
          "offsetInBeginSection": 851,
          "offsetInEndSection": 1021,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33623450",
          "text": "CONCLUSION\nMachine learning provides a tool that can rapidly and accurately distinguish between COVID-19 and influenza cases.",
          "offsetInBeginSection": 1426,
          "offsetInEndSection": 1551,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32490031",
          "text": "BACKGROUND\nThere is currently a lack of nonspecific laboratory indicators as a quantitative standard to distinguish between the 2019 coronavirus disease (COVID-19) and an influenza A or B virus infection.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090987",
          "text": "tes,* were analyzed. Using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes, complications in patient",
          "offsetInBeginSection": 756,
          "offsetInEndSection": 906,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32905055",
          "text": "Since coronavirus disease 2019 (COVID-19) might circulate in the following seasons, it is essential to understand how COVID-19 influences other respiratory diseases, especially influenza.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34111501",
          "text": "ed with COVID-19 compared to influenza, a finding that may be driven largely by illness severity. Hence, the combined impact of these two illnesses on",
          "offsetInBeginSection": 1394,
          "offsetInEndSection": 1544,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33137167",
          "text": "Moreover, MDW \u2265 20 and NLR > 5 effectively identified influenza infection (AUC: 0.7055).",
          "offsetInBeginSection": 874,
          "offsetInEndSection": 962,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35736988",
          "text": "However, there was no change in the influenza positivity rate between pre-COVID-19 (29%) and COVID-19 (30%) period.",
          "offsetInBeginSection": 1101,
          "offsetInEndSection": 1216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33907612",
          "text": "Gene ontology analysis showed that the innate and adaptive immune responses were significantly downregulated in COVID-19 versus healthy individuals.",
          "offsetInBeginSection": 1448,
          "offsetInEndSection": 1596,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36362465",
          "text": "Background: There is ongoing debate whether lung physiology of COVID-19-associated acute respiratory distress syndrome (ARDS) differs from ARDS of other origin.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32903584",
          "text": "Here, we hypothesize the order of symptom occurrence could help patients and medical professionals more quickly distinguish COVID-19 from other respiratory diseases, yet such essential information is largely unavailable.",
          "offsetInBeginSection": 354,
          "offsetInEndSection": 574,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33997112",
          "text": "(1) We show that COVID-19-CT-CXR, when used as additional training data, is able to contribute to improved deep-learning (DL) performance for the classification of COVID-19 and non-COVID-19 CT. (2) We collected CT images of influenza, another common infectious respiratory illness that may present similarly to COVID-19, and fine-tuned a baseline deep neural network to distinguish a diagnosis of COVID-19, influenza, or normal or other types of diseases on CT. (3) We fine-tuned an unsupervised one-class classifier from non-COVID-19 CXR and performed anomaly detection to detect COVID-19 CXR.",
          "offsetInBeginSection": 1098,
          "offsetInEndSection": 1692,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32511543",
          "text": "Influenza and COVID-19 patients could be distinguished statistically based on cytokine module expression, particularly after controlling for the significant effects of age on cytokine expression, but again with lower levels of most cytokines in COVID-19 subjects.",
          "offsetInBeginSection": 1738,
          "offsetInEndSection": 2001,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34050659",
          "text": "CONCLUSIONS\nWhile COVID-19 can cause a respiratory illness like influenza, it is associated with significantly greater severity of illness, longer hospital stays, and higher in-hospital deaths.",
          "offsetInBeginSection": 1628,
          "offsetInEndSection": 1821,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34981695",
          "text": "ID-19 over other viral infections. However, the differences between the groups were not substantial enough and would probably not suffice to distingui",
          "offsetInBeginSection": 1155,
          "offsetInEndSection": 1305,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590732",
          "text": "3+: ORadj \u2009=\u20090.45; 95% CI: 0.36-0.56, compared to 0). The influenza vaccination campaign template is effective at reaching those most at risk for seri",
          "offsetInBeginSection": 1435,
          "offsetInEndSection": 1585,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32490031",
          "text": "As such, our research provides a useful test for doctors to differentiate COVID-19 from influenza.",
          "offsetInBeginSection": 1265,
          "offsetInEndSection": 1363,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32127123",
          "text": "Since the symptoms are similar to other respiratory infections, differential diagnosis in travellers arriving from countries with wide-spread COVID-19 must include other more common infections such as influenza and other respiratory tract diseases.",
          "offsetInBeginSection": 298,
          "offsetInEndSection": 546,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36410319",
          "text": "hain reaction were included. We calculated adjusted odds ratios (aORs) and 95% CIs using logistic regression to assess clinical characteristics of par",
          "offsetInBeginSection": 509,
          "offsetInEndSection": 659,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34981695",
          "text": "AIM\nTo identify clinical and laboratory parameters that can assist in the differential diagnosis of coronavirus disease 2019 (COVID-19), influenza, and respiratory syncytial virus (RSV) infections.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34055833",
          "text": "It is important to characterize the differences in disease presentation and trajectory between COVID-19 patients and other patients with common respiratory illnesses.",
          "offsetInBeginSection": 98,
          "offsetInEndSection": 264,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34728719",
        "http://www.ncbi.nlm.nih.gov/pubmed/33128444",
        "http://www.ncbi.nlm.nih.gov/pubmed/34981695",
        "http://www.ncbi.nlm.nih.gov/pubmed/32511488",
        "http://www.ncbi.nlm.nih.gov/pubmed/33947345",
        "http://www.ncbi.nlm.nih.gov/pubmed/35736988",
        "http://www.ncbi.nlm.nih.gov/pubmed/34016619",
        "http://www.ncbi.nlm.nih.gov/pubmed/34050659",
        "http://www.ncbi.nlm.nih.gov/pubmed/36410319",
        "http://www.ncbi.nlm.nih.gov/pubmed/35411212",
        "http://www.ncbi.nlm.nih.gov/pubmed/33995342",
        "http://www.ncbi.nlm.nih.gov/pubmed/33137167",
        "http://www.ncbi.nlm.nih.gov/pubmed/32127123",
        "http://www.ncbi.nlm.nih.gov/pubmed/32905055",
        "http://www.ncbi.nlm.nih.gov/pubmed/33907612",
        "http://www.ncbi.nlm.nih.gov/pubmed/33821230",
        "http://www.ncbi.nlm.nih.gov/pubmed/32490031",
        "http://www.ncbi.nlm.nih.gov/pubmed/33901185",
        "http://www.ncbi.nlm.nih.gov/pubmed/32881022",
        "http://www.ncbi.nlm.nih.gov/pubmed/32511543",
        "http://www.ncbi.nlm.nih.gov/pubmed/36362465",
        "http://www.ncbi.nlm.nih.gov/pubmed/33090987",
        "http://www.ncbi.nlm.nih.gov/pubmed/34484383",
        "http://www.ncbi.nlm.nih.gov/pubmed/33869239",
        "http://www.ncbi.nlm.nih.gov/pubmed/33615750",
        "http://www.ncbi.nlm.nih.gov/pubmed/32832306",
        "http://www.ncbi.nlm.nih.gov/pubmed/32903584",
        "http://www.ncbi.nlm.nih.gov/pubmed/33970449",
        "http://www.ncbi.nlm.nih.gov/pubmed/32497283",
        "http://www.ncbi.nlm.nih.gov/pubmed/34111501",
        "http://www.ncbi.nlm.nih.gov/pubmed/33623450",
        "http://www.ncbi.nlm.nih.gov/pubmed/34590732",
        "http://www.ncbi.nlm.nih.gov/pubmed/33038391",
        "http://www.ncbi.nlm.nih.gov/pubmed/33135801",
        "http://www.ncbi.nlm.nih.gov/pubmed/34055833",
        "http://www.ncbi.nlm.nih.gov/pubmed/33997112",
        "http://www.ncbi.nlm.nih.gov/pubmed/34900356"
      ]
    },
    {
      "id": "6415c8f1690f196b51000017",
      "type": "factoid",
      "body": "Which form of cancer have paclitaxel, docetaxel, doxorubicin, and epirubicin been approved for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26918039",
          "text": "used in the treatment of a variety of cancers, including those of squamous histology. In their formulation, both agents require solvents, which have b",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 242,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18420499",
          "text": "xel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer.\n\n\nMETHODS\nWe enrolled 4950 women with axillary lymph node-posit",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 233,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8629032",
          "text": "rubicin (Farmitalia Carlo Erba, Milan, Italy) in patients with metastatic breast cancer. In addition to standard eligibility criteria, patients with c",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 319,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9865708",
          "text": "her doxorubicin or epirubicin has significant activity against metastatic breast cancer. However, the optimal schedule in terms of activity and toxici",
          "offsetInBeginSection": 90,
          "offsetInEndSection": 240,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11552225",
          "text": "While both paclitaxel and docetaxel may be effectively combined with doxorubicin in the treatment of metastatic breast cancer, the drug-drug interaction between paclitaxel and doxorubicin (but not of docetaxel and doxorubicin) warrants that certain restrictions be followed for safe use.",
          "offsetInBeginSection": 1324,
          "offsetInEndSection": 1611,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12473512",
          "text": "apeutic agents for the first-line and second-line treatment of metastatic breast cancer, and their clinical use is widespread. However, for women whos",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 262,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10426454",
          "text": "re among the most active cytotoxic agents for the treatment of metastatic breast cancer. Given their activity, relative non-cross-resistance, partiall",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11129728",
          "text": "The combination of paclitaxel and doxorubicin or epirubicin is highly active against metastatic breast cancer, yet may produce congestive heart failure.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8629032",
          "text": "We conclude that the combination paclitaxel/epirubicin is safe for patients with metastatic breast cancer and, at this early evaluation, shows promising antitumor activity.",
          "offsetInBeginSection": 1939,
          "offsetInEndSection": 2111,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11432615",
          "text": "BACKGROUND\nTreatment of metastatic breast cancer (MBC) with paclitaxel (T) and doxorubicin has yielded high response rates but the regimen is associated with significant cardiac toxicity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10403474",
          "text": "Given the single-agent activity of docetaxel and doxorubicin in metastatic breast cancer and their potential non-cross-resistance, several phase I/II pilot studies of either docetaxel/doxorubicin (TA) or TA plus cyclophosphamide (TAC) were conducted.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9516602",
          "text": "l) and epirubicin, the 4'-epimer of doxorubicin, in women with metastatic breast cancer. A total of 85 patients with histologically proven metastatic ",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 236,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18991787",
          "text": "ed survival gain. New drugs which have proven efficacy against metastatic breast cancer are Taxanes (Paclitaxel and Docetaxel), Vinorelbine, Capecitab",
          "offsetInBeginSection": 533,
          "offsetInEndSection": 683,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11970750",
          "text": "The sequential use of a doxorubicin combination followed by paclitaxel has been reported to improve disease-free and overall survival in patients with node-positive breast cancer beyond that obtained with doxorubicin/cyclophosphamide combinations.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17028669",
          "text": "Two taxanes, paclitaxel and docetaxel, are among the most widely used chemotherapeutic agents in solid tumor oncology, with efficacy against tumors of the breast, lung, head and neck, ovary, prostate, stomach and urothelium.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10511918",
          "text": "fers a new opportunity for devising effective therapy for patients with breast cancer. High response rates have been obtained by combining epirubicin ",
          "offsetInBeginSection": 79,
          "offsetInEndSection": 229,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27083592",
          "text": "irubicin-based regimens are both approved for the treatment of metastatic gastric cancer. We perform a systemic review with metanalysis to evaluate th",
          "offsetInBeginSection": 15,
          "offsetInEndSection": 165,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15039596",
          "text": "Less than half of breast cancer patients respond to second-line chemotherapy with paclitaxel after failing treatment with anthracyclines such as doxorubicin.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17296814",
          "text": "These initiatives, including prospective trials and retrospective examinations of large clinical experience, have involved agents previously approved by the FDA for use in ovarian cancer (e.g., cisplatin, paclitaxel, topotecan, and liposomal doxorubicin) and the development of new strategies for drugs approved for other malignant conditions (e.g., gemcitabine, docetaxel, etoposide, irinotecan, vinorelbine, and bevacizumab).",
          "offsetInBeginSection": 314,
          "offsetInEndSection": 741,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11552226",
          "text": "Investigation of the combination of the taxanes with doxorubicin in the treatment of breast cancer has logically progressed, with the ultimate goal of identifying a safe and effective regimen for use in the adjuvant setting.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27083592",
          "text": "of docetaxel and epirubicin-based chemotherapeutic regimens in metastatic gastric cancer. Other parameters as, comorbidity, concomitant diseases and p",
          "offsetInBeginSection": 1212,
          "offsetInEndSection": 1362,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9463787",
          "text": " available for both analogues in the advanced, metastatic setting of breast cancer. Both also have been compared as single agents with doxorubicin wit",
          "offsetInBeginSection": 846,
          "offsetInEndSection": 996,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17425475",
          "text": "Chemotherapy is of crucial importance in advanced gastric cancer patients, in order to obtain palliation of symptoms and improve survival.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14499011",
          "text": "he 1990s, the taxanes have emerged as the most powerful compounds in breast cancer. Paclitaxel and docetaxel have been evaluated in the metastatic set",
          "offsetInBeginSection": 54,
          "offsetInEndSection": 204,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27811367",
          "text": "rubicin + cyclophosphamide and paclitaxel in the treatment of metastatic/advanced breast cancer.\n\n\nRESULTS\nThis network meta-analysis included 8 rando",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 436,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35976445",
          "text": "gstanding,\u00a0Food and Drug Administration (FDA)-approved therapies against TNBC. Additionally, the FDA approved\u00a0PARP inhibitors such as olaparib and ate",
          "offsetInBeginSection": 696,
          "offsetInEndSection": 846,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14768404",
          "text": "In patients with advanced breast cancer, treatment with paclitaxel and doxorubicin has been shown to produce impressive overall response rates (up to 94%) and to prolong overall survival significantly over a combination of fluorouracil (5-FU), doxorubicin, and cyclophosphamide (Cytoxan, Neosar) in one prospective phase III clinical study.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 340,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11970739",
          "text": "The taxanes are emerging as the most powerful compounds in breast cancer. Both compounds, paclitaxel and docetaxel, have been evaluated in the metasta",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17990102",
          "text": "e a cornerstone in the treatment of patients with early and advanced breast cancer. Following the initial generation of trials conducted to prove thei",
          "offsetInBeginSection": 165,
          "offsetInEndSection": 315,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18420499",
          "text": "clophosphamide improves disease-free and overall survival in women with breast cancer. (ClinicalTrials.gov number, NCT00004125 [ClinicalTrials.gov].).",
          "offsetInBeginSection": 1592,
          "offsetInEndSection": 1742,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9463787",
          "text": "een evaluated in randomised trials as first-line treatment of non-small-cell lung cancer (NSCLC). The results of these trials taken together suggest t",
          "offsetInBeginSection": 1811,
          "offsetInEndSection": 1961,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12435293",
          "text": "Both of these agents are highly active in patients with advanced breast cancer.",
          "offsetInBeginSection": 240,
          "offsetInEndSection": 319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9463787",
          "text": "are not equitoxic. Either agent by itself, in the treatment of metastatic breast cancer, remains appropriate; however, lack of cumulative toxicity may",
          "offsetInBeginSection": 1335,
          "offsetInEndSection": 1485,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11396360",
          "text": "Doxorubicin/paclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32365878",
          "text": "BACKGROUND\nBreast cancer (BC) is a heterogeneous disease for which the commonly used chemotherapeutic agents primarily include the anthracyclines (doxorubicin, epirubicin), microtubule inhibitors (paclitaxel, docetaxel, eribulin), and alkylating agents (cyclophosphamide).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 272,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9865686",
          "text": "rance) are the most active cytotoxic agents in the treatment of advanced breast cancer. In the pre-taxane era, randomized trials demonstrated that dox",
          "offsetInBeginSection": 67,
          "offsetInEndSection": 217,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8604450",
          "text": "Docetaxel and paclitaxel appear to be valuable agents for use in anthracycline-resistant breast cancer patients, and may find a place in anthracycline-containing combination regimens.",
          "offsetInBeginSection": 1208,
          "offsetInEndSection": 1391,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11346678",
          "text": "Both compounds, paclitaxel and docetaxel, have been evaluated in metastatic settings before adjuvant trials proceeded.",
          "offsetInBeginSection": 138,
          "offsetInEndSection": 256,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16210917",
          "text": "In conclusion, this study suggests that paclitaxel is the most promising agent for combination protocols with gemcitabine and supports the use of gemcitabine/paclitaxel combination in the clinical management of advanced breast cancer.",
          "offsetInBeginSection": 1216,
          "offsetInEndSection": 1450,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33506375",
          "text": "ed with non-pregnant women.\n\n\nMETHODS\nPK data from 9, 20, 22 and 16 pregnant cancer patients from the International Network of Cancer, Infertility and",
          "offsetInBeginSection": 536,
          "offsetInEndSection": 686,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32365878",
          "text": "CONCLUSIONS\nTaken together, a cell polarity/EMP-enriched shRNA library screen identified relevant gene products that could be targeted alongside current chemotherapeutic agents for the treatment of invasive BC.",
          "offsetInBeginSection": 1838,
          "offsetInEndSection": 2048,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12108894",
          "text": "sive response rates and time to progression in a population of metastatic breast cancer patients with HER2/neu-positive tumors. The consistent demonst",
          "offsetInBeginSection": 1440,
          "offsetInEndSection": 1590,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16210917",
          "text": "d to provide a rationale for clinical investigations. To this end, CG5 breast cancer cells were treated in vitro with gemcitabine followed by epirubic",
          "offsetInBeginSection": 211,
          "offsetInEndSection": 361,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27811367",
          "text": "The findings revealed that, with regard to capecitabine alone regimen exhibited higher incidence of nausea/vomiting than doxorubicin + paclitaxel regimen, doxorubicin alone regimen and paclitaxel alone regimen in the treatment of patients with metastatic/advanced breast cancer (OR = 32.48, 95% CI = 1.65~2340.57; OR = 22.75, 95% CI = 1.03~1923.52; OR = 59.63, 95% CI = 2.22~5664.88, respectively).",
          "offsetInBeginSection": 468,
          "offsetInEndSection": 866,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12108894",
          "text": "The consistent demonstration of a high level of efficacy with manageable toxicity ensures the continued widespread investigation of docetaxel in metastatic breast cancer.",
          "offsetInBeginSection": 1568,
          "offsetInEndSection": 1738,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10511918",
          "text": "The schedule paclitaxel-->doxorubicin was more toxic as compared with doxorubicin-->paclitaxel, and an incidence of 18 to 20% of congestive heart failure was observed in patients with breast cancer given doxorubicin 60 mg/m2 followed by paclitaxel 125 to 200 mg/m2.",
          "offsetInBeginSection": 949,
          "offsetInEndSection": 1214,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8604450",
          "text": "ceton, NJ), has high levels of activity in patients with anthracycline-resistant breast cancer. Agents that are at least partially non-cross-resistant",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 322,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11970749",
          "text": "el 175 mg/ m2 over 3 hours on day 1) in a phase II study of 36 metastatic breast cancer patients. Treatment was well tolerated, with an ORR of 92% (95",
          "offsetInBeginSection": 1815,
          "offsetInEndSection": 1965,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9144689",
          "text": "Of a total of 85 patients entered, 68 patients with metastatic breast cancer were evaluable.",
          "offsetInBeginSection": 662,
          "offsetInEndSection": 754,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10203264",
          "text": "or in combination with the anthracycline, in earlier stages of metastatic breast cancer and indeed in the adjuvant treatment of early stage disease. T",
          "offsetInBeginSection": 1270,
          "offsetInEndSection": 1420,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10203264",
        "http://www.ncbi.nlm.nih.gov/pubmed/17296814",
        "http://www.ncbi.nlm.nih.gov/pubmed/11552226",
        "http://www.ncbi.nlm.nih.gov/pubmed/11970739",
        "http://www.ncbi.nlm.nih.gov/pubmed/12473512",
        "http://www.ncbi.nlm.nih.gov/pubmed/33506375",
        "http://www.ncbi.nlm.nih.gov/pubmed/27811367",
        "http://www.ncbi.nlm.nih.gov/pubmed/11432615",
        "http://www.ncbi.nlm.nih.gov/pubmed/26918039",
        "http://www.ncbi.nlm.nih.gov/pubmed/9865686",
        "http://www.ncbi.nlm.nih.gov/pubmed/11396360",
        "http://www.ncbi.nlm.nih.gov/pubmed/14499011",
        "http://www.ncbi.nlm.nih.gov/pubmed/8629032",
        "http://www.ncbi.nlm.nih.gov/pubmed/11346678",
        "http://www.ncbi.nlm.nih.gov/pubmed/10511918",
        "http://www.ncbi.nlm.nih.gov/pubmed/32365878",
        "http://www.ncbi.nlm.nih.gov/pubmed/9516602",
        "http://www.ncbi.nlm.nih.gov/pubmed/17990102",
        "http://www.ncbi.nlm.nih.gov/pubmed/9144689",
        "http://www.ncbi.nlm.nih.gov/pubmed/11129728",
        "http://www.ncbi.nlm.nih.gov/pubmed/35976445",
        "http://www.ncbi.nlm.nih.gov/pubmed/8604450",
        "http://www.ncbi.nlm.nih.gov/pubmed/14768404",
        "http://www.ncbi.nlm.nih.gov/pubmed/18991787",
        "http://www.ncbi.nlm.nih.gov/pubmed/11970749",
        "http://www.ncbi.nlm.nih.gov/pubmed/12435293",
        "http://www.ncbi.nlm.nih.gov/pubmed/10426454",
        "http://www.ncbi.nlm.nih.gov/pubmed/15039596",
        "http://www.ncbi.nlm.nih.gov/pubmed/16210917",
        "http://www.ncbi.nlm.nih.gov/pubmed/9865708",
        "http://www.ncbi.nlm.nih.gov/pubmed/11552225",
        "http://www.ncbi.nlm.nih.gov/pubmed/17028669",
        "http://www.ncbi.nlm.nih.gov/pubmed/17425475",
        "http://www.ncbi.nlm.nih.gov/pubmed/11970750",
        "http://www.ncbi.nlm.nih.gov/pubmed/9463787",
        "http://www.ncbi.nlm.nih.gov/pubmed/10403474",
        "http://www.ncbi.nlm.nih.gov/pubmed/18420499",
        "http://www.ncbi.nlm.nih.gov/pubmed/27083592",
        "http://www.ncbi.nlm.nih.gov/pubmed/12108894"
      ]
    },
    {
      "id": "63eeec79f36125a426000006",
      "type": "factoid",
      "body": "Talquetamab was developed for treatment of which disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11449698",
          "text": "cepted as a standard chemotherapy (SC) for initial treatment of pulmonary tuberculosis in Japan. We studied the frequency of the treatment completion,",
          "offsetInBeginSection": 81,
          "offsetInEndSection": 231,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8100702",
          "text": "OBJECTIVES\nThe objectives were to assess (a) the comparative merits of commonly used disease modifying drugs in the treatment of rheumatoid arthritis (RA) and (b) the influence of age, gender, and disease duration on the outcome of treatment.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33890981",
          "text": "cell redirecting bispecific antibody talquetamab is a promising novel antimyeloma agent. These results provide the preclinical rationale for ongoing s",
          "offsetInBeginSection": 1620,
          "offsetInEndSection": 1770,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36464766",
          "text": "CASE REPORT\nWe present the case of a 77-year-old male who received T cell redirecting bispecific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a second dose of talquetamab.",
          "offsetInBeginSection": 451,
          "offsetInEndSection": 715,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36464766",
          "text": "CASE REPORT\nWe present the case of a 77-year-old male who received T cell redirecting bispecific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a second dose of talquetamab.",
          "offsetInBeginSection": 451,
          "offsetInEndSection": 715,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25949982",
          "text": "ocrinology unit with excessive sweating. We started methimazole for Graves' disease. Without any additional immunosuppressive treatment, at week 12 of",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 245,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12772593",
          "text": "In this case report, it is suggested that tofisopam is effective for the treatment of PSVT.",
          "offsetInBeginSection": 920,
          "offsetInEndSection": 1011,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26193648",
          "text": "It was indicated that danaparoid sodium was an anticoagulant unlikely to cause adverse effects such as hemorrhage and might be an effective drug for treatment of portal venous thrombosis.",
          "offsetInBeginSection": 887,
          "offsetInEndSection": 1074,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33890981",
          "text": "Cell surface expression levels of GPRC5D, an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising target for immunotherapeutic strategies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36006441",
          "text": "as a surface protein on plasma cells and is a validated target for multiple myeloma (MM). A soluble form of BCMA (sBCMA) is elevated in the sera of pa",
          "offsetInBeginSection": 58,
          "offsetInEndSection": 208,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12772593",
          "text": "In this case report, the frequency of PSVT was significantly decreased and subjective symptoms of arrhythmia were eliminated after the administration of tofisopam.",
          "offsetInBeginSection": 460,
          "offsetInEndSection": 623,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36462062",
          "text": "From a historic lens, treatment for patients with relapsed/refractory multiple myeloma (R/R MM) has advanced significantly since the advent of immunomodulatory agents (IMiDs) in the 1990s, proteasome inhibitors in the 2000s, monoclonal antibodies in the 2010s, and CAR-T treatments in the 2020s.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 295,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26179525",
          "text": " developed aortitis during treatment with adalimumab (ADA) for ileocolic Crohn's disease (CD). The patient complained of a high fever, abdominal pain,",
          "offsetInBeginSection": 19,
          "offsetInEndSection": 169,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36462062",
          "text": "In this focused review, we discuss the novel Food & Drug Administration (FDA)-approved medications for R/R MM, including the recently approved first-in-class BCMA-directed bispecific antibody teclistamab.",
          "offsetInBeginSection": 533,
          "offsetInEndSection": 737,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18673132",
          "text": "Subjects with nonalcoholic fatty liver disease are at risk of progressive liver failure.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15866475",
          "text": "There have been many encouraging studies on medical treatment of pulmonary hydatid disease due to Echinococcus granulosus infection.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26193648",
          "text": ", and with anticoagulation therapy using danaparoid sodium for portal venous thrombosis. The portal venous thrombosis disappeared 4\u00a0weeks after the tr",
          "offsetInBeginSection": 538,
          "offsetInEndSection": 688,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26829845",
          "text": "Although various drugs have been used in the treatment of systemic sclerosis, a disease-modifying drug that can be a gold standard is yet to be defined.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26071892",
          "text": "OBJECTIVES\nTo develop a model of disease progression using multiple sclerosis (MS) as an exemplar.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9545827",
          "text": "A 40-year-old man with chronic myelogenous leukemia in chronic phase received an allogeneic marrow graft from his HLA identical brother.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10584579",
          "text": " which UFT was effective as a preoperative treatment for stage II b cervical cancer. The patient was a 66-year-old female whose chief complaint was br",
          "offsetInBeginSection": 19,
          "offsetInEndSection": 169,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28203197",
          "text": "ed positive for syphilis; however, systemic findings were scarce. Syphilitic uveitis was suspected, so we administered treatment for syphilis, anticoa",
          "offsetInBeginSection": 594,
          "offsetInEndSection": 744,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28203197",
          "text": "Postoperative examination of a fixed quantity of collected vitreous fluid for syphilis showed a Treponema pallidum hemagglutination value of 5,120 times the normal amount, thus confirming the syphilitic uveitis diagnosis.",
          "offsetInBeginSection": 1275,
          "offsetInEndSection": 1496,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26071892",
          "text": "CONCLUSION\nIt is possible to develop robust models of disability progression for chronic disease.",
          "offsetInBeginSection": 1319,
          "offsetInEndSection": 1416,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36464766",
        "http://www.ncbi.nlm.nih.gov/pubmed/26179525",
        "http://www.ncbi.nlm.nih.gov/pubmed/8100702",
        "http://www.ncbi.nlm.nih.gov/pubmed/25949982",
        "http://www.ncbi.nlm.nih.gov/pubmed/18673132",
        "http://www.ncbi.nlm.nih.gov/pubmed/33890981",
        "http://www.ncbi.nlm.nih.gov/pubmed/12772593",
        "http://www.ncbi.nlm.nih.gov/pubmed/36006441",
        "http://www.ncbi.nlm.nih.gov/pubmed/36462062",
        "http://www.ncbi.nlm.nih.gov/pubmed/15866475",
        "http://www.ncbi.nlm.nih.gov/pubmed/26829845",
        "http://www.ncbi.nlm.nih.gov/pubmed/9545827",
        "http://www.ncbi.nlm.nih.gov/pubmed/10584579",
        "http://www.ncbi.nlm.nih.gov/pubmed/11449698",
        "http://www.ncbi.nlm.nih.gov/pubmed/28203197",
        "http://www.ncbi.nlm.nih.gov/pubmed/26193648",
        "http://www.ncbi.nlm.nih.gov/pubmed/26071892"
      ]
    },
    {
      "id": "642321a5690f196b51000047",
      "type": "summary",
      "body": "Please summarize Feline Spongiform Encephalopathy(FSE",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11206004",
          "text": "Feline Spongiform Encephalopathy (FSE) is a related disorder in domestic cats.",
          "offsetInBeginSection": 199,
          "offsetInEndSection": 277,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783238",
          "text": "Here we report an immunohistological analysis of the first FSE-affected cheetah born in France.",
          "offsetInBeginSection": 168,
          "offsetInEndSection": 263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10349202",
          "text": "This review summarizes current knowledge of prion diseases and investigates connections between the bovine spongiform encephalopathy epidemic, observed in Great Britain since 1986, and the new variant of human Creutzfeldt-Jakob disease, reported for the first time in 1996.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 273,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19335885",
          "text": "BACKGROUND\nTwo domestic shorthair cats presenting with progressive hind-limb ataxia and increased aggressiveness were necropsied and a post mortem diagnosis of Feline Spongiform Encephalopathy (FSE) was made.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12442705",
          "text": "Feline spongiform encephalopathy was confirmed by histological brain examination and positive immunohistochemistry for PrPSc.",
          "offsetInBeginSection": 514,
          "offsetInEndSection": 639,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1279883",
          "text": "Thirteen cats were referred with clinical neurological signs potentially indicative of feline spongiform encephalopathy (FSE).",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 287,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35632724",
          "text": "To the best of our knowledge, this is the first report on genetic polymorphisms of the feline SPRN gene.",
          "offsetInBeginSection": 2047,
          "offsetInEndSection": 2151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18725465",
          "text": "Clinically, it presents as a progressive fatal neurologic syndrome that is not easily distinguished from other feline neurologic conditions.",
          "offsetInBeginSection": 332,
          "offsetInEndSection": 472,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33374431",
          "text": "However, to date, investigations of PRNP polymorphisms are rare in cats, which are the major host of feline spongiform encephalopathy (FSE).",
          "offsetInBeginSection": 284,
          "offsetInEndSection": 424,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35632724",
          "text": "However, genetic polymorphisms in the feline SPRN gene and structural characteristics of the Sho have not been investigated in cats, a major host of feline spongiform encephalopathy (FSE).",
          "offsetInBeginSection": 506,
          "offsetInEndSection": 694,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18284911",
          "text": "This review discusses the experimental approaches used to determine TSE transmissibility and infectivity and how they relate to natural disease and control measures.",
          "offsetInBeginSection": 963,
          "offsetInEndSection": 1128,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12296404",
          "text": "Feline spongiform encephalopathy (FSE) is thought to have resulted from consumption of food contaminated with bovine spongiform encephalopathy and the latter is believed to result from the consumption of food contaminated with scrapie.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16735593",
          "text": ", experimental sheep BSE, or feline spongiform encephalopathy (FSE) from a cheetah. PrP(res) distribution was comparable, whichever of the three BSE a",
          "offsetInBeginSection": 513,
          "offsetInEndSection": 663,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16598176",
          "text": "PD-weighted FSE provided detailed anatomical images of feline hip joints with superb depiction of subchondral bones of the femoral head and acetabulum.",
          "offsetInBeginSection": 318,
          "offsetInEndSection": 469,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14522860",
          "text": " reported. These include feline spongiform encephalopathy of zoological and domestic cats (FSE) and transmissible spongiform encephalopathy (TSE) of z",
          "offsetInBeginSection": 139,
          "offsetInEndSection": 289,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12783238",
        "http://www.ncbi.nlm.nih.gov/pubmed/33374431",
        "http://www.ncbi.nlm.nih.gov/pubmed/14522860",
        "http://www.ncbi.nlm.nih.gov/pubmed/1279883",
        "http://www.ncbi.nlm.nih.gov/pubmed/18725465",
        "http://www.ncbi.nlm.nih.gov/pubmed/16598176",
        "http://www.ncbi.nlm.nih.gov/pubmed/12296404",
        "http://www.ncbi.nlm.nih.gov/pubmed/19335885",
        "http://www.ncbi.nlm.nih.gov/pubmed/11206004",
        "http://www.ncbi.nlm.nih.gov/pubmed/16735593",
        "http://www.ncbi.nlm.nih.gov/pubmed/18284911",
        "http://www.ncbi.nlm.nih.gov/pubmed/12442705",
        "http://www.ncbi.nlm.nih.gov/pubmed/10349202",
        "http://www.ncbi.nlm.nih.gov/pubmed/35632724"
      ]
    },
    {
      "id": "6428d7da690f196b51000050",
      "type": "yesno",
      "body": "Can untranslated regions (UTRs) regulate gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21093468",
          "text": " (mRNA) 3' untranslated regions (UTRs) where they prevent translation or cause degradation of the message. Steroid hormone receptors (SHRs) are ligand",
          "offsetInBeginSection": 196,
          "offsetInEndSection": 346,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187351",
          "text": " regions (UTRs) of messenger RNAs. However, how the target sites change during evolution is largely unknown. MiR-iab-4 and miR-iab-4as are known to re",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 333,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23949786",
          "text": "However, the functions of the segment-specific regions of the UTRs are not well known.",
          "offsetInBeginSection": 210,
          "offsetInEndSection": 296,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18615019",
          "text": "Structured RNAs embedded in the untranslated regions (UTRs) of messenger RNAs can regulate gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20563548",
          "text": "5' untranslated regions (UTRs) are important sequence elements that modulate the expression of genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21912852",
          "text": "3' untranslated regions (UTRs) are important sequence elements that modulate the expression of genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32995550",
          "text": "n of gene expression; however, the exact sequence features contributing to gene regulation are not yet fully understood. In this study, we report the ",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29223924",
          "text": "To facilitate this activation, plant mRNA contains untranslated regions (UTRs) that significantly increase the coding capacity of the genome by producing multiple mRNA variants from the same gene.",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 387,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8813126",
          "text": "The 3' untranslated regions (3' UTRs) of R1 and R2 messages contain sequences that are important in regulating gene expression through changes in message stability.",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 347,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31234415",
          "text": "Single nucleotide polymorphisms located in 5' untranslated regions (5'UTRs) can regulate gene expression and have clinical impact.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16430990",
          "text": "gene expression can be regulated by the differential use of alternative untranslated regions. Tissue-specific expression of transcripts that have different untranslated regions (UTRs) can control protein expression",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 363,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30900191",
          "text": "egions (3' UTRs) of mRNA are actively involved in post-transcriptional regulations of gene expression. Although both shortening and lengthening of 3' ",
          "offsetInBeginSection": 88,
          "offsetInEndSection": 238,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29375488",
          "text": "Regulatory RNA regions within a transcript, particularly in the 5' untranslated region (5'UTR), have been shown in a variety of organisms to control the expression levels of these mRNAs in response to various metabolites or environmental conditions.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29165424",
          "text": "These structures may regulate cap-dependent translation initiation through helicase-mediated remodelling of RNA structures and higher-order RNA interactions, as well as cap-independent translation initiation through internal ribosome entry sites (IRESs), mRNA modifications and other specialized translation pathways.",
          "offsetInBeginSection": 329,
          "offsetInEndSection": 646,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985357",
          "text": "Many studies using reporter assays have demonstrated that 3' untranslated regions (3'-UTRs) regulate gene expression by controlling mRNA stability and translation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20346121",
          "text": "nscripts are not well characterized for many genes and often extend beyond the annotated regions. Since Affymetrix 3' expression arrays were designed ",
          "offsetInBeginSection": 52,
          "offsetInEndSection": 202,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32061268",
          "text": "However, the role of the trans-regulation of 3' UTRs during heart dysfunction remains elusive.",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 240,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22110399",
          "text": "Although previous efforts have demonstrated the functional importance of target sites on miRNAs, little is known about the influence of the rest of 3' untranslated regions (3'UTRs) of target genes on microRNA function.",
          "offsetInBeginSection": 67,
          "offsetInEndSection": 285,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20015997",
          "text": "To gain insight into the role of untranslated regions (UTRs) in regulation of foreign gene expression, replication, and pathogenicity of Newcastle disease virus (NDV), a green fluorescent protein (GFP) gene flanked by 5' and 3' UTRs of each NDV gene was individually expressed by recombinant NDVs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 297,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28740488",
          "text": "ortant features that are relevant to the post-transcriptional and translational regulation of gene expression. Most studies of bacterial UTRs have foc",
          "offsetInBeginSection": 51,
          "offsetInEndSection": 201,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29907706",
          "text": "The 3' untranslated regions (3'-UTRs) of mRNA are believed to be important in the control of chemokine gene expression.",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 345,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24067953",
          "text": "3' untranslated regions (UTRs) are known to play an important role in posttranscriptional regulation of gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20720301",
          "text": "Untranslated regions (UTRs) of eukaryotic mRNAs play crucial roles in post-transcriptional regulation of gene expression via the modulation of nucleocytoplasmic mRNA transport, translation efficiency, subcellular localization, and message stability.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23656324",
          "text": "Gene expression in chloroplasts is highly regulated during translation by sequence and secondary-structure elements in the 5' untranslated region (UTR) of mRNAs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33821006",
          "text": "Here, we reveal an unexpected role of extremely conserved 5' untranslated regions (UTRs) in noncanonical translational regulation that is linked to the emergence of essential developmental features in vertebrate species.",
          "offsetInBeginSection": 138,
          "offsetInEndSection": 358,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7662369",
          "text": "The 3' untranslated region (3' UTR) can control gene expression by affecting the localization, stability and translation of mRNAs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20563548",
          "text": " transient expression protoplasts. Therefore, the enhancements were independent of the promoter sequence. Real-time quantitative RT-PCR analysis showe",
          "offsetInBeginSection": 759,
          "offsetInEndSection": 909,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129533",
          "text": "These 3' untranslated regions (3' UTRs) hold the key for many aspects of regulated gene expression, influencing mRNA stability, protein synthesis, and ultimately protein function.",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 257,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24115048",
          "text": "In this article, we review recent progress in the characterization of mRNA 3'UTRs and discuss their implications in the understanding of 3'UTR-mediated gene regulation.",
          "offsetInBeginSection": 467,
          "offsetInEndSection": 635,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25577389",
          "text": "In particular, RNA elements lying in untranslated regions (5' and 3'UTRs) are poorly studied because of their peculiar features (i.e., a combination of primary and secondary structure elements) which also pose remarkable computational challenges.",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 329,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26400176",
          "text": "3' UTRs) of transcripts serve as important hubs for posttranscriptional gene expression regulation. Here, we find that the exonisation of intergenic A",
          "offsetInBeginSection": 29,
          "offsetInEndSection": 179,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23949786",
          "text": "The results revealed that the UTRs of all segments differently affected the protein expression levels and that the effect of the UTRs of PB1 segment on protein expression was significant.",
          "offsetInBeginSection": 755,
          "offsetInEndSection": 942,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18832370",
          "text": "Here, we have explored the incidence of G-quadruplex motifs in and around the untranslated regions (UTRs) of mRNA.",
          "offsetInBeginSection": 337,
          "offsetInEndSection": 451,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134127",
          "text": "MicroRNAs (miRNAs) regulate gene expression by pairing with complementary sequences in the 3' untranslated regions (UTRs) of transcripts.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30961831",
          "text": "The 5' and 3' untranslated regions (UTRs) regulate crucial aspects of post-transcriptional gene regulation that are necessary for the maintenance of cellular homeostasis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187351",
          "text": "These results indicate that these regions can be a potential source of generating new target sites, which results in multiple target genes for each miR in animals.",
          "offsetInBeginSection": 1376,
          "offsetInEndSection": 1539,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25708284",
          "text": "lated regions (UTRs) of mRNA molecules that bind to ligands and regulate the expression of downstream genes. Riboswitches typically regulate the expre",
          "offsetInBeginSection": 61,
          "offsetInEndSection": 211,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14601635",
          "text": " atypical 5' untranslated regions (UTRs) containing a high degree of RNA secondary structure, upstream open reading frames and internal ribosome entry segments. These features play a key role in the regulation of protein synthesis",
          "offsetInBeginSection": 306,
          "offsetInEndSection": 536,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23053542",
          "text": "Translation signals harbored by the 5' untranslated region (UTR) of plastid transcripts can profoundly affect the level of accumulation of proteins expressed from chimeric transgenes.",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 373,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20720301",
          "text": "We show that chromosome walking can be used for obtaining the sequence of UTRs, and then, based on this sequence, to discover SNPs in the noncoding regions of candidate genes from this species without an entire genomic sequence.",
          "offsetInBeginSection": 1238,
          "offsetInEndSection": 1466,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22846368",
          "text": " different species, and the relationship between these UTRs and the genome size and species gene number is not well understood. To address these quest",
          "offsetInBeginSection": 325,
          "offsetInEndSection": 475,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15659338",
          "text": "thus implicating the 5' untranslated region as a major site of translational regulation. Many growth-related mRNAs have atypical 5' UTRs, which are of",
          "offsetInBeginSection": 140,
          "offsetInEndSection": 290,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21075793",
          "text": "The 3' untranslated regions (3'UTRs) of eukaryotic genes regulate mRNA stability, localization and translation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30619487",
          "text": "Therefore, to deepen our understanding of gene expression regulation, delimitation of these regions with high accuracy is needed.",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 256,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23053542",
          "text": "However, transplastomic plants with the bacteriophage 5' UTRs controlling the aadA coding region exhibited fewer undesired recombinant species than plants containing the same marker gene regulated by the Nicotiana tabacum psbA 5' UTR.",
          "offsetInBeginSection": 1280,
          "offsetInEndSection": 1514,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29223924",
        "http://www.ncbi.nlm.nih.gov/pubmed/31234415",
        "http://www.ncbi.nlm.nih.gov/pubmed/32061268",
        "http://www.ncbi.nlm.nih.gov/pubmed/20720301",
        "http://www.ncbi.nlm.nih.gov/pubmed/22134127",
        "http://www.ncbi.nlm.nih.gov/pubmed/33821006",
        "http://www.ncbi.nlm.nih.gov/pubmed/29375488",
        "http://www.ncbi.nlm.nih.gov/pubmed/21093468",
        "http://www.ncbi.nlm.nih.gov/pubmed/21075793",
        "http://www.ncbi.nlm.nih.gov/pubmed/28740488",
        "http://www.ncbi.nlm.nih.gov/pubmed/32995550",
        "http://www.ncbi.nlm.nih.gov/pubmed/25577389",
        "http://www.ncbi.nlm.nih.gov/pubmed/7662369",
        "http://www.ncbi.nlm.nih.gov/pubmed/23656324",
        "http://www.ncbi.nlm.nih.gov/pubmed/29907706",
        "http://www.ncbi.nlm.nih.gov/pubmed/22846368",
        "http://www.ncbi.nlm.nih.gov/pubmed/15659338",
        "http://www.ncbi.nlm.nih.gov/pubmed/20563548",
        "http://www.ncbi.nlm.nih.gov/pubmed/23053542",
        "http://www.ncbi.nlm.nih.gov/pubmed/23949786",
        "http://www.ncbi.nlm.nih.gov/pubmed/24067953",
        "http://www.ncbi.nlm.nih.gov/pubmed/26400176",
        "http://www.ncbi.nlm.nih.gov/pubmed/21187351",
        "http://www.ncbi.nlm.nih.gov/pubmed/29165424",
        "http://www.ncbi.nlm.nih.gov/pubmed/30961831",
        "http://www.ncbi.nlm.nih.gov/pubmed/21912852",
        "http://www.ncbi.nlm.nih.gov/pubmed/30900191",
        "http://www.ncbi.nlm.nih.gov/pubmed/8813126",
        "http://www.ncbi.nlm.nih.gov/pubmed/28129533",
        "http://www.ncbi.nlm.nih.gov/pubmed/22110399",
        "http://www.ncbi.nlm.nih.gov/pubmed/25708284",
        "http://www.ncbi.nlm.nih.gov/pubmed/18832370",
        "http://www.ncbi.nlm.nih.gov/pubmed/20346121",
        "http://www.ncbi.nlm.nih.gov/pubmed/18615019",
        "http://www.ncbi.nlm.nih.gov/pubmed/14601635",
        "http://www.ncbi.nlm.nih.gov/pubmed/20015997",
        "http://www.ncbi.nlm.nih.gov/pubmed/16430990",
        "http://www.ncbi.nlm.nih.gov/pubmed/28985357",
        "http://www.ncbi.nlm.nih.gov/pubmed/24115048",
        "http://www.ncbi.nlm.nih.gov/pubmed/30619487"
      ]
    },
    {
      "id": "63f9cbb433942b094c00000c",
      "type": "yesno",
      "body": "Is alternative splicing associated with heart disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27049307",
          "text": "and 5 of the cTnT gene. Alternative splicing of cTnT exon 5 is developmentally regulated. cTnT isoforms containing exon 5 are expressed in the fetal a",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 259,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30468920",
          "text": "assembly of the contractile apparatus. Recently, FHOD3 mutations have been found associated with heart diseases. We identified novel FHOD3 splicing va",
          "offsetInBeginSection": 753,
          "offsetInEndSection": 903,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34273561",
          "text": "In humans, cardiac mRNA splicing is involved in the pathophysiology of heart failure.",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685889",
          "text": ",333 cis sQTLs involving 2,650 unique genes. Many sQTL-associated genes (40%) undergo alternative splicing. Using the National Human Genome Research I",
          "offsetInBeginSection": 428,
          "offsetInEndSection": 578,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15652472",
          "text": "(2005) demonstrate that a heart-specific knockout of one SR protein, ASF/SF2, produces cardiomyopathy and misregulation of specific alternative splicing events during early postnatal development.",
          "offsetInBeginSection": 170,
          "offsetInEndSection": 365,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32276354",
          "text": "In this review, we summarize the updated knowledge relative to RBM20 and PTBP1 structure and molecular function; their role in alternative splicing mechanisms involved in the heart development and function; RBM20 mutations associated with idiopathic dilated cardiovascular disease (DCM); and the consequences of RBM20-altered expression or dysfunction.",
          "offsetInBeginSection": 904,
          "offsetInEndSection": 1256,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30051286",
          "text": "Here, we review our current knowledge of alternative splicing in the heart, with a particular focus on the factors controlling cardiac alternative splicing and their role in cardiomyopathies and subsequent heart failure.",
          "offsetInBeginSection": 757,
          "offsetInEndSection": 977,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561820",
          "text": " from individual genes; however, aberrant mRNA splicing is associated with various conditions, including heart disease. A recent study provides new me",
          "offsetInBeginSection": 76,
          "offsetInEndSection": 226,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24358217",
          "text": "Alternative splicing could play a role in the control of gene expression during CKD but it does not seem to be a major mechanism.",
          "offsetInBeginSection": 1578,
          "offsetInEndSection": 1707,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938400",
          "text": "e been reported in human heart defects. Defects in alternative splicing are associated with many heart diseases, yet relatively little is known about ",
          "offsetInBeginSection": 213,
          "offsetInEndSection": 363,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938400",
          "text": "Several genes that have splicing regulated by GATA4 have functional consequences and many are associated with dilated cardiomyopathy, suggesting a novel role for GATA4 in achieving the necessary cardiac proteome in normal and stress-responsive conditions.",
          "offsetInBeginSection": 2062,
          "offsetInEndSection": 2317,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32273884",
          "text": "Alternative splicing alterations can contribute to human disease. The ability of an RNA-binding protein to regulate alternative splicing outcomes can ",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34573439",
          "text": "The aim of this review is to provide a brief insight into some of the available findings on the role of alternative splicing in cardiovascular disease, with a focus on atherosclerosis, myocardial infarction, heart failure, dilated cardiomyopathy and circular RNAs in myocardial infarction.",
          "offsetInBeginSection": 1066,
          "offsetInEndSection": 1355,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20699644",
          "text": ", although it remains to be described whether specific splice variants are associated with developmental states and pathological conditions. We aimed ",
          "offsetInBeginSection": 344,
          "offsetInEndSection": 494,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35862102",
          "text": "However, mechanisms that maintain triadin isoform composition in the heart remain elusive.",
          "offsetInBeginSection": 588,
          "offsetInEndSection": 678,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33425250",
          "text": "In this mini-review, we aim to illustrate I) mechanisms and regulation of alternative splicing, II) alternative splicing associated human disease, III) computational tools for the quantification of isoforms and alternative splicing from RNA-seq.",
          "offsetInBeginSection": 928,
          "offsetInEndSection": 1173,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29438341",
          "text": "Using Rbm20 knockout rat heart, we revealed that RBM20 is not a splicing regulator of Novex variants.",
          "offsetInBeginSection": 1404,
          "offsetInEndSection": 1505,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29186814",
          "text": "Alteration of Cav1.2 channel function has been implicated in multiple cardiovascular diseases, such as hypertension and cardiac hypertrophy.",
          "offsetInBeginSection": 128,
          "offsetInEndSection": 268,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29438341",
          "text": " and whether Novex isoforms are associated with heart disease remains completely unknown. Cross-species exon comparison with the mVISTA online tool re",
          "offsetInBeginSection": 391,
          "offsetInEndSection": 541,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26965269",
          "text": "distinct functions. The dysregulations of alternative splicing have been found to be closely associated with various human diseases; thus new approach",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124440",
          "text": "CONCLUSIONS\nOur data indicate that mRNA splicing is broadly altered in human heart disease and that patterns of aberrant RNA splicing accurately assign samples to control or disease classes.",
          "offsetInBeginSection": 1609,
          "offsetInEndSection": 1799,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846640",
          "text": "Here, we review our current knowledge of alternative splicing in the heart, with a particular focus on the major and minor spliceosome, the factors controlling RNA splicing, and the role of alternative splicing in cardiac development and disease.",
          "offsetInBeginSection": 1055,
          "offsetInEndSection": 1301,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29304022",
          "text": "ecular mechanism of how this splicing factor is associated with dilated cardiomyopathy. Here, we review our current knowledge of muscle-specific splic",
          "offsetInBeginSection": 444,
          "offsetInEndSection": 594,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124440",
          "text": "Altered mRNA splicing occurs in association with several types of cancer, and a small number of disease-associated changes in splicing have been reported in heart disease.",
          "offsetInBeginSection": 98,
          "offsetInEndSection": 269,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21859973",
          "text": "A number of human diseases are associated with alternative mRNA splicing, which has received comparatively little attention in the study of cardiac disease.",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 435,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27825848",
          "text": "man, mis-regulation of alternative splicing has been associated with heart failure. In this short review, we focus on alternative splicing of sarcomer",
          "offsetInBeginSection": 385,
          "offsetInEndSection": 535,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938400",
          "text": "olved in cytoskeleton organization and calcium ion import, with functional consequences associated with the protein isoforms.\n\n\nCONCLUSIONS\nThis study",
          "offsetInBeginSection": 1685,
          "offsetInEndSection": 1835,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20339475",
          "text": "n includes only the N2B type exons. The alterations in splicing and titin isoform expression in human heart disease provide impetus for future detaile",
          "offsetInBeginSection": 625,
          "offsetInEndSection": 775,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846640",
          "text": "In the heart, alternative splicing is increasingly being recognized as an important layer of post-transcriptional gene regulation.",
          "offsetInBeginSection": 629,
          "offsetInEndSection": 759,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29186814",
          "text": "More importantly, alternative splicing of certain exons of Cav1.2 has been reported to be regulated by splicing factors such as RNA-binding Fox-1 homolog 1/2 (Rbfox 1/2), polypyrimidine tract-binding protein (PTBP1) and RNA-binding motif protein 20 (RBM20).",
          "offsetInBeginSection": 765,
          "offsetInEndSection": 1022,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35082143",
          "text": "ng organ development, and, in numerous diseases, splicing programs revert to fetal isoform expression. We previously found that extensive splicing cha",
          "offsetInBeginSection": 43,
          "offsetInEndSection": 193,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35862102",
          "text": "Trdn-as maintains cardiac function, at least in part, by regulating alternative splicing of the triadin gene. Knockout of Trdn-as in mice downregulates cardiac triadin, impairs Ca2+ handling, and causes premature death",
          "offsetInBeginSection": 1542,
          "offsetInEndSection": 1760,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30321814",
          "text": "Here, we report that juvenile cardiomyocyte-specific PRMT1-deficient mice develop severe dilated cardiomyopathy and exhibit aberrant cardiac alternative splicing.",
          "offsetInBeginSection": 413,
          "offsetInEndSection": 575,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23775418",
          "text": "Here, we review the impact that changes in alternative splicing have on individual genes and on whole biological processes associated with heart disease.",
          "offsetInBeginSection": 572,
          "offsetInEndSection": 725,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25980689",
          "text": "Therefore, its deregulation frequently leads to several neurological human disorders.",
          "offsetInBeginSection": 364,
          "offsetInEndSection": 449,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21859973",
          "text": " Overexpression of either splicing factor resulted in an increase in truncated mRNA and a concomitant decrease in the full-length SCN5A transcript.\n\n\nCONCLUSIONS\nOf the 17 mRNA splicing factors upregulated in heart failure, RBM25 and LUC7L3 were sufficient to explain the increase in truncated forms and the reduction in full-length Na+ channel transcript. Because the reduction in channels was in the range known to be associated with sudden death",
          "offsetInBeginSection": 1114,
          "offsetInEndSection": 1562,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30468920",
          "text": " Recently, FHOD3 mutations have been found associated with heart diseases. We identified novel FHOD3 splicing variants differentially expressed in human tissues and provided evidences that FHOD3 transcripts are specific RBM20 and PTBP1 targets. Furthermore, we demonstrated that the expression of RBM20 and PTBP1 promoted the alternative shift, from inclusion to exclusion, of selected FHOD3 exons. These results indicate that RBM20 and PTBP1 play a role in the actin filament functional organization mediated by FHOD3 isoforms and suggest their possible involvement in heart diseases",
          "offsetInBeginSection": 791,
          "offsetInEndSection": 1375,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22939879",
          "text": "These observations may shed light on a mechanism whereby cardiac function and arrhythmic risk are associated and allow for refined predictions of which patients may be at highest arrhythmic risk or suffer from Na(+) channel blocking anti-arrhythmic drug complications.",
          "offsetInBeginSection": 962,
          "offsetInEndSection": 1230,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24552714",
          "text": "However, the role of alternative splicing in cardiac hypertrophy is yet unknown.",
          "offsetInBeginSection": 501,
          "offsetInEndSection": 581,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15988035",
          "text": "minant-negative expression, suggesting that there is sex-specific modulation of splicing activity. The cardiac defects in MHC-CELFdelta mice are direc",
          "offsetInBeginSection": 590,
          "offsetInEndSection": 740,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18380349",
          "text": "There are several well-characterized examples in which disruption of alternative splicing is a cause of disease.",
          "offsetInBeginSection": 368,
          "offsetInEndSection": 480,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26116573",
          "text": "We found that loss of rbfox1 led to progressive cardiac contractile dysfunction and heart failure.",
          "offsetInBeginSection": 441,
          "offsetInEndSection": 539,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20699644",
          "text": "p. The main findings are that: (1) cardiac Ca(V)3.2 T-type Ca channels are subject to considerable alternative splicing, (2) there is preferential exp",
          "offsetInBeginSection": 993,
          "offsetInEndSection": 1143,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20699644",
          "text": "predominant form, and (4) alternative splicing confers a variant-specific voltage-dependent facilitation of Ca(V)3.2 channels. We conclude that Ca(V)3",
          "offsetInBeginSection": 1529,
          "offsetInEndSection": 1679,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34273561",
          "text": "Mechanistically, SLM2 mediates intron retention, prevents exon exclusion, and thereby mediates alternative splicing of the mRNA regions encoding the variable proline-, glutamate-, valine-, and lysine-rich (PEVK) domain and another part of the I-band region of titin.",
          "offsetInBeginSection": 771,
          "offsetInEndSection": 1037,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34651015",
          "text": "From decades of studies, alternative splicing has been shown to occur in multiple tissues, including the brain, heart, testis, skeletal muscle, and liver.",
          "offsetInBeginSection": 152,
          "offsetInEndSection": 306,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30612603",
          "text": "r in their biological actions. Proximal splicing that includes an exon 8a sequence results in pro-angiogenic VEGF-A165a, whereas distal splicing inclu",
          "offsetInBeginSection": 667,
          "offsetInEndSection": 817,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26846640",
        "http://www.ncbi.nlm.nih.gov/pubmed/26965269",
        "http://www.ncbi.nlm.nih.gov/pubmed/22561820",
        "http://www.ncbi.nlm.nih.gov/pubmed/15652472",
        "http://www.ncbi.nlm.nih.gov/pubmed/27049307",
        "http://www.ncbi.nlm.nih.gov/pubmed/30051286",
        "http://www.ncbi.nlm.nih.gov/pubmed/22939879",
        "http://www.ncbi.nlm.nih.gov/pubmed/21859973",
        "http://www.ncbi.nlm.nih.gov/pubmed/24552714",
        "http://www.ncbi.nlm.nih.gov/pubmed/15988035",
        "http://www.ncbi.nlm.nih.gov/pubmed/34573439",
        "http://www.ncbi.nlm.nih.gov/pubmed/25685889",
        "http://www.ncbi.nlm.nih.gov/pubmed/26116573",
        "http://www.ncbi.nlm.nih.gov/pubmed/24358217",
        "http://www.ncbi.nlm.nih.gov/pubmed/20339475",
        "http://www.ncbi.nlm.nih.gov/pubmed/32276354",
        "http://www.ncbi.nlm.nih.gov/pubmed/34651015",
        "http://www.ncbi.nlm.nih.gov/pubmed/34273561",
        "http://www.ncbi.nlm.nih.gov/pubmed/20124440",
        "http://www.ncbi.nlm.nih.gov/pubmed/30321814",
        "http://www.ncbi.nlm.nih.gov/pubmed/18380349",
        "http://www.ncbi.nlm.nih.gov/pubmed/35082143",
        "http://www.ncbi.nlm.nih.gov/pubmed/23775418",
        "http://www.ncbi.nlm.nih.gov/pubmed/20699644",
        "http://www.ncbi.nlm.nih.gov/pubmed/25980689",
        "http://www.ncbi.nlm.nih.gov/pubmed/35862102",
        "http://www.ncbi.nlm.nih.gov/pubmed/30468920",
        "http://www.ncbi.nlm.nih.gov/pubmed/27825848",
        "http://www.ncbi.nlm.nih.gov/pubmed/29186814",
        "http://www.ncbi.nlm.nih.gov/pubmed/32273884",
        "http://www.ncbi.nlm.nih.gov/pubmed/29438341",
        "http://www.ncbi.nlm.nih.gov/pubmed/29304022",
        "http://www.ncbi.nlm.nih.gov/pubmed/30612603",
        "http://www.ncbi.nlm.nih.gov/pubmed/33425250",
        "http://www.ncbi.nlm.nih.gov/pubmed/35938400"
      ]
    },
    {
      "id": "61fa941ec9dfcb9c09000005",
      "type": "yesno",
      "body": "Should Intepirdine be used for Alzheimer's disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29848076",
          "text": "cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors. Paradoxically, 5-HT6 receptor agonists have also been shown ",
          "offsetInBeginSection": 1014,
          "offsetInEndSection": 1164,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9179132",
          "text": "rement after instillation of tropicamide cannot be used as a reliable diagnostic test for Alzheimer's disease. Moreover, test-retest reliability with ",
          "offsetInBeginSection": 1482,
          "offsetInEndSection": 1632,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29212555",
          "text": "BACKGROUND\nIn an effort to intervene earlier in Alzheimer's disease (AD), clinical trials are testing promising candidate therapies in preclinical disease.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32321414",
          "text": "It is predicted that some FDA-approved drugs, such as Paracetamol, Risperidone, Escitalopram, Simvastatin, Cilostazoand, and Ritalin-SR, could also be used in off-label ways for AD.",
          "offsetInBeginSection": 1829,
          "offsetInEndSection": 2010,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34095437",
          "text": "le safety profile similar to placebo.\n\n\nDISCUSSION\nIntepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo",
          "offsetInBeginSection": 969,
          "offsetInEndSection": 1119,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34095437",
          "text": "INTRODUCTION\nA previous phase 2b study supported the use of the 5-HT6 receptor antagonist intepirdine as adjunctive therapy to donepezil for Alzheimer's disease (AD) dementia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
          "text": "gress in current clinical trials and warrant consideration as emerging treatments for AD. Areas covered: This review discusses 5-HT6 antagonists curre",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 771,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21752148",
          "text": "BACKGROUND AND PURPOSE\nTo provide guidance regarding the most appropriate voxel-based morphometry (VBM)-derived method for assessing hippocampal atrophy in early Alzheimer's disease (AD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19012869",
          "text": "Thus, rDNA specific methylation pattern could be involved in AD and be used as a marker of the disease or of its progression.",
          "offsetInBeginSection": 336,
          "offsetInEndSection": 461,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
          "text": "Expert opinion: If current Phase-3 trials are positive, 5-HT6 antagonists such as Idalopirdine and Intepirdine may be considered as supplementary treatments to ChEI's and NMDA receptor antagonists for the symptomatic treatment of AD.",
          "offsetInBeginSection": 1152,
          "offsetInEndSection": 1385,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34189249",
          "text": "intepirdine, a serotonin receptor antagonist, in patients with dementia with Lewy bodies (DLB).\n\n\nMETHODS\nHEADWAY-DLB was a multinational, double-blin",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 242,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19903022",
          "text": "The identification of noninvasive diagnostic biomarkers of AD is becoming increasingly important to make diagnosis more widely available to clinics with limited access to neuropsychological testing or state-of-the-art brain imaging, reduce the cost of clinical diagnosis, provide a biological measure to track the course of therapeutic intervention, and most importantly, allow for earlier diagnosis--possibly even during the prodromal phase--with hopes of therapeutic intervention prior to appreciable neurodegeneration.",
          "offsetInBeginSection": 657,
          "offsetInEndSection": 1178,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34189249",
        "http://www.ncbi.nlm.nih.gov/pubmed/9179132",
        "http://www.ncbi.nlm.nih.gov/pubmed/29848076",
        "http://www.ncbi.nlm.nih.gov/pubmed/32321414",
        "http://www.ncbi.nlm.nih.gov/pubmed/21752148",
        "http://www.ncbi.nlm.nih.gov/pubmed/19012869",
        "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
        "http://www.ncbi.nlm.nih.gov/pubmed/34095437",
        "http://www.ncbi.nlm.nih.gov/pubmed/19903022",
        "http://www.ncbi.nlm.nih.gov/pubmed/29212555"
      ]
    },
    {
      "id": "6422e2f1690f196b51000043",
      "type": "factoid",
      "body": "What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158620",
          "text": "Targeted delivery of antisense oligonucleotides (ASO) to hepatocytes via the asialoglycoprotein receptor (ASGR) has improved the potency of ASO drugs \u223c30-fold in the clinic (1).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30570431",
          "text": "rotein receptor 1 to support selective targeting of RNAs expressed by hepatocytes. In this study we report the integrated assessment of data available",
          "offsetInBeginSection": 453,
          "offsetInEndSection": 603,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30345352",
          "text": " peptide-1 receptor (GLP1R) can productively deliver ASO cargo to pancreatic \u03b2-cells both in vitro and in vivo. Ligand-conjugated ASOs silenced target",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 611,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31303442",
          "text": "One example is the targeted delivery of ASOs to hepatocytes, achieved with N-acetylgalactosamine (GalNAc) conjugation to ASO, which results in selective uptake by asialoglycoprotein receptor (ASGR).",
          "offsetInBeginSection": 259,
          "offsetInEndSection": 457,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31099004",
          "text": "Herein we describe a targeted carrier system that can deliver siRNA to cancer cells overexpressing the human epidermal growth factor 2 (HER2) receptor.",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 340,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15894474",
          "text": "ive vector of antisense oligonucleotide (ASO) and plasmid DNA for the hepatocyte targeting delivery. Gal-LMWC has been successfully prepared and MTT c",
          "offsetInBeginSection": 256,
          "offsetInEndSection": 406,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546271",
          "text": "PA:LFn-GAL4:ASO transfection of non- or terminally-differentiated THP-1 cells and Vero cells resulted in 35.2 \u00b1 19.1%, 36.4 \u00b1 1.8% and 22.9 \u00b1 6.9% (respectively) Synt5 expression after treatment with 200 pmol of ASO and demonstrated versatility.",
          "offsetInBeginSection": 2003,
          "offsetInEndSection": 2248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29808997",
          "text": "eptor (ASGPR) can serve as potent targeting moieties for hepatocellular carcinoma (HCC) cells. However, efficient targeting to HCC via galactose moiet",
          "offsetInBeginSection": 209,
          "offsetInEndSection": 359,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16686729",
          "text": "SO and chemotherapy or small-interference RNA (siRNA) targeting the clusterin gene was also investigated.\n\n\nRESULTS\nBispecific ASO reduced Bcl-2 and B",
          "offsetInBeginSection": 756,
          "offsetInEndSection": 906,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992960",
          "text": "GalNAc conjugation also enhanced potency and duration of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice.",
          "offsetInBeginSection": 940,
          "offsetInEndSection": 1106,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28696185",
          "text": "These findings showed that ASO-modified nanoparticles could serve as a promising nanocarrier for targeted tumor cells.",
          "offsetInBeginSection": 1084,
          "offsetInEndSection": 1202,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34797690",
          "text": "ependent localization of ASOs delivered by a modified treatment of suspension cells. Our results show that in macrophages, the uptake rate of PS-ASOs ",
          "offsetInBeginSection": 1157,
          "offsetInEndSection": 1307,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26855051",
          "text": "Although a linker bearing a disulfide bond accumulated mainly in NPCs, hexamethylene succinimide linker accumulated mainly in hepatocytes.",
          "offsetInBeginSection": 806,
          "offsetInEndSection": 944,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35623403",
          "text": "The \u03b2-galactopyranoside-conjugated liposomes (GAL-liposome) targeting liver synthesized hepcidin were prepared by thin lipid film hydration method to encapsulate siRNA and the conjugation of \u03b2-galactopyranoside to the lipid nanocarrier was achieved by covalent chemistry.",
          "offsetInBeginSection": 256,
          "offsetInEndSection": 527,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19085118",
          "text": "ics and biodistribution, and suboptimal suppression of the target in tumor tissues. Raf-1 protein serine/threonine kinase is a druggable signaling mol",
          "offsetInBeginSection": 317,
          "offsetInEndSection": 467,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20964335",
          "text": "In conclusion, these siRNA conjugates have the potential for targeted delivery of siRNAs to hepatocytes and hepatic stellate cells for efficient gene silencing in vivo.",
          "offsetInBeginSection": 1273,
          "offsetInEndSection": 1441,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31641784",
          "text": "4M5.3-NbCXCR4 conjugate (4M5.3X4) efficiently targeted CXCR4+ T lymphocytes, specifically translocating siRNA by receptor-mediated endocytosis.",
          "offsetInBeginSection": 630,
          "offsetInEndSection": 773,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20964335",
          "text": "ne glycol) (M6P-PEG) for targeted delivery of siRNAs to hepatocytes and hepatic stellate cells (HSCs), respectively. These siRNA conjugates were purif",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 445,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546271",
          "text": "Atx complex formation with ASOs or siRNA was achieved via the in-frame fusion of either Saccharomyces cerevisiae GAL4 or Homo sapien sapien PKR (respectively) to a truncation of Atx lethal factor (LFn), which were used with Atx protective antigen (PA).",
          "offsetInBeginSection": 475,
          "offsetInEndSection": 727,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22970170",
          "text": "6% siRNA and exhibited a higher stability than naked siRNA in plasma. Hepatocyte-specific targeting was confirmed by in vivo delivery experiment, in w",
          "offsetInBeginSection": 1124,
          "offsetInEndSection": 1274,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16686729",
          "text": "OBJECTIVE\nTo determine whether a specifically designed bispecific (Bcl-2/Bcl-xL) antisense oligonucleotide (ASO) induces apoptosis and enhances chemosensitivity in human prostate cancer LNCaP cells, as Bcl-2 and Bcl-xL are both anti-apoptotic genes associated with treatment resistance and tumour progression in many malignancies, including prostate cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 357,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22443209",
          "text": "njugates were taken up by cancer cells but not normal mammary epithelial cells or human blood monocytes. By 120 min of incubation, most of the cells h",
          "offsetInBeginSection": 511,
          "offsetInEndSection": 661,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19245252",
          "text": "200 and 500 nm polymeric microspheres have been conjugated to siRNA targeted against EGFP expressed in human cervical cancer (HeLa) cells and shown to efficiently silence protein expression over 72 h, without detrimental cytotoxicity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31303442",
          "text": "Finally, GalNAc conjugation enhanced ASO activity in human circulating tumor cells from HCC patients, demonstrating the potential of this approach in primary human HCC tumor cells.",
          "offsetInBeginSection": 1117,
          "offsetInEndSection": 1297,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22970170",
          "text": "ere studied in vivo in a concanavalin A (ConA)-induced hepatitis model. C57BL/6 mice were treated with Gal-LipoNP Fas siRNA by i.v. injection 72 h bef",
          "offsetInBeginSection": 711,
          "offsetInEndSection": 861,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30570431",
          "text": "n laboratory test results as a function of dose level over time. With hepatocyte targeted delivery, the ED50 for the GalNAc3-conjugated PS-modified 2'",
          "offsetInBeginSection": 1134,
          "offsetInEndSection": 1284,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992960",
          "text": "mouse ASGPR, which results in enhanced ASO delivery to hepatocytes versus non-parenchymal cells. After internalization into cells, the GN3: -ASO conju",
          "offsetInBeginSection": 523,
          "offsetInEndSection": 673,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902800",
          "text": "A resulted in a decreased expression of Gal-1 in both murine and human GBM cells. Sequence specific RNAinterference, resulted in more than 50% Gal-1 r",
          "offsetInBeginSection": 784,
          "offsetInEndSection": 934,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34797690",
          "text": "We assessed the kinetics of uptake and subsequent intracellular distribution of AlexaFluor 488 (AF488)-labeled PS-ASOs and GalNAc-PS-ASOs in J774A.1 mouse macrophages and primary mouse or rat hepatocytes using simultaneous coherent anti-Stokes Raman scattering (CARS) and two-photon fluorescence (2PF) imaging.",
          "offsetInBeginSection": 691,
          "offsetInEndSection": 1001,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28335269",
          "text": "These results suggest that Gal-DOX-siRNA-L could effectively target tumor cells, enhance transfection efficacy and subsequently achieve the co-delivery of DOX and siRNA, demonstrating great potential for synergistic anti-tumor therapy.",
          "offsetInBeginSection": 1365,
          "offsetInEndSection": 1600,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15767784",
          "text": "ting xenoreactivity and the complement activation with human serum in PIEC cells. We also demonstrated the concordant inhibitory effect of siRNA and h",
          "offsetInBeginSection": 606,
          "offsetInEndSection": 756,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17441333",
          "text": "erase (ST6Gal I) on the cell adhesion and invasiveness of human cervical carcinoma cell line, HeLa with over-expressing ST6Gal I.\n\n\nMETHODS\nThe siRNA ",
          "offsetInBeginSection": 148,
          "offsetInEndSection": 298,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28335269",
          "text": "These Gal-DOX/siRNA-Ls showed stronger affinity to human hepatocellular carcinoma cells (Huh7) than other cells (lung epithelial carcinoma, A549).",
          "offsetInBeginSection": 794,
          "offsetInEndSection": 940,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15812240",
          "text": "ting xenoreactivity and the complement activation with human serum in PIEC cells. We also demonstrated the concordant inhibitory effect of siRNA and t",
          "offsetInBeginSection": 613,
          "offsetInEndSection": 763,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22970170",
          "text": " studied in vivo in a concanavalin A (ConA)-induced hepatitis model. C57BL/6 mice were treated with Gal-LipoNP Fas siRNA by i.v. injection 72 h before",
          "offsetInBeginSection": 714,
          "offsetInEndSection": 864,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29808997",
          "text": " (L4-LCP NPs) exhibited a superior siRNA delivery into HCC cells compared to normal hepatocytes. VEGF siRNAs delivered by L4-LCP NPs downregulated VEG",
          "offsetInBeginSection": 831,
          "offsetInEndSection": 981,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794086",
          "text": "verall reduction of the injury area in the Gal-LipoNP TLR4 siRNA treated mice. Additionally, neutrophil accumulation and lipid peroxidase-mediated tis",
          "offsetInBeginSection": 743,
          "offsetInEndSection": 893,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069408",
          "text": "Antisense oligonucleotide (ASO) therapeutics show tremendous promise for the treatment of previously intractable human diseases but to exert their effects on cellular RNA processing they must first cross the plasma membrane by endocytosis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 239,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25684095",
          "text": "Galectin-3 (Gal-3), a \u03b2-galactoside-binding lectin, serves as a pattern-recognition receptor (PRR) of dendritic cells (DCs) in regulating proinflammatory cytokine production.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17441333",
          "text": "METHODS\nThe siRNA and ASOs targeting to ST6Gal I were designed and synthesized chemically, and then with lipofectamine 2000, transferred into HeLa cells, which were cultured and divided into 7 groups: blank control group, liposome group, siRNA group transfected with ST6Gal I siRNA, ASO1 group transfected with ST6Gal I ASO whose target site is same as siRNA, ASO2 group transfected with ST6Gal I ASO whose target site is different with siRNA, siRNA+ASO1 group transfected with siRNA and its homologous ASO1, siRNA+ASO2 group transfected with siRNA and its nonhomologous ASO2.",
          "offsetInBeginSection": 280,
          "offsetInEndSection": 856,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26914862",
          "text": "GalNAc-ASO conjugates exhibited excellent potencies (ED50 0.5-2 mg/kg) for reducing the targeted mRNAs and proteins.",
          "offsetInBeginSection": 512,
          "offsetInEndSection": 628,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22386573",
          "text": "resulted in the inhibition of cell growth and proliferation of HeyA8 and SKOV3ip1 cells. Moreover, the ability of cells to migrate was significantly r",
          "offsetInBeginSection": 916,
          "offsetInEndSection": 1066,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28696185",
          "text": "polymer/TCS of 10:2.5, 10:5, 10:7 (w/w) were prepared for targeting cancer therapy. The amphiphilic PLA, amino terminated PEG graft copolymers were sy",
          "offsetInBeginSection": 176,
          "offsetInEndSection": 326,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340795",
          "text": "To this end, MDA-MB-231             and MDA-MB-468 breast cancer cells transfected with Nek2 siRNA or ASO were exposed             to various concentrations of paclitaxel and doxorubicin.",
          "offsetInBeginSection": 910,
          "offsetInEndSection": 1097,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17441333",
          "text": "CONCLUSION\nThe synthesized chemically specific siRNA targeting to ST6Gal I can effectively downregulate the ST6Gal I expression in HeLa cell and further lead to the decline of cell adhesion and invasiveness to ECM, and use of associating siRNA with ASO targeting to same gene but different oligonucleotide location possesses the synergy and additive effect on targeted gene expression knocked down.",
          "offsetInBeginSection": 1768,
          "offsetInEndSection": 2166,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35905589",
          "text": "Aptamer conjugation was associated with increased cellular effects in HCT116 cells, but not in HEK293 cells.",
          "offsetInBeginSection": 1022,
          "offsetInEndSection": 1130,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28158620",
        "http://www.ncbi.nlm.nih.gov/pubmed/26546271",
        "http://www.ncbi.nlm.nih.gov/pubmed/29069408",
        "http://www.ncbi.nlm.nih.gov/pubmed/19085118",
        "http://www.ncbi.nlm.nih.gov/pubmed/19245252",
        "http://www.ncbi.nlm.nih.gov/pubmed/30570431",
        "http://www.ncbi.nlm.nih.gov/pubmed/34797690",
        "http://www.ncbi.nlm.nih.gov/pubmed/31641784",
        "http://www.ncbi.nlm.nih.gov/pubmed/22443209",
        "http://www.ncbi.nlm.nih.gov/pubmed/22970170",
        "http://www.ncbi.nlm.nih.gov/pubmed/30345352",
        "http://www.ncbi.nlm.nih.gov/pubmed/31303442",
        "http://www.ncbi.nlm.nih.gov/pubmed/23340795",
        "http://www.ncbi.nlm.nih.gov/pubmed/28696185",
        "http://www.ncbi.nlm.nih.gov/pubmed/17441333",
        "http://www.ncbi.nlm.nih.gov/pubmed/26855051",
        "http://www.ncbi.nlm.nih.gov/pubmed/15812240",
        "http://www.ncbi.nlm.nih.gov/pubmed/26902800",
        "http://www.ncbi.nlm.nih.gov/pubmed/15767784",
        "http://www.ncbi.nlm.nih.gov/pubmed/15894474",
        "http://www.ncbi.nlm.nih.gov/pubmed/20964335",
        "http://www.ncbi.nlm.nih.gov/pubmed/22386573",
        "http://www.ncbi.nlm.nih.gov/pubmed/35905589",
        "http://www.ncbi.nlm.nih.gov/pubmed/29808997",
        "http://www.ncbi.nlm.nih.gov/pubmed/24992960",
        "http://www.ncbi.nlm.nih.gov/pubmed/25684095",
        "http://www.ncbi.nlm.nih.gov/pubmed/16686729",
        "http://www.ncbi.nlm.nih.gov/pubmed/26914862",
        "http://www.ncbi.nlm.nih.gov/pubmed/31099004",
        "http://www.ncbi.nlm.nih.gov/pubmed/28335269",
        "http://www.ncbi.nlm.nih.gov/pubmed/35623403",
        "http://www.ncbi.nlm.nih.gov/pubmed/21794086"
      ]
    },
    {
      "id": "64299fa957b1c7a315000002",
      "type": "summary",
      "body": "What is rebound COVID-19?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36324801",
          "text": "COVID-19 rebound was defined as documentation of negative then newly-positive SARS-CoV-2 tests.",
          "offsetInBeginSection": 666,
          "offsetInEndSection": 761,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36324801",
          "text": "Previous studies suggest that monoclonal antibodies are an effective outpatient treatment option for patients at high-risk of severe COVID-19, including those with systemic autoimmune rheumatic diseases (SARDs).Nirmatrelvir/ritonavir and molnupiravir are recently-authorized effective oral outpatient SARS-CoV-2 treatment options, but clinical trials were performed among the general population, mostly among unvaccinated and prior to Omicron viral variants.Oral outpatient SARS-CoV-2 treatments may result in COVID-19 rebound, characterized by newly-positive COVID-19 testing and recurrent symptoms, but no studies have investigated rebound prevalence among SARD patients.",
          "offsetInBeginSection": 1973,
          "offsetInEndSection": 2646,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35734093",
          "text": "Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36181334",
          "text": " infection is rebound COVID-19, which occurs between five and eight days following the cessation of antiviral treatment. Most case reports of rebound ",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 222,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33132535",
          "text": "o its end, will COVID-19 return again in what is known as a second rebound of the pandemic? In this work, we developed a predictive model that can est",
          "offsetInBeginSection": 444,
          "offsetInEndSection": 594,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35794889",
          "text": "Importance\nRecent case reports document that some patients who were treated with Paxlovid experienced rebound COVID-19 infections and symptoms 2 to 8 days after completing a 5-day course of Paxlovid.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32388934",
          "text": "till under global pandemic. China is facing the risks of importation and local rebound of COVID-19. Under the circumstances, preparations for medical ",
          "offsetInBeginSection": 33,
          "offsetInEndSection": 183,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35345769",
          "text": "00 daily cases, from May 6 to August 14, 2020) and a rebound phase (>100 daily cases, from August 15 to December 31, 2020).\n\n\nResults\nArea-level socio",
          "offsetInBeginSection": 842,
          "offsetInEndSection": 992,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35794889",
          "text": "Main Outcomes and Measures\nThree types of COVID-19 rebound outcomes (COVID-19 infections, COVID-19 related symptoms, and hospitalizations) were examined.",
          "offsetInBeginSection": 1194,
          "offsetInEndSection": 1347,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35982673",
          "text": ".1 was the predominant subvariant. The risks of both COVID-19 rebound infections and symptoms 2-8 days after Paxlovid treatment were higher in the BA.",
          "offsetInBeginSection": 959,
          "offsetInEndSection": 1109,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36472873",
          "text": "Importance\nSome patients treated with nirmatrelvir-ritonavir have experienced rebound of COVID-19 infections and symptoms; however, data are scarce on whether viral rebound also occurs in patients with COVID-19 receiving or not receiving molnupiravir.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 251,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32874016",
          "text": " double-peak dynamic behavior of the COVID-19 system is observed. The second wave rebound shows that the daily confirmed cases of the second peak even",
          "offsetInBeginSection": 953,
          "offsetInEndSection": 1103,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35192224",
          "text": "These findings quantitatively demonstrate the systematic drivers of the spread of COVID-19, and the framework proposed in this study will facilitate the targeted prevention and control of the ongoing COVID-19 pandemic.",
          "offsetInBeginSection": 1891,
          "offsetInEndSection": 2109,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35794889",
          "text": "The 7-day and 30-day COVID-19 rebound rates after Molnupiravir treatment were 5.86% and 8.59% for COVID-19 infection, 3.75% and 8.21% for COVID-19 symptoms, and 0.84% and 1.39% for hospitalizations.",
          "offsetInBeginSection": 1784,
          "offsetInEndSection": 1982,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35898366",
          "text": "We present the cases of COVID-19 relapse (COVID-19 rebound) in two patients following treatment with Paxlovid.",
          "offsetInBeginSection": 583,
          "offsetInEndSection": 693,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35309520",
          "text": "9 mitigation strategies are still in place. An effective COVID-19 mitigation protocol may facilitate a more successful rebound since consumers may per",
          "offsetInBeginSection": 54,
          "offsetInEndSection": 204,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33051302",
          "text": "ervention, COVID-19 will decrease temporarily during summer, rebound by autumn, and peak next winter. Validation based on data from May and June 2020 ",
          "offsetInBeginSection": 769,
          "offsetInEndSection": 919,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35690079",
          "text": "There was some rebound during COVID-19 recovery as a percentage of pre-COVID-19 volumes: 85.3% of pre-COVID-19 for screening mammography, 97.8% for diagnostic mammography, 91.5% for biopsies, and 92.0% for cancer diagnoses.",
          "offsetInBeginSection": 1145,
          "offsetInEndSection": 1368,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36091471",
          "text": "h-April) and reopenings (May-November), we estimated a small rebound in visits during reopenings. In park service areas where a greater proportion of ",
          "offsetInBeginSection": 627,
          "offsetInEndSection": 777,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33283034",
          "text": "We found that social unrest is likely associated with the rebound of the COVID-19 transmissibility, which might raise difficulties in the pandemic control.",
          "offsetInBeginSection": 250,
          "offsetInEndSection": 405,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36181334",
          "text": "The mechanisms of rebound COVID-19 remain unclear but may involve the development of resistance to the antiviral drug, impaired immunity to the virus, or insufficient drug dosing.",
          "offsetInBeginSection": 769,
          "offsetInEndSection": 948,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35982673",
          "text": "Paxlovid was authorized by FDA to treat mild-to-moderate COVID-19. In May 2022, the Centers for Disease Control and Prevention (CDC) issued a Health A",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34154977",
          "text": "CONCLUSIONS\nCOVID-19 patients treated with corticosteroids were classified into three response groups: success, rebound, and refractory, between which recovery time and prognosis differed.",
          "offsetInBeginSection": 1350,
          "offsetInEndSection": 1538,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32745860",
          "text": "Existing studies have shown that the COVID-19 pandemic caused a sharp drop in carbon emissions in 2020.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35970690",
          "text": "Limited evidence suggests most cases of rebound symptoms are mild and do not require further intervention.",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35794889",
        "http://www.ncbi.nlm.nih.gov/pubmed/34154977",
        "http://www.ncbi.nlm.nih.gov/pubmed/35898366",
        "http://www.ncbi.nlm.nih.gov/pubmed/35309520",
        "http://www.ncbi.nlm.nih.gov/pubmed/35345769",
        "http://www.ncbi.nlm.nih.gov/pubmed/32745860",
        "http://www.ncbi.nlm.nih.gov/pubmed/35192224",
        "http://www.ncbi.nlm.nih.gov/pubmed/32874016",
        "http://www.ncbi.nlm.nih.gov/pubmed/35734093",
        "http://www.ncbi.nlm.nih.gov/pubmed/36324801",
        "http://www.ncbi.nlm.nih.gov/pubmed/35690079",
        "http://www.ncbi.nlm.nih.gov/pubmed/33132535",
        "http://www.ncbi.nlm.nih.gov/pubmed/35970690",
        "http://www.ncbi.nlm.nih.gov/pubmed/33283034",
        "http://www.ncbi.nlm.nih.gov/pubmed/32388934",
        "http://www.ncbi.nlm.nih.gov/pubmed/36472873",
        "http://www.ncbi.nlm.nih.gov/pubmed/36181334",
        "http://www.ncbi.nlm.nih.gov/pubmed/35982673",
        "http://www.ncbi.nlm.nih.gov/pubmed/33051302",
        "http://www.ncbi.nlm.nih.gov/pubmed/36091471"
      ]
    },
    {
      "id": "6432fb1957b1c7a31500001e",
      "type": "list",
      "body": "What clinical applications is Zanubrutinib approved for in the United States?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35950210",
          "text": "ond-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients. Here, we review the use of BTK inhibitors in WM i",
          "offsetInBeginSection": 363,
          "offsetInEndSection": 513,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35770040",
          "text": "ial, the Food and Drug Administration (FDA) approved zanubrutinib for treating WM. This trial directly compared zanubrutinib to ibrutinib in patients ",
          "offsetInBeginSection": 1223,
          "offsetInEndSection": 1373,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33306268",
          "text": "ed accelerated approval in the United States for treatment of relapsed/refractory mantle cell lymphoma. The objective of this analysis was to develop ",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 322,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31875923",
          "text": "n's tyrosine kinase inhibitor with promising clinical activity in B-cell malignancies. Zanubrutinib was shown to be mainly metabolized through cytochr",
          "offsetInBeginSection": 49,
          "offsetInEndSection": 199,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737804",
          "text": "e the turn of the century. The majority of devices have been for cervical arthroplasty. By contrast, biologic devices were most likely to go to panel ",
          "offsetInBeginSection": 1662,
          "offsetInEndSection": 1812,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306909",
          "text": "BTK) approved for the treatment of Waldenstr\u00f6m's macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma. As a class, BTKs have been linke",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 262,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
          "text": "Zanubrutinib, a second-generation BTK inhibitor, was approved by the U.S. Food and Drug Administration (FDA) in late 2019 for r/r MCL on the basis of combined overall response rate of 84% in a total of 118 patients from two multicenter clinical trials, BGB-3111-AU-003 and BGB-3111-206.",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 549,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy.",
          "offsetInBeginSection": 543,
          "offsetInEndSection": 890,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35770040",
          "text": "Even though zanubrutinib has been the third and last BTK inhibitor to currently penetrate the market for B-cell lymphoproliferative malignancies, we highlight the emergence of zanubrutinib as a key player in the forefront of the therapeutic landscape in WM.",
          "offsetInBeginSection": 1833,
          "offsetInEndSection": 2090,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL who have received at least one anti-CD20-based therapy.",
          "offsetInBeginSection": 3210,
          "offsetInEndSection": 3439,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "Results of clinical studies on zanubrutinib treatment appear promising in patients with several types of B-cell malignancies, including mantle cell lymphoma (MCL), Waldenstr\u00f6m macroglobulinemia (WM), marginal zone lymphoma (MZL), chronic lymphocytic leukemia, and small lymphocytic lymphoma.",
          "offsetInBeginSection": 2590,
          "offsetInEndSection": 2881,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7535842",
          "text": " high-dose chemotherapy and bone marrow transplantation, peripheral-blood progenitor mobilization, and supportive care of leukemia patients.\n\n\nCONCLUS",
          "offsetInBeginSection": 1057,
          "offsetInEndSection": 1207,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753893",
          "text": "In addition to ibrutinib and acalabrutinib, the FDA recently approved zanubrutinib for the treatment of patients with relapsed/refractory MCL based on the results of two Phase 2 clinical trials showing overall response rates of 85-87% with complete responses in 30-77% of patients.",
          "offsetInBeginSection": 414,
          "offsetInEndSection": 695,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32869675",
          "text": "Zanubrutinib is currently approved for the treatment of patients with relapsed mantle cell lymphoma and has demonstrated an impressive safety and efficacy profile.",
          "offsetInBeginSection": 701,
          "offsetInEndSection": 864,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306909",
          "text": "nated cryptococcosis in the setting of zanubrutinib use for Waldenstr\u00f6m's macroglobulinemia. At the time of diagnosis, his Waldenstr\u00f6m's macroglobulin",
          "offsetInBeginSection": 1137,
          "offsetInEndSection": 1287,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34051727",
          "text": "BACKGROUND\nZanubrutinib is a Bruton's tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35680835",
          "text": "In this review the clinical application and new progress for zanubrutinib in B-cell lymphoma was summarized briefly.",
          "offsetInBeginSection": 544,
          "offsetInEndSection": 660,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29189604",
          "text": "research to support eventual approval in the United States for human and veterinary use. This article will briefly review key information about this p",
          "offsetInBeginSection": 1521,
          "offsetInEndSection": 1671,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36252483",
          "text": "oved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). While its role in pulmon",
          "offsetInBeginSection": 611,
          "offsetInEndSection": 761,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33777941",
          "text": "In most cases, these compounds have been used for the treatment of B-lymphocyte tumors.",
          "offsetInBeginSection": 694,
          "offsetInEndSection": 781,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34558376",
          "text": "6, zanubrutinib, BGB-3111, and Waldenstr\u00f6m macroglobulinemia. Prospective clinical trials evaluating the efficacy and safety of ibrutinib, acalabrutin",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 458,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36252483",
          "text": "s approved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). While its role in ",
          "offsetInBeginSection": 605,
          "offsetInEndSection": 755,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32861286",
          "text": "utinib, are all approved in the United States for the treatment of relapsed mantle cell lymphoma (MCL). BTKi as a class have become the preferred ther",
          "offsetInBeginSection": 82,
          "offsetInEndSection": 232,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32869675",
          "text": "Zanubrutinib is currently approved for the treatment of patients with relapsed mantle cell lymphoma and has demonstrated an impressive safety and efficacy profile.",
          "offsetInBeginSection": 701,
          "offsetInEndSection": 864,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34664792",
          "text": "bolism and transport of zanubrutinib, and its potential for clinical drug-drug interactions (DDIs). Phenotyping studies indicated cytochrome P450 (CYP",
          "offsetInBeginSection": 176,
          "offsetInEndSection": 326,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34250620",
          "text": "RESULTS AND DISCUSSION\nCategorization of drugs as antineoplastic agents, use of the cost accounting method in the drug pricing system, \"orphan\" designation and accelerated approval designation in the United States emerged as significant factors in the logistic regression analysis, predicting a waiver for confirmatory clinical trials (p\u00a0\u2264\u00a00.05).",
          "offsetInBeginSection": 1709,
          "offsetInEndSection": 2055,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34558376",
          "text": "anubrutinib, have been evaluated in prospective clinical trials for the treatment of Waldenstr\u00f6m macroglobulinemia. All three agents have demonstrated",
          "offsetInBeginSection": 1159,
          "offsetInEndSection": 1309,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34558376",
          "text": "been evaluated in prospective clinical trials for the treatment of Waldenstr\u00f6m macroglobulinemia. All three agents have demonstrated high overall resp",
          "offsetInBeginSection": 1177,
          "offsetInEndSection": 1327,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31933167",
          "text": "Zanubrutinib received accelerated approval in the USA on 14 November 2019 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, based on overall response rate (ORR) seen in phase II and I/II clinical trials.",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 428,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
          "text": "These current results and areas of further interest indicate an exciting future for zanubrutinib in the treatment of MCL.",
          "offsetInBeginSection": 1180,
          "offsetInEndSection": 1301,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34250620",
          "text": "Regulatory authorities have established several expedited regulatory pathways, such as accelerated approval designation in the United States (1992) and conditional approval regulation in Japan (2017).",
          "offsetInBeginSection": 88,
          "offsetInEndSection": 288,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34491123",
          "text": "Zanubrutinib was designed to achieve improved therapeutic concentrations and minimize off-target activities putatively accounting, in part, for the adverse effects seen with other BTK inhibitors.Areas covered: This drug profile covers zanubrutinib clinical pharmacology and the translation of pharmacokinetics (PK) and pharmacodynamics (PD) to clinical efficacy and safety profiles, by highlighting key differences between zanubrutinib and other BTK inhibitors.",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 572,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36461747",
          "text": "This study provides insights into the clinical pharmacology studies needed for drugs to treat rare diseases and would help both the regulators and drug developers to identify challenges and opportunities in conducting clinical pharmacology assessments for drugs developed to treat rare diseases.",
          "offsetInBeginSection": 1523,
          "offsetInEndSection": 1818,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29172975",
          "text": "Extrapolation allowed biosimilars to be approved for indications in which clinical studies were not conducted.",
          "offsetInBeginSection": 1513,
          "offsetInEndSection": 1623,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25792124",
          "text": "CONCLUSIONS\nIn patients with prior MI or PAD who have not had a previous stroke or TIA, vorapaxar added to standard therapy is effective for long-term secondary prevention of thrombotic CV events, while increasing moderate or severe bleeding.",
          "offsetInBeginSection": 1451,
          "offsetInEndSection": 1693,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21239834",
          "text": "ted States, deferiprone is only available in studies, for emergency use, or on a \"compassionate-use\" basis). Many trials and worldwide clinical experi",
          "offsetInBeginSection": 382,
          "offsetInEndSection": 532,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21239834",
        "http://www.ncbi.nlm.nih.gov/pubmed/32861286",
        "http://www.ncbi.nlm.nih.gov/pubmed/29189604",
        "http://www.ncbi.nlm.nih.gov/pubmed/31933167",
        "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
        "http://www.ncbi.nlm.nih.gov/pubmed/33306268",
        "http://www.ncbi.nlm.nih.gov/pubmed/7535842",
        "http://www.ncbi.nlm.nih.gov/pubmed/31875923",
        "http://www.ncbi.nlm.nih.gov/pubmed/35770040",
        "http://www.ncbi.nlm.nih.gov/pubmed/34051727",
        "http://www.ncbi.nlm.nih.gov/pubmed/34558376",
        "http://www.ncbi.nlm.nih.gov/pubmed/36252483",
        "http://www.ncbi.nlm.nih.gov/pubmed/27737804",
        "http://www.ncbi.nlm.nih.gov/pubmed/34491123",
        "http://www.ncbi.nlm.nih.gov/pubmed/34250620",
        "http://www.ncbi.nlm.nih.gov/pubmed/35680835",
        "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
        "http://www.ncbi.nlm.nih.gov/pubmed/25792124",
        "http://www.ncbi.nlm.nih.gov/pubmed/34664792",
        "http://www.ncbi.nlm.nih.gov/pubmed/35306909",
        "http://www.ncbi.nlm.nih.gov/pubmed/32869675",
        "http://www.ncbi.nlm.nih.gov/pubmed/36461747",
        "http://www.ncbi.nlm.nih.gov/pubmed/29172975",
        "http://www.ncbi.nlm.nih.gov/pubmed/35950210",
        "http://www.ncbi.nlm.nih.gov/pubmed/32753893",
        "http://www.ncbi.nlm.nih.gov/pubmed/33777941"
      ]
    },
    {
      "id": "61f7cb37882a024a10000029",
      "type": "yesno",
      "body": "Is rilonacept effective for pericarditis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36250662",
          "text": "RHAPSODY (rilonacept inhibition of interleukin-1 alpha and beta for recurrent pericarditis: a pivotal symptomatology and outcomes study) evaluated the efficacy and safety of rilonacept (IL-1\u03b1 and -\u03b2 cytokine trap) in recurrent pericarditis.",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 383,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33200890",
          "text": "-1 has been implicated as a mediator of recurrent pericarditis. The efficacy and safety of rilonacept, an interleukin-1\u03b1 and interleukin-1\u03b2 cytokine t",
          "offsetInBeginSection": 22,
          "offsetInEndSection": 172,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35874710",
          "text": "Rilonacept was efficacious and safe for the treatment of CAPS, FMF, recurrent pericarditis, and sJIA.",
          "offsetInBeginSection": 1842,
          "offsetInEndSection": 1943,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24839206",
          "text": "OBJECTIVE\nTo assess the efficacy and safety of rilonacept, an interleukin-1 inhibitor, in a randomized, double-blind, placebo-controlled trial.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36398320",
          "text": "It is safe and efficacious in the treatment of recurrent pericarditis in the RHAPSODY II and III trials.",
          "offsetInBeginSection": 780,
          "offsetInEndSection": 884,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18668535",
          "text": "OBJECTIVE\nTo assess the efficacy and safety of rilonacept (Interleukin-1 [IL-1] Trap), a long-acting and potent inhibitor of IL-1, in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 285,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754188",
          "text": "Treatment with rilonacept had a substantial steroid-sparing effect and was generally well-tolerated.",
          "offsetInBeginSection": 2062,
          "offsetInEndSection": 2162,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36316102",
          "text": "rapies while transitioning to rilonacept monotherapy was feasible without triggering pericarditis recurrence.\n\n\nTRIAL REGISTRATION NUMBER\nNCT03737110.",
          "offsetInBeginSection": 1909,
          "offsetInEndSection": 2059,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33882846",
          "text": " and as an exploratory endpoint in a Phase 2 trial evaluating the efficacy and safety of rilonacept (IL-1\u03b1/IL-1\u03b2 cytokine trap) to treat RP.\n\n\nMETHODS",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 301,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35350578",
          "text": "In the era of tailored medicine, anti-IL-1 agents such as anakinra and rilonacept have been demonstrated highly effective in patients with recurrent pericarditis associated with an inflammatory phenotype.",
          "offsetInBeginSection": 2149,
          "offsetInEndSection": 2353,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32324502",
          "text": "Rilonacept, a soluble IL-1 receptor chimeric fusion protein neutralizing IL-1\u03b1 and IL-1\u03b2, has also shown promising results in a phase II study in recurrent/refractory pericarditis.",
          "offsetInBeginSection": 1590,
          "offsetInEndSection": 1770,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33618510",
          "text": "Interleukin-1 inhibitors, such as anakinra and rilonacept, significantly reduce the risk of recurrences in patients with RP while on treatment.",
          "offsetInBeginSection": 1132,
          "offsetInEndSection": 1275,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34459270",
          "text": "In the Phase III trial, rilonacept was associated with a lower risk of recurrence, more persistent clinical response, and higher amount of days with no or minimal pericarditis symptoms, compared with placebo.",
          "offsetInBeginSection": 589,
          "offsetInEndSection": 797,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18668591",
          "text": "All patients received an initial loading dose of 300 mg of rilonacept by subcutaneous injection, were evaluated 6 and 10 days later for clinical efficacy, and remained off treatment until a clinical flare occurred.",
          "offsetInBeginSection": 478,
          "offsetInEndSection": 692,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19649332",
          "text": "It is yet to be determined whether rilonacept would be an effective treatment for other chronic inflammatory conditions such as gout, familial Mediterranean fever and systemic juvenile idiopathic arthritis.",
          "offsetInBeginSection": 1993,
          "offsetInEndSection": 2199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35639340",
          "text": "Both anakinra and rilonacept have demonstrated efficacy in randomized trials of patients with recurrent pericarditis.",
          "offsetInBeginSection": 663,
          "offsetInEndSection": 780,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34008144",
          "text": "th additional morbidity from long-term steroid use. Recent randomized trials indicate the efficacy of the interleukin-1 inhibitors anakinra and rilona",
          "offsetInBeginSection": 225,
          "offsetInEndSection": 375,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33229362",
          "text": "play a major role in RP. This phase II study evaluated rilonacept efficacy and safety in RP.\n\n\nMETHODS\nThis multicentre, open-label study enrolled adu",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 313,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35311434",
          "text": ") and rilonacept (an IL-1\u03b1 and IL-1\u03b2 trap) have shown that IL-1 blockade reduces recurrences. These trials also helped in phenotyping patients with RP",
          "offsetInBeginSection": 977,
          "offsetInEndSection": 1127,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34738773",
          "text": "Anti-interleukin-1 agents (anakinra, rilonacept), assessed in two RCT, were effective in the reduction of recurrences, compared with placebo (10% vs.78%, RR=0.14; 95% CI 0.05-0.35, P<0.001).",
          "offsetInBeginSection": 1593,
          "offsetInEndSection": 1783,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23485476",
          "text": ", with >70% of patients having no flares, and demonstrated an acceptable safety and tolerability profile.\n\n\nTRIAL REGISTRATION\nClinicalTrials.gov, htt",
          "offsetInBeginSection": 1600,
          "offsetInEndSection": 1750,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33737453",
          "text": "CONCLUSIONS\nIn patients with RP, anti-IL-1 agents (anakinra and rilonacept) are efficacious for prevention of recurrences, without severe adverse events.",
          "offsetInBeginSection": 1549,
          "offsetInEndSection": 1702,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23485476",
          "text": "CONCLUSION\nRilonacept significantly reduced the occurrence of GFs associated with initiation of ULT, with >70% of patients having no flares, and demonstrated an acceptable safety and tolerability profile.",
          "offsetInBeginSection": 1501,
          "offsetInEndSection": 1705,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34556390",
          "text": " by an evident inflammatory recurrent phenotype, and recent data have shown the striking efficacy of anakinra and rilonacept in these patients. The pr",
          "offsetInBeginSection": 1006,
          "offsetInEndSection": 1156,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33737453",
          "text": "After a median follow-up of 14 months (IQR,12-39), patients receiving anti-IL-1 agents (anakinra or rilonacept) had a significantly reduction in pericarditis recurrences (incidence rate ratio 0.06, 95% CI 0.03 to 0.14), compared with placebo and/or standard medical therapy.",
          "offsetInBeginSection": 872,
          "offsetInEndSection": 1146,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34319478",
          "text": "nt pericarditis, has recently reached phase 3 with promising results in terms of efficacy and safety. Alterations in the function of the inflammasome ",
          "offsetInBeginSection": 476,
          "offsetInEndSection": 626,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33708123",
          "text": "anakinumab, an anti-IL-1\u03b2 monoclonal antibody, and rilonacept, a soluble decoy receptor. However, other promising agents, such as gevokizumab, IL-1\u03b2 b",
          "offsetInBeginSection": 1169,
          "offsetInEndSection": 1319,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22549879",
          "text": "OBJECTIVE\nTo evaluate the efficacy and safety of the interleukin-1 inhibitor rilonacept (interleukin-1 Trap) for gout flare prevention during initiation of uric acid-lowering therapy (ULT).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24839206",
          "text": "CONCLUSION\nRilonacept was generally well tolerated and demonstrated efficacy in active systemic JIA.",
          "offsetInBeginSection": 1594,
          "offsetInEndSection": 1694,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34459270",
          "text": "OBJECTIVE\nTo review the pharmacology, efficacy, and safety of rilonacept for the prevention and treatment of recurrent pericarditis (RP).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22223180",
          "text": "CONCLUSION\nThe current findings indicate that rilonacept significantly reduces the frequency of gout flares during the initial period of treatment with urate-lowering therapy, with a favorable safety profile.",
          "offsetInBeginSection": 1792,
          "offsetInEndSection": 2000,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34156376",
          "text": "Rilonacept (Araclyst) has been approved to treat recurrent pericarditis and to reduce the risk of recurrence in adults and children 12 years of age and older.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34569270",
          "text": "Currently, anakinra and rilonacept, have demonstrated beneficial impact in clinical outcomes with a reasonable safety profile in randomized clinical trials.",
          "offsetInBeginSection": 810,
          "offsetInEndSection": 966,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34160952",
          "text": "Other IL-1 receptor antagonists have shown promising results (canakinumab, rilonacept).",
          "offsetInBeginSection": 1115,
          "offsetInEndSection": 1202,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34334059",
          "text": "AREAS COVERED\nThe review is aimed at providing an update on the efficacy and safety of current medical therapies for recurrent pericarditis including most recent advances represented by anti IL-1 agents.",
          "offsetInBeginSection": 560,
          "offsetInEndSection": 763,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36316102",
          "text": "ith rilonacept, which was hypothesised to allow accelerated withdrawal of common multidrug pericarditis regimens.\n\n\nMETHODS\nRHAPSODY was a multicentre",
          "offsetInBeginSection": 462,
          "offsetInEndSection": 612,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18668535",
          "text": "Rilonacept was generally well tolerated; the most common adverse events were injection site reactions.",
          "offsetInBeginSection": 1615,
          "offsetInEndSection": 1717,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32866928",
          "text": "Rilonacept (KPL-914), an interleukin-1\u03b1 and \u03b2 inhibitor, is in development for the treatment of RP.",
          "offsetInBeginSection": 242,
          "offsetInEndSection": 341,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34599390",
          "text": "Colchicine, an inhibitor of NLRP3 inflammasome formation, and IL-1-targeted therapies, such as anakinra and rilonacept, were found to effectively blunt the acute inflammation and reduce the risk for recurrences.",
          "offsetInBeginSection": 1048,
          "offsetInEndSection": 1259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23031624",
          "text": "ormalized biomarkers of inflammation. Rilonacept exhibited a generally favorable safety and tolerability profile in adult and pediatric patients with ",
          "offsetInBeginSection": 1665,
          "offsetInEndSection": 1815,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754188",
          "text": "OBJECTIVE\nTo determine the long-term safety and efficacy of rilonacept, an anti-interleukin-1 fusion protein, in patients with active systemic juvenile idiopathic arthritis (JIA).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36316102",
          "text": "Investigators initiated rilonacept at the labelled dose level and discontinued oral pericarditis therapies during the 12-week run-in; randomised patients received study drug as monotherapy.",
          "offsetInBeginSection": 743,
          "offsetInEndSection": 932,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34650361",
          "text": "kin 1 blockers anakinra and rilonacept, particularly indicated in refractory forms dependent on corticosteroids. Other medically relevant therapeutic ",
          "offsetInBeginSection": 624,
          "offsetInEndSection": 774,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18668591",
          "text": "RESULTS\nIn all patients, clinical symptoms typically induced by cold (rash, fever, and joint pain/swelling) improved within days of rilonacept administration.",
          "offsetInBeginSection": 1438,
          "offsetInEndSection": 1596,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23031624",
          "text": "Safety was evaluated in all patients, and efficacy was evaluated using a validated composite key symptom score in 56 patients.",
          "offsetInBeginSection": 793,
          "offsetInEndSection": 919,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34459270",
          "text": "CONCLUSION\nRilonacept is a safe, once weekly, subcutaneously administered IL-1 \"trap,\" indicated for the treatment of RP, and reduction in risk of recurrent pericarditis in adults and children \u226512 years of age.",
          "offsetInBeginSection": 1562,
          "offsetInEndSection": 1772,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25028379",
          "text": "OBJECTIVE\nTo evaluate the safety and efficacy of once-weekly subcutaneous rilonacept 160 mg for prevention of gout flares in patients initiating or continuing urate-lowering therapy (ULT).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34528670",
          "text": "For patients with corticosteroid-dependent and colchicine-resistant recurrent pericarditis with evidence of systemic inflammation, as evidenced by elevated C-reactive protein, the efficacy and safety of anakinra (2\u2009mg/kg/day up to 100\u2009mg/day subcutaneously usually for at least 6\u2009months, then tapered) and rilonacept (320\u2009mg subcutaneously for the first day followed by 160\u2009mg subcutaneously weekly) have been clearly demonstrated in observational studies and randomized controlled clinical trials.",
          "offsetInBeginSection": 835,
          "offsetInEndSection": 1333,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33229362",
          "text": "Rilonacept led to rapid and sustained improvement in pain, inflammation (CRP and pericarditis manifestations) and HRQOL. CSs were successfully tapered or discontinued; safety was consistent with known rilonacept safety profile",
          "offsetInBeginSection": 1672,
          "offsetInEndSection": 1898,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18668591",
          "text": "This pilot study was conducted to assess the safety and efficacy of rilonacept (IL-1 Trap), a long-acting IL-1 receptor fusion protein, in patients with FCAS.",
          "offsetInBeginSection": 248,
          "offsetInEndSection": 406,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33708123",
        "http://www.ncbi.nlm.nih.gov/pubmed/35639340",
        "http://www.ncbi.nlm.nih.gov/pubmed/19649332",
        "http://www.ncbi.nlm.nih.gov/pubmed/23754188",
        "http://www.ncbi.nlm.nih.gov/pubmed/34319478",
        "http://www.ncbi.nlm.nih.gov/pubmed/25028379",
        "http://www.ncbi.nlm.nih.gov/pubmed/34650361",
        "http://www.ncbi.nlm.nih.gov/pubmed/34334059",
        "http://www.ncbi.nlm.nih.gov/pubmed/33737453",
        "http://www.ncbi.nlm.nih.gov/pubmed/34569270",
        "http://www.ncbi.nlm.nih.gov/pubmed/34528670",
        "http://www.ncbi.nlm.nih.gov/pubmed/34156376",
        "http://www.ncbi.nlm.nih.gov/pubmed/23485476",
        "http://www.ncbi.nlm.nih.gov/pubmed/35350578",
        "http://www.ncbi.nlm.nih.gov/pubmed/23031624",
        "http://www.ncbi.nlm.nih.gov/pubmed/18668591",
        "http://www.ncbi.nlm.nih.gov/pubmed/34599390",
        "http://www.ncbi.nlm.nih.gov/pubmed/34160952",
        "http://www.ncbi.nlm.nih.gov/pubmed/36398320",
        "http://www.ncbi.nlm.nih.gov/pubmed/32866928",
        "http://www.ncbi.nlm.nih.gov/pubmed/33229362",
        "http://www.ncbi.nlm.nih.gov/pubmed/22223180",
        "http://www.ncbi.nlm.nih.gov/pubmed/22549879",
        "http://www.ncbi.nlm.nih.gov/pubmed/35874710",
        "http://www.ncbi.nlm.nih.gov/pubmed/35311434",
        "http://www.ncbi.nlm.nih.gov/pubmed/34738773",
        "http://www.ncbi.nlm.nih.gov/pubmed/36316102",
        "http://www.ncbi.nlm.nih.gov/pubmed/24839206",
        "http://www.ncbi.nlm.nih.gov/pubmed/34008144",
        "http://www.ncbi.nlm.nih.gov/pubmed/33200890",
        "http://www.ncbi.nlm.nih.gov/pubmed/32324502",
        "http://www.ncbi.nlm.nih.gov/pubmed/34556390",
        "http://www.ncbi.nlm.nih.gov/pubmed/36250662",
        "http://www.ncbi.nlm.nih.gov/pubmed/18668535",
        "http://www.ncbi.nlm.nih.gov/pubmed/34459270",
        "http://www.ncbi.nlm.nih.gov/pubmed/33882846",
        "http://www.ncbi.nlm.nih.gov/pubmed/33618510"
      ]
    },
    {
      "id": "6413712a201352f04a00003e",
      "type": "list",
      "body": "The 1p19q co-deletion is associated with what types of tumors?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30661193",
          "text": "g prognostic information as well as prediction of treatment response in gliomas. Accurate determination of the IDH mutation status and 1p19q co-deleti",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34125374",
          "text": "INTRODUCTION\nAnaplastic oligodendrogliomas are high-grade gliomas defined molecularly by 1p19q co-deletion.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33361717",
          "text": "Together with isocitrate dehydrogenase (IDH) mutation, co-deletion of 1p19q (1p19q codel) is a prerequisite for diagnosis of oligodendroglioma, making it imperative that histopathology laboratories introduce testing for 1p19q codel.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971646",
          "text": "ty and review the process of 1p19q co-deletion assessment using FISH in gliomas from a clinician's perspective. We also consider common alternative me",
          "offsetInBeginSection": 956,
          "offsetInEndSection": 1106,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33482430",
          "text": "In the WHO glioma classification guidelines grade (glioblastoma versus lower-grade glioma), IDH mutation and 1p/19q co-deletion status play a central role as they are important markers for prognosis and optimal therapy planning.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
          "text": "Combined immunohistochemical analysis assessed by INA expression and/or the lack of CIC expression was strongly associated with the 1p/19q co-deletion in oligodendroglial tumors, indicating a potential surrogate marker of the 1p/19q state.",
          "offsetInBeginSection": 871,
          "offsetInEndSection": 1110,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19624298",
          "text": "We confirmed the high incidence (82%) of combined 1p19q deletion in LGOs and the feasibility of successful FISH testing in paraffin embedded specimens up to 10-years-old.",
          "offsetInBeginSection": 1214,
          "offsetInEndSection": 1384,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35114775",
          "text": "Of the 26 tumours, 6 oligodendrogliomas had 1p19q co-deletion and the remaining 3 oligodendrogliomas showed no co-deletion.",
          "offsetInBeginSection": 746,
          "offsetInEndSection": 869,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18416660",
          "text": "ion, a translocation that defines a subset of oligodendroglial tumors, and anaplastic oligodendrogliomas in particular. A further likely prognostic bi",
          "offsetInBeginSection": 513,
          "offsetInEndSection": 663,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28340142",
          "text": "Tumor purity was found to be significantly decreased in high-risk IDH-mutant with 1p/19q co-deletion gliomas and IDH-wild-type glioblastomas but not in IDH-wild-type lower grade or IDH-mutant, non-co-deleted gliomas.",
          "offsetInBeginSection": 1342,
          "offsetInEndSection": 1558,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971646",
          "text": "1p19q co-deletion is a chromosomal alteration associated with primary brain tumours of oligodendroglial histology.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23344797",
          "text": "However, there are still unanswered questions regarding whether upfront chemotherapy, omitting/deferring radiotherapy, in the desire to avoid late neurocognitive toxicity of radiotherapy should be the initial therapy for AO tumors with codeleted 1p19q, or whether temozolomide, an oral agent with a better toxicity profile, can be substituted for procarbazine, lomustine, and vincristine (PCV).",
          "offsetInBeginSection": 1292,
          "offsetInEndSection": 1686,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "text": "H results for 1p19q co-deletions (n\u2009=\u20099) or EGFR amplification (n\u2009=\u20098). Gliomas positive for 1p19q co-deletions did not have other frequently recurren",
          "offsetInBeginSection": 547,
          "offsetInEndSection": 697,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18565359",
          "text": "uation. Data concerning low-grade gliomas were more controversial. Oligodendroglial tumors with 1p deletion or 1p19q codeletion seemed to have a bette",
          "offsetInBeginSection": 1462,
          "offsetInEndSection": 1612,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29704080",
          "text": "BACKGROUND\nThe purpose of this study is to map spatial metabolite differences across three molecular subgroups of glial tumors, defined by the IDH1/2 mutation and 1p19q-co-deletion, using magnetic resonance spectroscopy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25537428",
          "text": "While IDH mutation and TP53 mutation are significantly associated with AA (p\u00a0<\u00a00.0001), IDH mutation and 1p19q co-deletion were significantly associated with AO/AOA (p\u00a0<\u00a00.0001).",
          "offsetInBeginSection": 544,
          "offsetInEndSection": 722,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30656222",
          "text": "Our objective was to evaluate the differences in pattern of care and outcome by comparing grade II and grade III molecularly defined 1p19q co-deleted gliomas.",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 283,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18710393",
          "text": "Co-deletion of chromosome arms 1p and 19q, characteristic of oligodendroglial tumors, was recently found to be mediated by t(1;19)(q10;p10).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21653654",
          "text": "A strong INA protein expression has been reported in oligodendroglial tumours and was associated with 1p19q deletion.",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 240,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31807523",
          "text": "BACKGROUND\nGliomas are the most frequently occurring malignant brain cancers.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
          "text": "The lack of CIC expression was detected in 13 cases (68\u00a0%) of oligodendroglial tumors with the 1p/19q co-deletion, and in only 1 case of oligodendroglial tumors without the 1p/19q co-deletion (5\u00a0%, P\u00a0<\u00a00.0001).",
          "offsetInBeginSection": 660,
          "offsetInEndSection": 870,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32005184",
          "text": "BACKGROUND\nGliomas consist of a heterogeneous group of tumors. This study aimed to report the incidences of O6-methylguanine-DNA-methyltransferase (MG",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19507310",
          "text": "In pure O codeletion 1p19q was detected more frequently (in O -- 75%, in AO -- 56%) than in mixed tumors (in OA -- 31%, in AOA -- 35%).",
          "offsetInBeginSection": 1170,
          "offsetInEndSection": 1305,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "text": "a broader picture of the genomic alterations occurring in glioma cases. Gliomas with 1p19q co-deletion had a relatively quiet genome, apart from the s",
          "offsetInBeginSection": 1193,
          "offsetInEndSection": 1343,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20035368",
          "text": "Seven of the eight tumors with co-deletion of 1p/19q were WHO grade II gliomas.",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 861,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28488951",
          "text": "-deleted/partially deleted oligodendroglioma, oligoastrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma. OS and progression-free ",
          "offsetInBeginSection": 278,
          "offsetInEndSection": 428,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19139367",
          "text": "rrelated to the 1p19q codeletion, a favorable prognostic marker of oligodendroglial tumors.\n\n\nRESULTS\nINA expression was strong (>10% positive cells) ",
          "offsetInBeginSection": 266,
          "offsetInEndSection": 416,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
          "text": "\u03b1-Internexin (INA) has been proposed as a biomarker of oligodendroglial tumors with the 1p/19q co-deletion.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28488951",
          "text": "Median time to radiotherapy in 47 patients (44%) was 34.7 months and 41.2 months in 9 patients with co-deleted/incompletely co-deleted anaplastic oligodendroglioma/anaplastic oligoastrocytoma who received upfront temozolomide alone.",
          "offsetInBeginSection": 1115,
          "offsetInEndSection": 1347,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19624298",
          "text": "The purpose of the present study was to investigate potential prognostic factors in low-grade oligodendrogliomas (LGOs), particularly 1p19q deletion, due to its proven prognostic significance in anaplastic oligodendrogliomas.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29547090",
          "text": "8.9%); 140 cases of IDH-mutant, 1p19q-intact (49.0%); and 85 cases of IDH-mutant, 1p19q-codeleted (29.7%) tumors. Kaplan-Meier analysis showed that an",
          "offsetInBeginSection": 968,
          "offsetInEndSection": 1118,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34729052",
          "text": "The objectives of the current study were to assess the frequency of IDH mutation, ATRX expression loss, p53 overexpression, and 1p/19q co-deletion detection in adult diffuse gliomas (Grade II, III, and IV) and to correlate them with clinicopathological and histopathological features.",
          "offsetInBeginSection": 491,
          "offsetInEndSection": 775,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30661193",
          "text": "CONCLUSION\nUsing machine-learning algorithms, high accuracy was achieved in the prediction of IDH genotype in gliomas and moderate accuracy in a three-group prediction including IDH genotype and 1p19q codeletion.",
          "offsetInBeginSection": 1359,
          "offsetInEndSection": 1571,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20081802",
          "text": "In glial tumors, the loss of heterozygosity of the 1p and 19q chromosomal arms is thought to be a marker of good prognosis in oligodendroglial tumors.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "text": "RESULTS\nGenome-wide alterations involving copy number changes and loss of heterozygosity were identified in 17 glioma samples with positive FISH results for 1p19q co-deletions (n\u2009=\u20099) or EGFR amplification (n\u2009=\u20098).",
          "offsetInBeginSection": 404,
          "offsetInEndSection": 618,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28340142",
          "text": "Background\nCo-deletion of 1p and 19q marks a diffuse glioma subtype associated with relatively favorable overall survival; however, heterogeneous clinical outcomes are observed within this category.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34729052",
          "text": "CONCLUSION\nThe results of the present study indicate that IHC including IDH1/2, ATRX, and p53 is useful for the molecular classification of diffuse gliomas, which could be useful for the evaluation of prognosis, especially Grade III and II.",
          "offsetInBeginSection": 1439,
          "offsetInEndSection": 1679,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24608451",
          "text": "Polysomies involving 1p and/or 19q with or without deletions were seen in 76.9% of mixed oligoastrocytic tumors, 7.7% of pure OD tumors and one glioblastoma.",
          "offsetInBeginSection": 1185,
          "offsetInEndSection": 1342,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20587495",
          "text": "sociated with the 1p19q codeletion were predominantly located in the frontal lobe (p=0.044). The magnetic resonance image characteristics of indistinc",
          "offsetInBeginSection": 589,
          "offsetInEndSection": 739,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34729052",
          "text": "The World Health Organization incorporated isocitrate dehydrogenase (IDH) mutations and 1p/19q co-deletion with histopathological features into an \"integrated diagnosis\" in the revised classification of tumors of CNS.",
          "offsetInBeginSection": 116,
          "offsetInEndSection": 333,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446099",
          "text": "The authors describe a case wherein a 1p19q deletion in a disseminated tumor with mixed immunohistochemical features of oligodendroglioma and neurocytoma was encountered and treated.",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 340,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20035368",
          "text": "In contradistinction to previous reports, loss of 1p/19q occurs commonly in insular oligodendroglial tumors.",
          "offsetInBeginSection": 1284,
          "offsetInEndSection": 1392,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23254140",
          "text": "Here we present a case with detailed genetic evidence that suggests that mesenchymal metaplasia sarcomatous transformation is possible in classic oligodendrogliomas with 1p19q codeletions.",
          "offsetInBeginSection": 1417,
          "offsetInEndSection": 1605,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31807523",
          "text": "on, and the most prominent MGMT methylation, as previously described in glioma prognosis. Further, triple-negative patients have poorer PFS, indicatin",
          "offsetInBeginSection": 1501,
          "offsetInEndSection": 1651,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24608451",
          "text": "had an OD component. 1p and 19q codeletions were seen in 72.7% of oligodendrogliomas (World Health Organization [WHO] Grade II), 90.9% of anaplastic o",
          "offsetInBeginSection": 454,
          "offsetInEndSection": 604,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26017892",
          "text": "OBJECTIVE\nCIC gene is frequently mutated in oligodendroglial tumors with 1p19q codeletion.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30991699",
          "text": "Among these genes, CHI3L1 and NTRK2 were identified as factors that can be associated with IDH status and 1p/19q co-deletion to distinguish between prognostic groups of glioma from the TCGA cohort.",
          "offsetInBeginSection": 893,
          "offsetInEndSection": 1090,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24608451",
          "text": "early molecular change in the genesis of OD tumors, which is retained at the time of progression. Mixed tumors more frequently show polysomies of 1p a",
          "offsetInBeginSection": 1380,
          "offsetInEndSection": 1530,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30371623",
          "text": "nation (area under the curve [AUC], 0.803) and calibration. (2) For grade II tumors, subgroup analysis found that enhancing margin (poorly vs well def",
          "offsetInBeginSection": 1008,
          "offsetInEndSection": 1158,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29550880",
          "text": "el) provides significant diagnostic and prognostic value in lower-grade gliomas. As ATRX mutation and 1p19q codel are mutually exclusive, ATRX immunoh",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 198,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32005184",
        "http://www.ncbi.nlm.nih.gov/pubmed/34125374",
        "http://www.ncbi.nlm.nih.gov/pubmed/21653654",
        "http://www.ncbi.nlm.nih.gov/pubmed/30661193",
        "http://www.ncbi.nlm.nih.gov/pubmed/20587495",
        "http://www.ncbi.nlm.nih.gov/pubmed/24608451",
        "http://www.ncbi.nlm.nih.gov/pubmed/31807523",
        "http://www.ncbi.nlm.nih.gov/pubmed/33482430",
        "http://www.ncbi.nlm.nih.gov/pubmed/35114775",
        "http://www.ncbi.nlm.nih.gov/pubmed/19507310",
        "http://www.ncbi.nlm.nih.gov/pubmed/18416660",
        "http://www.ncbi.nlm.nih.gov/pubmed/20081802",
        "http://www.ncbi.nlm.nih.gov/pubmed/18565359",
        "http://www.ncbi.nlm.nih.gov/pubmed/30656222",
        "http://www.ncbi.nlm.nih.gov/pubmed/20035368",
        "http://www.ncbi.nlm.nih.gov/pubmed/23254140",
        "http://www.ncbi.nlm.nih.gov/pubmed/25537428",
        "http://www.ncbi.nlm.nih.gov/pubmed/28488951",
        "http://www.ncbi.nlm.nih.gov/pubmed/34729052",
        "http://www.ncbi.nlm.nih.gov/pubmed/26017892",
        "http://www.ncbi.nlm.nih.gov/pubmed/30991699",
        "http://www.ncbi.nlm.nih.gov/pubmed/18710393",
        "http://www.ncbi.nlm.nih.gov/pubmed/19624298",
        "http://www.ncbi.nlm.nih.gov/pubmed/20446099",
        "http://www.ncbi.nlm.nih.gov/pubmed/29550880",
        "http://www.ncbi.nlm.nih.gov/pubmed/23344797",
        "http://www.ncbi.nlm.nih.gov/pubmed/19139367",
        "http://www.ncbi.nlm.nih.gov/pubmed/28340142",
        "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
        "http://www.ncbi.nlm.nih.gov/pubmed/29547090",
        "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
        "http://www.ncbi.nlm.nih.gov/pubmed/29704080",
        "http://www.ncbi.nlm.nih.gov/pubmed/25971646",
        "http://www.ncbi.nlm.nih.gov/pubmed/33361717",
        "http://www.ncbi.nlm.nih.gov/pubmed/30371623"
      ]
    },
    {
      "id": "6429ad3857b1c7a315000003",
      "type": "factoid",
      "body": "The X-inactive specific transcript (Xist) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does Xist encode?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9601019",
          "text": "ch maps to the X chromosome inactivation centre (Xic) and encodes an untranslated RNA. Truncation of Xist RNA by gene targeting is lethal for female e",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657585",
          "text": "Xist encodes a noncoding RNA that influences the probability that the cis-linked X chromosome will be silenced.",
          "offsetInBeginSection": 81,
          "offsetInEndSection": 192,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26477563",
          "text": "Thus, the Xist gene carries within its coding sequence an antisense RNA that drives Xist expression.",
          "offsetInBeginSection": 813,
          "offsetInEndSection": 913,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23166390",
          "text": "e master regulator of X-inactivation. The Xist gene produces a non-coding RNA that functions as the primary switch for X-inactivation, coating the X c",
          "offsetInBeginSection": 432,
          "offsetInEndSection": 582,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14973270",
          "text": "This non-coding RNA becomes upregulated on the X chromosome that is to be inactivated upon differentiation.",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 185,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16227973",
          "text": "mes is inactivated in females to enable dosage compensation for X-linked gene products. In rodents and marsupials, only the X chromosome of paternal o",
          "offsetInBeginSection": 37,
          "offsetInEndSection": 187,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9487391",
          "text": "ipt (Xist) gene, which is known now to represent the master switch locus regulating X inactivation. In adult cells Xist is transcribed exclusively fro",
          "offsetInBeginSection": 231,
          "offsetInEndSection": 381,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21471966",
          "text": "The developmental regulation of this process has been extensively investigated in mice, where the X chromosome of paternal origin (Xp) is silenced during early embryogenesis owing to imprinted expression of the regulatory RNA, Xist (X-inactive specific transcript).",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 388,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25000994",
          "text": "evelopment and is initiated by a unique locus, which produces a long noncoding RNA, Xist. The Xist transcript triggers gene silencing in cis by coatin",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 391,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20950563",
          "text": ", relies on monoallelic activation of the Xist gene. Xist produces a non-coding RNA that can coat the chromosome from which it is transcribed in cis a",
          "offsetInBeginSection": 166,
          "offsetInEndSection": 316,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9722171",
          "text": "The Xist transcript does not encode a protein but remains sequestered within the nucleus and co-localises with the inactive X chromosome.",
          "offsetInBeginSection": 367,
          "offsetInEndSection": 504,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9069284",
          "text": "Xist is unusual in that it appears not to code for a protein but produces a nuclear RNA which colocalizes with the inactive X chromosome.",
          "offsetInBeginSection": 654,
          "offsetInEndSection": 791,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32482714",
          "text": "gulator of X chromosome inactivation in mammals. Xist produces a long noncoding (lnc)RNA that accumulates over the entire length of the chromosome fro",
          "offsetInBeginSection": 63,
          "offsetInEndSection": 213,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30496473",
          "text": "X-inactive-specific transcript (Xist) is a long noncoding RNA (lncRNA) essential for inactivating one of the two X chromosomes in mammalian females.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1423611",
          "text": "The gene does not contain any significant conserved ORFs and thus does not appear to encode a protein, suggesting that XIST may function as a structural RNA within the nucleus.",
          "offsetInBeginSection": 532,
          "offsetInEndSection": 708,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15145348",
          "text": "It also produces the Xist transcript, a remarkable RNA that coats the X chromosome in cis and triggers its silencing.",
          "offsetInBeginSection": 267,
          "offsetInEndSection": 384,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7604357",
          "text": "It is transcribed exclusively from inactive X chromosomes, and its noncoding transcript seems to be essential for cis inactivation.",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 303,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17333537",
          "text": " X-linked genes relative to XY males. In eutherian mammals X inactivation is regulated by the X-inactive specific transcript (Xist), a cis-acting non-coding RNA",
          "offsetInBeginSection": 128,
          "offsetInEndSection": 288,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26739568",
          "text": "X-inactive specific transcript (Xist) long noncoding RNA (lncRNA) is thought to catalyze silencing of X-linked genes in cis during X-chromosome inactivation, which equalizes X-linked gene dosage between male and female mammals.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17333537",
        "http://www.ncbi.nlm.nih.gov/pubmed/9722171",
        "http://www.ncbi.nlm.nih.gov/pubmed/30496473",
        "http://www.ncbi.nlm.nih.gov/pubmed/7604357",
        "http://www.ncbi.nlm.nih.gov/pubmed/20657585",
        "http://www.ncbi.nlm.nih.gov/pubmed/20950563",
        "http://www.ncbi.nlm.nih.gov/pubmed/1423611",
        "http://www.ncbi.nlm.nih.gov/pubmed/25000994",
        "http://www.ncbi.nlm.nih.gov/pubmed/15145348",
        "http://www.ncbi.nlm.nih.gov/pubmed/23166390",
        "http://www.ncbi.nlm.nih.gov/pubmed/9069284",
        "http://www.ncbi.nlm.nih.gov/pubmed/21471966",
        "http://www.ncbi.nlm.nih.gov/pubmed/32482714",
        "http://www.ncbi.nlm.nih.gov/pubmed/9601019",
        "http://www.ncbi.nlm.nih.gov/pubmed/26477563",
        "http://www.ncbi.nlm.nih.gov/pubmed/14973270",
        "http://www.ncbi.nlm.nih.gov/pubmed/26739568",
        "http://www.ncbi.nlm.nih.gov/pubmed/16227973",
        "http://www.ncbi.nlm.nih.gov/pubmed/9487391"
      ]
    },
    {
      "id": "63f92fd033942b094c00000b",
      "type": "summary",
      "body": "What are microexons?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508",
          "text": "The splicing of microexons (very small exons) is frequently dysregulated in the brain of individuals with autism spectrum disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34155820",
          "text": "Microexons are small sized (\u226451\u2009bp) exons which undergo extensive alternative splicing in neurons, microglia, embryonic stem cells, and cancer cells, giving rise to cell type specific protein isoforms.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35895262",
          "text": "However, the analysis of RNAs-seq data for detection and quantification of microexons, extremely short exons of length up to 30\u00a0nt, require specialized computational workflows.",
          "offsetInBeginSection": 196,
          "offsetInEndSection": 372,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10805741",
          "text": "ns six copies of the simple sequence GGGGCUG. The enhancer activates heterologous microexons and will work when located either upstream or downstream ",
          "offsetInBeginSection": 716,
          "offsetInEndSection": 866,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31559909",
          "text": "Neuronal microexons represent the most highly conserved class of alternative splicing events and their timed expression shapes neuronal biology, including neuronal commitment and differentiation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34836511",
          "text": "BACKGROUND\nMicroexons are a particular kind of exon of less than 30 nucleotides in length.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33859668",
          "text": "Exons with a length \u2264 30 nt are defined as microexons that are unique in identification.",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 243,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30526869",
          "text": "(2018) uncover novel mechanisms by which the cell regulates splicing of cryptic splice sites and microexons.",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 225,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33378678",
          "text": "Overall, our findings identify QKI as an alternative splicing regulator governing a network of Rho GTPase microexons with implications for CNS remyelination and MS patients.",
          "offsetInBeginSection": 936,
          "offsetInEndSection": 1109,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33621242",
          "text": "expression or activity of splicing factors (SFs). Microexons are extremely small exons (3-27 nucleotides long) that are highly evolutionarily conserve",
          "offsetInBeginSection": 73,
          "offsetInEndSection": 223,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142",
          "text": "Microexons (\u226427 nt) play critical roles in nervous system development and function but create unique challenges for the splicing machinery.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27502555",
          "text": "We discover a conserved AS program comprising hundreds of alternative exons, microexons and introns that is differentially regulated in planarian stem cells, and comprehensively identify its regulators.",
          "offsetInBeginSection": 396,
          "offsetInEndSection": 598,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29571299",
          "text": "We use SUPPA2 to identify novel Transformer2-regulated exons, novel microexons induced during differentiation of bipolar neurons, and novel intron retention events during erythroblast differentiation.",
          "offsetInBeginSection": 513,
          "offsetInEndSection": 713,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525873",
          "text": "These microexons modulate the function of interaction domains of proteins involved in neurogenesis.",
          "offsetInBeginSection": 475,
          "offsetInEndSection": 574,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33482885",
          "text": "BACKGROUND\nMicroexons, exons that are \u2264\u200930 nucleotides, are a highly conserved and dynamically regulated set of cassette exons.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30388412",
          "text": "Here, we describe a CRISPR-based strategy for the genome-wide elucidation of pathways that control splicing and apply it to microexons with important functions in nervous system development and that are commonly misregulated in autism.",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 425,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31999954",
          "text": "Microexons represent the most highly conserved class of alternative splicing, yet their functions are poorly understood.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30833759",
          "text": "Neuronal microexons represent the most conserved class of alternative splicing in vertebrates, and are critical for proper brain development and function.",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35145097",
          "text": "It is challenging to identify the smallest microexons (\u226415-nt) due to their small size.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35858306",
          "text": "evealing that the vertebrate retina expresses the largest number of tissue-enriched microexons of all tissue types. A subset of these microexons is in",
          "offsetInBeginSection": 293,
          "offsetInEndSection": 443,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28188674",
          "text": "However, an underappreciated aspect is the ability of the spliceosome to recognize a set of very small (3-30 nucleotide, 1-10 amino acid) exons named microexons.",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 244,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32535349",
          "text": "The discovery and characterization of a network of highly conserved neuronal microexons has provided fundamental new insight into mechanisms underlying nervous system development and function, as well as an important basis for pathway convergence in autism spectrum disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20659428",
          "text": "Thus microexons provide a mechanism for the control of tissue-specific interactions of ITSN1 and Src with their partners.",
          "offsetInBeginSection": 1254,
          "offsetInEndSection": 1375,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32286305",
          "text": "ORQAS leverages ribosome profiling to uncover a widespread and evolutionarily conserved impact of differential splicing on translation, particularly of microexon-containing isoforms.",
          "offsetInBeginSection": 885,
          "offsetInEndSection": 1067,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35089784",
          "text": "tricted to neurons by the posttranscriptional processing of the enhancer of microexons (eMIC) domain in Srrm234. In Drosophila, this processing is dep",
          "offsetInBeginSection": 347,
          "offsetInEndSection": 497,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30404949",
          "text": "skipping of microexons is an increasingly recognized class of alternative splicing events. However, the functional significance of microexons and thei",
          "offsetInBeginSection": 26,
          "offsetInEndSection": 176,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25838543",
          "text": "The main component of the altered AS program comprises 3- to 27-nucleotide (nt) neural microexons, an emerging class of highly conserved AS events associated with the regulation of protein interaction networks in developing neurons and neurological disorders.",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 1041,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20659428",
          "text": "Comparative sequence analysis of ITSN1 and Src genes revealed the conservation of alternatively spliced microexons affecting the structure of the SH3 domains in vertebrates.",
          "offsetInBeginSection": 288,
          "offsetInEndSection": 461,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34469739",
          "text": "These isoforms are enriched in loss-of-function mutations and microexons, are co-expressed with a unique set of partners, and have higher prenatal expression.",
          "offsetInBeginSection": 517,
          "offsetInEndSection": 675,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33378678",
          "text": "Splicing analysis reveals a role for QKI in regulating microexon networks of the Rho GTPase pathway.",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 395,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508",
          "text": "RBFOX2 and PTBP1 were found to directly bind to microexon-containing pre-mRNAs and to control their splicing in such cells.",
          "offsetInBeginSection": 787,
          "offsetInEndSection": 910,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34155820",
          "text": "In this review, we discuss the unique characteristics of microexons, and how RBPs participate in regulating their inclusion and exclusion during splicing.",
          "offsetInBeginSection": 898,
          "offsetInEndSection": 1052,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30404949",
          "text": " and the diglycine to the leading edge. These data highlight microexon skipping as a mechanism to spatially restrict signaling and provide a mechanist",
          "offsetInBeginSection": 891,
          "offsetInEndSection": 1041,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34346508",
        "http://www.ncbi.nlm.nih.gov/pubmed/34836511",
        "http://www.ncbi.nlm.nih.gov/pubmed/20659428",
        "http://www.ncbi.nlm.nih.gov/pubmed/35895262",
        "http://www.ncbi.nlm.nih.gov/pubmed/31999954",
        "http://www.ncbi.nlm.nih.gov/pubmed/35858306",
        "http://www.ncbi.nlm.nih.gov/pubmed/33859668",
        "http://www.ncbi.nlm.nih.gov/pubmed/34469739",
        "http://www.ncbi.nlm.nih.gov/pubmed/33621242",
        "http://www.ncbi.nlm.nih.gov/pubmed/25525873",
        "http://www.ncbi.nlm.nih.gov/pubmed/25838543",
        "http://www.ncbi.nlm.nih.gov/pubmed/30388412",
        "http://www.ncbi.nlm.nih.gov/pubmed/33378678",
        "http://www.ncbi.nlm.nih.gov/pubmed/31559909",
        "http://www.ncbi.nlm.nih.gov/pubmed/28188674",
        "http://www.ncbi.nlm.nih.gov/pubmed/32286305",
        "http://www.ncbi.nlm.nih.gov/pubmed/34155820",
        "http://www.ncbi.nlm.nih.gov/pubmed/35089784",
        "http://www.ncbi.nlm.nih.gov/pubmed/35145097",
        "http://www.ncbi.nlm.nih.gov/pubmed/34348142",
        "http://www.ncbi.nlm.nih.gov/pubmed/10805741",
        "http://www.ncbi.nlm.nih.gov/pubmed/30526869",
        "http://www.ncbi.nlm.nih.gov/pubmed/29571299",
        "http://www.ncbi.nlm.nih.gov/pubmed/30833759",
        "http://www.ncbi.nlm.nih.gov/pubmed/32535349",
        "http://www.ncbi.nlm.nih.gov/pubmed/33482885",
        "http://www.ncbi.nlm.nih.gov/pubmed/30404949",
        "http://www.ncbi.nlm.nih.gov/pubmed/27502555"
      ]
    },
    {
      "id": "64041f38201352f04a00001f",
      "type": "yesno",
      "body": "Is tebentafusp effective for uveal melanoma?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19032679",
          "text": "therapeutic option today against metastatic uveal melanoma, has not proved to be effective. Therefore, new molecular targets important for malignant p",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 332,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489097",
          "text": "therapeutic option today against metastatic uveal melanoma, has not proved to be effective. Therefore, new molecular targets important for malignant p",
          "offsetInBeginSection": 184,
          "offsetInEndSection": 334,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35716258",
          "text": "PURPOSE\nAnti-angiogenesis drug therapy is ineffective in treating uveal melanoma since it only targets angiogenesis leaving vasculogenic mimicry aside.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35115315",
          "text": "Tebentafusp, the first drug shown to extend overall survival in people with uveal melanoma, was greenlighted by the FDA in late January to treat patients with inoperable or metastatic forms of the aggressive eye cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33572586",
          "text": "Thus far, no effective methods of pharmacotherapy of this cancer have been found.",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 215,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35804863",
          "text": "cell receptor against the cancer molecule tebentafusp showed impressive antitumor effects. Meanwhile, oncolytic viruses and small molecule inhibitors ",
          "offsetInBeginSection": 1143,
          "offsetInEndSection": 1293,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34754859",
          "text": " signs of recurrence at 1 year after surgery.\n\n\nCONCLUSION\nSurgery is an effective treatment for metastatic uveal melanoma. In patients with liver met",
          "offsetInBeginSection": 1100,
          "offsetInEndSection": 1250,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
          "text": "Data showing a proven overall survival benefit with a systemic treatment are lacking.",
          "offsetInBeginSection": 211,
          "offsetInEndSection": 296,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23116575",
          "text": "However, there are still no effective therapies against metastatic uveal melanoma, which is almost always fatal.",
          "offsetInBeginSection": 428,
          "offsetInEndSection": 540,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27183438",
          "text": "n primary malignant intraocular tumor in adults and still lacks effective systemic therapies. Annexin A2 receptor (AXIIR), a receptor for Annexin II, ",
          "offsetInBeginSection": 32,
          "offsetInEndSection": 182,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20375921",
          "text": "n the remaining case. Uveal melanoma, like cutaneous melanoma, commonly expresses GPNMB. Ongoing clinical trials of CDX-011 should be extended to pati",
          "offsetInBeginSection": 1488,
          "offsetInEndSection": 1638,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22453016",
          "text": "Nearly half of primary uveal melanoma tumors metastasize, but there are currently no effective therapies for metastatic uveal melanoma.",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 207,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36442912",
          "text": " people of Asian or Pacific Island ancestry. While uveal melanoma is most common in Caucasian populations, other HLA-restricted cancer therapeutics ar",
          "offsetInBeginSection": 703,
          "offsetInEndSection": 853,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32816891",
          "text": "RESULTS\nTebentafusp was generally well-tolerated and active in both patients with metastatic uveal melanoma and patients with metastatic cutaneous melanoma.",
          "offsetInBeginSection": 705,
          "offsetInEndSection": 861,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29206651",
          "text": "PURPOSE OF REVIEW\nCurrently, there are no U.S. Food and Drug Administration-approved or effective treatment options for advanced-stage uveal melanoma.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
          "text": "CONCLUSIONS\nTreatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma.",
          "offsetInBeginSection": 1945,
          "offsetInEndSection": 2112,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34754859",
          "text": "Nearly half of all primary uveal melanoma tumors metastasize; yet, there are currently no effective treatments for metastatic uveal melanoma.",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 252,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22270078",
          "text": "The current treatment of metastatic uveal melanoma is limited by the lack of effective systemic therapy.",
          "offsetInBeginSection": 324,
          "offsetInEndSection": 428,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36102132",
          "text": "ith investigator choice therapy.\n\n\nEXPERT OPINION\nTebentafusp has transformed the treatment paradigm for metastatic uveal melanoma and should be the p",
          "offsetInBeginSection": 759,
          "offsetInEndSection": 909,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29692251",
          "text": "So far, there have been no effective targeted therapeutic agents in patients with uveal melanoma.",
          "offsetInBeginSection": 87,
          "offsetInEndSection": 184,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32747420",
          "text": "Currently, there are no approved targeted therapies and very few effective treatments for this cancer.",
          "offsetInBeginSection": 75,
          "offsetInEndSection": 177,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1589858",
          "text": "However, several new approaches involving interferons and interleukin and combination chemotherapy have shown some activity against metastatic cutaneous melanoma.",
          "offsetInBeginSection": 306,
          "offsetInEndSection": 468,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23222249",
          "text": "imary tumour locally, but once the tumour has metastasised, there are no curative therapies. Traditionally, the diagnosis of uveal melanoma and progno",
          "offsetInBeginSection": 205,
          "offsetInEndSection": 355,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26712692",
          "text": "Although durable cancer regression can be achieved in metastatic cutaneous melanoma with immunotherapies that augment naturally existing antitumor T-cell responses, the role of these treatments for metastatic uveal melanoma remains unclear.",
          "offsetInBeginSection": 103,
          "offsetInEndSection": 343,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31563544",
          "text": "ven effective in cutaneous melanoma -such as immunotherapy- have little or no success in uveal melanoma. Several independent studies have recently ide",
          "offsetInBeginSection": 488,
          "offsetInEndSection": 638,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35236927",
          "text": "Tebentafusp, a first in class ImmTAC (Immune-mobilizing monoclonal TCRs against cancer), has now shown an overall survival benefit when compared to investigator's choice.",
          "offsetInBeginSection": 569,
          "offsetInEndSection": 739,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31344957",
          "text": "RESULTS\nBecause few clinical trials have been conducted for metastasized uveal melanoma, no definitive treatment strategy exists for this rare disease.",
          "offsetInBeginSection": 842,
          "offsetInEndSection": 993,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36229663",
          "text": "iographic progression. Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previ",
          "offsetInBeginSection": 1301,
          "offsetInEndSection": 1451,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29497459",
          "text": "Despite effective primary therapy, nearly 50% of patients will develop metastatic disease.",
          "offsetInBeginSection": 104,
          "offsetInEndSection": 194,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34944815",
          "text": "While treatment of the primary tumor is often effective, 36-50% of patients develop metastatic disease primarily to the liver.",
          "offsetInBeginSection": 133,
          "offsetInEndSection": 259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31336704",
          "text": "In contrast to cutaneous melanoma, kinase inhibitors and immune checkpoint inhibitors are usually ineffective in patients with metastatic uveal melanoma.",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 331,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33839690",
          "text": "rolong survival among patients with an aggressive form of eye cancer. If approved, tebentafusp could become the standard of care for metastatic uveal ",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35254876",
          "text": "o assess its safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity in patients with metastatic uveal melanoma (mUM).\n\n\nMETHODS",
          "offsetInBeginSection": 206,
          "offsetInEndSection": 356,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32954611",
          "text": "In contrast to cutaneous melanoma, there is no standard-of-care treatment for metastasized uveal melanoma.",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 359,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29692251",
          "text": "e on uveal melanoma remains unknown.\n\n\nOBJECTIVE\nWe evaluated the anti-tumor effects of artesunate on uveal melanoma cells, and analyzed in terms of W",
          "offsetInBeginSection": 553,
          "offsetInEndSection": 703,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34944815",
          "text": "While selective targeting of Gq and G11 provides a potential therapeutic strategy to treat uveal melanoma, it is evident that improved inhibitors and methods of delivery are needed.",
          "offsetInBeginSection": 1006,
          "offsetInEndSection": 1187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35468881",
          "text": "Chemotherapy resistance poses an obstacle for effective treatment of uveal melanoma.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31811271",
          "text": "As visible light easily penetrates the eyes, we hypothesized that an optogenetics approach can be an effective treatment of uveal melanoma without surgery.",
          "offsetInBeginSection": 419,
          "offsetInEndSection": 574,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36094043",
          "text": "This medication, tebentafusp, is likely to improve life expectancy for all patients with metastatic melanoma assuming they have appropriate human leukocyte antigen (HLA) markers.",
          "offsetInBeginSection": 912,
          "offsetInEndSection": 1090,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36442912",
          "text": "This approval generated significant excitement, given the relative paucity of effective systemic therapies for advanced uveal melanoma.",
          "offsetInBeginSection": 237,
          "offsetInEndSection": 372,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35060440",
          "text": "With its novel mechanism of action, degree of efficacy and safety profile, tebentafusp is expected to change the standard of care for treating metastatic and, potentially localized, uveal melanoma.",
          "offsetInBeginSection": 1164,
          "offsetInEndSection": 1361,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36065296",
          "text": "ntly validated by the FDA's approval of tebentafusp for treatment of metastatic uveal melanoma. ImmTAV\u00ae are an application of this technology undergoi",
          "offsetInBeginSection": 550,
          "offsetInEndSection": 700,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29692251",
          "text": "CONCLUSION\nArtesunate may be a potential interest for the therapy of uveal melanoma.",
          "offsetInBeginSection": 1660,
          "offsetInEndSection": 1744,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31344957",
          "text": "However, encouraging results have been found for some very recently investigated agents such as the bispecific tebentafusp, for which a remarkably increased one-year overall survival rate, and similarly increased disease control rate, were observed in early phase studies.",
          "offsetInBeginSection": 1086,
          "offsetInEndSection": 1358,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34999237",
          "text": "The final frontier in conquering uveal melanoma lies in solving these issues to cure metastatic disease.",
          "offsetInBeginSection": 589,
          "offsetInEndSection": 693,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35364557",
          "text": "While it is clear that tebentafusp has an important role to play in this tumor type, the exact line is not yet well known.",
          "offsetInBeginSection": 1139,
          "offsetInEndSection": 1261,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24001901",
          "text": "ls both at primary and metastatic sites. However, TRAIL therapy lacks tumor specificity in the current delivery systems for uveal melanoma treatment, ",
          "offsetInBeginSection": 260,
          "offsetInEndSection": 410,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20375921",
          "text": "Despite genomic differences between cutaneous and uveal melanomas, therapies based on shared biological factors could be effective against both tumor types.",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 247,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35172589",
          "text": "However, the most recent phase III study results for tebentafusp, a member of a new-in-class molecule, are raising hopes for stage IV uveal melanoma patients.",
          "offsetInBeginSection": 405,
          "offsetInEndSection": 563,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32725406",
          "text": " taken into registration-intent clinical trials: tebentafusp, a T cell redirecting agent, and IDE196, an oral protein kinase C inhibitor. Treatment of",
          "offsetInBeginSection": 655,
          "offsetInEndSection": 805,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26712692",
        "http://www.ncbi.nlm.nih.gov/pubmed/32747420",
        "http://www.ncbi.nlm.nih.gov/pubmed/27183438",
        "http://www.ncbi.nlm.nih.gov/pubmed/32816891",
        "http://www.ncbi.nlm.nih.gov/pubmed/35716258",
        "http://www.ncbi.nlm.nih.gov/pubmed/34944815",
        "http://www.ncbi.nlm.nih.gov/pubmed/33572586",
        "http://www.ncbi.nlm.nih.gov/pubmed/20375921",
        "http://www.ncbi.nlm.nih.gov/pubmed/35364557",
        "http://www.ncbi.nlm.nih.gov/pubmed/35468881",
        "http://www.ncbi.nlm.nih.gov/pubmed/33839690",
        "http://www.ncbi.nlm.nih.gov/pubmed/36094043",
        "http://www.ncbi.nlm.nih.gov/pubmed/35115315",
        "http://www.ncbi.nlm.nih.gov/pubmed/23116575",
        "http://www.ncbi.nlm.nih.gov/pubmed/34999237",
        "http://www.ncbi.nlm.nih.gov/pubmed/16489097",
        "http://www.ncbi.nlm.nih.gov/pubmed/1589858",
        "http://www.ncbi.nlm.nih.gov/pubmed/29206651",
        "http://www.ncbi.nlm.nih.gov/pubmed/34754859",
        "http://www.ncbi.nlm.nih.gov/pubmed/35172589",
        "http://www.ncbi.nlm.nih.gov/pubmed/36442912",
        "http://www.ncbi.nlm.nih.gov/pubmed/36065296",
        "http://www.ncbi.nlm.nih.gov/pubmed/35804863",
        "http://www.ncbi.nlm.nih.gov/pubmed/22270078",
        "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
        "http://www.ncbi.nlm.nih.gov/pubmed/23222249",
        "http://www.ncbi.nlm.nih.gov/pubmed/22453016",
        "http://www.ncbi.nlm.nih.gov/pubmed/31344957",
        "http://www.ncbi.nlm.nih.gov/pubmed/35254876",
        "http://www.ncbi.nlm.nih.gov/pubmed/19032679",
        "http://www.ncbi.nlm.nih.gov/pubmed/29497459",
        "http://www.ncbi.nlm.nih.gov/pubmed/32725406",
        "http://www.ncbi.nlm.nih.gov/pubmed/31811271",
        "http://www.ncbi.nlm.nih.gov/pubmed/31336704",
        "http://www.ncbi.nlm.nih.gov/pubmed/35060440",
        "http://www.ncbi.nlm.nih.gov/pubmed/24001901",
        "http://www.ncbi.nlm.nih.gov/pubmed/32954611",
        "http://www.ncbi.nlm.nih.gov/pubmed/31563544",
        "http://www.ncbi.nlm.nih.gov/pubmed/35236927",
        "http://www.ncbi.nlm.nih.gov/pubmed/36102132",
        "http://www.ncbi.nlm.nih.gov/pubmed/29692251",
        "http://www.ncbi.nlm.nih.gov/pubmed/36229663"
      ]
    },
    {
      "id": "6426bb49690f196b5100004d",
      "type": "summary",
      "body": "What is the Fenton reaction",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26948406",
          "text": "m 5.0 nM to 1.0 \u03bcM with a detection limit of 2.4 nM. Because of the rapid kinetics of Fenton reaction and high specificity for H2O2, the proposed meth",
          "offsetInBeginSection": 1128,
          "offsetInEndSection": 1278,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496478",
          "text": "INTRODUCTION\nFenton reaction is the main source of free radicals in biological systems.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16896806",
          "text": "chelates are formed which inhibit the Fenton reaction owing to a full Fe(II) coordination sphere. In addition to natural nucleotides, we investigated ",
          "offsetInBeginSection": 1200,
          "offsetInEndSection": 1350,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19806722",
          "text": "The photo-Fenton reaction, oxidation of photoproduced ferrous iron by hydrogen peroxide, produces reactive oxidants that may be important to degradation of biologically and chemically recalcitrant organic compounds in surface waters at circum-neutral pH.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23414832",
          "text": "ium dioxide) and the Fenton reaction exhibited synergistically enhanced hydroxyl (OH) radical generation. Dihydroxybenzoic acid (DHBA) concentration a",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 260,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17166556",
          "text": "Fenton reaction is a powerful oxidation technology used for the oxidation of groundwater pollutants.",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31476718",
          "text": "Fenton reaction is widely used for hazardous pollutant degradation. Reducing agents (RAs) have been proven to be efficient in promoting the generation",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10401608",
          "text": "As anticipated, the Fenton reaction initiates radical formation in all the above targets.",
          "offsetInBeginSection": 761,
          "offsetInEndSection": 850,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34190261",
          "text": "s that FeII-counteranion complexes are the real catalyst for fast aqueous Fenton reactions. In addition, we found that the Fenton oxidation mediated b",
          "offsetInBeginSection": 708,
          "offsetInEndSection": 858,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34494817",
          "text": "Ferroptosis therapy (FT) based on the Fenton reaction of ferrous nanoparticles has been becoming a unique strategy for cancer treatment; however, current ferrous nanoparticles suffer from slower Fenton reaction kinetics, lower ferroptosis efficacy, and long-term toxicity, so it is urgent to construct biocompatible ferrous nanomaterials with highly efficient Fenton reaction activity for cancer FT.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 399,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35780882",
          "text": "It has been well recognized that the Fenton reaction requires a rigorous pH control and suffers from the fast self-degradation of H2O2.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33301975",
          "text": "Photo-Fenton reaction is a more effective technique for pollutant disposal than photocatalytic reaction.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35395600",
          "text": " in aqueous environments. The Fenton reaction, as an effective organic pollution treatment technology, is particularly suitable for the treatment of a",
          "offsetInBeginSection": 292,
          "offsetInEndSection": 442,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30991337",
          "text": "Bimetallic Fe/Al system for the Fenton reaction in water involves both surface-mediated and aqueous-phase reactions.",
          "offsetInBeginSection": 1221,
          "offsetInEndSection": 1337,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36080218",
          "text": "The Fenton reaction is the reaction between iron and hydrogen peroxide, generating hydroxyl radical, which is highly reactive and highly toxic to living cells.",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 309,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26948406",
          "text": "on, which cleaves FDNA to detach ROX from PTAD, thus in turn, lights the ROX fluorescence. Under physiological condition, H2O2 can be determined from ",
          "offsetInBeginSection": 980,
          "offsetInEndSection": 1130,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32369069",
          "text": "The Fenton reaction is regarded as an advanced oxidation process that can efficiently remediate environmental pollutants.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10401608",
          "text": " radical yield from the Fenton reaction vs. the radical yield from Fe2+ + O2 reactions. When [O2]/[H2O2] < 10, the Fenton reaction dominates target molecule radical formation",
          "offsetInBeginSection": 1057,
          "offsetInEndSection": 1231,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35098712",
          "text": "Fenton reaction has important implications in biology- and environment-related remediation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33684817",
          "text": "Electro-, photo-, microwave/ultrasound-Fenton reactions or the synergistic Fenton reaction have been shown to exhibit excellent metal complex treatment capabilities.",
          "offsetInBeginSection": 631,
          "offsetInEndSection": 796,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22105135",
          "text": "TIRON) was studied by cyclic voltammetry to better understand the enhanced reactivity of the DHB driven Fenton reaction. It was determined that the am",
          "offsetInBeginSection": 641,
          "offsetInEndSection": 791,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34130454",
          "text": "The Fenton reaction is considered to be of great significance in the initial attack of lignocellulose in wood-decaying fungi.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11695453",
          "text": "Abstract Fenton reaction has been often used to treat industrial wastewater or landfill leachate.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34190261",
          "text": "take place in the human body and have been demonstrated to cause oxidative DNA damage. However, the molecular-level understanding of DNA damage mediat",
          "offsetInBeginSection": 29,
          "offsetInEndSection": 179,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31259456",
          "text": "In this review, the power of a classical chemical reaction, the Fenton reaction for initiating radical polymerizations, is demonstrated.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32596808",
          "text": "Fenton reaction-mediated oncotherapy is an emerging strategy which uses iron ions to catalytically convert endogenous hydrogen peroxide into hydroxyl radicals, the most reactive oxygen species found in biology, for efficient cancer therapy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15963810",
          "text": "This study highlights that the iron redox cycling is driven by Fenton reaction whatever Fenton mechanism is considered.",
          "offsetInBeginSection": 756,
          "offsetInEndSection": 875,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19579234",
          "text": "The kinetics of the Fenton reaction was studied in detail. A second reaction step in the presence of excess H2O2 is attributed to formation of the com",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23148728",
          "text": "We concluded that a ferryl-oxo species produced from Fenton's reagent serves as the primary oxidizing agent in the Fenton reaction.",
          "offsetInBeginSection": 1238,
          "offsetInEndSection": 1369,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31476718",
          "text": "Results show the catalytic performance of RAs in BA degradation by Fenton reaction followed an order of NH2OH > AA > Cys.",
          "offsetInBeginSection": 535,
          "offsetInEndSection": 656,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35098712",
          "text": "This leads to a 33-fold higher H2O2 utilization efficiency in comparison with Fe(II)/H2O2 Fenton reaction, and the pseudo-first-order reaction rate constant (kobs) increases 38-fold that of Fe(III)/H2O2 under equivalent conditions.",
          "offsetInBeginSection": 605,
          "offsetInEndSection": 836,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28531840",
          "text": "The Fenton process, one of several advanced oxidation processes, describes the reaction of Fe(II) with hydrogen peroxide.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22105135",
          "text": "It has been reported that the dihydroxybenzene (DHB) driven Fenton reaction is more efficient to degrade recalcitrant substrates than the simple Fenton reaction.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16896806",
          "text": "Highly reactive OH radicals, formed in an iron-ion catalyzed Fenton reaction, are implicated in many pathological conditions.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35780882",
          "text": "iron anode oxidation). Eighty percent of 1,2-DCA were degraded by the CaO2-based Fenton reaction. The final pH was neutral, inferring that the reactio",
          "offsetInBeginSection": 765,
          "offsetInEndSection": 915,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32668496",
          "text": "on reaction was used to improve the adsorption ability of chitosan. The formed Fe3+ in Fenton reaction was utilized. HO\u00b7 broke the hydrogen bonds and ",
          "offsetInBeginSection": 1393,
          "offsetInEndSection": 1543,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35036895",
          "text": "A variety of multifunctional nanomaterials such as metal-, metal oxide-, and metal-sulfide-based nanocatalysts have been designed and constructed to trigger the in situ Fenton or Fenton-like reaction within the tumor microenvironment (TME) to generate highly cytotoxic hydroxyl radicals (\u2022OH), which is highly efficient for the killing of tumor cells.",
          "offsetInBeginSection": 489,
          "offsetInEndSection": 840,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20129729",
          "text": "We observed the formation of surface Fe(II)-CS/GLA complex using microscopic analyses and identified Fe oxidation (Fe(II) to Fe(III)) coupled with H(2)O(2) reduction on the Fe(II)-CS/GLA surfaces during the modified Fenton reaction.",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 1014,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16504301",
          "text": "The Fenton or Fenton-type reaction between aqueous ferrous ion and hydrogen peroxide generates a highly oxidizing species, most often formulated as hydroxyl radical or ferryl ([Fe(IV)O](2+)).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32668496",
          "text": "The Fenton reaction generates highly reactive HO\u2022, which has been applied effectively.",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 217,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15963810",
          "text": "Modeling studies have shown that the Fenton reaction of iron(II) with H2O2 can contribute, in a significant amount, to OH radicals production in cloud droplets.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31343117",
          "text": "Here, the Fenton reaction is used to prepare silk hydrogels through oxidation of tyrosine residues in silk fibroin, leading to dityrosine crosslinking.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34676840",
          "text": "Meanwhile, the heat generated during the PTT process could improve the efficiency of the Fenton reaction.",
          "offsetInBeginSection": 1095,
          "offsetInEndSection": 1200,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35036895",
          "text": "CDT is a new emerging nanocatalyst-based therapeutic strategy for the in situ treatment of tumors via the Fenton reaction or Fenton-like reaction, which has got fast progress in recent years because of its high specificity and activation by endogenous substances.",
          "offsetInBeginSection": 225,
          "offsetInEndSection": 488,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10401608",
          "text": "Because of the high physiological ratio of [O2]/[H2O2] (> or = 10(3)), we hypothesize that the Fenton reaction with pre-existing H2O2 is only a minor initiator of free radical oxidations and that the major initiators of biological free radical oxidations are the oxidizing species formed by the reaction of Fe2+ with dioxygen.",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 400,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35188517",
          "text": "Cu2+ in BCG can be reduced to Cu+ by black phosphorus quantum dots (BPQDs), triggering a Cu+-mediated Fenton-like reaction to degrade H2O2 and generate abundant \u02d9OH for cancer CDT.",
          "offsetInBeginSection": 464,
          "offsetInEndSection": 644,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34676840",
          "text": "uate the treatment effect. In this study, we developed an iron ions-mediated Fenton reaction combined with a PTT treatment platform based on a metal-o",
          "offsetInBeginSection": 432,
          "offsetInEndSection": 582,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30165316",
          "text": "As a typical advanced oxidation technology, the Fenton reaction has been employed for the disinfection, owing to the strong oxidizability of hydroxyl radicals (\u00b7OH).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26899649",
          "text": "The heterogeneous Fenton reaction can generate highly reactive hydroxyl radicals (OH) from reactions between recyclable solid catalysts and H2O2 at acidic or even circumneutral pH.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27542932",
          "text": "The microbially driven Fenton reaction may thus be applied as an ex situ platform for simultaneous degradation of at least three (and potentially more) commingled contaminants.",
          "offsetInBeginSection": 1810,
          "offsetInEndSection": 1986,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19806722",
        "http://www.ncbi.nlm.nih.gov/pubmed/16896806",
        "http://www.ncbi.nlm.nih.gov/pubmed/35188517",
        "http://www.ncbi.nlm.nih.gov/pubmed/26899649",
        "http://www.ncbi.nlm.nih.gov/pubmed/20129729",
        "http://www.ncbi.nlm.nih.gov/pubmed/34676840",
        "http://www.ncbi.nlm.nih.gov/pubmed/35780882",
        "http://www.ncbi.nlm.nih.gov/pubmed/30165316",
        "http://www.ncbi.nlm.nih.gov/pubmed/11695453",
        "http://www.ncbi.nlm.nih.gov/pubmed/35395600",
        "http://www.ncbi.nlm.nih.gov/pubmed/32596808",
        "http://www.ncbi.nlm.nih.gov/pubmed/31476718",
        "http://www.ncbi.nlm.nih.gov/pubmed/16504301",
        "http://www.ncbi.nlm.nih.gov/pubmed/32369069",
        "http://www.ncbi.nlm.nih.gov/pubmed/15963810",
        "http://www.ncbi.nlm.nih.gov/pubmed/17166556",
        "http://www.ncbi.nlm.nih.gov/pubmed/34190261",
        "http://www.ncbi.nlm.nih.gov/pubmed/23148728",
        "http://www.ncbi.nlm.nih.gov/pubmed/28531840",
        "http://www.ncbi.nlm.nih.gov/pubmed/32668496",
        "http://www.ncbi.nlm.nih.gov/pubmed/10401608",
        "http://www.ncbi.nlm.nih.gov/pubmed/25496478",
        "http://www.ncbi.nlm.nih.gov/pubmed/22105135",
        "http://www.ncbi.nlm.nih.gov/pubmed/27542932",
        "http://www.ncbi.nlm.nih.gov/pubmed/34130454",
        "http://www.ncbi.nlm.nih.gov/pubmed/23414832",
        "http://www.ncbi.nlm.nih.gov/pubmed/30991337",
        "http://www.ncbi.nlm.nih.gov/pubmed/19579234",
        "http://www.ncbi.nlm.nih.gov/pubmed/34494817",
        "http://www.ncbi.nlm.nih.gov/pubmed/35036895",
        "http://www.ncbi.nlm.nih.gov/pubmed/35098712",
        "http://www.ncbi.nlm.nih.gov/pubmed/31259456",
        "http://www.ncbi.nlm.nih.gov/pubmed/36080218",
        "http://www.ncbi.nlm.nih.gov/pubmed/33301975",
        "http://www.ncbi.nlm.nih.gov/pubmed/31343117",
        "http://www.ncbi.nlm.nih.gov/pubmed/33684817",
        "http://www.ncbi.nlm.nih.gov/pubmed/26948406"
      ]
    }
  ]
}